CN101333185A

CN101333185A - Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient

Info

Publication number: CN101333185A
Application number: CNA2008101336480A
Authority: CN
Inventors: 西泽玲奈; 高冈义和; 柴山史朗
Original assignee: Ono Pharmaceutical Co Ltd
Current assignee: Ono Pharmaceutical Co Ltd
Priority date: 2003-03-14
Filing date: 2004-03-12
Publication date: 2008-12-31
Also published as: ZA200507365B; CN1787996B; CN101333186A; CN1787996A

Abstract

The invention relates to nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient. The compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

Description

Nitogen-contained heterocycle derivant and include medicine of the compound as active component

The application is the applying date on March 12nd, 2004, Application No. 200480013002.9, the divisional application of the Chinese invention patent application of entitled " nitogen-contained heterocycle derivant and comprising medicine of the compound as active component ".

Technical field

The present invention relates to the compound that (1) formula (I) is represented

(wherein all symbols have with hereafter described in identical implication), its salt or its solvate, or its prodrug, and the disease that (2) treatment and/or prevention are mediated by CCR5, including the compound represented with formula (I), its salt or its solvate, or its prodrug are used as active component.

Background technology

Known chemotactic factor (CF) is the basic protein with endogenous leukocyte chemotactic and activation capacity and strong heparin affinity.It is now recognized that chemotactic factor (CF) is directed not only to the control of the infiltration of particular leukocyte when inflammation and immune response, and it is related to lymphocyte development in physiological conditions and the migration of target-seeking and blood cell precursors and body cell.

Differentiation, propagation and the cell death of haemocyte are controlled by various types of cell factors.In live body, inflammation betides part, and the breaking up of lymphocyte, maturation etc. are carried out at the position of some determinations.That is, the cell migration of various needs is to the position of some determinations and is gathered in there, cause a series of inflammation and immune response.Therefore, in addition to the differentiation of cell, propagation and death, the migration of cell is also a kind of essential phenomenon.

The migration of haemocyte in vivo first starts at the stage of development, starts from the transfer of the permanent hemoposieis by baby's liver in the starting hemoposieis to marrow in AGM areas.Moreover, the precursor of T cell and thymus gland dendritic cell is migrated to marrow by baby's liver, then migrate to thymus gland, and carry out under thymus gland environment cell differentiation.The T cell for receiving Clones Selection is migrated to secondary lymphoid tissue, and participates in the immune response in periphery.Skin is activated and the langerhans cell migration that breaks up is to the T cell area of regional nodes by capturing antigen, and activates Naive T cells therein as dendritic cell.Memory T cell is revert in lymph node again by lymphatic vessel and blood vessel in itself.In addition, the T cell, gamma delta T cells, NKT cells and dendritic cell in B cell, enteric epithelium are migrated and broken up from marrow without thymus gland, to participate in immune response.

The migration of chemotactic factor (CF) cell different from these is extremely related.Chemokine receptors is by following mechanism and the control height correlation of inflammation and immune response, and in the mechanism, chemokine receptors is expressed in various specific cells with some specific cycles, and effector cell accumulates in the region for producing chemotactic factor (CF).

Immune Deficiency Syndrome (being referred to as AIDS) is that caused by human immunodeficiency virus (hereinafter referred to " HIV "), this is that people thirst for obtaining one of disease of its treatment method in recent years.Once HIV CD4- positive cells (it is main target cell) are completed, HIV just repeatedly breeds in patient's body, and can break the T cell that ring undertakes immunologic function completely sooner or later.In this process, immunologic function is gradually reduced, and is caused to have a fever, is suffered from diarrhoea, the various immune deficiency illnesss such as enlargement of lymph nodes, and the illness is easy to cause the complication with the various opportunistic infections such as pneumocystis carinii pneumonia.This kind of symptom is exactly AIDS breaking-outs, and knows them and cause and deteriorate the malignant tumours such as Kaposi sarcomas.

It is used as the method for prevention and treatment AIDS recently, (1) is for example had attempted to by passing through to the growth for suppressing HIV with RTI or protease inhibitors, and (2) to with the active chemoprophylaxis of immunological enhancement and mitigation opportunistic infections.

The helper T lymphocyte for being responsible for immune system center is the main body of HIV.From 1985 just it is known that memebrane protein CD4s (Cell, 52,631 (1985)) of the HIV in infection using expression on T cell film.CD4 molecules are made up of 433 amino acid residues, in addition to ripe helper cell, it is expressed it has also been found that in the Langerhans cell in macrophage, some B cells, vascular endothelial cell, skin histology, the dendritic cell in lymphoid tissue, spongiocyte of central nervous system etc..However, due to it is disclosed that what HIV was completed alone not by CD4 molecules, it has been suggested that outside CD4 molecules, it is also possible to there are the other factorses relevant with the HIV of cell.

CCR5, it is RANTES, MIP-1 α and MIP-1 β acceptor, and is also used for during the HIV of macrophage tropic (R5) (Science, 272,1955 (1996)).

Therefore, it is possible to compete HIV material with CCR5, or it can be combined with inhibition of HIV and then prevent the virus from the material combined with CCR5, HIV inhibitor can be turned into.

According to the above it is believed that CCR5 acceptors are strongly related to inflammation, immunological diseases or HIV.For example, it is thought that they are related to following disease：Various inflammatory disease (asthma, ephritis, nephrosis, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis etc.), immunity disease (autoimmune disease, organ-graft refection, immunosupress, psoriasis, multiple sclerosis etc.), HIV infections (Immune Deficiency Syndrome etc.), anaphylactia (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, anaphylaxis Eosinophilic Gastroenteritis etc.), ischemia-reperfusion injury, ARDS, with the shock of bacterium infection, diabetes, or metastasis of cancer etc..

It has been reported that the amino piperidine derivatives that formula (a) is represented

(wherein R^1aFor hydrogen atom or C1-12 alkyl, R^2aAnd R^3aIt is each independently hydrogen atom or C1-12 alkyl, X^aFor nitrogen-atoms or oxygen atom, A^aFor

(wherein R^4aFor hydrogen atom, C1-12 alkyl, C3-8 cycloalkyl, aryl, substitution aryl, aryl-C (=O)-or aryl-CH (OH)-, R^5aFor hydrogen, C1-12 alkyl, C1-4 alkoxies, halogen or COR, R^6aFor hydrogen, C1-12 alkyl or substituted C1-4 alkyl.Condition is that the definition of each symbol is quoted for part) it can be used as inhibitors of chemokine receptors (with reference to WO02/79186 specifications).

It is selectivity CCR1 receptor antagonists to have described the sulfonic acid of formula (b) expression (with reference to WO02/102787 specifications).

In addition, 1- (4- pyridine radicals)-bridged piperazine derivatives are recited as CCR5 antagonists (referring to US6,391,865 specifications).

On the other hand, it has been reported that thriazaspiro [5.5] undecane derivative, its quaternary ammonium salt or its N- oxide, or its pharmacology acceptable salt, adjust the activity of chemotactic factor (CF)/chemokine receptors, therefore it can be used for preventing and/or treating a variety of inflammatory diseases, asthma, atopic dermatitis, nettle rash, anaphylactia (allergic bronchopulmonary aspergillosis or anaphylaxis acidophilia enterogastritis etc.), ephritis, nephrosis, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemia reperfusion conditions, multiple sclerosis, ulcerative colitis, ARDS, cytotoxicity is suffered a shock, diabetes, autoimmune disease, organ-graft refection, immunosupress, cancer metastasis and acquired immunodeficiency syndrome (with reference to WO01/40227 specifications).

The compound of formula (c) expression is described

(wherein mc and nc, it is identical or different, it is 0 or integer 1 or 2, Alk^3cFor covalent bond or straight or branched C1-6 alkylidene chains, R^1cAnd R^2c, it is identical or different, it is respectively hydrogen atom or straight or branched C1-6 alkyl, D^cFor optionally substituted fragrance or heteroaryl perfume base, E^cFor optionally substituted C7-10 cycloalkyl, C7-10 cycloalkenyl groups or C7-10 polycyclic aliphatics base) conditioning agent that is CXCR3 (with reference to WO03/070242 specifications).

Invention description

The compound for adjusting CCR5 acceptors can be used for the disease of prevention and treatment CCR5 acceptor interventions.It is therefore desirable for the CCR5 conditioning agents of exploitation safety, especially CCR5 antagonists.

In order to find the compound for specifically combining and adjusting CCR5 acceptors, present inventor has carried out substantial amounts of research and found, the compound that described target can be represented by formula (I) is realized, so as to complete the present invention.

The present invention relates to

1. the compound that formula (I) is represented：

Wherein R¹Expression hydrogen atom can protected acidic-group；

X and Y represent key or comprising interval base of 1~3 atom as main chain independently of one another；

Ring A and ring B, it is identical or different, each represent to have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical；

Ring D represents to have the 3- of substituent to 15- person's nitrogen heterocycle；

R²Represent (1) hydrogen atom; (2) there can be the alkyl of substituent; (3) cyano group; (4) can protected hydroxyl; (5) there can be the amino of substituent; (6) oxo group, (7) can have the 3- of substituent to 15- element heterocycles base or (8)=N-OR⁶, wherein R⁶Hydrogen atom or C1-4 alkyl are represented,

Its salt or its solvate, or its prodrug；

2. according to above-mentioned 1 compound, wherein R¹For can protected acidic-group,

3. according to above-mentioned 2 compound, wherein described acidic-group is carboxylic acid or sulfonamide,

4. according to above-mentioned 1 compound, wherein X and Y are each independently key or the divalent group selected from following groups：(1)-CR⁷R⁸-, (2)-NR⁹-, (3)-CO-, (4)-O-, (5)-S-, (6)-SO-, (7)-SO₂- and (8)-C (=N-OR¹⁰)-, wherein R⁷And R⁸Hydrogen atom, C1-4 alkyl ,-OR are represented independently of one another¹¹Or phenyl；R⁹Represent hydrogen atom, C1-4 alkyl, or phenyl；R¹⁰And R¹¹Hydrogen atom or C1-4 alkyl are represented independently of one another,

5. according to above-mentioned 4 compound, wherein X is key ,-O- or-CH₂-,

6. according to above-mentioned 1 compound, wherein Y is C1-3 alkylidenes,

7. according to above-mentioned 1 compound, its middle ring D for that can have the 5- of substituent to 10- person's nitrogen heterocycle,

8. according to above-mentioned 1 compound, its middle ring A and ring B are identical or different, and the 5- of substituent can be had to 10- person's carbocylic radical or heterocyclic radical by being respectively,

9. according to above-mentioned 1 compound, its middle ring A and ring B are identical or different, are respectively the 5- or 6- person's aromatic rings can with substituent,

10. according to above-mentioned 1 compound, wherein R²For

Wherein arrow represents the bonding position with ring D；R⁵¹、R⁵²And R⁵³(1) hydrogen atom is represented independently of one another, (2) there can be the alkyl of substituent, (3) there can be the 3- of substituent to 15- element heterocycle bases, (4) there can be the C1-4 alkoxies of substituent, (5) phenoxy group or (6) can with substituent can have the benzyloxy of substituent

11. according to above-mentioned 1 compound, it is the compound that formula (Ia) is represented：

Its middle ring D^1aFor that can have the piperidines or piperazine of substituent and other symbol has such as the identical implication described in above-mentioned 1；

12. according to above-mentioned 1 compound, it is selected from

(1) N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] Methanesulfomide,

(2) N- [4- (4- { [4- (butyl { [(6- methyl -3- pyridine radicals) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] Methanesulfomide,

(3) N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } -3,5- dimethyl -1H- pyrazol-1-yls) phenyl] Methanesulfomide,

(4) N- [4- (4- { [4- (butyl { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

(5) 3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] benzamide,

(6) N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (phenyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide,

(7) 5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2- fluorobenzamides,

(8) 5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorobenzamides,

(9) N- [4- (4- { [4- (butyl { [(3- cyano group -4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide, and

(10) N- [4- (4- { [4- (butyl { [(3- hydroxy-cyclohexyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide, and

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1,3-thiazoles -4- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide,

13.CCR5 conditioning agents, including compound, its salt or its solvate according to above-mentioned 1, or its prodrug,

14. according to above-mentioned 13 CCR5 conditioning agents, it is CCR5 antagonists,

15. according to above-mentioned 13 CCR5 conditioning agents, it is for treating and/or preventing the medicine by the CCR5 diseases intervened；

16. according to above-mentioned 15 CCR5 conditioning agents, wherein being human immunodeficiency virus infection by the CCR5 diseases intervened；

17. according to above-mentioned 16 CCR5 conditioning agents, wherein human immunodeficiency virus infection is acquired immunodeficiency syndrome；

18. according to above-mentioned 15 CCR5 conditioning agents, wherein being immunity disease by the CCR5 diseases intervened；

19. according to above-mentioned 18 CCR5 conditioning agents, wherein immunity disease is organ-graft refection；

20. according to above-mentioned 15 CCR5 conditioning agents, wherein being inflammatory disease by the CCR5 diseases intervened；

21. according to above-mentioned 20 CCR5 conditioning agents, wherein inflammatory disease is asthma；

22. it is a kind of be used to preventing and/or treat human immunodeficiency virus infection, the medicine of immunity disease or inflammatory disease, it includes compound, its salt or its solvate represented according to above-mentioned 1 formula (I), or its prodrug；

23. pharmaceutical composition, it includes compound, its salt or its solvate or its prodrug represented according to above-mentioned 1 formula (I)；

24. a kind of medicine, it includes compound, its salt or its solvate or its prodrug represented according to above-mentioned 1 formula (I), one or at least two RTIs of combination, protease inhibitors, CCR2 antagonists, CCR3 antagonists, CCR4 antagonists, CCR5 antagonists, CXCR4 antagonists, fusion inhibitor, the antibody of anti-HIV-1 surface antigen and HIV-1 vaccines.

25. a kind of method treated or prevented in mammal by the CCR5 diseases intervened, described method includes compound, its salt or its solvate represented to the formula (I) that mammal applies effective dose, or its prodrug：

Wherein R¹Expression hydrogen atom can protected acidic-group；

R²Represent (1) hydrogen atom; (2) there can be the alkyl of substituent; (3) cyano group; (4) can protected hydroxyl; (5) there can be the amino of substituent; (6) oxo group, (7) can have the 3- of substituent to 15- element heterocycles base or (8)=N-OR⁶, wherein R⁶Represent hydrogen atom or C1-4 alkyl；

26. compound, its salt or its solvate that formula (I) is represented, or its prodrug are preparing the purposes in being used to prevent and/or treat the medicine of the disease intervened by CCR5：

Wherein R¹Expression hydrogen atom can protected acidic-group；

Ring A and ring B, it is identical or different, represent to have the 3- of substituent independently of one another to 15- person's carbocylic radical or heterocyclic radical；

R²Represent (1) hydrogen atom; (2) there can be the alkyl of substituent; (3) cyano group; (4) can protected hydroxyl; (5) there can be the amino of substituent; (6) oxo group, (7) can have the 3- of substituent to 15- element heterocycles base or (8)=N-OR⁶, wherein R⁶Represent hydrogen atom or C1-4 alkyl.

R¹" can protected acidic-group " represented represents " acidity " that can be protected by " protection group ".The example of " acidic-group " includes hydroxyl, alkoxy, carboxyl (- COOH), sulfonic group (sulfo ,-SO₃H), sulfinic acid base (sulfino ,-SO₂H), sulfonamide (- SO₂NH₂Or-NR¹⁰¹SO₃H(R¹⁰¹For hydrogen atom or can have substituent alkyl)), phosphonate group (phosphono ,-PO (OH)₂), phenol (- C₆H₄OH) or polytype Br φ nsted acid as have from it can remove as proton hydrogen residue containing azo-cycle." Br φ nsted acid ", which refers to, can supply hydrogen ion the material of other materials.The example of " having the residue containing azo-cycle that can remove the hydrogen as proton from it " includes：

It is preferred that " acidic-group " be carboxyl or sulfonamide.More preferably sulfonamide.

The example of " protection group " include having the alkyl of substituent, C1-6 alkoxies, the amino can with substituent,

Or

" alkyl " in " alkyl can with substituent " includes, for example, C1-15 alkyl such as methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, sec-butyl, the tert-butyl group, amyl group, hexyl, heptyl, octyl group, nonyl, decyl, undecyl, dodecyl, tridecyl, myristyl, pentadecyl etc.；C3-8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopenta, cyclohexyl etc.；C2-10 alkenyls such as vinyl, pi-allyl, 2- methacrylics, 2- cyclobutenyls, 3- cyclobutenyls, 3- octenyls etc.；C2-10 alkynyls such as acetenyl, 2-propynyl, 3- hexin bases etc.；C3-10 cycloalkenyl groups such as cyclopropanyl, cyclopentenyl, cyclohexenyl group etc.；C6-14 aryl such as phenyl, naphthyl etc.；C7-16 aralkyl such as benzyl, phenylethyl etc.；(C3-8 cycloalkyl)-(C1-4 alkyl) such as cyclohexyl methyl, cyclohexyl-ethyl, Cyclohexylpropyl, 1- methyl isophthalic acids-cyclohexyl methyl, cyclopropylethyl.

" substituent " in " alkyl can with substituent " includes,For example,(1) nitro,(2) hydroxyl,(3) oxo,(4) thio (thioxo),(5) cyano group,(6) carbamoyl,(7) amino carbonyl replaced by C1-8 hydrocarbon etc. is (such as,N- butylamino carbonyls,N- Cyclohexylmethylamino carbonyls,N- butyl-N- Cyclohexylmethylamino carbonyls,N- cyclohexylaminocarbonyls,Phenyl amino carbonyl etc.),(8) carboxyl,(9) C1-4 alkoxy-carbonyls such as methoxycarbonyl,Ethoxy carbonyl etc.,(10) sulfonic group,(11) halogen such as fluorine,Chlorine,Bromine or iodine,(12) the C1-4 lower alkoxies that can be optionally substituted by halogen are (such as,Methoxyl group,Ethyoxyl,Propoxyl group,Isopropoxy,Butoxy,Isobutoxy,Sec-butoxy,Butoxy,Difluoro-methoxy or trifluoro,Ethyoxyl),(13) phenoxy group,(14) halogenated phenoxy such as o-,M- or p- chlorophenoxies,Or o-,M- or p- bromobenzene epoxides etc.,(15) C1-4 lower alkylthios such as methyl mercapto,Ethylmercapto group,Positive rosickyite base,Isopropyisulfanyl,Positive butylthio,Tertiary butylthio etc.,(16) thiophenyl,(17) C1-4 lower alkyl sulfinyls such as methylsulfinyl or ethylsulfinyl etc.,(18) C1-4 lower alkylsulfonyl radicals such as mesyl or ethylsulfonyl etc.,(19) amino,(20) C1-6 lower acyl aminos such as acetyl-amino or propanoylamino etc.,(21) primary or secondary amino replaced by alkyl is (such as,Methylamino,Ethylamino,N-propyl amino,Isopropylamino,N-butylamino,Dimethylamino,Diethylamino,Cyclohexylamino,1- carbamoyl -2- Cyclohexylethylaminos,N- butyl-N- Cyclohexylmethylaminos or phenyl amino etc.),(" alkyl " has " alkyl " identical implication as described above and can be by oxo,Can be by optional substituent (such as,Hydrocarbon) substitution amino,Carbamoyl,Halogen or hydroxyl etc. replace),(22) C1-4 lower acyls such as formoxyl or acetyl group etc.,(23) benzoyl,(24) 5 or 6 element heterocycle bases such as 2- or 3- thienyls,2- or 3- furyls,3-,4- or 5- pyrazolyls,4- THP trtrahydropyranyls,2-,4- or 5- thiazolyls,3-,4- or 5- isothiazolyls,2-,4- or 5- oxazolyls,3-,4- or 5- isoxazolyls,2-,4- or 5- imidazole radicals,1,2,3- or 1,2,4- triazolyls,1H or 2H- tetrazole radicals,2-,3- or 4- pyridine radicals,2-,4- or 5- pyrimidine radicals,3- or 4- pyridazinyls,Quinolyl,Isoquinolyl or indyl etc.,Beyond carbon atom,It may include that 1~4 is selected from oxygen,The hetero atom of sulphur and nitrogen simultaneously optionally has 1~4 substituent,Described substituent is selected from (a) halogen such as bromine,Chlorine,Or fluorine,(b) optionally by the substituted hydrocarbon such as oxo or hydroxyl such as methyl,Ethyl,Propyl group,Isopropyl,Benzyl,Cyclohexyl,Cyclohexyl methyl or cyclohexyl-ethyl etc.,(" alkyl " has " alkyl " identical implication as described above),(c) halogenated phenoxy such as o-,M- or p- chlorophenoxies,Or o-,M- or p- bromobenzene epoxides etc.,And (d) oxo etc.,(25) C1-10 haloalkyls such as difluoromethyl,Trifluoromethyl,Trifluoroethyl or trichloroethyl etc.,(26) hydroxyl imide base,(27) alkoximino such as methoxyl group imido grpup or ethoxyimino etc.,(28) alkyl sulfonyl-amino such as methane sulfonylamino,Ethylsulphsulphonylamino or benzylsulphonyl amino etc.,Or (29) arlysulfonylamino such as phenyl sulfonyl amino or p- tosyl amino etc.." alkyl can with substituent " can have 1~10 substituent for being selected from above-mentioned (1)~(29).If " alkyl " is cycloalkyl, cycloalkenyl group, aryl or aralkyl, it can have 1~4 C1-4 low alkyl group such as methyl, ethyl, propyl group, isopropyl or butyl etc. to be used as substituent.When the number of substituent is 2 or more, each substituent may be the same or different.

Amino-substituent in " protection group " in " amino can with substituent " includes above-mentioned " alkyl ".

" C1-6 alkoxies " in " protection group " includes, for example, methoxyl group, ethyoxyl, propoxyl group, butoxy, amoxy or hexyloxy etc..

R¹In preferably as " protection group " can to have the alkyl of substituent, and more preferably C1-4 alkyl etc..

R¹" can protected acidic-group " represented includes, for example, ester such as methoxycarbonyl or ethoxy carbonyl or acid amides such as carbamoyl.

It is preferred that R¹For-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴、-COOR¹⁰⁵、-CONR¹⁰⁶R¹⁰⁷(wherein R¹⁰²R¹⁰⁷There is the identical implication with foregoing description for hydrogen atom or above-mentioned protection group and other symbols) and more preferably-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴。

" comprising interval base of 1~3 atom as main chain " that X and Y are represented refers to the interval base formed by 1~3 continuous backbone atoms of main chain.In this case, " numbers of backbone atoms " should be calculated as main chain most short atom." having the interval base of 1~3 atom as main chain " includes, for example, divalent group, including 1~3 is selected from-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- and-C (=N-OR¹⁰)-(wherein R⁷And R⁸Hydrogen atom, C1-4 alkyl ,-OR independently of one another¹¹Or phenyl, R⁹For hydrogen atom, C1-4 alkyl or phenyls, R¹⁰And R¹¹It is each independently hydrogen atom or C1-4 alkyl).In this case, " C1-4 alkyl " includes methyl, ethyl, propyl group or butyl etc..Specifically, " having interval base of 1~3 atom as main chain " includes, for example ,-CR⁷R⁸-、-NR⁹- ,-CO- ,-O- ,-S- ,-C (=N-OR¹⁰)-、-NR⁹CO-、-CONR⁹-、-NR⁹COCR⁷R⁸- or-CONR⁹CR⁷R⁸- (wherein R⁷-R¹⁰With with foregoing description identical implication).Interval base preferably in " having interval base of 1~3 atom as main chain " that X is represented is-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- or-C (=N-OR¹⁰)-(wherein R⁷And R⁸It is each independently hydrogen atom, C1-4 alkyl ,-OR¹¹Or phenyl, R⁹For hydrogen atom, C1-4 alkyl or phenyls, R¹⁰And R¹¹It is each independently hydrogen atom or C1-4 alkyl) etc..

It is preferred that X be key ,-O- or-CH₂- etc..

It is preferred that Y " there is the interval base of 1~3 atom as main chain " for representing be " C1-3 alkylidenes "." C1-3 alkylidenes " includes methylene, ethylidene or propylidene etc..It is highly preferred that Y is methylene.

" 3- to 15- person's carbocyclic ring " in " can have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical " that ring A and ring B are represented includes, for example, " cyclic hydrocarbon " etc.." cyclic hydrocarbon " includes, for example, " undersaturated cyclic hydrocarbon " or " cyclic hydrocarbon of saturation "." cyclic hydrocarbon of saturation " includes, for example, cycloalkane such as cyclopropane, cyclobutane, pentamethylene, hexamethylene, cycloheptane, cyclooctane, cyclononane, cyclodecane, ring hendecane, cyclododecane, ring tridecane, the ring tetradecane or cyclopentadecane etc.；Perhydro pentalene (pentalene)；Perhydro Azulene；Perhydro indenes；Perhydronaphthalene；Perhydro heptalene；Spiral shell [4.4] nonane；Spiral shell [4.5] decane；Spiral shell [5.5] hendecane；Two rings [2.2.1] heptane；Two rings [3.1.1] heptane；Two rings [2.2.2] octane；Adamantane；Adamantane (noradamantane) etc. drops." undersaturated cyclic hydrocarbon " includes, for example, cycloolefin such as cyclopentene, cyclohexene, cycloheptene, cyclo-octene, cyclopentadiene, cyclohexadiene, cycloheptadiene or cyclo-octadiene etc.；Benzene；Pentalene (pentalene)；Azulene；Indenes；Indane；Naphthalene；Dihydronaphthalene；Naphthane；Heptalene；Xenyl；as-indacene；s-indacene；Acenaphthene；Acenaphthene；Fluorenes；phenalene；It is luxuriant and rich with fragrance；Anthracene；Two rings [2.2.1] hept-2-ene"；Two rings [3.1.1] hept-2-ene"；Two rings [2.2.2] oct-2-ene etc..

" 3- to 15- element heterocycles " in " can have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical " that ring A and ring B are represented includes " undersaturated 3- to 15- element heterocycles " or " 3- of saturation to 15- element heterocycles ".

" undersaturated 3- to 15- element heterocycles " includes, for example, pyrroles, imidazoles, triazole, tetrazolium, pyrazoles, pyridine, pyrazine, pyrimidine, pyridazine, azepine

, diaza

, furans, pyrans, oxa-

Thiophene, thiapyran, thia

, oxazole, isoxazoles, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazines, oxazepine, oxa- diaza

, thiadiazoles, thiazine, thiadiazine, sulphur azepine

Sulphur diaza

, indoles, iso-indoles, indolizine, benzofuran, isobenzofuran, benzothiophene, isothiophene, dithia naphthalene, indazole, quinoline, isoquinolin, quinolizine (quinolizine), purine, 2,3- benzodiazines, pteridine, 1,5- benzodiazines, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, chromene, benzo oxa-

, benzo oxazepine

, benzo oxa- diaza

Benzo thia

, benzothiazepine

, benzimidazole thiophanate diaza

, benzo-aza, benzodiazepine

Benzofuraxan, diazosulfide, BTA, carbazole, beta- carbolines, acridine, azophenlyene (phenazine), dibenzofurans, xanthene (xanthene), dibenzothiophenes, phenthazine, phenoxazine, Fen Evil thiazines (phenoxathiin), thianthrene (thianthrene), phenanthridines (phenanthridine), phenanthroline (phenanthroline), perimidine, pyrrolin, imidazoline, triazoline, four oxazolines, pyrazoline, dihydropyridine, tetrahydropyridine, dihydro pyrazine, tetrahydrochysene pyrazine, dihydro-pyrimidin, tetrahydropyrimidine, dihydrogen dazin, tetrahydro pyridazine, dihydro azepine

, tetrahydrochysene azepine

, dihydro diaza

, tetrahydrochysene diaza

Dihydrofuran, dihydropyran, dihydro oxa-, tetrahydrochysene oxa-

, dihydro-thiophene, dihydro thiapyran, dihydro thia

, tetrahydrochysene thia

, dihydro-oxazole, dihydro-isoxazole, thiazoline, dihydro isothiazole, dihydro furazan, Er Qing oxadiazoles, Er Qing oxazines, Er Qing oxadiazines, dihydro oxazepine

, tetrahydrochysene oxazepine

, dihydro oxa- diaza

, tetrahydrochysene oxa- diaza

, thiodiazoline, dihydro thiazine, dihydro thiadiazine, dihydro sulphur azepine

, tetrahydrochysene sulphur azepine

, dihydro sulphur diaza, tetrahydrochysene sulphur diaza, indoline, isoindoline, Dihydrobenzofuranes, dihydroisobenzofuran, dihydrobenzo thiophene, dihydro isothiophene, dihydro-indazol, EEDQ, tetrahydroquinoline, dihydro-isoquinoline, tetrahydroisoquinoline, dihydro 2, 3- benzodiazines, tetrahydrochysene 2, 3- benzodiazines, dihydro 1, 5- benzodiazines, tetrahydrochysene 1, 5- benzodiazines, dihydro-quinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydro quinazoline, dihydro cinnoline, tetrahydrochysene cinnoline, benzo thioxane, Er hydrogen benzoxazines, dihydrobenzo thiazine, pyrazolo morpholine, Er hydrogen benzoxazoles, dihydro-benzothiazole, dihydrobenzo imidazoles, dihydrobenzo azepine, tetrahydro benzo azepine

, dihydrobenzo diaza

, tetrahydro benzo diaza

, benzo dioxepan, dihydrobenzo oxazepine

, tetrahydro benzo oxazepine

, dihydro carbazole, tetrahydro carbazole, acridan, tetrahydro acridine, dihydro-dibenzo furans, dihydro-dibenzo thiophene, tetrahydrochysene dibenzofurans, tetrahydrochysene dibenzothiophenes, dioxa indane, benzo dioxane, chroman, benzo dithiolane, the own ring of the sulphur of benzo two etc.." 3- of saturation to 15- element heterocycles " includes, for example, aziridine, azetidine, Fang Xinyin (azocane), pyrrolidines, imidazolidine, triazolidine, four oxazolidines, pyrazolidine, piperidines, piperazine, perhydro pyrimidine, perhydro pyridazine, perhydroazepinyl

, perhydro diazaOxirane (oxirane), oxetanes (oxetane), tetrahydrofuran, oxinane, perhydro oxa-

, thiirane (thiirane), Thietane (thietane), thiophane, tetrahydric thiapyran, perhydro thia

, Si Qing oxazole (oxazolidines), tetrahydrochysene isoxazole (isoxazole alkyls), tetrahydro-thiazoles (thiazolidine), tetrahydrochysene isothiazole (isothiazolidine), tetrahydrochysene furazan, Si Qing oxadiazole (oxadiazoles alkane), Si Qing oxazines, Si Qing oxadiazines, perhydro oxazepine

, perhydro oxa- diaza

, thiodiazolidine (thiadiazolidine), tetrahydrochysene thiazine, tetrahydrochysene thiadiazine, perhydro sulphur azepine

, perhydro sulphur diaza

, morpholine, thiomorpholine, thioxane (o thioxane), perhydro benzofuran, perhydro isobenzofuran, perhydro benzothiophene, perhydro isothiophene, perhydro indazole, perhydro quinoline, perhydro isoquinolin, perhydro 2,3- benzodiazines, perhydro 1,5- benzodiazines, perhydro quinoxaline, perhydro quinazoline, perhydro cinnoline, perhydro benzoxazole, perhydro benzothiazole, perhydro benzimidazole, perhydro carbazole, perhydro acridine, perhydro dibenzofurans, perhydro dibenzothiophenes, dioxolanes, dioxane, dithiolane, the own ring of two sulphur,Deng.

It is preferred that ring A and ring B " 3- to 15- person's carbocylic radical or heterocyclic radical " that represents be " 5- to 10- person's carbocylic radical or heterocyclic radical ".Specifically, " 5- to 10- person's carbocylic radical " includes, for example, the C5-10 cyclic hydrocarbon of saturation such as C5-10 cycloalkane is (such as, pentamethylene, hexamethylene or cycloheptane) or undersaturated C5-10 cyclic hydrocarbon such as C5-10 cycloolefins (e.g., cyclopentene, cyclohexene, cycloheptene, cyclo-octene, cyclopentadiene, cyclohexadiene, cycloheptadiene or cyclo-octadiene)；Benzene；Naphthalene；Indenes etc.." 5- to 10- element heterocycles base " includes undersaturated 5- to 10- element heterocycles base such as pyrroles, imidazoles, triazole, tetrazolium, pyrazoles, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diaza

, furans, pyrans, oxa-

, thiophene, thiapyran, thia

, oxazole, isoxazoles, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazines, oxazepineOxa- diaza

, thiadiazoles, thiazine, thiadiazine, sulphur azepine

, sulphur diaza

, indoles, iso-indoles, indolizine, benzofuran, isobenzofuran, benzothiophene, isothiophene, dithia naphthalene, indazole, quinoline, isoquinolin, quinolizine, purine, 2, 3- benzodiazines, pteridine, 1, 5- benzodiazines, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, chromene, benzofuraxan, diazosulfide, BTA, pyrrolin, imidazoline, triazoline, four oxazolines, pyrazoline, dihydropyridine, tetrahydropyridine, dihydro pyrazine, tetrahydrochysene pyrazine, dihydro-pyrimidin, tetrahydropyrimidine, dihydrogen dazin, tetrahydro pyridazine, dihydro azepine

, tetrahydrochysene azepine, dihydro diaza

, tetrahydrochysene diaza

, dihydrofuran, dihydropyran, dihydro oxa-

, tetrahydrochysene oxa-, dihydro-thiophene, dihydro thiapyran, dihydro thia

, tetrahydrochysene thia

, tetrahydrochysene oxazepine

, dihydro oxa- diaza, tetrahydrochysene oxa- diaza

, thiodiazoline, dihydro thiazine, dihydro thiadiazine, dihydro sulphur azepine

, tetrahydrochysene sulphur azepine

, dihydro sulphur diaza

, tetrahydrochysene sulphur diaza

, indoline, isoindoline, Dihydrobenzofuranes, dihydroisobenzofuran, dihydrobenzo thiophene, dihydro isothiophene, dihydro-indazol, EEDQ, tetrahydroquinoline, dihydro-isoquinoline, tetrahydroisoquinoline, dihydro 2, 3- benzodiazines, tetrahydrochysene 2, 3- benzodiazines, dihydro 1, 5- benzodiazines, tetrahydrochysene 1, 5- benzodiazines, dihydro-quinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydro quinazoline, dihydro cinnoline, tetrahydrochysene cinnoline, benzo thioxane, Er hydrogen benzoxazines, dihydrobenzo thiazine, pyrazolo morpholine, Er hydrogen benzoxazoles, dihydro-benzothiazole, dihydrobenzo imidazoles, dioxa indane, benzo dioxane, chroman, benzo dithiolane or the own ring of the sulphur of benzo two；Or 5- is to heterocyclic radical such as pyrrolidines, imidazolidine, triazolidine, four oxazolidines, pyrazolidine, piperidines, piperazine, perhydro pyrimidine, perhydro pyridazine, the perhydroazepinyl of 10- person's saturation

, perhydro diaza

, tetrahydrofuran, oxinane, perhydro oxa-

, thiophane, tetrahydric thiapyran, perhydro thia

Perhydro oxa- diaza, thiodiazolidine (thiadiazolidine), tetrahydrochysene thiazine, tetrahydrochysene thiadiazine, perhydro sulphur azepine

, perhydro sulphur diaza

, morpholine, thiomorpholine, thioxane, perhydro benzofuran, perhydro isobenzofuran, perhydro benzothiophene, perhydro isothiophene, perhydro indazole, perhydro quinoline, perhydro isoquinolin, perhydro 2,3- benzodiazines, perhydro 1,5- benzodiazines, perhydro quinoxaline, perhydro quinazoline, perhydro cinnoline, perhydro benzoxazole, perhydro benzothiazole, perhydro benzimidazole, dioxolanes, dioxane, dithiolane, the own ring of two sulphur etc..

Deng.

It is highly preferred that ring A or ring B is " undersaturated 5- to 10- person's carbocylic radical or heterocyclic radical "." undersaturated 5- to 10- person's carbocylic radical or heterocyclic radical " is " undersaturated 5- to 10- person's cyclic hydrocarbon " or " undersaturated 5- to 10- element heterocycles base ".More preferably 5- or 6- aromatic rings such as benzene, pyrroles, imidazoles, triazole, tetrazolium, pyrazoles, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furans, thiophene, oxazole, isoxazoles, thiazole, isothiazole, furazan, oxadiazoles or thiadiazoles etc..

" substituent " in " can have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical " that ring A or ring B are represented includes,For example,(1) there can be the alkyl of substituent (" alkyl can with substituent " has " alkyl can with substituent " identical implication as described above),(2) the C1-6 alkoxies that can be replaced by halogen atom are (such as,Methoxyl group,Ethyoxyl,Propoxyl group,Isopropoxy,N-butoxy,Isobutoxy,Sec-butoxy,Tert-butoxy or trifluoromethoxy),(3) (C1-4 alkoxies)-(C1-4 alkyl) group such as methoxy ethyl etc.,(4) phenoxy group,(5) C1-8 alkanoyls such as formoxyl,Acetyl group,Propiono,Positive bytyry,Iso- bytyry or cyclohexyl-carbonyl etc.,(6) benzoyl,(7) C1-8 alkanoyloxies such as formyloxy,Acetoxyl group,Propionyloxy,Positive butyryl acyloxy,Iso- butyryl acyloxy or cyclohexyl carbonyloxy group etc.,Or benzoyloxy,(8) carboxyl,(9) C2-7 alkoxy carbonyls such as methoxycarbonyl,Ethoxy carbonyl,Positive propoxy carbonyl,Iso- propoxycarbonyl,N-butoxycarbonyl,Isobutoxy carbonyl,Tert-butoxycarbonyl etc.),(10) carbamoyl,(11) mono--C1-4 alkyl-carbamoyls of N- such as N- methylcarbamoyls,N- ethylaminocarbonyls,N- propvlcarbamovls,N- isopropylcarbamoyls or N- Butylcarbamoyls etc.,(12)N,- C1-4 alkyl-carbamoyls such as the N of N- bis-,N- formyl-dimethylaminos,N,N- diethylamino formoxyls,N,N- dipropylaminos formoxyl or N,N- dibutylamino formoxyls etc.,(13) amino carbonyl of ring-type such as 1- aziridinyls carbonyl,1- azelidinyl carbonyls,1- pyrrolidinylcarbonyls,1- piperidino carbonyls,N methyl piperazine base carbonyl,Morpholino carbonyl etc.,(14) halogen atom such as fluorine,Chlorine,Bromine or iodine,(15) single-,Two-or three-halo-C1-4 alkyl such as chloromethyl,Dichloromethyl,Trifluoromethyl or trifluoroethyl etc.,(16) oxo group,(17) amidino groups,(18) imido grpup,(19) amino,(20) single-C1-4 alkyl aminos such as methylamino,Ethylamino,Propylcarbamic,Isopropylamino or butylamino etc.,(21) two-C1-4 alkyl aminos such as dimethylaminos,Diethylamino,Dipropylamino,Diisopropylaminoethyl or dibutylamino etc.,(22) amino of 3-~6- person's ring-type,In addition to a nitrogen-atoms,It includes carbon atom and 1~3 is selected from oxygen,The hetero atom of sulphur and nitrogen is (such as,Aziridinyl,Azelidinyl,Pyrrolidinyl,Pyrrolinyl,Pyrrole radicals,Imidazole radicals,Pyrazolyl,Imidazolidinyl,Piperidino (piperidino),Morpholino,Dihydropyridine base,Pyridine radicals,N methyl piperazine base or NEP base (piperadinyl) etc.),(23) C 1-8 alkyl amides such as formamide,Acetamide,Trifluoroacetamide,Propionamide,Butyramide,Isobutyramide,Cyclohexylcarbonylamino etc.,(24) benzamido,(25) carbamoylamino,(26) N-C1-4 alkyl-carbamoyls amino such as N- methylcarbamoyls amino,N- ethylaminocarbonyl amino,N- propylcarbamoylaminos,N- isopropylcarbamoyl amino,N- Butylcarbamoyl amino etc.,(27)N,- C 1-4 alkyl-carbamoyls amino such as the N of N- bis-,N- formyl-dimethylamino amino,N,N- diethylamino Formylaminos,N,N- dipropylamino Formylaminos,N,N- dibutylamino Formylaminos etc.,(28) C1-3 alkylenedioxy groups such as methylenedioxy or ethylene epoxide etc.,(29)-B(OH)₂(30) hydroxyl, (31) epoxy radicals, (32) nitro, (33) cyano group, (34) sulfydryl, (35) sulfonic group base, (36) sulfinic acid base base, (37) phosphonate group, (38) sulfamoyl, (39) C1-6 monoalkyls sulfamoyl such as N- Methylsulfamoyls, N- ethylsulfamovls, N- propylsulfamovs, N- isopropylsulfamoyls base or N- Butylsulfamoyl bases etc., (40) two-C1-4 alkylsulfamoyl groups such as N, N- DimethylsuIfamoyls, N, N- diethyl amino sulfonyl, N, N- dipropyl sulfamoyl or N, N- dibutylamine sulfonyl etc., (41) C1-6 alkylthio groups such as methyl mercapto, ethylmercapto group, rosickyite base, isopropyisulfanyl, positive butylthio, secondary butylthio or tertiary butylthio etc., (42) thiophenyl, (43) C1-6 alkyl sulphinyls, such as methylsulfinyl, ethylsulfinyl, propylsulfenyl or butylsulfinyl etc., (44) phenylsufinyl, (45) C1-6 alkyl sulphonyls such as mesyl, ethylsulfonyl, sulfonyl propyl base or butyl sulfonyl etc., (46) phenyl sulfonyl, or (47) azido etc., 1~10 above-mentioned substituent can the interchangeable position substitution on ring A and ring B.When the number of substituent is 2 or more, each substituent is identical or different.Preferred substituent in ring A and ring B is can have alkyl, alkoxy, carboxyl or alkyl amide of substituent etc., and more preferably alkyl or alkoxy.

" nitrogen heterocyclic ring " in " can have the 3- of substituent to 15- person's nitrogen heterocycle " that ring D is represented refers to beyond carbon atom, can be comprising 1~3 the heteroatomic heterocycle selected from nitrogen, oxygen and sulphur atom in addition at least one nitrogen-atoms." 3- to 15- person's nitrogen heterocyclic ring " includes " undersaturated 3- to 15- person's nitrogen heterocyclic ring " and " 3- of saturation to 15- person's nitrogen heterocyclic ring ".

" undersaturated 3- to 15- person's nitrogen heterocyclic ring " includes, for example, pyrroles, imidazoles, triazole, tetrazolium, pyrazoles, indoles, iso-indoles, indazole, purine, benzimidazole, benzo-aza

, benzodiazepine

BTA, carbazole, B-carboline, phenthazine, phenoxazine, perimidine, pyrrolin, imidazoline, triazoline, four oxazolines, pyrazoline, dihydropyridine, tetrahydropyridine, dihydro pyrazine, tetrahydrochysene pyrazine, dihydro-pyrimidin, tetrahydropyrimidine, dihydrogen dazin, tetrahydro pyridazine, dihydro azepine

, tetrahydrochysene azepine

Dihydro diaza

, tetrahydrochysene diaza

Tetrahydrochysene oxazepine

, dihydro oxa- diaza

, tetrahydrochysene oxa- diaza, thiodiazoline, dihydro thiazine, dihydro thiadiazine, dihydro sulphur azepine

, dihydro sulphur diaza

, tetrahydrochysene sulphur diaza

Indoline, isoindoline, dihydro-indazol, EEDQ, tetrahydroquinoline, dihydro-isoquinoline, tetrahydroisoquinoline, dihydro 2,3- benzodiazines, tetrahydrochysene 2,3- benzodiazines, dihydro 1,5- benzodiazines, tetrahydrochysene 1,5- benzodiazines, dihydro-quinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydro quinazoline, dihydro cinnoline, tetrahydrochysene cinnoline, Er hydrogen benzoxazine, dihydrobenzo thiazine, pyrazolo morpholine, Er hydrogen benzoxazole, dihydro-benzothiazole, dihydrobenzo imidazoles, dihydrobenzo azepine

, tetrahydro benzo azepine

Dihydrobenzo diaza

, tetrahydro benzo diaza

, dihydrobenzo oxazepine

, tetrahydro benzo oxazepine, dihydro carbazole, tetrahydro carbazole, acridan, tetrahydro acridine etc.." 3- of saturation to 15- person's nitrogen heterocyclic ring " includes, for example, aziridine, azetidine, Fang Xinyin, pyrrolidines, imidazolidine, triazolidine, four oxazolidines, pyrazolidine, piperidines, piperazine, perhydro pyrimidine, perhydro pyridazine, perhydroazepinyl, perhydro diaza

, perhydro oxa- diaza

, thiodiazolidine (thiadiazolidine), tetrahydrochysene thiazine, tetrahydrochysene thiadiazine, tetrahydrochysene sulphur azepine

, perhydro sulphur azepine

Perhydro sulphur diaza

, morpholine, thiomorpholine, perhydro indazole, perhydro quinoline, perhydro isoquinolin, perhydro 2,3- benzodiazines, perhydro 1,5- benzodiazines, perhydro quinoxaline, perhydro quinazoline, perhydro cinnoline, perhydro benzoxazole, perhydro benzothiazole, perhydro benzimidazole, perhydro carbazole, perhydro acridine,

Deng.

It is preferred that " 3- to 15- person's nitrogen heterocyclic ring " be " 5- to 10- person's nitrogen heterocyclic ring "." undersaturated 5- to 10- person's nitrogen heterocyclic ring " includes, for example, pyrroles, imidazoles, triazole, tetrazolium, pyrazoles, indoles, iso-indoles, indazole, purine, benzimidazole, BTA, pyrrolin, imidazoline, triazoline, four oxazolines, pyrazoline, dihydropyridine, tetrahydropyridine, dihydro pyrazine, tetrahydrochysene pyrazine, dihydro-pyrimidin, tetrahydropyrimidine, dihydrogen dazin, tetrahydro pyridazine, dihydro azepine

, tetrahydrochysene azepine

, dihydro diaza

Tetrahydrochysene diaza

, tetrahydrochysene oxazepine

Dihydro oxa- diaza, tetrahydrochysene oxa- diaza

, thiodiazoline, dihydro thiazine, dihydro thiadiazine, dihydro sulphur azepine

, tetrahydrochysene sulphur azepine

, dihydro sulphur diaza

, tetrahydrochysene sulphur diaza

Indoline, isoindoline, dihydro-indazol, EEDQ, tetrahydroquinoline, dihydro-isoquinoline, tetrahydroisoquinoline, dihydro 2,3- benzodiazines, tetrahydrochysene 2,3- benzodiazines, dihydro 1,5- benzodiazines, tetrahydrochysene 1,5- benzodiazines, dihydro-quinoxaline, tetrahydroquinoxaline, dihydroquinazoline, tetrahydro quinazoline, dihydro cinnoline, tetrahydrochysene cinnoline, Er hydrogen benzoxazine, dihydrobenzo thiazine, pyrazolo morpholine, Er hydrogen benzoxazole, dihydro-benzothiazole, dihydrobenzo imidazoles etc.." heterocycles of the 5- to 10- person containing nitrification " includes, for example, Fang Xinyin, pyrrolidines, imidazolidine, triazolidine, four oxazolidines, pyrazolidine, piperidines, piperazine, perhydro pyrimidine, perhydro pyridazine, perhydroazepinyl

, perhydro diaza

, perhydro oxa- diaza

, thiodiazolidine (thiadiazolidine), tetrahydrochysene thiazine, tetrahydrochysene thiadiazine, perhydro sulphur azepine, perhydro sulphur diaza

, morpholine, thiomorpholine, perhydro indazole, perhydro quinoline, perhydro isoquinolin, perhydro 2,3- benzodiazines, perhydro 1,5- benzodiazines, perhydro quinoxaline, perhydro quinazoline, perhydro cinnoline, perhydro benzoxazole, perhydro benzothiazole, perhydro benzimidazole,

Deng.

Furthermore it is preferred that " nitrogen heterocyclic ring " be piperidines or piperazine.More preferably piperidines.

" substituent " in " can have the 3- of substituent to 15- person's nitrogen heterocycle " that ring D is represented can have " substituent " in " can the 3- with substituent to 15- person's carbocylic radical or heterocyclic radical " that represented such as above-mentioned ring A and ring B same implication.

Preferably, ring D replaces without substituent or by the alkyl with substituent, single-C1-4 alkyl aminos or two-C1-4 alkyl aminos etc..It is highly preferred that ring D does not have substituent.

R²" alkyl " in " alkyl can with substituent " that represents has such as R¹" alkyl can with substituent " identical implication defined in " protection group " of " can protected acidic-group " that represents.It is preferred that R²" alkyl can with substituent " represented is the alkyl replaced by oxo group or (C3-8 cycloalkyl)-(the C1-4 alkyl) replaced by oxo group.

In R²In, " can protected hydroxyl " be " hydroxyl " that can be protected by " protection group "." protection group " of hydroxyl includes, for example, (1) C1-6 alkyl (e.g., methyl, ethyl or n-propyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (2) C6-10 aryl (e.g., phenyl or naphthyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (3) C7-12 aralkyl (e.g., benzyl, phenylethyl or naphthyl methyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (4) formoxyl, (5) C1-6 alkyl-carbonyl (e.g., acetyl group or propiono etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (6) C6-10 aryl-Epoxide carbonyl (e.g., phenyloxycarbonyl or naphthoxycarbonyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (7) C6-10 aryl-carbonyl (e.g., benzoyl or naphthyl carbonyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (8) C7-12 aralkyl-carbonyl (e.g., benzyloxycarbonyl group or phenylethylcarbonyl etc.), it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., (9) pyranose or furyl, it can have 1~4 and be selected from halogen atom such as chlorine, bromine or fluorine etc.；C1-6 alkyl such as methyl, ethyl or n-propyl etc.；C6-10 aryl such as phenyl or naphthyl etc.；C7-12 aralkyl such as benzyl or phenylethyl etc.；And the substituent of nitro etc., or (10) three-C1-4 aIkylsilyl groups such as trimethyl silyls or triethylsilyl etc..

R²" substituent " in " amino can with substituent " that represents includes the alkyl ,-SO can with substituent₂R²⁰¹,=NR²⁰²、-OR²⁰³(wherein R²⁰¹-R²⁰³For that can have the alkyl of substituent) etc.." alkyl can with substituent " has such as R¹" alkyl can with substituent " defined in " protection group " of " can protected acidic-group " that represents same implication.R²Preferred " substituent " of the amino of substituent " can have " be " can the alkyl with substituent ".

R²" can have the 3- of substituent to 15- element heterocycles base " represented has " can have the 3- of substituent to 15- element heterocycles base " the identical implication represented such as ring A or ring B.It is preferred that R²" can have the 3- of substituent to 15- element heterocycles base " represented is can have the piperidines or piperazine of substituent and more preferably

(wherein arrow represents the bonding position with ring D, and R³¹、R³²、R³³And R³⁴" substituent " the identical implication of " can the 3- with substituent to 15- element heterocycles base " that has that such as ring A or ring B represent independently of one another).

It is preferred that R²For, for example, can have the alkyl of substituent or can have amino of substituent etc., and more preferably

(wherein arrow represents the bonding position with ring D, and R⁵¹、R⁵²、R⁵³And R⁵⁴Be each independently hydrogen atom, can have substituent alkyl, can have substituent 3- to 15- element heterocycles base, can have substituent C1-4 alkoxies, can have substituent phenoxy group or can have substituent benzyloxy) etc..The alkyl of substituent " can have " and " can have the 3- of substituent to 15- element heterocycles base " has the same implication as above recorded respectively.C1-4 alkoxies include, for example, methoxyl group, ethyoxyl, propoxyl group, isopropoxy, butoxy, isobutoxy, sec-butoxy or butoxy etc..C1-4 alkoxies, phenoxy group or benzyloxy can have optional substituent.The substituent of C1-4 alkoxies, phenoxy group or benzyloxy includes, for example, " substituent " of above-mentioned " alkyl can with substituent ".

Preferably, R⁵¹、R⁵²、R⁵³Or R⁵⁴For hydrogen atom, there can be the alkyl of substituent or there can be the 3- of substituent to 15- element heterocycle bases etc..In addition, wherein R⁵²And R⁵³Any of for the compound of hydrogen atom be preferred.

In the present invention, including above-mentioned preferred group and ring combination formula (I) represent compound be preferred.For example, its middle ring D is piperidines or piperazine and Y is the compound of methylene, i.e. the compound that formula (Ia) is represented

(its middle ring D^1aFor that can have the piperidines or piperazine and other symbols of substituent that there is the identical implication with foregoing description)；Compound, its middle ring D is piperidines or piperazine, R²For

That is, the compound that formula (Ib) is represented

(wherein all symbols have the identical implication with foregoing description)；Compound, wherein R¹For-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴, X is key ,-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- ,-C (=N-OR¹⁰)-(wherein R⁷And R⁸It is each independently hydrogen atom, C1-4 alkyl ,-OR¹¹Or phenyl, R⁹For hydrogen atom, C1-4 alkyl or phenyls, R¹⁰And R¹¹It is each independently hydrogen atom or C1-4 alkyl), Y is methylene, and ring A and ring B are each independently the benzene can with substituent, and ring D is piperidines and R²For

That is, the compound that formula (Ic) is represented

(wherein R^1-1aFor-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴, X^1aFor key ,-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- ,-C (=N-OR¹⁰)-(wherein R⁷And R⁸It is each independently hydrogen atom, C1-4 alkyl ,-OR¹¹Or phenyl, R⁹For hydrogen atom, C1-4 alkyl or phenyls, R¹⁰And R¹¹It is each independently hydrogen atom or C1-4 alkyl), ring A^1aWith ring B^1aIt is each independently the benzene can with substituent, ring D^1bFor that can have the piperidines and other symbols of substituent that there is the identical implication with foregoing description)；Or compound, wherein R¹For-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴, X is key ,-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- ,-C (=N-OR¹⁰)-(wherein R⁷And R⁸It is each independently hydrogen atom, C1-4 alkyl ,-OR¹¹Or phenyl, R⁹For hydrogen atom, C1-4 alkyl or phenyls, R¹⁰And R¹¹It is each independently hydrogen atom or C1-4 alkyl), Y is methylene, and ring A and ring B are each independently the benzene or undersaturated list-heterocyclic radical can with substituent, and ring D is piperidines or piperazine, R²For

That is, the compound that formula (Id) is represented

(its middle ring A^1bWith ring B^1bThe benzene or 5- or 6- person's aromatic rings and other symbols of substituent can be had with the identical implication with foregoing description by being each independently) etc. be preferred.

Specifically, compound of the invention is included in the compound described in embodiment, or

2- [3- methyl -4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperazine -1- bases]-N- phenyl caproamides,

N- { 4- [4- ({ 4- [(anilinocarbonyl) (butyl) amino] -4 '-methyl isophthalic acid, 4 '-connection piperidines -1 '-yl } methyl) phenoxy group] phenyl } Methanesulfomide,

N- [4- (4- { [3- [(anilinocarbonyl) (butyl) amino] -4- (3- fluorophenyls) pyrrolidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [3- (butylamino) -4- (3- fluorophenyls) pyrrolidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- butyl-N- (1- { 3- ethyls -1- [4- (mesyl) benzyl] -1H- pyrazoles -4- bases } piperidin-4-yl)-N '-phenylurea,

N- butyl-N- [1- ({ 4- methyl -2- [4- (trifluoromethyl) phenyl] -1H- imidazoles -5- bases } methyl) piperidin-4-yl]-N '-phenylurea,

N- { 4- [4- ({ 3- [(anilinocarbonyl) (butyl) amino] -8- azabicyclics [3.2.1] octyl- 8- yls } methyl) phenoxy group] phenyl } Methanesulfomide,

N- [4- (4- { [4- (3- isopropyl -5- methyl -4H-1,2,4- triazole-4-yls) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- (2- methyl isophthalic acid H- benzimidazole -1- bases) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- [(anilinocarbonyl) (butyl) amino] -3,4- EEDQs -1 (2H)-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- ((the 2H)-yl of 2- oxo -3- phenyl -6- propyl group tetrahydropyrimidine -1) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- (4- { 4- [(3- butyl -2- oxos -1,2,3,3a, 4,5- hexahydro -6H- pyridos [4,3,2-de] quinazoline -6- bases) methyl] phenoxy group } phenyl) Methanesulfomide,

N- (4- { 4- [(1- butyl -2- oxos -4- phenyl octahydro pyrido [4,3-d] pyrimidine -6 (2H)-yl) methyl] phenoxy group } phenyl) Methanesulfomide,

N- { 4- [4- ({ 8- [(anilinocarbonyl) (butyl) amino] -3- azabicyclics [3.2.1] oct-3-yl } methyl) phenoxy group] phenyl } Methanesulfomide,

N- [4- (4- { [(2Z) -1- butyl -2- (phenyl imine base) hexahydro -2H- pyridos [4,3-d] [(the 4H)-yl of 1,3] oxazines -6] methyl } phenoxy group) phenyl] Methanesulfomides or

N- [7- ({ 4- [(anilinocarbonyl) (butyl) amino] piperidin-1-yl } methyl) -9H- xanthenes (xanthen) -2- bases] Methanesulfomide etc..

Particularly preferably in the compound described in embodiment, its salt and its solvate and its prodrug.

More preferably

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- (butyl { [(6- methyl -3- pyridine radicals) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } -3,5- dimethyl -1H- pyrazol-1-yls) phenyl] Methanesulfomide,

N- [4- (4- { [4- (butyl { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] benzamide,

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (phenyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide,

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2- fluorobenzamides,

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorobenzamides,

N- [4- (4- { [4- (butyl { [(3- cyano group -4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide,

N- [4- (4- { [4- (butyl { [(3- hydroxy-cyclohexyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomides or

Its salt and its solvate, and its prodrug.

Unless otherwise indicated, all isomers are included in the present invention.For example, alkyl, alkenyl, alkynyl, alkoxy, alkylthio group, alkylidene, alkylene group and alkynylene include the group of straight or branched.In addition, from double bond, ring, condensed ring isomers (E-, Z-, cis-, trans-isomer), isomers (R-, the S- isomers from asymmetric carbon atom, α-, β-conformation, enantiomer, diastereomer), optical activity isomer (D-, L-, d-, l- isomers), polar compound (the big compound of polarity from chromatographic isolation, the small compound of polarity), equilibrium mixture, rotational isomer, the mixture of its arbitrary proportion, and racemic mixture are also included in the present invention.

In the present invention, unless otherwise indicated, it will be apparent to those skilled in the art that symbol

The back side (i.e. α-configuration) of the bonding direction as paper is represented,

It is (i.e. beta configuration) before paper to represent bonding direction,Represent the mixture of α-configuration and beta configuration.

The compound of the present invention can change into corresponding salt by conventional method.Described salt is preferably the acceptable salt of pharmacology.

Described salt includes alkali metal salt, alkali salt, ammonium salt, amine salt and acid-addition salts etc..

It is preferred that water soluble salt.Suitable salt is, for example, alkali metal (such as potassium and sodium) salt, alkaline-earth metal (such as calcium and magnesium) salt, ammonium salt, and pharmaceutically acceptable organic amine (such as tetramethyl-ammonium, triethylamine, methyl amine, dimethyl amine, cyclopenta amine, benzyl amine, phenethyl amine, piperidines, monoethanolamine, diethanol amine, three (methylol) aminomethanes, lysine, arginine and N- methyl-D-glucosamines) salt.

It is preferred that acid-addition salts be water soluble salt.Suitable acid-addition salts are, for example, the salt of inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid, and organic acid such as acetic acid, lactic acid, tartaric acid, benzoic acid, citric acid, methanesulfonic acid, ethyl sulfonic acid, benzene sulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid salt.

Compound and its salt shown in formula (1) can change into corresponding solvate.

It is preferred that solvate be nontoxic water soluble salt.Suitable solvate is, for example, the solvate of water and alcohol (such as ethanol).

Compound or the acceptable salt of its pharmacology shown in all formulas (I) are all preferred, and compound or the acceptable salt of its pharmacology specifically described in embodiment are preferred.

The quaternary ammonium salt of compound shown in formula (I) is the nitrogen of compound shown in formula (I) by R⁰Quaternized compound.

R⁰For C1-8 alkyl or the C1-8 alkyl being substituted by phenyl.

The N- oxides of compound shown in formula (I) are the oxidized compounds of nitrogen of compound shown in formula (I).

The prodrug of formula (I) compound refers to the compound that an accepted way of doing sth (I) compound is converted by using the reaction of the enzyme in live body, hydrochloric acid in gastric juice etc..For example; prodrug on formula (I) compound; when formula (I) compound has amino; compound amino quilt therein; for example; acylation, alkylation or phosphorylated are (such as; compound; the amino of wherein formula (I) compound is acylated by eicosane, alanyl, pentyl amino carbonylation; (5- methyl -2- oxo -1,3- dioxo amylene -4- bases) methoxycarbonyl, tetrahydrofuran, pyrrol ylmethyl, oxy acid methyl neopentyl, acetoxymethylated, tert-butylation etc.)；When the compound of formula (I) has hydroxyl; compound hydroxyl quilt therein; for example; acylated, alkylation, phosphorylation or boration (e.g., the hydroxyl of compound wherein formula (I) compound is carbonylated by acetylating, palmitoylation, propionating, pivaloyl, succinylation, fumarylated, alanyl or dimethylaminomethyl)；And the carboxyl quilt of formula (I) compound, for example, esterification or amidatioon are (such as, compound, the carboxyl of formula (I) compound is prepared into ethyl ester, phenylester, phenylethylester, carboxymethyl ester, dimethylaminomethyl ester, oxy acid methyl neopentyl ester, ethoxycarbonyloxyethyl ester, 2- benzos [c] furanone base ester, (5- methyl -2- oxo -1,3- dioxo amylene -4- bases) methyl ester, cyclohexyloxy carbonyl ethyl ester or methyl nitrosourea).These compounds can be prepared with method known per se.The prodrug of formula (I) compound can be hydrate or non-hydrate.The prodrug of formula (I) compound is alternatively the compound for converting an accepted way of doing sth (I) compound in physiological conditions, such as exist " Iyakuhin no kaihatsu; Vol.7 (Bunshi-sekkei); described in pp.163-198 (Hirokawa-Shoten), 1990 ".And formula (I) compound can be also marked (such as with radio isotope³H、¹⁴C、³⁵S、¹²⁵I etc.).

The preparation method of the compounds of this invention：

The compound that formula (I) of the present invention is represented can be prepared by the method and the known method of combination being suitably modified, as using the method described in method as described below, embodiment or in Comprehensive Organic Transformations：Method described in A Guide to Functional GroupPreparations, 2nd Edition (Richard C.Larock, John Wiley＆Sons Inc, 1999).In various methods described below, initial substance can be used in its salt form.The example of the salt includes the salt of above-mentioned formula (I) compound.

In the compound that formula (I) is represented, wherein the interval base adjacent with ring D is-CH₂- ,-CO- or-SO₂- compound can be by being prepared to alkylation, amidatioon or sulfuryl amine that formula (II) is represented

(wherein Z is hydroxyl or leaving group (e.g., halogen atom, p- tosyloxies, methanesulfonyloxy group, trifluorometanesulfonyloxy etc.), Y¹' key or to be used as the interval base of main chain, Y comprising 1 or 2 atom²' it is-CH₂- ,-CO- or-SO₂-, and R¹', X ', ring A ' and ring B ' there is same R respectively¹, X, ring A and the same implications of ring B.Condition is, if necessary, R¹', X ', ring A ' or carboxyl, hydroxyl, amino or sulfydryl in ring B ' can be protected.Other symbols have and foregoing description identical implication) and

The compound that formula (III) is represented

(wherein R²' there is same R respectively with ring D '²With D identical implications.Condition is, if necessary R²' or carboxyl, hydroxyl, amino or sulfydryl in ring D ' can be protected), if necessary, then remove protection group.

Alkylation is known.For example, can be carried out in organic solvent (e.g., dimethyl sulfoxide (DMSO)) under conditions of alkali (e.g., potassium carbonate or sodium carbonate) and sodium iodide or KI are present in 0~150 DEG C of temperature range.

Amidation method is known.E.g., including following methods

(1) by carboxylic acid halides,

(2) by mixing acid anhydrides,

(3) condensing agent is utilized.

These methods are explained as follows.

(1) by the method for carboxylic acid halides can for example by by carboxylic acid and carboxylic acid halides (such as, oxalyl chloride or thionyl chloride) carried out in organic solvent (e.g., chloroform, dichloromethane, ether or tetrahydrofuran) or under the conditions of solvent-free under -20 DEG C to reflux temperature.And the acyl halide derivative then obtained can with amine in organic solvent (such as, chloroform, dichloromethane, ether or tetrahydrofuran) in the presence of alkali (e.g., pyridine, triethylamine, dimethylaniline, dimethyl aminopyridine or diisopropyl ethyl amine etc.) 0~40 DEG C reaction.Or, obtained chloride derivative can be reacted in organic solvent (e.g., dioxane, tetrahydrofuran) with amine using alkaline aqueous solution (e.g., sodium acid carbonate, sodium hydroxide) at 0~40 DEG C.

(2) it can be carried out as follows by mixing the method for acid anhydrides, for example, by by carboxylic acid and carboxylic acid halides (such as, pivalyl chloride, toluene sulfochloride or mesyl chloride) or acid derivative is (such as, ethyl chloroformate or isobutyl chlorocarbonate) in organic solvent (such as, chloroform, dichloromethane, ether, tetrahydrofuran) in or without solvent, in alkali (such as, pyridine/triethylamine, dimethylaniline, dimethyl aminopyridine or diisopropyl ethyl amine) in the presence of 0~40 DEG C progress.And then by obtained mixing anhydride ester derivs can with amine in organic solvent (e.g., chloroform, dichloromethane, ether or tetrahydrofuran) 0~40 DEG C progress.

(3) it can be carried out in the following manner using the method for condensing agent, for example, by formic acid and amine in organic solvent (such as, chloroform, dichloromethane, dimethylformamide, ether or tetrahydrofuran) in or without under solvent, presence or absence of alkali (such as, pyridine, triethylamine, dimethylaniline or dimethyl aminopyridine) under the conditions of, using condensing agent (such as, 1, 3- dicyclohexylcarbodiimides (DCC), 1- ethyls -3- [3- (dimethylamino) propyl group] carbodiimide (EDC), 1, 1 '-carbonyl dimidazoles (CDI), the chloro- 1- methyl pyridinium iodides of 2-, or 1- propane phosphonic acids cyclic anhydride (PPA)), in the presence of I-hydroxybenzotriazole (HOBt), carried out at 0~40 DEG C.

Reaction described in (1), (2) and (3) can be carried out to obtain good result under the inert gas atmosphere (e.g., argon gas, nitrogen) for avoiding water.

Sulfuryl amine is known.For example, can by by sulfonic acid and carboxylic acid halides (such as, oxalyl chloride or thionyl chloride, phosphorus pentachloride or phosphorus trichloride) in organic solvent (e.g., chloroform, dichloromethane, dichloroethanes, ether, tetrahydrofuran or methyl tertiary butyl ether(MTBE)) or it is solvent-free under -20 DEG C to reflux temperature carry out.And then by obtained sulfonic acid halide derivative can with amine in organic solvent (such as, chloroform, dichloromethane, ether or tetrahydrofuran) in the presence of alkali (e.g., diisopropyl ethyl amine, pyridine, triethylamine, dimethylaniline or dimethyl aminopyridine etc.) 0~40 DEG C progress.

The removal of protection group is known and carried out using following methods.

The protection group of carboxyl includes, for example, methyl, ethyl, pi-allyl, the tert-butyl group, trichloroethyl, benzyl (Bn) or phenacyl etc..

The protection group of hydroxyl includes, for example, methyl, trityl, methoxy (MOM), 1- ethoxyethyl groups (EE), methoxvethoxvmethvl (MEM), 2- THP trtrahydropyranyls (THP), trimethyl silyl (TMS), triethylsilyl (TES), t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS), acetyl group (Ac), valeryl, benzoyl, benzyl (Bn), to methoxy-benzyl, allyloxy carbonyl (Alloc) or 2, 2, 2- tri-chloroethoxy base carbonyls (Troc) etc..

The protection group of amino includes; for example, benzyloxycarbonyl, tert-butoxycarbonyl, allyloxy carbonyl (Alloc), 1- methyl isophthalic acids-(4- xenyls) ethoxy carbonyl (Bpoc), trifluoroacetyl group, 9- fluorenylmethoxycarbonyl groups, benzyl (Bn), to methoxy-benzyl, benzyloxymethyl (BOM) or 2- (trimethyl silyl) ethoxyl methyl (SEM) etc..

The protection group of mercaptan includes, for example, benzyl, methoxy-benzyl, methoxy (MOM), 2- THP trtrahydropyranyls (THP), diphenyl methyl or acetyl group (Ac).

Carboxyl, hydroxyl, amino or mercapto protection group in addition to including above-mentioned protection group, include other protection groups that readily selected property is removed.For example, deprotection reaction is using in T.W.Greene etc., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, the method described in 1999 is carried out.

Carboxyl, hydroxyl, the removing method of the protection group of amino or mercapto are known per se.For example,

(1) with the hydrolysis of alkali；

(2) deprotection reaction in acid condition；

(3) deprotection reaction of hydrogenolysis is utilized；

(4) deprotection reaction of silicyl；

(5) deprotection reaction of metal is utilized；And

(6) deprotection reaction of metal complex etc. is utilized.

Relevant these methods are described in detail below：

(1) can so it be carried out using the method for alkali deprotection reaction; for example; with the hydroxide (sodium hydroxide, potassium hydroxide or lithium hydroxide etc.) of alkali metal; the hydroxide (barium hydroxide or calcium hydroxide etc.) or carbonate (sodium carbonate or potassium carbonate etc.) of alkaline-earth metal; its aqueous solution or in the mixture of organic solvent (methanol, tetrahydrofuran Huo dioxanes etc.), is carried out at 0~40 DEG C.

(2) method of deprotection reaction can be carried out so in acid condition; for example; in organic solvent (dichloromethane, chloroform, dioxanes, ethyl acetate or anisole etc.); using organic acid (acetic acid, trifluoroacetic acid, methanesulfonic acid or p-methyl benzenesulfonic acid etc.) or inorganic acid (hydrochloric acid or sulfuric acid etc.) or its mixture (hydrobromic acid/acetic acid etc.), carried out at 0~100 DEG C.

(3) can so it be carried out by the method for the deprotection reaction of hydrogenolysis, for example, in solvent (ether (tetrahydrofuran, dioxane, dimethoxy-ethane or ether etc.), alcohol (methanol or ethanol etc.), benzene class (benzene or toluene etc.), ketone (acetone or methyl ethyl ketone etc.), nitrile (acetonitrile etc.), acid amides (dimethylformamide etc.), water, ethyl acetate, acetic acid, or the mixture including two or more solvents etc.) in, in catalyst (palladium carbon, palladium black, palladium dydroxide, platinum oxide or Raney nickel etc.) in the presence of, under the nitrogen atmosphere of atmospheric pressure or malleation or in the presence of ammonium formate, in progress at 0~200 DEG C.

(4) method of the deprotection reaction containing silicyl can be carried out so, for example, in organic solvent (tetrahydrofuran or acetonitrile etc.) miscible with water, with tetrabutyl ammonium fluoride, in progress at 0~40 DEG C.

(5) can so it be carried out using the method for the deprotection reaction of metal; for example; in acid flux material (acetic acid or the buffer solution that pH is 4.2~7.2; or the mixture of above-mentioned solution and organic solvent such as tetrahydrofuran) in; in the presence of zinc powder; with or without ultrasonic wave, in progress at 0~40 DEG C.

(6) can so it be carried out using the method for the deprotection reaction of metal complex, for example, in organic solvent (dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane or ethanol etc.) or water in, or in its mixture, in capture agent (tri-butyl tin hydride, triethyl silicane, dimetone, morpholine, diethylamine or pyrrolidines etc.) and organic acid (acetic acid, formic acid, 2 ethyl hexanoic acid etc.) and/or acylate (2 ethyl hexanoic acid sodium or 2 ethyl hexanoic acid potassium etc.) in the presence of, in the case of presence or absence of phosphonate reagent (triphenylphosphine etc.), with metal complex (tetrakis triphenylphosphine palladium (0), two (triphenylphosphine) palladium bichlorides (II), acid chloride (II), three (triphenylphosphine) radium chlorides (I) etc.), in progress at 0~40 DEG C.

Moreover, as other methods for removing protection groups apart from the above, T.W.Greene may refer to, Protective Groups in Organic Synthesis, Wiley, New York, 1999.

Well known to those skilled in the art to be, target compound of the invention can easily be prepared by the selection of these methods.

In the compound that formula (I) is represented, wherein R²For that can have the compound of the amino of substituent, i.e. the compound that formula (I-a) is represented

(wherein R^2-1It is that the amino and other symbols can with substituent have identical implication with foregoing description) reduction amination of the compound of the compound that is represented using formula (IV) and formula (V) expression prepares

(wherein all symbols have the identical implication with foregoing description)

(wherein R³⁰¹And R³⁰², it is identical or different, it is hydrogen atom or with " substituent " identical implication with above-mentioned the amino of substituent " can have ", and other symbols have the identical implication with foregoing description.Condition is, if necessary, R³⁰¹Or R³⁰²In carboxyl, hydroxyl, amino or sulfydryl can be protected), if necessary, then remove protection group.

Reduction amination is known.For example, can be in organic solvent (such as, dichloroethanes, dichloromethane or dimethylformamide) in tertiary amine (such as, triethylamine or diisopropyl ethyl amine) and reducing agent (e.g., sodium triacetoxy borohydride or sodium cyanoborohydride) in the presence of 0~40 DEG C progress.

The removal of protection group can be carried out using the above method.

In the compound that formula (I) is represented, compound, wherein R²For

(wherein R³⁰⁴、R³⁰⁵And R³⁰⁶Identical or different, with " substituent " identical implication with above-mentioned ring A and ring B " can have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical " represented, and other symbols are with the identical implication with foregoing description), that is, the compound that formula (I-b) is represented

The compound that (wherein all symbols have the identical implication with foregoing description) can be represented by being cyclized formula (VI) is prepared

(wherein T be C1-4 alkyl, C5-6 it is mono--carbocyclic ring, or by C5-6 it is mono--the cyclosubstituted C1-4 alkyl of carbon or 5- or 6- person's list-heterocycle comprising 1 or 2 nitrogen-atoms and/or 1 oxygen atom, R³⁰⁴′、R³⁰⁵' and R³⁰⁶' there is such as R respectively³⁰⁴、R³⁰⁵And R³⁰⁶Identical implication, and other symbols have identical implication as described above.Condition is, if necessary, R³⁰⁴′、R³⁰⁵' and R³⁰⁶' in carboxyl, hydroxyl, amino or sulfydryl can be protected), if necessary, then remove protection group.

Cyclisation is known.For example, can be in organic solvent (e.g., dichloroethanes or toluene), using tertiary amine (e.g., triethylamine or diisopropyl ethyl amine) or sour (e.g., acetic acid or trifluoroacetic acid), or without tertiary amine or acid in 60~120 DEG C of progress.The cyclisation is carried out when cracking T groups.

The removal of protection group can be carried out using the above method.

In the compound that formula (I) is represented, compound, wherein R²For

That is, the compound that formula (I-c) is represented

It is prepared by the compound that (wherein all symbols have the identical implication with foregoing description) can be represented by being cyclized formula (VII)

(wherein all symbols have the identical implication with foregoing description), if necessary, then removes protection group.

Cyclisation is known.For example, can be carried out in organic solvent (e.g., dichloroethanes or toluene) with sour (e.g., hydrochloric acid, sulfonic acid or p- toluenesulfonic acids) at 60~120 DEG C.

The removal of protection group can be carried out using the above method.

In the compound that formula (I) is represented, compound wherein R²For

That is, the compound that formula (I-d) is represented

The compound that the compound and (X) that (wherein all symbols have the identical implication with foregoing description) represents using formula (IX) are represented is prepared by following reactions

(wherein R⁵¹' there is such as R⁵¹Identical implication and other symbols have the identical implication with foregoing description.Condition is, if necessary, R⁵¹' in carboxyl, hydroxyl, amino or sulfydryl can be protected)

R⁵²′-COOH(X)

(wherein R⁵²' there is such as R⁵²Identical implication and other symbols have the identical implication with foregoing description.Condition is, when necessary, R⁵²' carboxyl, hydroxyl, amino or sulfydryl can be protected), when necessary, then remove protection group.

The reaction is known.For example, can in organic solvent (e.g., DMF, toluene or tetrahydrofuran) with alkali (e.g., pyridine, triethylamine, dimethylaniline, dimethyl aminopyridine or diisopropyl ethyl amine) 20~120 DEG C progress.

The removal of protection group can be carried out using the above method.

In addition, prepared by the reaction between the compound that the compound that formula (I-d) is represented can be represented using formula (IX) compound and formula (XI) is represented

R⁵²′-NH₂(XI)

(wherein symbol has such as above-mentioned identical implication), if necessary, then removes protection group.

The reaction is known.For example, can be carried out in organic solvent (e.g., tetrahydrofuran or DMF) in the presence of triphosgene and alkali (e.g., triethylamine) at 0~40 DEG C.In addition, it can be in organic solvent (e.g., dichloromethane or DMF) 1, with alkali (e.g., triethylamine or N-methylmorpholine) or not with alkali in 0~80 DEG C of reaction in the presence of the double -1H- imidazoles (CDI) of 1 '-carbonyl.

The removal of protection group can be carried out using the above method.

In the compound that formula (I) is represented, compound, wherein Y are methylene, i.e. the compound that following formula (I-e) is represented

It is prepared by the reduction amination for the compound that the compound and formula (III) that (wherein all symbols have the identical implication with foregoing description) can be represented by formula (XII) are represented

Reduction amination is known.For example, can be in organic solvent (such as, dichloroethanes, dichloromethane, dimethylformamide, acetic acid or its mixture) in the presence of reducing agent (e.g., sodium triacetoxy borohydride, sodium cyanoborohydride or sodium borohydride) 0~40 DEG C progress.

The removal of protection group can be carried out using the above method.

In the compound that formula (I) is represented, compound, 1 nitrogen-atoms of wherein at least is quaternary ammonium salt, i.e. formula (I-2) compound

(wherein R^1-2、R^2-2、X²、Y², ring A², ring B²With ring D²There is such as R respectively¹、R², X, Y, ring A, ring B and ring D identical implications, and N²For nitrogen-atoms.Condition is that at least one nitrogen-atoms is quaternary ammonium salt, and Q is halogen) can be by the way that formula (I) compound be prepared with the reaction of formula (VIII) compound

R⁰-Q(VIII)

(wherein R^oFor C1-4 alkyl or the C1-4 alkyl being substituted by phenyl, and Q is halogen).

The reaction is known, and can, for example, in 0~40 DEG C of progress in organic solvent (acetone, dimethylformamide or methyl ethyl ketone etc.).

In formula (I) compound, compound, 1 nitrogen of wherein at least is N- oxides, i.e. the compound of formula (I-3)

(wherein R^1-3、R^2-3、X³、Y³, ring A³, ring B³With ring D³There is same R respectively¹、R², X, Y, ring A, ring B and ring D identical implications, and N³For nitrogen-atoms.Condition is that at least one nitrogen represents N- oxides) it can be prepared by aoxidizing formula (I) compound.

The oxidation is known per se; and can so it carry out; for example; in appropriate organic solvent (dichloromethane, chloroform, benzene, hexane or tert-butyl alcohol etc.); in excessive oxidant (hydrogen peroxide, sodium metaperiodate, acyl group nitrous acid, sodium perborate, peroxidating sour (such as 3- chlorine benzylhydroperoxide or peracetic acid), OXONE (trade marks; OXONE is the abbreviation of permonosulphuric acid potassium), potassium permanganate or chromic acid etc.) in the presence of, in being carried out at 20~60 DEG C.

The compound of the present invention can be reacted or be improved by these some of reactions and be prepared.

In the compound that formula (I) is represented, the compound in addition to above-claimed cpd is easily prepared by the known method of combination, such as in Comprehensive Organic Transformations：Method described in A Guide toFunctional Group Preparations, 2nd Edition (Richard C.Larock, John Willey＆Sons Inc, 1999).

Other initial compounds or compound as reagent are known compounds, can easily be prepared by the combination of known method, such as in Comprehensive Organic Transformations：A Guide to Functional Group Preparations, 2nd Edition (Richard C.Larock, JohnWilley＆Sons Inc, or Elmer J.Rauckman et al. 1999), J.Org.Chem., vol.41, No.3, method described in 1976, p564-565 etc..

In each reaction of this specification, using the reaction of heating, road, can be carried out by water-bath, oil bath, sand bath and microwave as known for one of ordinary skill in the art.

In each reaction of this specification, the solid-phase reagent that polymer (for example, polystyrene, polyacrylamide, polypropylene or polyethylene glycol etc.) can be used to carry.

In each reaction of present specification, the product of gained can be purified by conventional technique.For example, by using the efficient liquid phase of silica gel or silicon magnesium, by thin layer layer chromatography, by ion exchange resin, by agent for capturing resin, by column chromatography, can be purified by normal pressure or vacuum distillation by washing or recrystallization.Purifying can be carried out to each reaction, can also be carried out after several reactions.

Toxicity：

The toxicity of the compound of the present invention is very low, it can be considered that the compound is pharmaceutical safety.

Medicinal application：

The compound regulation animal of the formula (I) of the present invention, the particularly effect of the CCR5 acceptors of people, so they can be used for preventing and/or treating various inflammatory disease (asthma, ephritis, nephrosis, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis etc.), immunity disease (autoimmune disease, organ-graft refection, immunosupress, psoriasis, multiple sclerosis etc.), HIV infections (Immune Deficiency Syndrome etc.), anaphylactia (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, anaphylaxis Eosinophilic Gastroenteritis etc.), ischemia-reperfusion injury, ARDS, with the shock of bacterium infection, diabetes, or metastasis of cancer etc..

For such use, compound, its salt, its hydrate or its prodrug of formula (I) of the invention can be normally administered either systemically or locally, typically oral or parenteral administration.

The dosage of administration is depended on, for example, age, body weight, disease, required therapeutic effect, method of administration and treatment duration.In adult, everyone dosage is generally 1~1000mg of oral administration, up to several times daily；And parenteral (preferably intravenously administrable) 1~100mg, up to several times daily；Or by the daily successive administration of vein 1~24 hour.

As described above, the dosage used depends on various conditions.Accordingly, there exist the situation that can be used below or above above-mentioned dosage range.

The compound of the present invention can be administered with following form, for example, the solid form of oral administration, the liquid form of oral administration, injection, liniment or the suppository of Parenteral administration.

The solid form of oral administration includes tablet agent, pill, capsule, dispersible powder and particle.Capsule includes hard shell capsules and soft capsule.

In this solid dosage forms, one or more reactive compounds can be with carrier (such as lactose, mannitol, glucose, microcrystalline cellulose or starch), binding agent (such as hydroxypropyl cellulose, polyvinylpyrrolidone or aluminosilicate magnesium), disintegrant (such as cellulose glycolic calcium), lubricant (such as magnesium stearate), stabilizer, and solution auxiliary material (such as glutamic acid or aspartic acid) mixing, and prepared according to well-known method in conventional pharmaceutical practice.When needing, these solid dosage forms can scribble coating agent (such as sugar, gelatin, hydroxypropyl cellulose or Hydroxypropyl Methylcellulose Phathalate), can also scribble two or more films.Moreover, the capsule in the capsule that the material such as gelatin that easily absorb are made can be included by being coated.

The liquid form of oral administration includes pharmaceutically acceptable solution, suspension, emulsion, syrup and elixir.In this kind of formulation, one or more reactive compounds can be dissolved, suspended or be emulsifiable in diluent (such as purified water, ethanol or its mixture) commonly used in the art.In addition, this liquid dosage form can also include some additives, such as wetting agent, suspending agent, emulsifying agent, sweetener, flavor enhancement, spices, preservative or buffer.

The injection of Parenteral administration include aseptic aqueous solution, suspension, emulsion and solid dosage forms, the solid dosage forms using it is preceding dissolving or be suspended in solvent, immediately after for injecting.In injection, one or more reactive compounds can dissolve, suspend or be emulsifiable in solvent.The solvent includes distilled water for injection, salt solution, vegetable oil, propane diols, polyethylene glycol, alcohol (such as ethanol), or its mixture.Parenteral solution can include some additives, such as stabilizer, solution assistant agent (such as glutamic acid, aspartic acid or POLYSORBATE80 (registration mark)), suspending agent, emulsifying agent, console agent, buffer, preservative.They can sterilize in final step, can also be prepared according to sterilizing methods.Sterile solid dosage forms such as lyophilized product can also be made in they, and it can immediately after be injected using being preceding dissolved in sterilized water or some other sterile diluents.

The other forms of Parenteral administration include the liquid of external application, ointment and skin liniment, inhalant, spray, suppository and the vaginal plug for vagina administration, and it includes one or more reactive compounds, and can be prepared according to known method.

Spray can include the other materials in addition to diluent, such as stabilizer (such as sodium sulphate), isotonic buffer agent (such as common salt, sodium citrate or citric acid).For the preparation of this spray, for example, it can use the method described in United States Patent (USP) 2868691 or 3095355.

Compound, its salt, its hydrate or its prodrug of the formula (I) of the present invention can be used together with other medicines, for example, the medicament (medicament for particularly preventing and/or treating AIDS) of prevention and/or treatment HIV.In this case, the medicine equally can individually or simultaneously be used with pharmaceutically acceptable excipient, binding agent, disintegrant, lubricant, stabilizer, solubilizer, diluent etc., so that pharmaceutical preparation is made, moreover, its can as prevent and/or treatment HIV pharmaceutical composition is oral or parenteral.

Compound, its salt, its hydrate or its prodrug of the formula (I) of the present invention, the HIV-I of resistance is obtained to the medicament (medicament for particularly preventing and/or treating AIDS) obtained to other preventions and/or treatment HIV, with infection inhibitory activity.Therefore, it can be also used for the medicine of other preventions and/or treatment HIV to its no longer valid HIV- infected patient.In this case, although can be used alone the compound of the present invention, its medicament or other medicines that the HIV of resistance can also be obtained with the HIV-1 bacterial strains prevented and/or treatment is infected are used together.

The drug regimen of the present invention compound, its salt, its hydrate or its prodrug including formula (I) with not suppressing HIV, thus makes prevention and/or the effect for the treatment of HIV obtain enhanced situation than unitary agent.

Include with the example for being used to prevent and/or treat the other medicines of HIV that compound, its salt, its hydrate or its prodrug composition of the formula (I) of the present invention are used：RTI, protease inhibitors, chemokine antagonists (such as CCR2 antagonists, CCR3 antagonists, CCR4 antagonists, CCR5 antagonists and CXCR4 antagonists), fusion inhibitor, the antibody of HIV-1 surface antigens and HIV-1 vaccine.

RTI is in particular (1) nucleosides/NRTI：Retrovir (the name of an article：Retrovir), the retrovir (name of an article：Videx), the zalcitabine (name of an article：HIVID), the stavudine (name of an article：Zerit), the Lamivudine (name of an article：Epivir), the Abacavir (name of an article：Ziagen), adefovirdipivoxil, adefovir dipivoxil, the emtricitabine (name of an article：) or the PMPA (names of an article Coviracil：Tenofovir) etc.；And (2) non-nucleoside reverse transcriptase inhibitor：NVP (the name of an article：Viramune), the delavirdine (name of an article：Rescriptor), the delavirdine (name of an article：Sustiva, Stocklin) or capravirine (AG1549) etc..

Protease inhibitors is in particular the indinavir (name of an article：Crixivan), the Ritonavir (name of an article：Norvir), the nelfinavir (name of an article：Viracept), the inverase (name of an article：Invirase, Fortovase), the amprenavir (name of an article：Agenerase), the Lopinavir (name of an article：) or tipranavir etc. Kaletra.

It is used as the inside part of chemokine antagonists, including chemokine receptors, its derivative, the antibody of non-peptide micromolecular compound or chemokine receptors.

The inside part of chemokine receptors is in particular MIP-1 α, MIP-1 β, RANTES, SDF-1 α, SDF-1 β, MCP-1, MCP-2, MCP-4, eotaxin and MDC etc..

The derivative of internal part is in particular AOP-RANTES, Met-SDF-1 α, Met-SDF-1 β etc..

It is Pro-140 etc. the antibody specific of chemokine receptors.

The instantiation of CCR2 antagonists is shown in WO99/07351, WO99/40913, WO00/46195, WO00/46196, WO00/46197, WO00/46198, WO00/46199, WO00/69432 or WO00/69815 specification, or sees Bioorg.Med.Chem.Lett.,10, 1803 (2000) etc..

The instantiation of CCR3 antagonists is shown in DE19837386, WO99/55324, WO99/55330, WO00/04003, WO00/27800, WO00/27835, WO00/27843, WO00/29377, WO00/31032, WO00/31033, WO00/34278, WO00/35449, WO00/35451, WO00/35452, WO00/35453, WO00/35454, WO00/35876, WO00/35877, WO00/41685, WO00/51607, WO00/51608, WO00/51609, WO00/51610, WO00/53172, WO00/53600, WO00/58305, WO00/59497, WO00/59498, WO00/59502, WO00/59503, WO00/62814, WO00/73327 or WO01/09088 etc. specification.

CCR5 antagonists are in particular TAK-779, SCH-351125 (SCH-C), SCH-417690 (SCH-D), UK-427857, GW873140A (ONO-4128), TAK-220 etc..In addition, it is additionally included in specification WO99/17773, WO99/32100, WO00/06085, WO00/06146, WO00/10965, WO00/06153, WO00/21916, WO00/37455, EP1013276, WO00/38680, WO00/39125, WO00/40239, WO00/42045, WO00/53175, WO00/42852, WO00/66551, WO00/66558, WO00/66559, WO00/66141, WO00/68203, JP2000309598, WO00/51607, WO00/51608, WO00/51609, WO00/51610, WO00/56729, WO00/59497, WO00/59498, WO00/59502, WO00/59503, WO00/76933, WO98/25605, WO99/04794 or WO99/38514, or in Bioorg.Med.Chem.Lett.,10, the compound described in 1803 (2000) etc..

Compound described in specification of the instantiation of CXCR4 antagonists for AMD-3100, AMD-070, T-22, KRH-1120, KRH-1636 or WO00/66112 etc..

The instantiation of fusion inhibitor is T-20 (pentafuside) and T-1249 etc..

The example of combinations thereof medicament is used to illustrate the present invention, is not limitation of the present invention.

The representative instance of the general dosage level of following RTI or protease inhibitors clinical tests is used to illustrate the present invention, is not limitation of the present invention.

Retrovir：100mg capsules, each dosage of 200mg, three times a day；300mg tablets, each dosage of 300mg, twice daily；

Didanosine：25~200mg tablets, each dosage of 125~200mg, twice daily；

Zalcitabine：0.375~0.75mg tablets, each dosage of 0.75mg, three times a day；

Stavudine：15~40mg capsules, each dosage of 30~40mg, twice daily；

Lamivudine：150mg tablets, each dosage of 150mg, twice daily；

Abacavir：300mg tablets, each dosage of 300mg, twice daily；

NVP：200mg tablets, each dosage of 200mg, 14 days once a day, then twice daily；

Delavirdine：100mg tablets, each dosage of 400mg, three times a day；

Efavirenz：50~200mg capsules, each dosage of 600mg, once a day；

Indinavir：200~400mg capsules, each dosage of 800mg, three times a day；

Ritonavir：100mg capsules, each dosage of 600mg, twice daily；

Nelfinavir：250mg tablets, each dosage of 750mg, three times a day；

Inverase：200mg capsules, 1,200mg each dosage, three times a day；

Amprenavir：50~150mg tablets, 1,200mg each dosage, twice daily.

The effect of the present invention

The compound that the formula (I) of the present invention is represented has CCR5 antagonisms, therefore they can be used for the disease that prevention and/treatment are intervened by CCR5 acceptors.

The best mode carried out an invention

The present invention is illustrated based on reference example, embodiment, biological example or preparation example, but the invention is not limited in this.

In chromatographic isolation and TLC, the solvent in bracket gives the volume ratio of eluting solvent and developing solvent and solvent for use.

Unless otherwise indicated, NMR data is¹H-NMR data.

The solvent in bracket in NMR gives the solvent used in measurement.

All compounds described in this manual utilize ACD/Name (registration marks, ver.6.0, Advanced Chemistry Development Inc.) or ACD/Name Batch (registration marks, ver.4.5, Advanced Chemistry Development Inc.) name, or be named according to IUPAC naming systems.For example, the compound that following formula is represented

It is named as N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] cyclohexane carboxamide hydrochloride.

Embodiment 1：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) piperidines -4- alcohol

4- hydroxy piperidines (1.74g) and acetic acid (2.5mL) are added in dimethylformamide (25mL) solution to 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehyde (2.50g), and solution is stirred.Sodium triacetoxy borohydride (2.18g) is added into reaction solution and stirs solution 2 days.Complete after reaction, reaction solution is neutralized into 2N sodium hydrate aqueous solutions and is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated over magnesium sulfate.Obtained residue is purified through silica gel column chromatography and (dichloromethane: methanol=10: 1) obtains the title compound (1.90g) with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.48；

NMR(DMSO-d₆)：δ 1.29-1.42 (m, 2H), 1.63-1.73 (m, 2H), 1.95-2.05 (m, 2H), 2.59-2.68 (m, 2H), 2.95 (s, 3H), 3.38 (s, 2H), 3.43 (m, 1H), 4.51 (d, J=4.5Hz, 1H), 6.91 (d, J=8.5Hz, 2H), 6.99 (d, J=9.0Hz, 2H), 7.21 (d, J=9.0Hz, 2H), 7.25 (d, J=8.5Hz, 2H), 9.59 (br s, 1H).

Embodiment 2：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) piperidin-4-one

The compound (1.79g) prepared into embodiment 1 adds triethylamine (3mL) in the solution (5mL) of dimethyl sulfoxide (DMSO).In the case where being cooled with ice, sulfur trioxide pyridine complex (1.52g) is added into reaction solution and stirs solution 1 hour.After the completion of reaction, add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated over magnesium sulfate.Obtained residue is purified through silica gel column chromatography and (dichloromethane: methanol=20: 1) obtains the title compound (1.76g) with following physical datas.

TLC:Rf0.51 (chloroforms: methanol=10: 1)；

NMR(DMSO-d₆)：δ 2.33 (t, J=6.0Hz, 4H), 2.66 (t, J=6.0Hz, 4H), 2.95 (s, 3H), 3.57 (s, 2H), 6.94 (d, J=8.5Hz, 2H), 7.00 (d, J=9.0Hz, 2H), 7.22 (d, J=9.0Hz, 2H), 7.33 (d, J=8.5Hz, 2H), 9.59 (s, 1H).

Embodiment 3：

N- [4- (4- { [4- (butylamino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

N-butylamine (0.2mL) and triethylamine (0.2mL) are added in solution (5mL) of the compound (400mg) prepared into embodiment 2 in dimethylformamide and solution is stirred.Sodium triacetoxy borohydride (440mg) is added into reaction solution and stirs solution 20 hours.After the completion of reaction, add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated over magnesium sulfate.Obtained residue is purified into (dichloromethane: methanol=5: 1) through silica gel column chromatography.4N hydrogen chloride/ethyl acetate solution is added into reactant mixture, the compound (267mg) of the invention with following physical datas is concentrated to give.

TLC:Rf0.22 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.99 (t, J=7.5Hz, 3H), 1.38-1.51 (m, 2H), 1.63-1.74 (m, 2H), 1.97-2.10 (m, 2H), 2.31-2.41 (m, 2H), 2.95 (s, 3H), 3.02-3.08 (m, 2H), 3.10-3.18 (m, 2H), 3.45 (m, 1H), 3.55-3.65 (m, 2H), 4.31 (s, 2H), 7.03 (d, J=9.0Hz, 2H), 7.06 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.53 (d, J=9.0Hz, 2H).

Embodiment 4：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] -2- (tetrahydrochysene -2H- pyrans -4- bases) acetamide hydrochloride

4- oxinanes guanidine-acetic acid (70mg), 1- ethyls -3- (3- dimethylaminopropyls) carbodiimide hydrochloride (105mg) and dimethyl aminopyridine (155mg) are added in solution (3mL) of the compound (183mg) prepared into embodiment 3 in dimethylformamide and solution is stirred overnight.After the completion of reaction, add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated over magnesium sulfate.Obtained residue is purified into (dichloromethane: methanol=25: 1) through silica gel column chromatography.4N hydrogen chloride/ethyl acetate solution is added into reactant mixture, the compound (79mg) of the invention with following physical datas is concentrated to give.

TLC:(the chloroforms: methanol=10: 1) of Rf 0.49；

NMR(CD₃OD)：δ 0.98 (t, J=7.0Hz, 3H), 1.24-1.69 (m, 8H), 1.87-2.40 (m, 7H), 2.95 (s, 3H), 3.02-3.48 (m, 6H), 3.49-3.61 (m, 2H), 3.87-3.95 (m, 2H), 4.12 (m, 1H), 4.27-4.30 (m, 2H), (7.03 d, J=9.0Hz, 2H), (7.06 d, J=8.5Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.49 d, J=8.5Hz, 2H).

Embodiment 4 (1)：

2- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl]-N- propyl amine hydrochlorates

By the same step as described in 3 → embodiment of embodiment 4, n-butylamine and 4- oxinane guanidine-acetic acids are replaced respectively using n-propyl amine and corresponding cyclohexyl-acetic acid, the compound of the invention with following physical datas is obtained.

TLC:Rf0.40 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 0.86-1.39 (m, 9H), 1.48-2.14 (m, 9H), 2.22 (d, J=7.0Hz, 2H), 2.27-2.39 (m, 2H), 2.95 (s, 3H), 3.02-3.25 (m, 4H), 3.49-3.61 (m, 2H), 4.13 (m, 1H), 4.27-4.29 (m, 2H), (7.03 d, J=9.0Hz, 2H), (7.06 d, J=8.5Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.49 d, J=8.5Hz, 2H).

Reference example 1：

1- tert-butoxycarbonyl -4- butylamino piperidines

N-butylamine (6.0mL) and triethylamine (7.0mL) are added into solution (200mL) of the 1- tert-butoxycarbonylpiperidine -4- ketone (10.0g) in dimethylformamide and solution is stirred.Sodium triacetoxy borohydride (16.0g) is added into reaction solution and stirs solution 1.5 hours.After the completion of reaction, add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated obtains the title compound with following physical datas over magnesium sulfate.

TLC:Rf0.28 (chloroforms: methanol=10: 1)；

NMR(CDCl₃)：δ 0.92 (t, J=7.0Hz, 3H), 1.19-1.53 (m, 6H), 1.45 (s, 9H), 1.82-1.87 (m, 2H), 2.55-2.66 (m, 3H), 2.74-2.82 (m, 2H), 4.00-4.10 (m, 2H).

Reference example 2：

1- tert-butoxycarbonyls -4- (N- cyclohexyl-carbonyl-N- butylaminos) piperidines

Cyclohexyl-acetic acid (7.5g), 1- ethyls -3- [3- (dimethylamino) propyl group] carbodiimide hydrochlorides (14.5g) and DMAP (9.2g) are added into the dichloromethane solution (100mL) of the compound prepared in reference example 1 and solution is stirred overnight.After the completion of reaction, add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated over magnesium sulfate.Obtained residue is purified through silica gel column chromatography and (hexane: ethyl acetate=1: 1) obtains the title compound (8.97g) with following physical datas.

TLC:Rf0.50 (hexanes: ethyl acetate=2: 1)；

NMR(CDCl₃)：δ 0.87-1.01 (m, 2H), 0.95 (t, J=7.5Hz, 3H), 1.05-1.81 (m, 16H), 1.46 (s, 9H), 1.89 (m, 1H), 2.16 (d, J=7.0Hz, 2H), 2.68-2.85 (m, 2H), 3.08-3.18 (m, 2H), 4.09-4.35 (m, 2H), 4.52 (m, 1H).

Reference example 3：

4- [(N- cyclohexyl-carbonyl-N- butyl) amino] piperidine hydrochlorate

Trifluoroacetic acid (20mL) is added into the dichloromethane solution (20mL) of the compound (8.92g) prepared in reference example 2 and stirs solution 30 minutes.After the completion of reaction, reaction solution is alkalized with 1N sodium hydrate aqueous solutions and extracted with dichloromethane.Organic layer salt water washing, is dried and concentrated over magnesium sulfate.4N hydrogen chloride/ethyl acetate solution is added into obtained residue, the title compound (7.98g) with following physical datas is concentrated to give.

TLC:Rf0.35 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.92-1.08 (m, 2H), 0.98 (t, J=7.5Hz, 3H), 1.15-2.36 (m, 17H), 2.23 (d, J=7.0Hz, 2H), 3.01-3.30 (m, 4H), 3.41-3.53 (m, 2H), 4.15 (m, 1H).

Embodiment 5 (1)-embodiment 5 (54)

Hydrochloride is changed into using such as same method of the embodiment 1 described in and using conventional method; 4- hydroxy piperidines are replaced using the compound or corresponding amine derivative prepared in reference example 3; and 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehydes or corresponding aldehyde derivatives are utilized, obtain following compounds of the invention.

Embodiment 5 (1)：

N- butyl -2- cyclohexyl-N- [1- (4- { 2- methoxyl groups -4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] acetamide hydrochloride

TLC:Rf0.49 (chloroforms: methanol=10: 1)；

NMR(CDCl₃)：δ 0.87-1.01 (m, 2H), 0.93 (t, J=7.0Hz, 3H), 1.07-2.06 (m, 15H), 2.19 (d, J=7.0Hz, 2H), 2.49-2.84 (m, 4H), 3.02 (s, 3H), 3.17-3.27 (m, 2H), 3.49-3.59 (m, 2H), 3.81 (s, 3H), 4.10 (br s, 2H), 4.72 (m, 1H), 6.88-6.93 (m, 3H), 6.99 (d, J=8.5Hz, 1H), 7.13 (d, J=2.5Hz, 1H), 7.53 (d, J=8.5Hz, 2H), 7.94 (br s, 1H), 12.14 (s, 1H).

Embodiment 5 (2)：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] cyclohexane carboxamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.62；

NMR(CD₃OD)：δ 7.55-7.46 (m, 2H), 7.29 (d, J=8.7Hz, 2H), 7.10-7.00 (m, 4H), 4.33-4.25 (m, 2H), 4.19 (m, 1H), 3.62-3.48 (m, 2H), 3.30-3.02 (m, 4H), 2.95 (s, 3H), 2.48 (m, 1H), 2.35-2.08 (m, 2H), 1.98-1.63 (m, 7H), 1.63-1.18 (m, 9H), 1.03-0.88 (m, 3H).

Embodiment 5 (3)：

N- butyl -2- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.62；

NMR(CD₃OD)：δ 7.55-7.46 (m, 2H), 7.29 (d, J=9.0Hz, 2H), 7.10-7.00 (m, 4H), 4.32-4.24 (m, 2H), 4.16 (m, 1H), 3.63-3.48 (m, 2H), 3.30-3.01 (m, 4H), 2.95 (s, 3H), 2.40-2.08 (m, 4H), 2.00-1.60 (m, 8H), 1.60-1.10 (m, 7H), 1.10-0.90 (m, 5H).

Embodiment 5 (4)：

N- butyl -3- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] propionamide hydrochloride

TLC:Rf0.64 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 7.56-7.46 (m, 2H), 7.29 (d, J=9.0Hz, 2H), 7.10-7.00 (m, 4H), 4.32-4.23 (m, 2H), 4.16 (m, 1H), 3.62-3.47 (m, 2H), 3.30-3.00 (m, 4H), 2.95 (s, 3H), 2.50-2.03 (m, 4H), 2.02-1.84 (m, 2H), 1.82-1.60 (m, 5H), 1.60-1.10 (m, 10H), 1.05-0.83 (m, 5H).

Embodiment 5 (5)：

N- butyl -2- cyclohexyl-N- { 1- [(3,5- dimethyl -1- { 4- [(mesyl) amino] phenyl } -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } acetamide hydrochloride

TLC:Rf0.41 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 0.91-1.06 (m, 2H), 0.98 (t, J=7.5Hz, 3H), 1.14-1.83 (m, 13H), 1.89-1.97 (m, 2H), 2.23 (d, J=6.5Hz, 2H), 2.32-2.40 (m, 2H), 2.36 (s, 3H), 2.39 (s, 3H), 3.04 (s, 3H), 3.12-3.29 (m, 4H), 3.61-3.71 (m, 2H), 4.25 (s, 2H), 4.27 (m, 1H), (7.41 d, J=9.0Hz, 2H), (7.46 d, J=9.0Hz, 2H).

Embodiment 5 (6)：

N- (1- { 4- [4- (amino-sulfonyl) phenoxy group] benzyl } piperidin-4-yl)-N- butyl -2- cyclohexyl acetamide hydrochlorides

TLC:Rf0.37 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 0.91-1.04 (m, 2H), 0.98 (t, J=7.0Hz, 3H), 1.12-1.99 (m, 15H), 2.22 (d, J=6.5Hz, 2H), 2.25-2.36 (m, 2H), 2.97-3.30 (m, 4H), 3.46-3.60 (m, 2H), 4.10 (m, 1H), 4.29 (s, 2H), (7.13 d, J=9.0Hz, 2H), (7.17 d, J=8.5Hz, 2H), (7.55 d, J=8.5Hz, 2H), (7.90 d, J=9.0Hz, 2H).

Embodiment 5 (7)：

N- butyl -2- cyclohexyl-N- [1- ({ 4 '-[(mesyl) amino] biphenyl -3- bases } methyl) piperidin-4-yl] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.87-1.05 (m, 2H), 0.96 (t, J=7.0Hz, 3H), 1.13-2.14 (m, 15H), 2.21 (d, J=7.0Hz, 2H), 2.25-2.38 (m, 2H), 2.99 (s, 3H), 3.08-3.28 (m, 4H), 3.54-3.65 (m, 2H), 4.15 (m, 1H), 4.37-4.39 (m, 2H), 7.36 (d, J=9.0Hz, 2H), 7.47 (d, J=7.5Hz, 1H), 7.57 (t, J=7.5Hz, 1H), 7.67 (d, J=9.0Hz, 2H), 7.74-7.82 (m, 2H).

Embodiment 5 (8)：

N- { 4- [4- ({ 4- [butyl (2- cyclohexyl-ethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:Rf0.32 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 0.94 (t, J=7.0Hz, 3H), 0.98-1.08 (m, 2H), 1.18-1.41 (m, 7H), 1.53-1.80 (m, 8H), 2.24-2.49 (m, 4H), 2.96 (s, 3H), 3.05-3.21 (m, 6H), 3.70-3.81 (m, 3H), 4.32 (d, J=13.0Hz, 1H), 4.53 (d, J=13.0Hz, 1H), 7.04 (d, J=9.0Hz, 2H), 7.08 (d, J=8.5Hz, 2H), 7.30 (d, J=9.0Hz, 2H), 7.56 (d, J=8.5Hz, 2H).

Embodiment 5 (9)：

N- [(1S) -2- amino -1- (cyclohexyl methyl) -2- oxoethyls] -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide hydrochlorides

TLC:Rf0.34 (chloroforms: methanol=4: 1)；

NMR(CD₃OD)：δ 0.84-1.06 (m, 2H), 1.13-1.41 (m, 4H), 1.55-2.14 (m, 11H), 2.59 (m, 1H), 2.95 (s, 3H), 2.97-3.09 (m, 2H), 3.50-3.59 (m, 2H), 4.29 (s, 2H), 4.39 (dd, J=9.5,5.5Hz, 1H), (7.03 d, J=9.0Hz, 2H), (7.06 d, J=9.0Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.49 d, J=9.0Hz, 2H).

Embodiment 5 (10)：

N- { 4- [4- ({ 4- [(3S) -3- (cyclohexyl methyl) -2,5- dioxopiperazine -1- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：(the brd of δ 7.49, J=8.7Hz, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.07 (brd, J=8.7Hz, 2H), 7.03 (brd, J=9.0Hz, 2H), 4.44 (m, 1H), 4.29 (s, 2H), 4.04 (d, J=16.8Hz, 1H), 3.96 (t, J=6.6Hz, 1H), 3.83 (d, J=16.8Hz, 1H), 3.64-3.52 (m, 2H), 3.15 (m, 2H), 2.95 (s, 3H), 2.20-1.60 (m, 10H), 1.49 (m, 1H), 1.39-1.10 (m, 4H), 1.09-0.80 (m, 2H).

Embodiment 5 (11)：

N- { 4- [4- ({ 4- [4- (cyclohexyl-carbonyl) -2- oxypiperazin -1- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:0.45 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 7.50 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 4.50 (m, 1H), 4.26 (m, 1H), 4.23 (s, 2H), 4.14 (m, 1H), 3.82-3.76 (m, 2H), 3.53-3.33 (m, 4H), 3.09-3.01 (m, 2H), 2.95 (s, 3H), 2.65 (m, 1H), 2.19-1.88 (m, 4H), 1.79-1.70 (m, 5H), 1.49-1.21 (m, 5H).

Embodiment 5 (12)：

N- butyl -2- cyclohexyl-N- [1- (4- { 2- methoxyl groups -4- [(mesyl) amino] phenoxy group } benzyl) piperidines -3- bases] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.49；

NMR(CDCl₃)：δ 0.87-1.00 (m, 2H), 0.94 (t, J=7.5Hz, 3H), 1.08-1.93 (m, 16H), 2.11 (d, J=7.0Hz, 2H), 2.25 (m, 1H), 2.45-2.64 (m, 2H), 3.02 (s, 3H), 3.18-3.37 (m, 4H), 3.80 (s, 3H), 3.86-4.00 (m, 2H), 4.20 (dd, J=13.0, 4.0Hz, 1H), 6.87-6.92 (m, 3H), 6.99 (d, J=8.5Hz, 1H), 7.13 (d, J=2.5Hz, 1H), 7.55 (d, J=8.5Hz, 2H), 7.83 (br s, 1H), 11.87 (s, 1H).

Embodiment 5 (13)：

N- butyl -2- cyclohexyl-N- [1- (4- { [(4- aminomethyl phenyls) sulfonyl] amino } benzyl) piperidin-4-yl] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.45；

NMR(CD₃OD)：δ 0.89-1.06 (m, 2H), 0.96 (t, J=7.0Hz, 3H), 1.12-2.09 (m, 15H), 2.21 (d, J=7.0Hz, 2H), 2.22-2.32 (m, 2H), 2.36 (s, 3H), 2.97-3.27 (m, 4H), 3.41-3.54 (m, 2H), 4.11 (m, 1H), 4.18-4.20 (m, 2H), (7.21 d, J=8.5Hz, 2H), (7.29 d, J=8.5Hz, 2H), (7.36 d, J=8.5Hz, 2H), (7.69 d, J=8.5Hz, 2H).

Embodiment 5 (14)：

1- (4- (4- (N- cyclohexylmethylcarbonyl-N- methane sulfonylaminos) phenoxy group) benzyl) -4- (N- propyl group-N- cyclohexylmethylcarbonylaminos) piperidine hydrochlorate

TLC:(the chloroforms: methanol=10: 1) of Rf 0.82；

NMR(CD₃OD)：δ 0.77-1.39 (m, 13H), 1.47-1.96 (m, 16H), 2.05 (d, J=7.0Hz, 2H), 2.22 (d, J=7.0Hz, 2H), 2.24-2.41 (m, 2H), 3.04-3.26 (m, 4H), 3.48 (s, 3H), 3.51-3.65 (m, 2H), 4.13 (m, 1H), 4.31-4.33 (m, 2H), (7.13 d, J=9.0Hz, 2H), (7.18 d, J=8.5Hz, 2H), (7.38 d, J=9.0Hz, 2H), (7.56 d, J=8.5Hz, 2H).

Embodiment 5 (15)：

4- (4- { [4- (4- benzoyl bromides) piperidin-1-yl] methyl } phenoxy group) benzoate hydrochlorate

TLC:Rf0.35 (chloroforms: methanol=10: 1)；

NMR(DMSO-d₆)：δ 1.83-2.15 (m, 4H), 2.94-3.09 (m, 2H), 3.39-3.50 (m, 2H), 3.65 (s, 1H), 4.31 (br s, 2H), 7.09 (d, J=9.0Hz, 2H), 7.19 (d, J=8.5Hz, 2H), 7.65 (d, J=8.5Hz, 2H), 7.76 (d, J=8.5Hz, 2H), 7.93 (d, J=8.5Hz, 2H), 7.97 (d, J=9.0Hz, 2H), 10.52 (br s, 1H), 12.86 (br s, 1H).

Embodiment 5 (16)：

4- [4- ({ 4- [(3S) -3- (cyclohexyl methyl) -2,5- dioxopiperazine -1- bases] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：(the brd of δ 8.04, J=8.7Hz, 2H), 7.59 (brd, J=8.1Hz, 2H), 7.17 (brd, J=8.1Hz, 2H), 7.07 (brd, J=8.7Hz, 2H), 4.46 (m, 1H), 4.34 (s, 2H), 4.05 (d, J=17.1Hz, 1H), 3.97 (dd, J=6.6, 5.4Hz, 1H), 3.85 (d, J=17.1Hz, 1H), 3.68-3.53 (m, 2H), 3.17 (m, 2H), 2.24-2.04 (m, 2H), 1.94 (m, 1H), 1.84-1.56 (m, 7H), 1.48 (m, 1H), 1.38-1.08 (m, 4H), 1.08-0.80 (m, 2H).

Embodiment 5 (17)：

The chloro- 2- of 5- { 4- [1- (3,4- dimethoxy-benzyl) piperidin-4-yl] benzyl } -1H- iso-indoles -1,3 (2H)-dione hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 7.86-7.81 (m, 2H), 7.33 (d, J=8.0Hz, 2H), 7.23 (d, J=8.0Hz, 2H), 7.14 (s, 1H), 7.06-7.01 (m, 3H), 4.78 (s, 2H), 4.26 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.58-3.54 (m, 2H), 3.10-3.00 (m, 2H), 2.90 (m, 1H), 2.10-1.90 (m, 4H).

Embodiment 5 (18)：

N- butyl -2- cyclohexyl-N- [1- (4- phenoxy benzyls) piperidin-4-yl] acetamide hydrochloride

TLC:Rf0.82 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 7.50-7.37 (m, 4H), 7.18 (t, J=7.2Hz, 1H), 7.07-7.02 (m, 4H), 4.27 (s, 2H), 4.15 (m, 1H), 3.60-3.50 (m, 2H), 3.30-3.00 (m, 4H), 2.20-2.00 (m, 4H), 2.00-1.80 (m, 2H), 1.80-1.40 (m, 8H), 1.40-1.10 (m, 5H), 1.00-0.90 (m, 2H), 0.97 (t, J=7.4Hz, 3H).

Embodiment 5 (19)：

4- [4- ({ 4- [butyl (Cyclohexylacetyl) amino] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

TLC:Rf0.43 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 8.04 (d, J=8.3Hz, 2H), 7.56 (d, J=8.3Hz, 2H), 7.17 (d, J=8.3Hz, 2H), 7.07 (d, J=8.3Hz, 2H), 4.31 (s, 2H), 4.16 (m, 1H), 3.60-3.50 (m, 2H), 3.30-3.00 (m, 4H), 2.20-2.00 (m, 4H), 2.00-1.80 (m, 2H), 1.80-1.40 (m, 8H), 1.40-1.10 (m, 5H), 1.00-0.90 (m, 2H), 0.97 (t, J=7.0Hz, 3H).

Embodiment 5 (20)：

N- butyl -2- cyclohexyl-N- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.47；

NMR(CD₃OD)：δ 7.58-7.45 (m, 5H), 4.24 (s, 2H), 4.15 (m, 1H), 3.60-3.50 (m, 2H), 3.30-3.00 (m, 4H), 2.37 (s, 3H), 2.36 (s, 3H), 2.40-2.10 (m, 4H), 2.00-1.80 (m, 2H), 1.80-1.40 (m, 8H), 1.40-1.10 (m, 5H), 1.00-0.90 (m, 2H), 0.98 (t, J=7.4Hz, 3H).

Embodiment 5 (21)：

N- butyl -2- cyclohexyl-N- (1- { [1- (4- hydroxy phenyls) -3,5- dimethyl -1H- pyrazoles -4- bases] methyl } piperidin-4-yl) acetamid dihydrochloride

TLC:Rf0.37 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 7.26 (d, J=9.0Hz, 2H), 6.92 (d, J=9.0Hz, 2H), 4.24 (s, 2H), 4.15 (m, 1H), 3.70-3.60 (m, 2H), 3.30-3.00 (m, 4H), 2.37 (s, 3H), 2.32 (s, 3H), 2.40-2.20 (m, 4H), 2.00-1.80 (m, 2H), 1.80-1.40 (m, 8H), 1.40-1.10 (m, 5H), 1.00-0.90 (m, 2H), 0.98 (t, J=7.4Hz, 3H).

Embodiment 5 (22)：

N- { 4- [4- ({ 4- [4- (cyclohexyl-carbonyl) piperazine -1- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:Rf0.59 (dichloromethane: methanol=5: 1)；

NMR(CD₃OD)：δ 1.21-1.49 (m, 6H), 1.70-1.98 (m, 10H), 2.20-2.35 (m, 2H), 2.60-2.70 (m, 2H), 2.95 (s, 3H), 2.95-3.23 (m, 4H), 3.55-3.80 (m, 4H), 4.28 (s, 2H), 7.03 (d, J=8.5Hz, 2H), 7.06 (d, J=8.5Hz, 2H), 7.29 (d, J=8.5Hz, 2H), (7.49 d, J=8.5Hz, 2H).

Embodiment 5 (23)：

N- { 4- [4- ({ 4- [5- (cyclohexyl-carbonyl) -2,5- diazabicylos [2.2.1] hept- 2- yls] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.46；

NMR(CD₃OD)：δ 1.15-1.49 (m, 6H), 1.60-1.98 (m, 10H), 2.35-2.88 (m, 6H), 2.95 (s, 3H), 3.08-3.72 (m, 4H), 3.89 (d, J=9.5Hz, 1H), 4.04 (s, 2H), 4.62 (d, J=22.5Hz, 1H), 7.01 (d, J=8.7Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.28 (d, J=8.7Hz, 2H), 7.42 (d, J=8.7Hz, 2H).

Embodiment 5 (24)：

2- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] acetamide hydrochloride

TLC:Rf0.46 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 0.89-1.00 (m, 2H), 1.21-1.29 (m, 3H), 1.68-1.71 (m, 8H), 2.03 (d, J=6.9Hz, 2H), 2.11-2.16 (m, 2H), 2.95 (s, 3H), 3.06-3.14 (m, 2H), 3.49-3.53 (m, 2H), 3.90 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.47 d, J=8.7Hz, 2H).

Embodiment 5 (25)：

2- cyclohexyl-N- [1- (4- phenoxy benzyls) piperidin-4-yl] acetamide hydrochloride

TLC:Rf0.62 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 1.13-1.29 (m, 3H), 1.67-1.78 (m, 8H), 2.03 (d, J=6.9Hz, 2H), 2.12-2.15 (m, 2H), 3.05-3.13 (m, 2H), 3.49-3.53 (m, 2H), 3.90 (m, 1H), 4.27 (s, 2H), 7.02-7.08 (m, 4H), 7.18 (m, 1H), 7.37-7.42 (m, 2H), 7.46-7.50 (m, 2H).

Embodiment 5 (26)：

2- cyclohexyl-N- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } acetamid dihydrochloride

TLC:Rf0.40 (dichloromethane: methanol=10: 1)；

NMR(CD₃OD)：δ 0.91-1.02 (m, 2H), 1.14-1.34 (m, 3H), 1.69-1.85 (m, 8H), 2.05 (d, J=6.9Hz, 2H), 2.13-2.19 (m, 2H), 2.36 (s, 3H), 2.38 (s, 3H), 3.14-3.24 (m, 2H), 3.61-3.66 (m, 2H), 3.93 (m, 1H), 4.25 (s, 2H), 7.45-7.60 (m, 5H).

Embodiment 5 (27)：

N- { 4- [4- ({ 4- [(5S) -5- (cyclohexyl methyl) -1- isopropyl -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:Rf0.69 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.80-2.36 (m, 24H), 2.95 (s, 3H), 3.04 (m, 1H), 3.46-3.69 (m, 3H), 3.78-4.12 (m, 3H), 4.26 (brs, 2H), 7.00-7.18 (m, 4H), 7.26-7.34 (m, 2H), 7.40-7.48 (m, 2H).

Embodiment 5 (28)：

N- { 4- [4- ({ 4- [(5S) -5- (cyclohexyl methyl) -1- (2- methoxy ethyls) -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.80-2.32 (m, 21H), 2.95 (s, 3H), 2.84-3.02 (m, 3H), 3.40-3.60 (m, 4H), 3.80-4.14 (m, 3H), 4.26 (brs, 2H), 7.00-7.14 (m, 4H), 7.21-7.32 (m, 2H), 7.41-7.52 (m, 2H).

Embodiment 5 (29)：

N- { 4- [4- ({ 4- [(5S) -5- (cyclohexyl methyl) -1- methyl -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.96 (m, 1H), 1.12-1.36 (m, 3H), 1.44-2.38 (m, 14H), 2.95 (s, 3H), 2.98 (m, 2H), 3.36 (brs, 3H), 3.42-3.60 (m, 2H), 3.86-4.34 (m, 2H), 4.25 (brs, 2H), 6.98-7.08 (m, 4H), 7.24-7.30 (m, 2H), 7.40-7.52 (m, 2H).

Embodiment 5 (30)：

N- { 4- [4- ({ 4- [(5S) -1- benzyls -5- (cyclohexyl methyl) -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 0.80-2.40 (m, 18H), 2.95 (s, 3H), 3.44-3.56 (m, 3H), 3.79 (m, 1H), 4.02-4.30 (m, 4H), 5.22 (m, 2H), 7.00-7.08 (m, 4H), 7.24-7.40 (m, 6H), 7.40-7.50 (m, 3H).

Embodiment 5 (31)：

(3S) -3- (cyclohexyl methyl) -1- isopropyls -6- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2,5- dione hydrochloride

TLC:Rf0.84 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.80-2.38 (m, 24H), 3.03 (m, 2H), 3.46-3.70 (m, 3H), 3.76-4.10 (m, 2H), 4.26 (brs, 2H), 7.00-7.06 (m, 4H), 7.19 (m, 1H), 7.36-7.58 (m, 4H).

Embodiment 5 (32)：

(3S) -3- (cyclohexyl methyl) -1- (2- methoxy ethyls) -6- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2,5- dione hydrochloride

TLC:Rf0.77 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.80-1.10 (m, 2H), 1.12-2.10 (m, 16H), 2.16-2.62 (m, 2H), 2.98-4.14 (m, 11H), 4.26 (brs, 2H), 7.00-7.10 (m, 4H), 7.18 (m, 1H), 7.30-7.54 (m, 4H).

Embodiment 5 (33)：

(3S) -1- benzyls -3- (cyclohexyl methyl) -6- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2,5- dione hydrochloride

TLC:Rf0.86 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.84-2.40 (m, 18H), 2.76-3.04 (m, 2H), 3.42-3.60 (m, 2H), 3.78 (m, 1H), 4.10 (m, 1H), 4.16-4.34 (m, 3H), 5.20 (m, 1H), 6.98-7.14 (m, 4H), 7.19 (m, 1H), 7.20-7.52 (m, 9H).

Embodiment 5 (34)：

(3S) -3- (cyclohexyl methyl) -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } -1- isopropyl piperazine -2,5- dione hydrochlorides

TLC:Rf0.74 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.84-2.36 (m, 24H), 2.36 (brs, 3H), 2.38 (brs, 3H), 3.04-3.24 (m, 2H), 3.60-4.10 (m, 5H), 4.25 (brs, 2H), 7.40-7.60 (m, 5H).

Embodiment 5 (35)：

(3S) -3- (cyclohexyl methyl) -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } -1- methyl piperazine -2,5- dione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.84-2.40 (m, 18H), 2.35 (m, 6H), 3.00 (brs, 3H), 3.09 (m, 2H), 3.56-3.70 (m, 2H), 3.82-4.12 (m, 2H), 4.24 (brs, 2H), 7.40-7.60 (m, 5H).

Embodiment 5 (36)：

(3S) -3- (cyclohexyl methyl) -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] piperidin-4-yl } -1- (2- methoxy ethyls) piperazine -2,5- dione hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.80-2.40 (m, 18H), 2.35 (brs, 3H), 2.38 (brs, 3H), 3.00-3.20 (m, 3H), 3.33 (s, 3H), 3.49-3.72 (m, 4H), 3.88-4.16 (m, 3H), 4.25 (brs, 2H), 7.40-7.62 (m, 5H).

Embodiment 5 (37)：

N- butyl -1- (4- phenoxy benzyls) piperidines -4- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.58；

NMR(CD₃OD)：δ 0.92 (t, J=7.2Hz, 3H), 1.28-1.52 (m, 4H), 1.82-2.05 (m, 4H), 2.49 (m, 1H), 2.98-3.07 (m, 2H), 3.16 (t, J=7.0Hz, 2H), 3.52-3.56 (m, 2H), 4.28 (s, 2H), 7.02-7.06 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7,37-7.42 (m, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 5 (38)：

N- (cyclohexyl methyl) -1- (4- phenoxy benzyls) piperidines -4- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.86-0.97 (m, 2H), 1.15-1.28 (m, 4H), 1.46 (m, 1H), 1.60-1.78 (m, 4H), 1.89-2.05 (m, 4H), 2.52 (m, 1H), 3.00 (d, J=7.2H z, 2H), 3.00-3.07 (m, 2H), 3.51-3.56 (m, 2H), 4.29 (s, 2H), 7.01-7.06 (m, 4H), 7.18 (m, 1H), 7.37-7.42 (m, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 5 (39)：

N- butyl-N- (cyclohexyl methyl) -1- (4- phenoxy benzyls) piperidines -4- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.89-1.00 (m, 5H), 1.18-1.71 (m, 13H), 1.92-2.00 (m, 5H), 2.92-3.55 (m, 6H), 3.51-3.55 (m, 2H), 4.28 (s, 2H), 7.02-7.07 (m, 4H), 7.18 (t, J=7.2Hz, 1H), 7.37-7.42 (m, 2H), (7.47 d, J=8.4Hz, 2H).

Embodiment 5 (40)：

1- benzyls -4- { [1- (4- phenoxy benzyls) piperidin-4-yl] carbonyl } piperazine dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.59；

NMR(CD₃OD)：δ 1.90-2.10 (m, 4H), 3.00-3.60 (m, 12H), 4.30 (s, 2H), 4.39 (s, 2H), 4.63 (m, 1H), 7.02-7.06 (m, 4H), 7.18 (t, J=7.0Hz, 1H), 7.37-7.42 (m, 2H), 7.48-7.58 (m, 7H).

Embodiment 5 (41)：

1- (cyclohexyl methyl) -4- { [1- (4- phenoxy benzyls) piperidin-4-yl] carbonyl } piperazine dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.62；

NMR(CD₃OD)：δ 1.02-1.43 (m, 5H), 1.70-2.01 (m, 10H), 3.03 (d, J=6.6Hz, 2H), 3.03-3.69 (m, 12H), 4.31 (s, 2H), 4.59 (m, 1H), 7.02-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.37-7.42 (m, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 5 (42)：

N- butyl -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.26；

NMR(CD₃OD)：δ 0.92 (t, J=7.2Hz, 3H), 1.30-1.52 (m, 4H), 1.84-2.04 (m, 4H), 2.48 (m, 1H), 2.95 (s, 3H), 2.95-3.07 (m, 2H), 3.16 (t, J=7.2Hz, 2H), 3.51-3.56 (m, 2H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), (7.47 d, J=8.7Hz, 2H).

Embodiment 5 (43)：

N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.28；

NMR(CD₃OD)：δ 0.85-1.00 (m, 2H), 1.15-1.46 (m, 5H), 1.65-2.13 (m, 8H), 2.49 (m, 1H), 2.95 (s, 3H), 3.00 (d, J=7.0Hz, 2H), 3.00-3.06 (m, 2H), 3.52-3.56 (m, 2H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.47 (d, J=8.4Hz, 2H).

Embodiment 5 (44)：

N- butyl-N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide hydrochlorides

TLC:Rf0.45 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 0.89-1.00 (m, 5H), 1.21-2.00 (m, 18H), 2.95 (s, 3H), 3.00-3.36 (m, 6H), 3.51-3.54 (m, 2H), 4.27 (s, 2H), 7.02-7.08 (m, 4H), (7.29 d, J=9.0Hz, 2H), (7.47 d, J=8.1Hz, 2H).

Embodiment 5 (45)：

N- { 4- [4- ({ 4- [(4- benzyl diethylenediamine -1- bases) carbonyl] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:Rf0.28 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 1.90-2.10 (m, 4H), 2.95 (s, 3H), 3.05-3.56 (m, 12H), 4.30 (s, 2H), 4.39 (s, 2H), 4.63 (m, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.47-7.55 (m, 7H).

Embodiment 5 (46)：

N- (4- { 4- [(4- { [4- (cyclohexyl methyl) piperazine -1- bases] carbonyl } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:Rf0.30 (chloroforms: methanol=10: 1)；

NMR(CD₃OD)：δ 1.05-1.43 (m, 5H), 1.70-2.01 (m, 10H), 2.95 (s, 3H), 3.03 (d, J=6.9Hz, 2H), 3.03-3.63 (m, 12H), 4.31 (s, 2H), 4.59 (m, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 5 (47)：

1- (cyclohexyl methyl) -4- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2- formic acid tri hydrochlorides

TLC:Rf0.07 (chloroforms: methanol: acetic acid=10: 1: 1)；

NMR(CD₃OD)：δ 1.01-1.11 (m, 2H), 1.19-1.41 (m, 4H), 1.66-2.02 (m, 8H), 2.19-2.31 (m, 2H), 2.97-3.37 (m, 8H), 3.45-3.64 (m, 3H), 3.80 (m, 1H), 4.29 (s, 2H), 4.35 (s, 1H), 7.01-7.06 (m, 4H), 7.18 (t, J=8.0Hz, 1H), 7.39 (t, J=8.0Hz, 2H), 7.52 (d, J=9.0Hz, 2H).

Embodiment 5 (48)：

1- benzyls -4- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2- formic acid tri hydrochlorides

TLC:(the chloroforms: methanol: acetic acid=10: 1: 1) of Rf 0.05；

NMR(CD₃OD)：δ 1.86-2.03 (m, 2H), 2.15-2.27 (m, 2H), 2.86-3.62 (m, 11H), 4.13-4.35 (m, 4H), 4.57 (d, J=12.5Hz, 1H), 7.01-7.06 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.39 (t, J=8.0Hz, 2H), 7.45-7.56 (m, 7H).

Embodiment 5 (49)：

1- (cyclohexyl-carbonyl) -4- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2- formic acid dihydrochlorides

TLC:(the chloroforms: methanol: acetic acid=10: 1: 1) of Rf 0.14；

NMR(CD₃OD)：δ 1.22-1.57 (m, 5H), 1.67-1.85 (m, 5H), 2.06-2.78 (m, 5H), 2.96-3.23 (m, 4H), 3.46-3.70 (m, 5H), 4.08 (m, 1H), 4.31 (m, 1H), 4.33 (s, 2H), 5.53 (s, 1H), 7.02-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.36-7.42 (m, 2H), (7.54 d, J=8.5Hz, 2H).

Embodiment 5 (50)：

1- benzoyls -4- [1- (4- phenoxy benzyls) piperidin-4-yl] piperazine -2- formic acid dihydrochlorides

TLC:(the chloroforms: methanol: acetic acid=10: 1: 1) of Rf 0.09；

NMR(CD₃OD)：δ 1.92-2.41 (m, 4H), 2.87-3.95 (m, 11H), 4.31 (s, 2H), 5.53 (s, 1H), 7.02-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.36-7.42 (m, 2H), 7.45-7.54 (m, 7H).

Embodiment 5 (51)：

4- (cyclohexyl methyl) -2- methyl isophthalic acids-[1- (4- phenoxy benzyls) piperidin-4-yl] piperazine trihydrochloride salt

TLC:(the chloroforms: methanol=10: 1) of Rf 0.18；

NMR(CD₃OD)：δ 0.97-1.13 (m, 2H), 1.20-1.44 (m, 3H), 1.55 (d, J=6.5Hz, 3H), 1.65-1.95 (m, 6H), 2.08-2.47 (m, 4H), 3.10-3.28 (m, 4H), 3.40-4.21 (m, 10H), 4.33 (s, 2H), 7.02-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.37-7.42 (m, 2H), 7.53 (d, J=8.5Hz, 2H).

Embodiment 5 (52)：

4- benzyl -2- methyl isophthalic acids-[1- (4- phenoxy benzyls) piperidin-4-yl] piperazine trihydrochloride salt

TLC:(the chloroforms: methanol=10: 1) of Rf 0.20；

NMR(CD₃OD)：δ 1.48 (d, J=6.5Hz, 3H), 2.01-2.38 (m, 4H), 3.12-3.25 (m, 2H), 3.38-3.72 (m, 8H), 3.92 (br s, 2H), 4.31 (s, 2H), 4.41 (d, J=13.0Hz, 1H), 4.47 (d, J=13.0Hz, 1H), 7.01-7.06 (m, 4H), (7.18 t, J=7.5Hz, 1H), 7.36-7.42 (m, 2H), 7.49-7.53 (m, 5H), 7.58-7.62 (m, 2H).

Embodiment 5 (53)：

4- (cyclohexyl-carbonyl) -2- methyl isophthalic acids-[1- (4- phenoxy benzyls) piperidin-4-yl] piperazine dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.38；

NMR(CD₃OD)：δ 1.16-1.57 (m, 8H), 1.66-1.84 (m, 5H), 2.05-2.75 (m, 5H), 3.00-4.73 (m, 12H), 4.33 (s, 2H), 7.01-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.36-7.42 (m, 2H), (7.53 d, J=8.5Hz, 2H).

Embodiment 5 (54)：

4- benzoyl -2- methyl isophthalic acids-[1- (4- phenoxy benzyls) piperidin-4-yl] piperazine dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 1.29-1.55 (br, 3H ,-Me), 2.07-2.54 (m, 4H), 3.09-4.17 (m, 12H), 4.33 (s, 2H), 7.01-7.07 (m, 4H), 7.18 (t, J=7.5Hz, 1H), 7.36-7.42 (m, 2H), 7.46-7.55 (m, 7H).

Reference example 4：

N- (4- (double (2- chloroethyls) the amino methyl phenoxy groups of 4-) phenyl) Methanesulfomide

N is added into solution of 4- (the 4- methanesulfonylaminobenzenes epoxide) benzaldehydes (1.27g) in dimethylformamide (5mL)/acetic acid (0.5mL); double (2- chloroethyls) amine (856mg) of N-, and solution is stirred at room temperature 10 minutes.Sodium triacetoxy borohydride (31.39g) is added into solution, is stirred at room temperature overnight.Add water into reactant mixture, be extracted with ethyl acetate three times.Extract is washed with salt solution (30mL), is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (hexane: ethyl acetate=5: 1) obtains the title compound (790mg) with following physical datas.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.60；

NMR(CDCl₃)：δ 7.32 (brd, J=8.4Hz, 2H), 7.22 (brd, J=8.7Hz, 2H), 7.01 (brd, J=8.7Hz, 2H), 6.96 (brd, J=8.4Hz, 2H), 3.72 (s, 2H), 3.51 (t, J=7.2Hz, 4H), 3.00 (s, 3H), 2.93 (t, J=7.2Hz, 4H).

Embodiment 6：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) -4- (1- meihoxycarbonylpentyls) piperazine

Amicar methyl ester hydrochloride (117mg) is added into solution of the compound (266mg) prepared in reference example 2 in dimethylformamide (3mL).The sodium iodide of triethylamine (0.267mL) and catalytic amount is added into obtained solution and is stirred overnight solution at 60 DEG C.Add water into reactant mixture, be extracted with ethyl acetate 3 times.By extract with salt water washing (30mL), the compound (210mg) of the invention obtained with following physical datas is dried and concentrated on anhydrous sodium sulfate.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.67；

NMR(CDCl₃)：δ 7.32-7.24 (m, 2H), 7.20 (brd, J=9.0Hz, 2H), 6.98 (brd, J=9.0Hz, 2H), 6.94 (brd, J=9.0Hz, 2H), 3.72 (s, 2H), 3.69 (s, 3H), 3.15 (dd, J=4.8,3.6Hz, 1H), 3.00 (s, 3H), 2.70-2.36 (m, 8H), 1.80-1.18 (m, 6H), 0.89 (t, J=5.4Hz, 3H).

Embodiment 7：

2- [4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperazine -1- bases] caproic acid dihydrochloride

2N sodium hydrate aqueous solutions (0.215mL) are added into the solution (5mL) of the compound (210mg) obtained in embodiment 6 in ethanol and are stirred overnight solution at 40 DEG C.Reactant mixture is concentrated.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=8: 1) and changes into hydrochloride using conventional method and obtains the compound (141.6mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.55；

NMR(CD₃OD)：δ 7.53 (brd, J=8.7Hz, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.06 (brd, J=8.7Hz, 2H), 7.03 (brd, J=9.0Hz, 2H), 4.37 (s, 2H), 3.75 (brt, J=6.3Hz, 1H), 3.56-3.34 (m, 8H), 2.95 (s, 3H), 1.92-1.80 (m, 2H), 1.48-1.32 (m, 4H), 1.00-0.86 (m, 3H).

Embodiment 8：

N- cyclohexyl -2- [4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperazine -1- bases] caproamide dihydrochloride

Cyclo-hexylamine (16.8 μ L), 1- ethyls -3- [3- (dimethylamino) propyl group] carbodiimide hydrochlorides (28.2mg) and I-hydroxybenzotriazole (19.87mg) are added in the solution (2mL) of the dimethylformamide of the compound (46.7mg) prepared into embodiment 7 and solution is stirred at room temperature overnight.Reactant mixture is concentrated.Obtained residue is purified through silica gel column chromatography and (chloroform: methanol=9: 1) and changes into hydrochloride using conventional method and obtains the compound (22.7mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.75；

NMR(CD₃OD)：δ 7.49 (brd, J=8.7Hz, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.05 (brd, J=9.0Hz, 2H), 7.02 (brd, J=8.7Hz, 2H), 4.30 (s, 2H), 3.68 (m, 1H), 3.50-3.00 (m, 8H), 2.95 (s, 3H), 1.90-1.58 (m, 8H), 1.44-1.12 (m, 9H), 0.92 (brt, J=7.5Hz, 3H).

Embodiment 9 (1)-embodiment 9 (3)

Utilize the same step as described in 7 → embodiment of reference example 4 → embodiment, 6 → embodiment 8; utilize 4- (4- methanesulfonylaminobenzenes epoxide) benzamide, Amicar methyl ester and cyclo-hexylamine; or them are replaced respectively using corresponding aldehyde derivatives, amino acid derivativges and amine derivative, obtain following compounds of the invention.

Embodiment 9 (1)：

N- (cyclohexyl methyl) -2- [4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperazine -1- bases] caproamide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.82；

NMR(CD₃OD)：(the brd of δ 7.53, J=8.7Hz, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.06 (brd, J=9.0Hz, 2H), 7.03 (brd, J=8.7Hz, 2H), 4.37 (s, 2H), 3.61 (m, 1H), 3.60-3.28 (m, 8H), 3.15 (dd, J=7.5, 15.0Hz, 1H), 2.99 (dd, J=7.5, 15.0Hz, 1H), 2.95 (s, 3H), 1.90-1.62 (m, 6H), 1.58-1.16 (m, 9H), 1.04-0.88 (m, 2H), 0.93 (t, J=7.2Hz, 3H).

Embodiment 9 (2)：

N- cyclohexyl -2- [4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperazine -1- bases] pentanamide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 7.52 (brd, J=6.6Hz, 2H), 7.29 (brd, J=8.4Hz, 2H), 7.10-7.01 (m, 4H), 4.36 (brs, J=2H), 3.69 (m, 1H), 3.60-3.20 (m, 9H), 2.95 (s, 3H), 1.92-1.70 (m, 6H), 1.65 (m, 1H), 1.46-1.14 (m, 7H), 0.97 (t, J=7.5Hz, 3H).

Embodiment 9 (3)：

2- (4- { 4- [4- (amino-sulfonyl) phenoxy group] benzyl } piperazine -1- bases)-N- cyclohexyl caproamide dihydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.84；

NMR(CD₃OD)：δ 7.90 (brd, J=9.3Hz, 2H), 7.63 (brd, J=11.4Hz, 2H), 7.18 (brd, J=11.4Hz, 2H), 7.13 (brd, J=9.3Hz, 2H), 4.45 (s, 2H), 3.80-3.42 (m, 9H), 1.96-1.56 (m, 7H), 1.46-1.18 (m, 10H), 0.93 (t, J=7.2Hz, 3H).

Reference example 5：

1- benzyloxycarbonyl -4- Cyclohexylmethylamino carbonyl piperidines -4- ylcarbamates

1- ethyls -3- [3- (dimethylamino) propyl group] carbodiimide hydrochloride (226mg), 4-N are added into the solution (2.5mL) of the dimethylformamide of 1- benzyloxycarbonyls -4- (tertbutyloxycarbonylamino) piperidines -4- formic acid (297mg), N- dimethylaminopyridines (144mg) and cyclohexyl methyl amine (0.15mL), and solution is stirred at room temperature overnight.Add water into reactant mixture, be extracted with ethyl acetate.By extract salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=40: 1-10: 1) obtains the title compound with following physical datas.

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.18.

Reference example 6：

4- Cyclohexylmethylamino carbonyl piperidines -4- ylcarbamates

5% palladium-charcoal (15mg) is added into the methanol solution (3mL) of the compound prepared in reference example 5.Reactant mixture is stirred at room temperature in a hydrogen atmosphere 2 hours.Under an argon atmosphere, reactant mixture is filtered into CELITE (trade name).Filtrate is concentrated and obtained residue is not purified for next reaction.

Embodiment 10：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) -4- Cyclohexylmethylamino carbonyls -4- (tertbutyloxycarbonylamino) piperidines dihydrochloride

4- (4- methanesulfonylaminobenzenes epoxide) benzaldehydes (274mg) and sodium triacetoxy borohydride (249mg) are added into solution of the compound prepared in reference example 6 in dimethylformamide (5mL) and acetic acid (0.2mL), and solution is stirred at room temperature overnight.Reactant mixture is concentrated, silica gel column chromatography purifying (ethyl acetate: methanol=50: 1-40: 1) and changes into hydrochloride using conventional method and obtains the title compound (190mg) with following physical datas.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.49；

NMR(CD₃OD)：δ 7.35 (d, J=9.0Hz, 2H), 7.25 (d, J=9.0Hz, 2H), 6.98 (d, J=9.0Hz, 2H), 6.96 (d, J=9.0Hz, 2H), 3.69 (s, 2H), 3.01-2.99 (m, 2H), 2.93 (s, 3H), 2.88-2.85 (m, 2H), 2.53-2.44 (m, 2H), 2.16-2.02 (m, 4H), 1.75-1.64 (m, 6H), 1.43 (s, 9H), 1.28-1.18 (m, 3H), 0.96-0.89 (m, 2H).

Embodiment 11：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) -4- Cyclohexylmethylamino carbonyl -4- amino piperidine dihydrochlorides

To the compound (190mg) prepared in embodiment 10 in tetrahydrofuran (4N hydrogen chloride/ethyl acetate solution (9mL) is added in the solution in 3mL) He dioxane (3mL), and solution is stirred at room temperature overnight.Reactant mixture is concentrated to give the compound of the invention with following physical datas.Described compound is not purified to be used for next reaction.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.35.

Embodiment 12 (1) and embodiment 12 (2)

Butyraldehyde (0.03mL) and sodium triacetoxy borohydride (103mg) are added in solution of the compound prepared into embodiment 11 in dimethylformamide (3mL) and acetic acid (0.1mL), and solution is stirred at room temperature overnight.Add water into reactant mixture, be extracted with ethyl acetate.By extract salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue (ethyl acetate: methanol=50: 1) (dichloromethane: methanol=10: 1) is purified with High Performance Thin Layer Chromatography through silica gel column chromatography, and changes into hydrochloride using conventional method and obtain the compound of the invention with following physical datas.

Embodiment 12 (1)：

4- (butylamino)-N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide dihydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 7.52 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.06 (d, J=9.0Hz, 2H), 7.03 (d, J=9.0Hz, 2H), (4.34 s, 2H), 3.70-3.56 (m, 3H), 3.20-2.79 (m, 7H), (2.95 s, 3H), 2.46-2.30 (m, 2H), 1.73-1.58 (m, 8H), (1.46-1.38 m, 2H), 1.28-1.15 (m, 3H), 1.05-0.95 (m, 2H), 0.97 (t, J=7.2Hz, 3H).

Embodiment 12 (2)：

N- (cyclohexyl methyl) -4- (dibutylamino) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines -4- carboxamide dihydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：δ 7.54 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 4.33 (s, 2H), 3.67-3.63 (m, 2H), 3.37-3.00 (m, 8H), 2.95 (s, 3H), 2.84-2.80 (m, 2H), 2.64-2.51 (m, 2H), 1.84-1.57 (m, 10H), 1.46-1.17 (m, 7H), 1.05-0.92 (m, 2H), 0.98 (t, J=7.2Hz, 6H).

Embodiment 13：

(2S) -2- { [4- [(butylamino) carbonyl] -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } -3- cyclohexylpropionic acid methyl ester hydrochlorides

L- Cyclohexylalanines (91.4mg), normal-butyl isocyanide (50.8 μ L) and triethylamine (74.5 μ L) are added in the methanol solution (5.3mL) of the compound (200mg) prepared into embodiment 2, and solution is stirred 12 hours at 65 DEG C.After 0 DEG C cools down, 4N hydrogen chloride/ethyl acetate solution (0.3mL) is added to wherein.Solution is stirred and concentrated.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=8: 1) and using conventional method changes into hydrochloride to obtain the compound (102.2mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.55；

NMR(CD₃OD)：δ 7.60-7.44 (m, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.09-6.96 (m, 4H), 4.31 (brs, 2H), 3.80-3.62 (m, 5H), 3.52-3.02 (m, 5H), 2.95 (s, 3H), 2.30-1.82 (m, 2H), 1.80-1.40 (m, 11H), 1.40-1.10 (m, 6H), 1.04-0.80 (m, 5H).

Embodiment 14：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) piperidin-4-yl methanol

Acetic acid (1.0mL) is added in the solution in dimethylformamide (10mL) to 4- piperidyls methanol (1.0g) and 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehydes (2.53g) and solution is stirred at room temperature 5 minutes.Sodium triacetoxy borohydride (2.75g) is added into reaction solution, is stirred for 12 hours.Water (20mL) and ethyl acetate (30mL) are added into reactant mixture, is stirred for and is extracted with ethyl acetate 3 times.Organic layer is washed with salt solution (15mL), is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography to (hexane: ethyl acetate=1: 1) to obtain the compound (2.40g) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.16；

NMR(CDCl₃)：δ 7.31-7.26 (m, 2H), 7.23-7.00 (m, 2H), 7.02-6.92 (m, 4H), 3.50 (d, J=6.3Hz, 2H), 3.47 (s, 2H), 3.00 (s, 3H), 2.98-2.86 (m, 2H), 1.97 (td, J=11.7,2.7Hz, 2H), 1.79-1.64 (m, 2H), 1.50 (m, 1H), 1.36-1.20 (m, 2H).

Embodiment 15：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) -4- piperidyl formaldehgdes

Triethylamine (3.43mL) and dimethyl sulfoxide (DMSO) (1.99mL) are added in solution of the compound (2.40g) prepared into embodiment 14 in dichloromethane (20mL).Sulfur trioxide pyridine complex (1.96g) is added into reactant mixture, is stirred at room temperature 5 hours.Add water into reactant mixture, it is used to extraction dichloromethane 3 times.Organic layer is washed with salt solution (20mL), is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography to (hexane: ethyl acetate=1: 1) to obtain the compound (3.04g) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.32；

NMR(CDCl₃)：δ 9.65 (d, J=1.2Hz, 1H), 7.32-7.24 (m, 2H), 7.24-7.18 (m, 2H), 7.02-6.90 (m, 4H), 3.47 (s, 2H), 3.00 (s, 3H), 2.82 (m, 2H), 2.26 (m, 2H), 2.11 (m, 2H), 1.90 (m, 2H), 1.71 (m, 2H).

Embodiment 16：

N- { 4- [4- ({ 4- [(5S) -1- butyl -5- (cyclohexyl methyl) -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

The compound (500mg) prepared in embodiment 15, N- (tert-butoxycarbonyl)-L- Cyclohexylalanines (396mg), the solution of n-butylamine (0.140mL) and 2- morpholinoethyls isocyanide (0.179mL) in methanol (13mL) are stirred 12 hours at 65 DEG C.Concentrated hydrochloric acid (0.5mL) is added into reaction solution, 2 hours is stirred for and concentrates.Dichloromethane (15mL) and sodium bicarbonate solution (15mL) are added to wherein.Solution is stirred and extracted 2 times with dichloromethane.Organic layer is washed with salt solution (15mL), is dried and concentrated on anhydrous sodium sulfate.1.25M acetic acid/ethyl acetate solution (20mL) is added into obtained residue and stirs solution 12 hours at 70 DEG C.Ethyl acetate is added into reaction solution, is washed with water.Sodium acid carbonate (15mL) is added to wherein, and solution is stirred and is extracted with ethyl acetate 2 times.Organic layer is washed with salt solution (15mL), is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=8: 1) and changes into hydrochloride using conventional method and obtains the compound (470.4mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.58；

NMR(CD₃OD)：δ 7.48 (brd, J=8.7Hz, 2H), 7.29 (brd, J=8.7Hz, 2H), 7.08-7.00 (m, 4H), 4.26 (s, 2H), 4.12 (m, 1：2H), 4.04-3.92 (m, 1H), 3.88 (d, J=5.2Hz, 1：2H), 3.82 (d, J=6.0Hz, 1：2Hz), 3.80 (m, 1：2H), 3.60-3.48 (m, 2H), (3.08-2.78 m, 3H), 2.95 (s, 3H), 2.34-2.10 (m, 1H), (2.10-1.44 m, 13H), 1.40-1.12 (m, 6H), 1.10-0.84 (m, 2H), 0.94 (t, J=7.2Hz, 3：2H), 0.93 (t, J=7.2Hz, 3：2H).

Embodiment 16 (1)-(3)

Utilize the same step as described in 14 → embodiment of embodiment, 15 → embodiment 16; N- (tert-butoxycarbonyl)-L- Cyclohexylalanines and 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehyde are replaced respectively using corresponding carboxylic acid and aldehyde, obtain the compounds of this invention with following physical datas.

Embodiment 16 (1)：

N- (4- { 4- [(4- { (5R) -1- butyl -5- [(R)-cyclohexyl (hydroxyl) methyl] -3,6- dioxopiperazine -2- bases } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.51；

NMR(CD₃OD)：δ 7.47 (brd, J=9.0Hz, 2H), 7.29 (brd, J=9.0Hz, 2H), 7.07-7.00 (m, 4H), 4.25 (s, 2H), 4.18 (m, 1H), 3.98-3.72 (m, 2H), 3.57-3.45 (m, 2H), 3.26 (m, 1H), 3.06-2.78 (m, 3H), 2.95 (s, 3H), 2.46-2.18 (m, 1H), 2.14-1.86 (m, 4H), 1.86-1.48 (m, 7H), 1.44-0.82 (m, 8H), 0.94 (t, J=7.2Hz, 3H).

Embodiment 16 (2)：

4- [4- ({ 4- [(5S) -1- butyl -5- (cyclohexyl methyl) -3,6- dioxopiperazine -2- bases] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the chloroforms: methanol=5: 1) of Rf 0.53；

NMR(CD₃OD)：δ 8.04 (brd, J=8.7Hz, 2H), 7.54 (brd, J=8.7Hz, 2H), 7.16 (brd, J=8.7Hz, 2H), 7.06 (brd, J=8.7Hz, 2H), 4.30 (s, 2H), 4.12 (m, 1/2H), 4.05-3.92 (m, 1H), 3.92-3.76 (m, 3/2H), 3.61-3.46 (m, 2H), 3.10-2.78 (m, 3H), 2.36-1.92 (m, 5H), 1.90-1.44 (m, 10H), 1.40-1.14 (m, 5H), 1.04-0.82 (m, 5H).

Embodiment 16 (3)：

4- { 4- [(4- { (5R) -1- butyl -5- [(R)-cyclohexyl (hydroxyl) methyl] -3,6- dioxopiperazine -2- bases } piperidin-1-yl) methyl] phenoxy group } benzoate hydrochlorate

TLC:(the chloroforms: methanol=5: 1) of Rf 0.39；

NMR(CD₃OD)：δ 8.07-8.00 (m, 2H), 7.60-7.46 (m, 2H), 7.17 (brd, J=8.7Hz, 2H), 7.10-7.00 (m, 2H), 4.30 (s, 2H), 4.21-4.14 (m, 1H), 4.00-3.74 (m, 2H), 3.72-3.46 (m, 2H), 3.26 (m, 1H), 3.09-2.84 (m, 3H), 2.50-2.20 (m, 2H), 2.16-1.88 (m, 5H), 1.88-1.48 (m, 6H), 1.44-0.84 (m, 10H).

Reference example 7

1- benzyls -4- [N- (2- dimethoxy-ethyls) amino] piperidines

Dimethoxy acetaldehyde (5.5mL), sodium triacetoxy borohydride (8.36g) and acetic acid (1.5mL) are added into the solution (100mL) of the dimethylformamide of 4- amino -1- benzyl piepridines (5g), and solution is stirred overnight.Add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=40: 1-1: 1) obtains the title compound (2.74g) with following physical datas.

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.27

NMR(CDCl₃)：δ 7.31-7.20 (m, 5H), 4.46 (t, J=5.5Hz, 1H), 3.50 (s, 2H), 3.38 (s, 6H), 2.87-2.83 (m, 2H), 2.74 (d, J=5.5Hz, 2H), 2.45 (m, 1H), 2.07-1.98 (m, 2H), 1.86-1.82 (m, 2H), 1.46-1.34 (m, 2H).

Reference example 8

1- benzyls -4- (N- (2- dimethoxy-ethyls)-N- (2- cyclohexylcarbonylaminos acetyl group) amino) piperidines

1- ethyls -3- [3- (dimethylamino) propyl group] carbodiimide hydrochloride (2.82g), 4-N are added into the dimethyl formamide solution (30mL) of the compound (2.74g) prepared in reference example 7, N- dimethyl aminopyridines (2.4g) and N- cyclohexyl-carbonyls glycine (2.0g), and solution is stirred at room temperature overnight.Add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=10: 1) obtains the title compound (1.45g) with following physical datas.

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.36.

Reference example 9：

4- (N- (2- dimethoxy-ethyls)-N- (2- cyclohexylcarbonylaminos acetyl group) amino) piperidines

Palladium dydroxide-charcoal (200mg) is added into the methanol solution (8mL) of the compound (900mg) prepared in reference example 7 and stirs solution 3 hours at 50 DEG C in a hydrogen atmosphere.After cooling, reactant mixture is filtered into CELITE (trade name) and filtrate is concentrated to give title compound.Compound is not purified to be used for next reaction.

Embodiment 17：

1- (4- (4- methanesulfonylaminobenzenes epoxide) benzyl) -4- (N- (2- dimethoxy-ethyls)-N- (2- cyclohexylcarbonylaminos acetyl group) amino) piperidines

4- (4- methanesulfonylaminobenzenes epoxide) benzaldehydes (270mg) and sodium triacetoxy borohydride (268mg) are added into dimethylformamide (5mL)/acetic acid (0.2mL) solution of the compound (300mL) prepared in reference example 9, and solution is stirred at room temperature overnight.Reactant mixture is concentrated and purified through silica gel column chromatography and (ethyl acetate: methanol=30: 1-10: 1) obtains the title compound (223mg) with following physical datas.

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.41；

NMR(CDCl₃)：δ 7.29-7.21 (m, 4H), 6.99 (d, J=9.0Hz, 2H), 6.94 (d, J=9.0Hz, 2H), 4.60 (t, J=5.5Hz, 1H), 4.20 (m, 1H), 4.13 (dd, J=16.5,4.0Hz, 2H), 3.56-3.33 (m, 6H), 3.40 (s, 6H), 3.05-2.96 (m, 2H), 2.19-1.22 (m, 15H).

Embodiment 18：

N- { 4- [4- ({ 4- [(the 2H)-yl of 4- (cyclohexyl-carbonyl) -2- oxos -3,4- dihydro pyrazine -1] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

P- toluenesulfonic acids (20mg) are added in suspension (9mL) of the compound prepared into embodiment 17 in toluene and by suspension in 100 DEG C of heating stirrings 3 hours.After cooling, the sodium bicarbonate aqueous solution of saturation is added into reactant mixture, is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.By obtained residue through silica gel column chromatography (ethyl acetate: methanol=30: 1) and High Performance Thin Layer Chromatography (dichloromethane: methanol=15: 1) purifies, and changes into hydrochloride to obtain the compound (20mg) of the invention with following physical datas using conventional method.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.78；

NMR(CD₃OD)：δ 7.50 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.06 (d, J=9.0Hz, 2H), 7.03 (d, J=9.0Hz, 2H), 6.60 (d, J=6.0Hz, 1H), 5.86 (d, J=6.0Hz, 1H), 4.58 (m, 1H), 4.30 (s, 2H), 4.27 (s, 2H), 3.61-3.57 (m, 2H), 3.20-3.12 (m, 2H), 2.95 (s, 3H), 2.26-1.21 (m, 15H).

Embodiment 18 (1)：

1- (1- benzyl piepridine -4- bases) -4- (cyclohexyl-carbonyl) -3,4- dihydro pyrazines -2 (1H) -one hydrochloride

Using such as the same step described in embodiment 18, the compound for replacing preparing in reference example 17 using the compound prepared in reference example 8 obtains the compounds of this invention with following physical datas.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 7.52 (s, 5H), 6.60 (d, J=6.0Hz, 1H), 5.84 (d, J=6.0Hz, 1H), 4.58 (m, 1H), 4.33 (s, 2H), 4.27 (s, 2H), 3.6-3.56 (m, 2H), 3.22-3.14 (m, 2H), 2.69 (m, 1H), 2.19-1.29 (m, 14H).

Embodiment 19：

E- types：4- [4- ({ 4- [(E)-(4- bromophenyls) (ethoxyimino) methyl] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

Z- types：4- [4- ({ 4- [(Z)-(4- bromophenyls) (ethoxyimino) methyl] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

Pyridine (5mL) and O- ethylhydroxylamine hydrochlorides (340mg) are added in the ethanol solution (10mL) of the compound (912mg) prepared into embodiment 5 (15), and solution is flowed back 3 hours.After the completion of reaction, reaction solution is concentrated.Water and 2N hydrochloric acid are added to wherein, and solution is extracted with ethyl acetate.By organic layer salt water washing and concentrate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=25: 1) and by 4N hydrogen chloride/ethyl acetate solution adds into obtained residue, is concentrated to give compound (the E- types of the invention with following physical datas：409mg, Z- type：500mg).

E- types：

TLC:(the chloroforms: methanol=10: 1) of Rf 0.37；

NMR(CD₃OD)：δ 1.29 (t, J=7.0Hz, 3H), 1.90-2.00 (m, 2H), 2.14-2.28 (m, 2H), 2.86-2.96 (m, 2H), 3.38-3.48 (m, 3H), 4.16 (s, 2H), 4.18 (q, J=7.0Hz, 2H), 7.02 (d, J=9.0Hz, 2H), 7.11 (d, J=9.0Hz, 2H), 7.36 (d, J=9.0Hz, 2H), 7.50 (d, J=9.0Hz, 2H), 7.52 (d, J=9.0Hz, 2H), 8.00 (d, J=9.0Hz, 2H).

Z- types：

TLC:(the chloroforms: methanol=10: 1) of Rf 0.35；

NMR(CD₃OD)：δ 1.16 (t, J=7.0Hz, 3H), 1.76-1.91 (m, 2H), 2.03-2.14 (m, 2H), 2.89 (m, 1H), 3.02-3.11 (m, 2H), 3.50-3.58 (m, 2H), 4.03 (q, J=7.0Hz, 2H), 4.31 (s, 2H), 7.06 (d, J=9.0Hz, 2H), 7.16 (d, J=9.0Hz, 2H), 7.25 (d, J=9.0Hz, 2H), 7.55 (d, J=9.0Hz, 2H), 7.57 (d, J=9.0Hz, 2H), 8.03 (d, J=9.0Hz, 2H).

Embodiment 20 (1)-embodiment 20 (79)

Hydrochloride is changed into using the same step as described in embodiment 1 and using conventional method; 4- hydroxy piperidines are replaced using corresponding amine derivative; and described compound is replaced using 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehydes or corresponding aldehyde derivatives, obtain following the compounds of this invention.

Embodiment 20 (1)：

N- benzyls -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：δ 1.92-2.03 (m, 4H), 2.51 (m, 1H), 2.82-2.92 (m, 2H), 2.95 (s, 3H), 3.40-3.44 (m, 2H), 4.15 (s, 2H), 4.35 (s, 2H), 7.02 (d, J=8.7Hz, 2H), (7.04 d, J=8.7Hz, 2H), 7.23-7.33 (m, 7H), 7.45 (d, J=8.7Hz, 2H).

Embodiment 20 (2)：

4- [4- ({ 4- [(Cyclohexylacetyl) amino] -1- piperidyls } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.37；

NMR(CD₃OD)：δ 0.94-1.00 (m, 2H), 1.14-1.30 (m, 4H), 1.60-1.80 (m, 6H), 1.99-2.17 (m, 5H), 3.08-3.16 (m, 2H), 3.52-3.56 (m, 2H), 3.92 (m, 1H), 4.31 (s, 2H), 7.07 (d, J=8.7Hz, 2H), 7.18 (d, J=8.7Hz, 2H), 7.56 (d, J=8.7Hz, 2H), (8.04 d, J=8.7Hz, 2H).

Embodiment 20 (3)：

4- [4- ({ 4- [(benzylamino) carbonyl] -1- piperidyls } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.26；

NMR(CD₃OD)：δ 1.90-2.08 (m, 4H), 2.56 (m, 1H), 2.99-3.07 (m, 2H), 3.48-3.53 (m, 2H), 4.28 (s, 2H), 4.36 (s, 2H), 7.06 (d, J=8.7Hz, 2H), 7.16 (d, J=8.4Hz, 2H), 7.21-7.34 (m, 5H), 7.54 (d, J=8.4Hz, 2H), 8.03 (d, J=8.7Hz, 2H).

Embodiment 20 (4)：

4- [4- ({ 4- [(butylamino) carbonyl] -1- piperidyls } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.20；

NMR(CD₃OD)：δ 0.93 (t, J=7.2Hz, 3H), 1.28-1.53 (m, 4H), 1.95-2.00 (m, 4H), 2.51 (m, 1H), 3.06-3.20 (m, 4H), 3.51-3.53 (m, 2H), 4.32 (s, 2H), 7.07 (d, J=9.0Hz, 2H), 7.17 (d, J=8.5Hz, 2H), 7.55 (d, J=8.5Hz, 2H), 8.04 (d, J=9.0Hz, 2H).

Embodiment 20 (5)：

4- { 4- [(4- { [(cyclohexyl methyl) amino] carbonyl } -1- piperidyls) methyl] phenoxy group } benzoate hydrochlorate

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.21；

NMR(CD₃OD)：δ 0.87 (m, 2H), 1.19-1.31 (m, 3H), 1.46 (m, 1H), 1.64-1.73 (m, 5H), 1.90-2.06 (m, 4H), 2.52 (m, 1H), 3.00-3.09 (m, 4H), 3.53-3.58 (m, 2H), 4.33 (s, 2H), (7.07 d, J=9.0Hz, 2H), (7.18 d, J=8.7Hz, 2H), (7.56 d, J=8.7Hz, 2H), (8.04 d, J=9.0Hz, 2H).

Embodiment 20 (6)：

N- (cyclohexyl methyl) -4- hydroxyls -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.36；

NMR(CD₃OD)：δ 0.82-1.02 (m, 2H), 1.12-1.36 (m, 4H), 1.49 (m, 1H), 1.60-1.88 (m, 6H), 2.31 (m, 2H), 2.95 (s, 3H), (3.04 brt, J=6.6Hz, 2H), 3.22-3.45 (m, 4H), 4.32 (s, 2H), 6.98-7.01 (m, 4H), (7.29 brd, J=9.0Hz, 2H), (7.50 brd, J=9.0Hz, 2H), 8.09 (m, 1H).

Embodiment 20 (7)：

N- (cyclohexyl methyl) -4- methoxyl groups -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.80-1.04 (m, 2H), 1.18-1.40 (m, 4H), 1.50 (m, 1H), 1.60-1.90 (m, 6H), 2.30 (m, 2H), 2.91 (s, 3H), 3.04 (m, 2H), 3.20-3.52 (m, 7H), 4.33 (s, 2H), 7.02-7.18 (m, 4H), 7.45 (brt, J=9.0Hz, 2H), 7.53 (brt, J=8.7Hz, 2H), 8.08 (m, 1H).

Embodiment 20 (8)：

N- [4- (4- { [4- (cyclohexyl-carbonyl) -1- piperazinyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.89；

NMR(CD₃OD)：δ 1.18-1.56 (m, 5H), 1.64-1.85 (m, 5H), 2.65 (m, 1H), 2.95 (m, 3H), 2.90-3.20 (m, 3H), 3.32-3.58 (m, 3H), 4.28 (m, 1H), 4.35 (s, 2H), 4.67 (m, 1H), 7.00-7.12 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.52 (brd, J=8.7Hz2H).

Embodiment 20 (9)：

N- [4- (4- { [4- (Cyclohexylacetyl) -1- piperazinyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.85；

NMR(CD₃OD)：δ 0.90-1.06 (m, 2H), 1.08-1.40 (m, 3H), 1.60-1.80 (m, 6H), 2.31 (brd, J=6.0Hz, 2H), 2.95 (s, 3H), 2.86-3.18 (m, 3H), 3.36-3.60 (m, 3H), 4.21 (m, 1H), 4.35 (s, 2H), 4.69 (m, 1H), 7.00-7.12 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.51 (brd, J=8.7Hz, 2H).

Embodiment 20 (10)：

N- (cyclohexyl methyl) -4- methyl isophthalic acids-(4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.80-1.00 (m, 2H), 1.12-1.32 (m, 4H), 1.49 (m, 1H), 1.62-1.80 (m, 6H), 2.22-2.34 (m, 2H), 2.95 (s, 6H), 2.96-3.08 (m, 2H), 3.24-3.38 (m, 4H), 4.22 (s, 2H), 6.98-7.10 (m, 4H), 7.29 (brd, J=9.3Hz, 2H), 7.46 (brd, J=8.7Hz, 2H), 7.81 (m, 1H).

Embodiment 20 (11)：

4- butoxy-N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.87；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 0.82-1.04 (m, 2H), 1.10-1.58 (m, 7H), 1.58-1.78 (m, 6H), 2.06-2.24 (m, 4H), 2.95 (s, 3H), 3.05 (t, J=3.0Hz, 2H), 3.08-3.44 (m, 6H), 4.32 (s, 2H), 7.00-7.12 (m, 4H), 7.29 (brd, J=8.7Hz, 2H), 7.50 (brd, J=8.7Hz, 2H), 8.00 (m, 1H).

Embodiment 20 (12)：

N- cyclohexyl -4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -1- piperazine carboxamides hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.77；

NMR(CD₃OD)：δ 1.08-1.44 (m, 5H), 1.58-1.92 (m, 5H), 2.95 (s, 3H), 2.95-3.60 (m, 9H), 4.31 (s, 2H), 7.00-7.12 (m, 4H), (7.29 brd, J=9.3Hz, 2H), (7.49 brd, J=8.4Hz, 2H).

Embodiment 20 (13)：

N- benzyls -4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -1- piperazine carboxamides hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 2.95 (s, 3H), 3.22 (m, 4H), 3.70 (m, 4H), 4.28 (s, 2H), 4.35 (s, 2H), 7.00-7.08 (m, 4H), 7.18-7.36 (m, 7H), 7.44-7.56 (m, 2H).

Embodiment 20 (14)：

4- (4- { 4- [(mesyl) amino] phenoxy group } benzyl)-N- phenyl -1- piperazine carboxamides hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 2.95 (s, 3H), 3.10-3.42 (m, 8H), 4.29 (s, 2H), 7.00-7.10 (m, 5H), 7.21-7.40 (m, 6H), 7.49 (brd, J=8.4Hz, 2H).

Embodiment 20 (15)：

N- [4- (4- { [4- (Cyclohexylacetyl) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.59；

NMR(CD₃OD)：δ 0.80-1.02 (m, 2H), 1.08-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.04-2.20 (m, 2H), 2.41 (d, J=6.9Hz, 2H), 2.72 (m, 1H), 2.95 (s, 3H), 3.05 (m, 2H), 3.48 (m, 2H), 4.27 (s, 2H), 7.00-7.10 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.48 (brd, J=9.0Hz, 2H).

Embodiment 20 (16)：

N- (4- { 4- [(4- hydroxyl -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.38；

NMR(CD₃OD)：δ 1.71-2.16 (m, 4H), 2.95 (s, 3H), 3.06-3.53 (m, 4H), 4.08 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=9,0Hz, 2H), 7.06 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), (7.48 d, J=9.0Hz, 2H).

Embodiment 20 (17)：

1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.36；

NMR(CD₃OD)：δ 1.83-2.21 (m, 4H), 2.54 (m, 1H), 2.95 (s, 3H), 2.98-3.06 (m, 2H), 3.52-3.56 (m, 2H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 20 (18)：

1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine carboxylic acid benzyl ester hydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.36；

NMR(CD₃OD)：δ 1.85-1.94 (m, 2H), 2.06-2.12 (m, 2H), 2.60-2.78 (m, 3H), 2.94 (s, 3H), 3.20-3.25 (m, 2H), 3.99 (s, 2H), 5.14 (s, 2H), 6.99-7.02 (m, 4H), 7.27 (d, J=8.7Hz, 2H), 7.32-7.36 (m, 5H), 7.40 (d, J=8.7Hz, 2H).

Embodiment 20 (19)：

1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyl amino carboxylates

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.35；

NMR(CD₃OD)：δ 1.42 (s, 9H), 1.42-1.53 (m, 2H), 1.81-1.85 (m, 2H), 2.07-2.14 (m, 2H), 2.83-2.87 (m, 2H), 2.93 (s, 3H), 3.30-3.36 (m, 1H), 3.49 (s, 2H), 6.93 (d, J=8.7Hz, 2H), 6.97 (d, J=8.7Hz, 2H), 7.24 (d, J=8.7Hz, 2H), (7.30 d, J=8.7Hz, 2H).

Embodiment 20 (20)：

N- { 4- [4- (1- piperidino methyls) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.34；

NMR(CD₃OD)：δ 1.48-1.97 (m, 6H), 2.90-2.99 (m, 2H), 2.95 (s, 3H), 3.42-3.46 (m, 2H), 4.25 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.47 (d, J=8.7Hz, 2H).

Embodiment 20 (21)：

N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] -2- tetrahydrochysene -2H- pyrans -4- yl acetamide hydrochlorides

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.17；

NMR(CD₃OD)：δ 1.20-1.40 (m, 2H), 1.54-1.64 (m, 2H), 1.67-1.84 (m, 2H), 1.88-2.21 (m, 5H), 2.95 (s, 3H), 3.06-3.18 (m, 2H), 3.30-3.46 (m, 2H), 3.46-3.56 (m, 2H), 3.85-3.97 (m, 3H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 20 (22)：

1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl)-N- (tetrahydrochysene -2H- pyrans -4- ylmethyls) -4- piperidine formyl amine hydrochlorates

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.18；

NMR(CD₃OD)：δ 1.18-1.32 (m, 2H), 1.56-1.64 (m, 2H), 1.73 (m, 1H), 1.84-2.10 (m, 4H), 2.53 (m, 1H), 2.95 (s, 3H), 2.96-3.11 (m, 4H), 3.28-3.42 (m, 2H), 3.49-3.58 (m, 2H), 3.87-3.96 (m, 2H), 4.29 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 20 (23)：

4- methyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] benzenesulfonamide, hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 1.56-1.76 (m, 2H), 1.84-2.04 (m, 2H), 2.41 (s, 3H), 2.95 (s, 3H), 3.00 (m, 1H), 3.14-3.45 (m, 4H), 4.20 (s, 2H), 6.98-7.10 (m, 4H), 7.22-7.34 (m, 2H), 7.38-7.52 (m, 4H), 7.72-7.80 (m, 2H).

Embodiment 20 (24)：

N- { [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] carbonyl } benzenesulfonamide, hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.44；

NMR(CD₃OD)：δ 1.68-1.86 (m, 2H), 1.92-2.10 (m, 2H), 2.53 (m, 1H), 2.95 (s, 3H), 2.90-3.04 (m, 2H), 3.42-3.54 (m, 2H), 4.26 (s, 2H), 6.98-7.06 (m, 4H), 7.22-7.36 (m, 2H), 7.40-7.50 (m, 2H), 7.52-7.62 (m, 2H), 7.68 (m, 1H), 8.00 (brd, J=7.5Hz, 2H).

Embodiment 20 (25)：

N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 1.70-1.92 (m, 2H), 2.08-2.26 (m, 2H), 2.95 (s, 3H), 2.98 (s, 3H), 3.00-3.18 (m, 2H), 3.28-3.46 (m, 2H), 3.54 (m, 1H), 4.22 (s, 2H), 6.98-7.10 (m, 4H), 7.26-7.34 (m, 2H), 7.42-7.56 (m, 2H).

Embodiment 20 (26)：

4- [(cyclohexyl-carbonyl) amino] -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine carboxylic acid hydrochlorides

TLC:(the chloroforms: methanol: acetic acid=20: 4: 1) of Rf 0.20；

NMR(CD₃OD)：δ 1.18-1.48 (m, 6H), 1.63-1.86 (m, 4H), 2.16-2.42 (m, 5H), 2.95 (s, 3H), 3.00-3.14 (m, 2H), 3.26-3.41 (m, 2H), 4.23 (s, 2H), 7.00-7.10 (m, 4H), (7.28 brd, J=9.0Hz, 2H), 7.47 (brd, J=8.7Hz, 2H)

Embodiment 20 (27)：

4- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] butanamide hydrochloride

TLC:(the methanol: dichloromethane=1: 8) of Rf 0.58；

NMR(CD₃OD)：δ 0.80-0.96 (m, 2H), 1.12-1.30 (m, 6H), 1.54-1.84 (m, 9H), 2.00-2.18 (m, 4H), 2.95 (s, 3H), 3.03-3.14 (m, 2H), 3.46-3.56 (m, 2H), 3.89 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 20 (28)：

3- cyclohexyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the methanol: dichloromethane=1: 8) of Rf 0.52；

NMR(CD₃OD)：δ 0.83-0.98 (m, 2H), 1.12-1.53 (m, 4H), 1.48 (dd, J=6.6,15.0Hz, 2H), 1.60-1.78 (m, 7H), 2.04-2.24 (m, 4H), 2.95 (s, 3H), 3.02-3.24 (m, 2H), 3.35-3.58 (m, 2H), 3.90 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.48 d, J=8.7Hz, 2H).

Embodiment 20 (29)：

N- [1- ({ 1- [4- (amino-sulfonyl) phenyl] -3,5- dimethyl -1H- pyrazoles -4- bases } methyl) -4- piperidyls] -2- cyclohexyl acetamid dihydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=6.6Hz, 2H) 2.10-2.20 (m, 2H), 2.39 (s, 3H), 2.44 (s, 3H), 3.10-3.30 (m, 2H), 3.60-3.70 (m, 2H), 3.90 (m, 1H), 4.26 (s, 2H), 7.70 (d, J=7.7Hz, 2H), 8.07 (d, J=7.7Hz, 2H).

Embodiment 20 (30)：

2- cyclohexyl-N- { 1- [(1- { 4- [(Cyclohexylamino) sulfonyl] phenyl } -3,5- dimethyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 8H), 1.60-1.90 (m, 13H), 2.05 (d, J=7.2Hz, 2H) 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.44 (s, 3H), 3.00-3.20 (m, 3H), 3.60-3.70 (m, 2H), 3.93 (m, 1H), 4.26 (s, 2H), 7.71 (d, J=8.7Hz, 2H), 8.03 (d, J=8.7Hz, 2H).

Embodiment 20 (31)：

2- cyclohexyl-N- [1- ({ 1- [4- ({ [2- (dimethylamino) ethyl] amino } sulfonyl) phenyl] -3,5- dimethyl -1H- pyrazoles -4- bases } methyl) -4- piperidyls] acetamide tri hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.08；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=6.9Hz, 2H) 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.47 (s, 3H), 2.95 (s, 6H), 3.10-3.20 (m, 6H), 3.60-3.70 (m, 2H), 3.90 (m, 1H), 4.26 (s, 2H), (7.78 d, J=8.9Hz, 2H), (8.07 d, J=8.9Hz, 2H).

Embodiment 20 (32)：

2- cyclohexyl-N- [1- ({ 3,5- dimethyl -1- [4- ({ [2- (4- morpholinyls) ethyl] amino } sulfonyl) phenyl] -1H- pyrazoles -4- bases } methyl) -4- piperidyls] acetamide tri hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=7.2Hz, 2H) 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.46 (s, 3H), 3.10-3.40 (m, 8H), 3.50-3.70 (m, 4H), 3.80-3.90 (m, 3H), 4.10-4.20 (m, 2H), 4.26 (s, 2H), (7.77 d, J=8.7Hz, 2H), (8.07 d, J=8.7Hz, 2H).

Embodiment 20 (33)：

2- cyclohexyl-N- { 1- [(1- { 4- [(dimethylamino) sulfonyl] phenyl } -3,5- dimethyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=6.9Hz, 2H) 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.46 (s, 3H), 2.74 (s, 6H), 3.10-3.20 (m, 2H), 3.60-3.70 (m, 2H), 3.90 (m, 1H), 4.26 (s, 2H), 7.76-7.80 (m, 2H), 7.94-7.97 (m, 2H).

Embodiment 20 (34)：

2- cyclohexyl-N- (1- { [1- (4- { [(2- hydroxyethyls) (methyl) amino] sulfonyl } phenyl) -3,5- dimethyl -1H- pyrazoles -4- bases] methyl } -4- piperidyls) acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=6.9Hz, 2H) 2.10-2.30 (m, 2H), 2.39 (s, 3H), 2.45 (s, 3H), 2.87 (s, 3H), 3.10-3.20 (m, 2H), 3.19 (t, J=5.9Hz, 2H), 3.60-3.80 (m, 2H), 3.69 (t, J=5.9Hz, 2H), 3.93 (m, 1H), 4.26 (s, 2H), 7.75 (d, J=8.7Hz, 2H), 7.99 (d, J=8.7Hz, 2H).

Embodiment 20 (35)：

2- cyclohexyl-N- { 1- [(1- { 4- [(diethylamino) sulfonyl] phenyl } -3,5- dimethyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.15 (t, J=7.1Hz, 6H), 1.10-1.40 (m, 3H), 1.60-1.75 (m, 6H), 1.75-1.90 (m, 2H), 2.05 (d, J=7.2Hz, 2H), 2.10-2.30 (m, 2H), 2.40 (s, 3H), 2.45 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 4H), 3.60-3.80 (m, 2H), 3.94 (m, 1H), 4.26 (s, 2H), 7.73 (d, J=8.6Hz, 2H), 7.99 (d, J=8.6Hz, 2H).

Embodiment 20 (36)：

2- cyclohexyl-N- [1- ({ 3,5- dimethyl -1- [4- (4- morpholinosulfonyls) phenyl] -1H- pyrazoles -4- bases } methyl) -4- piperidyls] acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.75 (m, 6H), 1.75-1.90 (m, 2H), 2.06 (d, J=7.2Hz, 2H), 2.10-2.30 (m, 2H), 2.40 (s, 3H), 2.48 (s, 3H), 3.02 (t, J=4.7Hz, 4H), 3.10-3.20 (m, 2H), 3.60-3.80 (m, 2H), 3.71 (t, J=4.7Hz, 4H), 3.94 (m, 1H), 4.27 (s, 2H), 7.80 (d, J=8.6Hz, 2H), 7.95 (d, J=8.6Hz, 2H).

Embodiment 20 (37)：

2- cyclohexyl-N- { 1- [(3,5- dimethyl -1- { 4- [(4- methyl isophthalic acids-piperazinyl) sulfonyl] phenyl } -1H- pyrazoles -4- bases) methyl] -4- piperidyls } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 6H), 1.80-2.00 (m, 2H), 2.06 (d, J=6.9Hz, 2H), 2.10-2.30 (m, 2H), 2.40 (s, 3H), 2.48 (s, 3H), 2.80-3.00 (m, 2H), 2.90 (s, 3H), 3.10-3.40 (m, 4H), 3.50-3.80 (m, 4H), 3.90-4.10 (m, 3H), 4.27 (s, 2H), (7.84 d, J=8.6Hz, 2H), (8.01 d, J=8.6Hz, 2H).

Embodiment 20 (38)：

[4- ({ 4- [4- ({ 4- [(Cyclohexylacetyl) amino] -1- piperidyls } methyl) -3,5- dimethyl -1H- pyrazol-1-yls] phenyl } sulfonyl) -1- piperazinyls] ethyl acetate tri hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.30 (t, J=7.1Hz, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=6.9Hz, 2H), 2.10-2.30 (m, 2H), 2.40 (s, 3H), 2.49 (s, 3H), 3.10-3.20 (m, 2H), 3.40-4.00 (m, 11H), 4.22 (s, 2H), 4.27 (s, 2H), (4.29 q, J=7.2Hz, 2H), (7.84 d, J=8.6Hz, 2H), (8.02 d, J=8.6Hz, 2H).

Embodiment 20 (39)：

2- cyclohexyl-N- { 1- [(3,5- dimethyl -1- { 4- [(mesyl) amino] phenyl } -1H- pyrazoles -4- bases) methyl] -4- piperidyls } acetamid dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.45；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.90 (m, 8H), 2.05 (d, J=7.2Hz, 2H), 2.10-2.30 (m, 2H), 2.36 (s, 3H), 2.37 (s, 3H), 3.03 (s, 3H), 3.10-3.20 (m, 2H), 3.60-3.70 (m, 2H), 3.90 (m, 1H), 4.24 (s, 2H), 7.39-7.46 (m, 4H).

Embodiment 20 (40)：

2- cyclohexyl-N- [1- (4- { 2,6- dimethyl -4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.03 (d, J=6.9Hz, 2H), 2.07 (s, 6H), 2.10-2.20 (m, 2H), 2.97 (s, 3H), 3.00-3.10 (m, 2H), 3.40-3.60 (m, 2H), 3.90 (m, 1H), 4.24 (s, 2H), 6.84 (d, J=3.9Hz, 2H), 7.04 (s, 2H), (7.45 d, J=8.7Hz, 2H).

Embodiment 20 (41)：

N- (1- { 4- [4- (amino-sulfonyl) phenoxy group] benzyl } -4- piperidyls) -2- cyclohexyl acetamide hydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.33；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.04 (d, J=7.2Hz, 2H), 2.10-2.20 (m, 2H), 3.00-3.10 (m, 2H), 3.50-3.60 (m, 2H), 3.92 (m, 1H), 4.32 (s, 2H), 7.11-7.19 (m, 4H), 7.58-7.62 (m, 2H), 7.88-7.93 (m, 2H).

Embodiment 20 (42)：

2- cyclohexyl-N- (1- { 4- [4- (mesyl) phenoxy group] benzyl } -4- piperidyls) acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.05 (d, J=6.9Hz, 2H), 2.10-2.20 (m, 2H), 3.00-3.10 (m, 2H), 3.12 (s, 3H), 3.50-3.60 (m, 2H), 3.91 (m, 1H), 4.33 (s, 2H), 7.19-7.23 (m, 4H), 7.59 (d, J=8.6

Hz, 2H), 7.95 (d, J=8.6Hz, 2H).

Embodiment 20 (43)：

2- cyclohexyl-N- [1- (4 '-[(mesyl) amino] -1,1 '-biphenyl -3- bases } methyl) -4- piperidyls] acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.38；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.02 (d, J=6.9Hz, 2H), 2.10-2.20 (m, 2H), 2.99 (s, 3H), 3.00-3.10 (m, 2H), 3.50-3.60 (m, 2H), 3.90 (m, 1H), 4.37 (s, 2H), 7.35 (d, J=8.7Hz, 2H), 7.45-7.60 (m, 2H), 7.67 (d, J=8.7Hz, 2H), 7.70-7.80 (m, 2H).

Embodiment 20 (44)：

2- cyclohexyl-N- (1- { 4- [4- (methyl mercapto) phenoxy group] benzyl } -4- piperidyls) acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.03 (d, J=7.2Hz, 2H), 2.10-2.20 (m, 2H), 2.47 (s, 3H), 3.00-3.10 (m, 2H), 3.50-3.60 (m, 2H), 3.90 (m, 1H), 4.27 (s, 2H), 6.99 (d, J=8.5Hz, 2H), 7.04 (d, J=8.5Hz, 2H) 7.32 (d, J=8.5Hz, 2H), (7.48 d, J=8.5Hz, 2H).

Embodiment 20 (45)：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.34；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.10 (t, J=7.4Hz, 3H), 1.20-1.70 (m, 4H), 1.80-2.10 (m, 2H), 2.20-2.50 (m, 2H), 2.35 (q, J=7.6Hz, 2H), 2.95 (s, 3H), 3.00-3.40 (m, 4H), 3.40-3.60 (m, 2H), 4.11 (m, 1H), 4.26 (s, 2H), 7.03 (d, J=8.9Hz, 2H), 7.06 (d, J=8.9Hz, 2H) 7.29 (d, J=8.9Hz, 2H), (7.48 d, J=8.9Hz, 2H).

Embodiment 20 (46)：

N- benzyls-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 1.08 (t, J=7.5Hz, 3H), 1.80-2.00 (m, 2H), 2.00-2.20 (m, 2H), 2.37 (q, J=7.5Hz, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.40-3.60 (m, 2H), 4.22 (s, 2H), 4.40 (m, 1H), 4.61 (s, 2H), 7.00-7.05 (m, 4H), 7.22-7.46 (m, 7H), 7.45 (d, J=8.4Hz, 2H).

Embodiment 20 (47)：

N- (2- methoxy ethyls)-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 1.07 (t, J=7.4Hz, 3H), 1.90-2.00 (m, 2H), 2.42 (q, J=7.4Hz, 2H), 2.40-2.60 (m, 2H), 2.96 (s, 3H), 3.00-3.20 (m, 2H), 3.34 (s, 3H), 3.40-3.60 (m, 4H), 4.05 (m, 1H), 4.28 (s, 2H), 7.01-7.06 (m, 4H), 7.28-7.31 (m, 2H), 7.51-7.56 (m, 2H).

Embodiment 20 (48)：

N- (3- hydroxybutyls)-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 1.10 (t, J=7.2Hz, 3H), 1.19 (t, J=6.0Hz, 2H), 1.60-1.80 (m, 2H), 1.80-2.40 (m, 6H), 2.41 (q, J=7.4Hz, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.40-3.60 (m, 4H), 3.80 (m, 1H), 4.05 (m, 1H), 4.28 (s, 2H), 7.03 (t, J=8.7Hz, 2H), (7.05 t, J=7.4Hz, 2H), (7.29 t, J=7.4Hz, 2H), (7.50 t, J=8.7Hz, 2H).

Embodiment 20 (49)：

N- (cyclohexyl methyl)-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.54；

NMR(CD₃OD)：δ 0.87-0.91 (m, 2H), 1.07 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.60-1.80 (m, 4H), 1.80-2.00 (m, 2H), 2.36 (q, J=7.2Hz, 2H), 2.40-2.60 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.16 (d, J=7.5Hz, 2H), 3.40-3.60 (m, 2H), 3.80 (m, 1H), 4.26 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 20 (50)：

4- (acetyl-amino)-N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=9: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.80-1.00 (m, 2H), 1.08-1.32 (m, 4H), 1.48 (m, 1H), 1.60-1.78 (m, 4H), 2.05 (brs, 3H), 2.10-2.50 (m, 4H), 2.95 (s, 3H), 3.00 (t, J=6.3Hz, 2H), 3.04-3.50 (m, 4H), 4.30 (s, 2H), 6.98-7.08 (m, 4H), 7.28 (brd, J=9.0Hz, 2H), 7.49 (brd, J=8.7Hz, 2H).

Embodiment 20 (51)：

4- [4- ({ 4- [(Cyclohexylacetyl) amino] -1- piperidyls } methyl) phenoxy group] phenylmethane sulfonic acid ester hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.20-1.40 (m, 3H), 1.60-1.80 (m, 8H), (2.04 d, J=7.2Hz, 2H), 2.10-2.20 (m, 2H), 3.10-3.20 (m, 2H), 3.23 (s, 3H), 3.40-3.60 (m, 2H), 3.91 (m, 1H), 4.29 (s, 2H), 7.08-7.14 (m, 4H), 7.34 (d, J=8.6Hz, 2H), 7.54 (d, J=8.6Hz, 2H).

Embodiment 20 (52)：

N- (Cvclopropvlmethvl)-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] propionamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 0.30-0.40 (m, 2H), 0.60-0.70 (m, 2H), 0.95 (m, 1H), 1.10 (t, J=7.4Hz, 3H), 1.90-2.10 (m, 2H), 2.40-2.60 (m, 2H), 2.43 (q, J=7.2Hz, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.22 (d, J=6.3Hz, 2H), 3.45-3.60 (m, 2H), 4.00 (m, 1H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.27-7.32 (m, 2H), 7.50 (t, J=8.1Hz, 2H).

Embodiment 20 (53)：

N- (2- cyclohexyl-ethyls) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.89-0.97 (m, 2H), 1.18-1.41 (m, 7H), 1.60-1.74 (m, 4H), 1.87-2.04 (m, 4H), 2.47 (m, 1H), 2.95 (s, 3H), 2.95-3.04 (m, 2H), 3.16-3.21 (m, 2H), 3.52-3.56 (m, 2H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.47 d, J=8.7Hz, 2H).

Embodiment 20 (54)：

2- cyclohexyl-N- (1- { 4- [4- (methylsulfinyl) phenoxy group] benzyl } -4- piperidyls) acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.21；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.04 (d, J=6.9Hz, 2H), 2.10-2.20 (m, 2H), 2.80 (s, 3H), 3.10-3.20 (m, 2H), 3.50-3.60 (m, 2H), 3.90 (m, 1H), 4.31 (s, 2H), (7.16 d, J=8.7Hz, 2H), (7.22 d, J=9.0Hz, 2H), (7.58 d, J=9.0Hz, 2H), (7.74 d, J=8.7Hz, 2H).

Embodiment 20 (55)：

N- [2- (ethylmercapto group) ethyl] -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：δ 1.23 (t, J=7.5Hz, 3H), 1.88-2.08 (m, 4H), 2.46-2.67 (m, 5H), 2.94-3.07 (m, 2H), 2.95 (s, 3H), 3.37 (t, J=7.0Hz, 2H), 3.52-3.56 (m, 2H), 4.28 (s, 2H), (7.03 d, J=9.0Hz, 2H), (7.06 d, J=9.0Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.48 d, J=9.0Hz, 2H).

Embodiment 20 (56)：

2- cyclohexyl-N- [1- (4- { 2- methoxyl groups -4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.03 (d, J=6.9Hz, 2H), 2.10-2.20 (m, 2H), 2.99 (s, 3H), 3.00-3.20 (m, 2H), 3.40-3.60 (m, 2H), 3.72 (s, 3H), 3.89 (m, 1H), 4.31 (s, 2H), 6.83-6.94 (m, 3H), 6.99-7.05 (m, 2H), 7.39-7.45 (m, 2H).

Embodiment 20 (57)：

2- cyclohexyl-N- [1- (4- { 3- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：δ 0.90-1.10 (m, 2H), 1.10-1.40 (m, 3H), 1.60-1.80 (m, 8H), 2.04 (d, J=6.9Hz, 2H), 2.10-2.20 (m, 2H), 2.96 (s, 3H), 3.00-3.20 (m, 2H), 3.40-3.60 (m, 2H), 3.90 (m, 1H), 4.29 (s, 2H), 6.79 (dd, J=7.5,2.4Hz, 1H), 6.95-7.01 (m, 2H), 7.08-7.11 (m, 2H), 7.31-7.34 (m, 1H), 7.51-7.54 (m, 2H).

Embodiment 20 (58)：

N- [4- (4- { [4- (Cyclohexylacetyl) -3- methyl isophthalic acids-piperazinyl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.72；

NMR(CD₃OD)：δ 0.82-1.44 (m, 8H), 1.60-1.85 (m, 6H), 2.30-2.42 (m, 2H), 2.95 (s, 3H), 2.95-3.65 (m, 5H), 4.10-5.15 (m, 4H), 7.00-7.12 (m, 4H), 7.24-7.38 (m, 2H), (7.52 brd, J=8.7Hz, 2H).

Embodiment 20 (59)：

1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyl cyclohexylcarbamate hydrochlorides

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 1.06-1.42 (m, 6H), 1.54-1.92 (m, 6H), 1.95-2.17 (m, 2H), 2.26 (m, 1H), 2.95 (s, 3H), 3.05-3.58 (m, 5H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (dd, J=4.2,8.7Hz, 2H).

Embodiment 20 (60)：

(2R, 3R) -3- cyclohexyl -3- hydroxyls -2- ({ [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] carbonyl } amino) propionate hydrochlorate

TLC:(the dichloromethane: methanol=8: 2) of Rf 0.23；

NMR(CD₃OD)：δ 1.00-1.34 (m, 5H), 1.48 (m, 1H), 1.58-1.80 (m, 4H), 1.83-2.11 (m, 5H), 2.58 (m, 1H), 2.95 (s, 3H), 2.87-3.00 (m, 2H), 3.40-3.49 (m, 2H), 3.51 (t, J=6.0Hz, 1H), 4.18 (s, 2H), 4.39 (d, J=6.0Hz, 1H), (7.02 d, J=8.7Hz, 2H), (7.03 d, J=8.7Hz, 2H), (7.28 d, J=8.7Hz, 2H), (7.46 d, J=8.7Hz, 2H).

Embodiment 20 (61)：

N- butyl -2- cyclohexyl-N- [1- (4- { 3- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.32；

NMR(CD₃OD)：δ 0.80-1.10 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.20-1.40 (m, 5H), 1.40-1.60 (m, 2H), 1.60-2.00 (m, 8H), 2.30-2.40 (m, 2H), 2.32 (d, J=7.2Hz, 2H), 2.96 (s, 3H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.30 (s, 2H), 6.80 (m, 1H), 6.95 (m, 1H), 7.00 (m, 1H), 7.08 (d, J=8.7Hz, 2H), 7.33 (t, J=8.1Hz, 1H), 7.55-7.61 (m, 2H).

Embodiment 20 (62)：

4- [4- ({ 4- [butyl (caproyl) amino] -1- piperidyls } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the chloroforms: methanol=10: 1) of Rf 0.34；

NMR(CD₃OD)：δ 0.90-1.00 (m, 3H), 0.97 (t, J=7.4Hz, 3H), 1.20-1.40 (m, 6H), 1.50-1.70 (m, 4H), 1.80-2.00 (m, 2H), 2.20-2.40 (m, 4H), 3.00-3.20 (m, 4H), 3.50-3.70 (m, 2H), 4.10 (m, 1H), 4.31 (s, 2H), (7.07 d, J=9.0Hz, 2H), (7.17 d, J=9.0Hz, 2H), (7.56 d, J=9.0Hz, 2H), (8.04 d, J=9.0Hz, 2H).

Embodiment 20 (63)：

4- [4- ({ 4- [benzyl (caproyl) amino] -1- piperidyls } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.86 (t, J=7.2Hz, 3H), 1.20-1.50 (m, 4H), 1.50-1.70 (m, 2H), 1.88-1.95 (m, 2H), 2.00-2.20 (m, 2H), 2.30-2.40 (m, 2H), 3.00-3.20 (m, 2H), 3.50-3.60 (m, 2H), 4.27 (s, 2H), 4.45 (m, 1H), 4.62 (s, 2H), 7.03-7.07 (m, 2H), 7.13-7.37 (m, 7H), 7.52 (d, J=8.4Hz, 2H), 8.01-8.04 (m, 2H).

Embodiment 20 (64)：

N- butyl -2- cyclohexyl-N- [1- (4- { 2- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.20-1.40 (m, 5H), 1.40-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 2.98 (s, 3H), 3.00-3.30 (m, 4H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.28 (s, 2H), 6.98 (m, 1H), 7.12 (d, J=8.7Hz, 2H), 7.18-7.21 (m, 2H), 7.52-7.54 (m, 3H).

Embodiment 20 (65)：

Benzyl butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] carbamate hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.77；

NMR(CD₃OD)：(the t of δ 0.90, J=7.2Hz, 3H), 1.21-1.36 (m, 2H), 1.42-1.58 (m, 2H), 1.88-2.00 (m, 2H), 2.09-2.34 (m, 2H), 2.95 (s, 3H), 3.00-3.14 (m, 2H), 3.17-3.28 (m, 2H), 3.43-3.58 (m, 2H), 3.93 (m, 1H), 4.25 (s, 2H), 5.12 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.24-7.38 (m, 7H), 7.47 (d, J=8.7Hz, 2H).

Embodiment 20 (66)：

Benzyl allyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] carbamate hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.75；

NMR(CD₃OD)：δ 1.90-2.01 (m, 2H), 2.09-2.19 (m, 2H), 2.95 (s, 3H), 3.01-3.12 (m, 2H), 3.44-3.55 (m, 2H), 3.89 (d, J=5.5Hz, 2H), 4.03 (m, 1H), 4.25 (s, 2H), 5.09-5.21 (m, 2H), 5.13 (s, 2H), 5.83 (ddd, J=22.5,10.2,5.4Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.25-7.38 (m, 7H), (7.47 d, J=8.7Hz, 2H).

Embodiment 20 (67)：

Benzyl 2- butynyls [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] carbamate hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.76；

NMR(CD₃OD)：δ 1.75 (t, J=2.1Hz, 3H), 1.95-2.08 (m, 2H), 2.18-2.36 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.47-3.57 (m, 2H), 4.03 (d, J=2.1Hz, 2H), 4.07 (m, 1H), 4.26 (s, 2H), 5.16 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.25-7.41 (m, 7H), 7.47 (d, J=8.7Hz, 2H).

Embodiment 20 (68)：

N- butyl -2- cyclohexyl-N- (1- { 3- [(mesyl) amino] -4- phenoxy benzyls } -4- piperidyls) acetamide hydrochloride

TLC:(the chloroforms: methanol: acetic acid=20: 2: 1) of Rf 0.48；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.50-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 3.04 (s, 3H), 3.05-3.30 (m, 4H), 3.50-3.70 (m, 2H), 4.14 (m, 1H), 4.28 (s, 2H), 6.89 (d, J=8.4Hz, 1H), 7.10 (d, J=7.5Hz, 2H), 7.20-7.29 (m, 2H), 7.40-7.46 (m, 2H), 7.68 (d, J=2.1Hz, 1H).

Embodiment 20 (69)：

N- butyl -2- cyclohexyl-N- { 1- [4- (4-nitrophenoxy) benzyl] -4- piperidyls } acetamide hydrochloride

TLC:(the chloroforms: methanol: acetic acid=20: 2: 1) of Rf 0.54；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.98 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.50-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.22 (d, J=6.6Hz, 2H), 2.30-2.40 (m, 2H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 4.19 (m, 1H), 4.34 (s, 2H), 7.16 (d, J=9.1Hz, 2H), 7.24 (d, J=8.4Hz, 2H), 7.63 (d, J=8.4Hz, 2H), 8.27 (d, J=9.1Hz, 2H).

Embodiment 20 (70)：

4- [4- ({ 4- [butyl (Cyclohexylacetyl) amino] -1- piperidyls } methyl) phenoxy group] phenylmethane sulfonic acid ester hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.79；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.40-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 3.00-3.20 (m, 4H), 3.23 (s, 3H), 3.50-3.60 (m, 2H), 4.18 (m, 1H), 4.29 (s, 2H), (7.11 d, J=9.0Hz, 4H), (7.35 d, J=9.0Hz, 2H), (7.54 d, J=9.0Hz, 2H).

Embodiment 20 (71)：

N- butyl -2- cyclohexyl-N- [1- (4- { 2- methyl -4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.40-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.16 (s, 3H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 2.96 (s, 3H), 3.00-3.20 (m, 4H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.25 (s, 2H), 6.91-6.98 (m, 3H), 7.13 (dd, J=8.6, 2.6Hz, 1H), 7.20 (m, 1H), 7.44-7.49 (m, 2H).

Embodiment 20 (72)：

N- butyl -2- cyclohexyl-N- [1- (4- { 2,6- dimethyl -4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.33；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.40-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.07 (s, 6H), 2.21 (d, J=6.6Hz, 2H), 2.30-2.40 (m, 2H), 2.97 (s, 3H), 3.00-3.20 (m, 4H), 3.50-3.60 (m, 2H), 4.17 (m, 1H), 4.24 (s, 2H), 6.86 (d, J=8.7Hz, 2H), 7.04 (s, 2H), (7.45 d, J=8.7Hz, 2H).

Embodiment 20 (73)：

N- butyl-N- [1- (4- { the chloro- 4- of 2- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] -2- cyclohexyl acetamide hydrochlorides

TLC:(the chloroforms: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.4Hz, 3H), 1.20-1.40 (m, 5H), 1.40-1.60 (m, 2H), 1.60-2.00 (m, 8H), 2.21 (d, J=6.6Hz, 2H), 2.30-2.40 (m, 2H), 3.01 (s, 3H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.27 (s, 2H), 6.99 (d, J=8.4Hz, 2H), 7.13 (d, J=9.0Hz, 1H), 7.24 (dd, J=9.0, 2.6Hz, 1H), 7.43 (d, J=2.6Hz, 1H), 7.48-7.52 (m, 2H).

Embodiment 20 (74)：

(2R) -2- cyclohexyl -2- hydroxy-ns-[1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 1.06-1.38 (m, 5H), 1.45-1.94 (m, 8H), 2.05-2.16 (m, 2H), 2.95 (s, 3H), 3.03-3.17 (m, 2H), 3.48-3.57 (m, 2H), 3.79 (d, J=4.0Hz, 1H), 3.96 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7H z, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.51 d, J=8.7Hz, 2H).

Embodiment 20 (75)：

(2S) -2- cyclohexyl -2- hydroxy-ns-[1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 1.06-1.38 (m, 5H), 1.45-1.94 (m, 8H), 2.05-2.16 (m, 2H), 2.95 (s, 3H), 3.03-3.17 (m, 2H), 3.48-3.57 (m, 2H), 3.79 (d, J=4.0Hz, 1H), 3.96 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.51 d, J=8.7Hz, 2H).

Embodiment 20 (76)：

2- [4- ({ 4- [butyl (Cyclohexylacetyl) amino] -1- piperidyls } methyl) phenoxy group] -5- [(mesyl) amino] benzoic acid methyl ester hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.90-1.00 (m, 2H), 0.97 (t, J=7.2Hz, 3H), 1.10-1.40 (m, 5H), 1.50-1.60 (m, 2H), 1.65-1.80 (m, 6H), 1.80-2.00 (m, 2H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 3.00 (s, 3H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 3.74 (s, 3H), 4.10 (m, 1H), 4.26 (s, 2H), 6.98 (d, J=8.7Hz, 2H), 7.10 (d, J=8.7Hz, 1H), 7.45-7.52 (m, 3H), 7.79 (d, J=3.0Hz, 1H).

Embodiment 20 (77)：

2- [4- ({ 4- [butyl (Cyclohexylacetyl) amino] -1- piperidyls } methyl) phenoxy group] -5- [(mesyl) amino] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.95-1.05 (m, 2H), 0.97 (t, J=7.3Hz, 3H), 1.10-1.40 (m, 5H), 1.50-1.80 (m, 8H), 1.80-2.00 (m, 2H), 2.21 (d, J=6.9Hz, 2H), 2.30-2.40 (m, 2H), 3.01 (s, 3H), 3.05-3.25 (m, 4H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.26 (s, 2H), 6.95 (d, J=8.7Hz, 2H), 7.09 (d, J=8.7Hz, 1H), 7.46-7.51 (m, 3H), 7.83 (d, J=2.7Hz, 1H).

Embodiment 20 (78)：

(2R)-N- butyl -2- cyclohexyl -2- hydroxy-ns-[1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.55；

NMR(CD₃OD)：δ 0.90-2.58 (m, 22H), 2.95 (s, 3H), 3.02-3.35 (m, 4H), 3.50-3.60 (m, 2H), 3.94-4.17 (m, 2H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.45-7.54 (m, 2H).

Embodiment 20 (79)：

(2S)-N- butyl -2- cyclohexyl -2- hydroxy-ns-[1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] acetamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.55；

Embodiment 20 (80)：

(3,4- is trans)-N- (cyclohexyl methyl) -3- methyl isophthalic acids-(4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=9: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.84-1.04 (m, 2H), 0.93 (d, J=6.0Hz, 3H), 1.14-1.34 (m, 4H), 1.48 (m, 1H), 1.60-1.80 (m, 4H), 1.88-2.04 (m, 2H), 2.06-2.18 (m, 2H), 2.72 (m, 1H), 2.88-3.12 (m, 3H), 2.95 (s, 3H), 3.22-3.60 (m, 2H), 4.28 (brs, 2H), 7.00-7.18 (m, 4H), (7.29 brd, J=9.0Hz, 2H), (7.48 brd, J=8.7Hz, 2H).

Embodiment 20 (81)：

(3,4- is cis)-N- (cyclohexyl methyl) -3- methyl isophthalic acids-(4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=9: 1) of Rf 0.25；

NMR(CD₃OD)：δ 0.82-1.06 (m, 2H), 1.00 (d, J=6.9Hz, 3H), 1.13-1.34 (m, 4H), 1.46 (m, 1H), 1.62-1.80 (m, 4H), 1.92-2.24 (m, 3H), 2.55 (m, 1H), 2.90-3.12 (m, 2H), 2.95 (s, 3H), 3.13-3.62 (m, 4H), 4.29 (brs, 2H), 6.98-7.10 (m, 4H), (7.29 brd, J=9.0Hz, 2H), (7.51 brd, J=8.7Hz, 2H).

Embodiment 20 (82)：

N- (cyclohexyl methyl) -1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -3- azetidine carboxamide hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.80-1.02 (m, 2H), 1.19-1.35 (m, 4H), 1.49 (m, 1H), 1.60-1.80 (m, 4H), 2.95 (s, 3H), 3.06 (m, 2H), 3.61 (m, 1H), 4.12-4.32 (m, 4H), 4.39 (s, 2H), 6.98-7.06 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.45 (brd, J=8.7Hz, 2H).

Embodiment 20 (83)：

(1R, 3s, 5S)-N- (cyclohexyl methyl) -8- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -8- azabicyclics [3.2.1] octane -3- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.85-1.04 (m, 2H), 1.20-1.36 (m, 4H), 1.46 (m, 1H), 1.60-1.78 (m, 4H), 1.85-1.90 (m, 2H), 2.08-2.16 (m, 4H), 2.38-2.50 (m, 2H), 2.88 (m, 1H), 2.95 (s, 3H), 3.00 (d, J=6.9Hz, 2H), 3.96 (m, 2H), 4.16 (s, 2H), 7.00-7.10 (m, 4H), 7.24-7.32 (m, 2H), (7.53 brd, J=8.7Hz, 2H).

Embodiment 20 (84)：

(3aR, 5s, 6aS)-N- (cyclohexyl methyl) -2- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) octahydro cyclopenta [c] pyrroles's -5- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.55；

NMR(CD₃OD)：δ 0.80-1.02 (m, 2H), 1.04-1.36 (m, 3H), 1.46 (m, 1H), 1.60-2.18 (m, 9H), 2.76-3.04 (m, 7H), 2.95 (s, 3H), 3.60-3.78 (m, 2H), 4.35 (s, 2H), 7.00-7.19 (m, 4H), 7.24-7.32 (m, 2H), 7.42-7.58 (m, 2H).

Embodiment 20 (85)：

(3aR, 5r, 6aS)-N- (cyclohexyl methyl) -2- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) octahydro cyclopenta [c] pyrroles's -5- carboxamide hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.80-1.00 (m, 2H), 1.10-1.36 (m, 3H), 1.42 (m, 1H), 1.60-1.82 (m, 6H), 2.18 (m, 1H), 2.24-2.38 (m, 2H), 2.78-3.40 (m, 9H), 2.95 (s, 3H), 4.30 (s, 2H), 7.00-7.10 (m, 4H), 7.22-7.38 (m, 2H), 7.42-7.58 (m, 2H).

Embodiment 21 (1)-(11)

By the same step as described in 14 → embodiment of embodiment, 15 → embodiment 16, described compound is replaced using N- (tert-butoxycarbonyl)-L- Cyclohexylalanines or corresponding carboxylic acid derivates；Corresponding aldehyde derivatives replace 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehyde；And described compound is replaced with n-butylamine or corresponding amine derivative, obtain the compound of the invention with following physical datas.

Embodiment 21 (1)：

(3S) -1- benzyls -3- (cyclohexyl methyl) -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.82-2.42 (m, 24H), 2.80-3.12 (m, 2H), 3.56-3.70 (m, 2H), 3.79 (m, 1H), 4.02-4.16 (m, 4H), 5.12-5.38 (m, 1H), 7.20-7.62 (m, 10H).

Embodiment 21 (2)：

(3S) -1- butyl -3- (cyclohexyl methyl) -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.80-1.08 (m, 5H), 1.10-1.42 (m, 6H), 1.42-2.38 (m, 14H), 2.78-3.08 (m, 3H), 3.44-3.60 (m, 2H), 3.62-4.14 (m, 3H), 4.26 (brs, 2H), 7.00-7.06 (m, 4H), 7.18 (m, 1H), 7.38-7.52 (m, 4H).

Embodiment 21 (3)：

(3R) -1- butyl -3- [(R)-cyclohexyl (hydroxyl) methyl] -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.62；

NMR(CD₃OD)：δ 0.86-2.48 (m, 23H), 2.81-3.08 (m, 3H), 3.27 (m, 1H), 3.45-3.58 (m, 2H), 3.64-4.00 (m, 2H), 4.18 (m, 1H), 4.25 (brs, 2H), 7.00-7.07 (m, 4H), 7.18 (m, 1H), 7.28-7.52 (m, 4H).

Embodiment 21 (4)：

(3S) -3- benzyl -1- butyl -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 0.78-2.30 (m, 12H), 2.52-3.96 (m, 9H), 4.14-4.28 (m, 2H), 4.38 (m, 1H), 6.98-7.52 (m, 14H).

Embodiment 21 (5)：

(3S) -1- butyl -3- cyclohexyl -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 0.78-1.00 (m, 3H), 1.00-2.38 (m, 20H), 2.78-3.08 (m, 3H), 3.48-4.04 (m, 5H), 4.26 (m, 2H), 6.98-7.10 (m, 4H), 7.18 (m, 1H), 7.39-7.54 (m, 4H).

Embodiment 21 (6)：

(3S) -1- butyl -3- (hydroxymethyl) -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.46；

NMR(CD₃OD)：δ 0.76-1.01 (m, 3H), 1.22-1.42 (m, 2H), 1.44-1.72 (m, 3H), 1.86-2.38 (m, 4H), 2.80-3.08 (m, 3H), 3.44-3.60 (m, 2H), 3.64-4.12 (m, 5H), 4.26 (brs, 2H), 6.96-7.10 (m, 4H), 7.18 (m, 1H), 7.36-7.52 (m, 4H).

Embodiment 21 (7)：

(3S) -1- butyl -3- (cyclohexyl methyl) -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.68；

NMR(CD₃OD)：δ 0.86-1.08 (m, 5H), 1.16-2.12 (m, 20H), 2.39 (m, 6H), 2.78-3.16 (m, 3H), 3.56-3.70 (m, 2H), 3.76-4.14 (m, 3H), 4.24 (brs, 2H), 7.47-7.56 (m, 5H).

Embodiment 21 (8)：

(3R) -1- butyl -3- [(R)-cyclohexyl (hydroxyl) methyl] -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.90-2.14 (m, 23H), 2.32-2.40 (m, 6H), 2.80-3.14 (m, 3H), 3.28 (m, 1H), 3.56-3.68 (m, 2H), 3.68-4.00 (m, 2H), 4.19 (m, 1H), 4.24 (brs, 2H), 7.42-7.60 (m, 5H).

Embodiment 21 (9)：

(3S) -3- benzyl -1- butyl -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.78-2.40 (m, 12H), 2.32-2.40 (m, 6H), 2.32-3.95 (m, 8H), 4.12-4.44 (m, 4H), 7.10-7.28 (m, 5H), 7.40-7.61 (m, 5H).

Embodiment 21 (10)：

(3S) -1- butyl -3- cyclohexyl -6- { 1- [(3,5- dimethyl -1- phenyl -1H- pyrazoles -4- bases) methyl] -4- piperidyls } -2,5- piperazinedione hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.80-1.00 (m, 3H), 1.02-2.22 (m, 20H), 2.32-2.40 (m, 6H), 2.80-3.18 (m, 3H), 3.58-4.08 (m, 5H), 4.24 (brs, 2H), 7.40-7.60 (m, 5H).

Embodiment 21 (11)：

(3S) -1- butyl -3- (cyclohexyl methyl) -6- [1- (4- phenoxy benzyls) -4- piperidyls] -2- piperazinones dihydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.82；

NMR(CD₃OD)：δ 0.95 (t, J=7.5Hz, 3H), 0.85-1.10 (m, 2H), 1.16-1.42 (m, 6H), 1.46-2.10 (m, 13H), 2.21 (m, 1H), 2.81 (m, 1H), 3.00-3.20 (m, 2H), 3.34-3.72 (m, 5H), 3.92-4.08 (m, 2H), 4.30 (s, 2H), 7.00-7.10 (m, 4H), 7.18 (m, 1H), 7.36-7.44 (m, 2H), (7.54 brd, J=8.4Hz, 2H).

Embodiment 22：

The mixture of N- { 4- [4- ({ 4- [(1E) -2- cyclohexyl-N- Ethoxyethanes imido grpups (ethaneimidyl)] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochlorides and N- { 4- [4- ({ 4- [(1Z) -2- cyclohexyl-N- Ethoxyethanes imido grpup] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

Using the same step as described in embodiment 19, the compound for replacing preparing in embodiment 5 (15) using the compound prepared in embodiment 20 (15) obtains the compounds of this invention with following physical datas.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.67,0.73；

NMR(CD₃OD)：δ 0.84-1.06 (m, 2H), 1.08-1.36 (m, 4H), 1.18 (t, J=7.2Hz, 3H), 1.58-2.18 (m, 9H), 2.23 (d, J=7.2Hz, 2H), 2.42 (m, 1H), 2.95 (s, 3H), 3.02 (m, 2H), 3.38-3.56 (m, 2H), 4.00 (q, J=7.2Hz, 2H), 4.26 (s, 2H), 7.00-7.10 (m, 4H), 7.22-7.36 (m, 2H), 7.47 (brd, J=8.4Hz, 2H).

Embodiment 23：

N- [4- (4- { [4- (butyl { [(1- methylcyclohexyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

The compound (117mg) prepared into embodiment 3 is in N; 1- cyclohexanecarboxylic acids (50mg) and diphenyl phosphoryl azide (0.077mL) are added in solution in dinethylformamide (3mL) and triethylamine (0.1mL), and solution is stirred 2 hours at 80 DEG C.After cooling, the sodium bicarbonate aqueous solution of saturation is added into reactant mixture, is extracted with ethyl acetate.By organic layer is with salt water washing and dries on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography (ethyl acetate) and High Performance Thin Layer Chromatography, and changes into hydrochloride to obtain the compound (58mg) of the invention with following physical datas using conventional method.

TLC:Rf 0.60 (ethyl acetate)；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.30-1.60 (m, 12H), 1.32 (s, 3H), 1.87-2.07 (m, 6H), 2.95 (s, 3H), 3.05-3.15 (m, 4H), 3.52-3.56 (m, 2H), 4.19 (m, 1H), 4.28 (s, 2H), (7.03 d, J=9.0Hz, 2H), (7.06 d, J=9.0Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.49 d, J=9.0Hz, 2H).

Embodiment 23 (1)-(151)

Using the same step as described in embodiment 23, using the compound or corresponding amine derivative prepared in embodiment 3, and 1- cyclohexanecarboxylic acids or corresponding carboxylic acid derivates are utilized, obtain following compounds of the invention.

Embodiment 23 (1)：

3- [({ [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] benzoate hydrochlorate

TLC:(the n-butanols: acetic acid: water=4: 2: 1) of Rf 0.75；

NMR(CD₃OD)：δ 1.70-1.96 (m, 2H), 2.10-2.30 (m, 2H), 2.96 (s, 3H), 3.07-3.20 (m, 2H), 3.46-3.60 (m, 2H), 3.84 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), 7.30 (d, J=8.7Hz, 2H), 7.35 (t, J=7.8Hz, 1H), 7.51 (d, J=8.7Hz, 2H), 7.59-7.66 (m, 2H), 8.04 (s, 1H).

Embodiment 23 (2)：

N- (4- { 4- [(4- { butyl [(butylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.51；

NMR(CD₃OD)：δ 0.92 (t, J=6.9Hz, 3H), 0.94 (t, J=6.9Hz, 3H), 1.40-1.26 (m, 4H), 1.56-1.42 (m, 4H), 1.95-1.83 (m, 2H), 2.20-2.02 (m, 2H), 2.95 (s, 3H), 3.17-3.05 (m, 6H), 3.60-3.50 (m, 2H), 4.13 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (3)：

N- (4- { 4- [(4- { butyl [(tert-butylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.33 (s, 9H), 1.40-1.25 (m, 2H), 1.58-1.44 (m, 2H), 1.92-1.83 (m, 2H), 2.10-1.97 (m, 2H), 2.95 (s, 3H), 3.15-3.02 (m, 4H), 3.58-3.50 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.30 (d, J=9.0Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (4)：

N- (4- { 4- [(4- { butyl [(Cyclohexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.62；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.95-1.10 (m, 18H), 2.20-2.02 (m, 2H), 2.95 (s, 3H), 3.18-3.02 (m, 4H), 3.60-3.50 (m, 3H), 4.18 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (5)：

N- (4- { 4- [(4- { benzyl [(butylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.84-0.95 (m, 3H), 1.14-1.50 (m, 4H), 1.86-2.09 (m, 4H), 2.95 (s, 3H), 3.01-3.12 (m, 2H), 3.13 (t, J=6.9Hz, 2H), 3.44-3.52 (m, 2H), 4.24 (s, 2H), 4.35 (m, 1H), 4.46 (s, 2H), 7.02 (d, J=9.0Hz, 2H), 7.04 (d, J=9.0Hz, 2H), 7.20-7.35 (m, 7H), (7.46 d, J=9.0Hz, 2H).

Embodiment 23 (6)：

N- (4- { 4- [(4- { benzyl [(Cyclohexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.70；

NMR(CD₃OD)：δ 1.02-1.40 (m, 6H), 1.52-2.08 (m, 8H), 2.95 (s, 3H), 3.02-3.13 (m, 2H), 3.44-3.60 (m, 3H), 4.22 (s, 2H), 4.39 (m, 1H), 4.43 (s, 2H), 7.02 (d, J=9.0Hz, 2H), 7.04 (d, J=9.0Hz, 2H), 7.20-7.36 (m, 7H), 7.46 (d, J=9.0Hz, 2H).

Embodiment 23 (7)：

N- (4- { 4- [(4- { benzyl [(ethylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.42；

NMR(CD₃OD)：δ 1.02-1.13 (m, 3H), 1.84-2.08 (m, 4H), 2.95 (s, 3H), 3.00-3.12 (m, 2H), 3.15-3.21 (m, 2H), 3.42-3.52 (m, 2H), 4.23 (s, 2H), 4.32 (m, 1H), 4.46 (s, 2H), (7.01 d, J=9.0Hz, 2H), (7.04 d, J=8.7Hz, 2H), 7.20-7.34 (m, 7H), 7.46 (d, J=8.7Hz, 2H).

Embodiment 23 (8)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (2- methoxy ethyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.55；

NMR(CD₃OD)：δ 1.12-1.44 (m, 6H), 1.54-2.13 (m, 8H), 2.95 (s, 3H), 3.02-3.14 (m, 2H), 3.28-3.40 (m, 2H), 3.37 (s, 3H), 3.42-3.58 (m, 5H), 4.13 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (9)：

4- [({ [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.30；

NMR(CD₃OD)：δ 1.71-1.82 (m, 2H), 2.21-2.26 (m, 2H), 2.96 (s, 3H), 2.99-3.17 (m, 2H), 3.52-3.57 (m, 2H), 3.84 (m, 1H), 4.30 (s, 2H), 7.03-7.08 (m, 4H), 7.30 (d, J=8.6Hz, 2H), 7.47 (d, J=8.6Hz, 2H), 7.51 (d, J=8.6Hz, 2H), (7.91 d, J=8.6Hz, 2H).

Embodiment 23 (10)：

N- [4- (4- { [4- (2,4- dioxos-Isosorbide-5-Nitrae-dihydro -3 (2H)-quinazolyl) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.62；

NMR(CD₃OD)：δ 1.93-1.97 (m, 2H), 2.95 (s, 3H), 2.96-3.30 (m, 4H), 3.55-3.59 (m, 2H), 4.31 (s, 2H), 5.19 (m, 1H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.13 (m, 1H), 7.22 (m, 1H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.63 (m, 1H), 8.02 (m, 1H).

Embodiment 23 (11)：

N- { 4- [4- ({ 4- [(anilinocarbonyl) (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.97 (t, J=7.5Hz, 3H), 1.30-1.45 (m, 2H), 1.54-1.66 (m, 2H), 1.94-2.04 (m, 2H), 2.14-2.32 (m, 2H), 2.95 (s, 3H), 3.05-3.18 (m, 2H), 3.24-3.34 (m, 2H), 3.51-3.63 (m, 2H), 4.19 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.23-7.34 (m, 7H), (7.51 d, J=8.7Hz, 2H).

Embodiment 23 (12)：

N- [4- (4- { [4- (butyl { [(2- phenylethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.75；

NMR(CD₃OD)：(the t of δ 0.90, J=7.2Hz, 3H), 1.20-1.46 (m, 4H), 1.84-1.93 (m, 2H), 2.00-2.18 (m, 2H), 2.79 (t, J=7.2Hz, 2H), 2.95 (s, 3H), 2.99-3.12 (m, 4H), 3.39 (t, J=7.2Hz, 2H), 3.48-3.57 (m, 2H), 4.06 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.13-7.27 (m, 5H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (13)：

N- [4- (4- { [4- (butyl { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 0.97 (t, J=7.5Hz, 3H), 1.33-1.44 (m, 2H), 1.55-1.66 (m, 2H), 1.94-2.02 (m, 2H), 2.14-2.30 (m, 2H), 2.95 (s, 3H), 3.04-3.14 (m, 2H), 3.22-3.32 (m, 2H), 3.52-3.62 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 6.97-7.08 (m, 6H), 7.27-7.33 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (14)：

N- [4- (4- { [4- (butyl { [(2,5- 3,5-dimethylphenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.79；

NMR(CD₃OD)：δ 0.99 (t, J=7.2Hz, 3H), 1.34-1.48 (m, 2H), 1.60-1.71 (m, 2H), 1.95-2.04 (m, 2H), 2.14-2.30 (m, 2H), 2.16 (s, 3H), 2.27 (s, 3H), 2.95 (s, 3H), 3.04-3.16 (m, 2H), 3.24-3.34 (m, 2H), 3.52-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.91-7.10 (m, 7H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (15)：

N- [4- (4- { [4- (benzyl { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.82；

NMR(CD₃OD)：δ 1.94-2.20 (m, 4H), 2.95 (s, 3H), 3.02-3.14 (m, 2H), 3.44-3.55 (m, 2H), 4.25 (s, 2H), 4.36 (m, 1H), 4.64 (s, 2H), 6.97 (d, J=8.7Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.24-7.41 (m, 9H), 7.46 (d, J=8.7Hz, 2H).

Embodiment 23 (16)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- methoxy ethyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.50；

NMR(CD₃OD)：δ 1.98-2.08 (m, 2H), 2.10-2.26 (m, 2H), 2.95 (s, 3H), 3.02-3.18 (m, 2H), 3.47 (s, 3H), 3.44-3.64 (m, 6H), 4.14 (m, 1H), 4.29 (s, 2H), 6.98-7.06 (m, 2H), 7.03 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.22-7.28 (m, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (17)：

N- { 4- [4- ({ 4- [butyl ({ [3- (methyl mercapto) phenyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.33-1.46 (m, 2H), 1.54-1.66 (m, 2H), 1.93-2.04 (m, 2H), 2.14-2.24 (m, 2H), 2.46 (s, 3H), 2.95 (s, 3H), 3.04-3.18 (m, 2H), 3.24-3.34 (m, 2H), 3.48-3.60 (m, 2H), 4.16 (m, 1H), 4.29 (s, 2H), 6.76 (m, 1H), 7.00-7.22 (m, 7H), 7.30 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (18)：

N- { 4- [4- ({ 4- [benzyl ({ [3- (methyl mercapto) phenyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.76；

NMR(CD₃OD)：δ 1.90-2.02 (m, 2H), 2.04-2.20 (m, 2H), 2.43 (s, 3H), 2.95 (s, 3H), 3.00-3.15 (m, 2H), 3.42-3.54 (m, 2H), 4.23 (s, 2H), 4.36 (m, 1H), 4.66 (s, 2H), 6.92 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.15 (d, J=7.8Hz, 2H), 7.25-7.39 (m, 9H), (7.45 d, J=8.7Hz, 2H).

Embodiment 23 (19)：

N- [4- (4- { [4- (butyl { [(the chloro- 6- aminomethyl phenyls of 2-) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.77；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.34-1.48 (m, 2H), 1.65-1.75 (m, 2H), 1.96-2.06 (m, 2H), 2.16-2.32 (m, 2H), 2.26 (s, 3H), 2.95 (s, 3H), 3.04-3.16 (m, 2H), 3.26-3.34 (m, 2H), 3.51-3.60 (m, 2H), 4.16 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.14-7.21 (m, 2H), 7.28-7.31 (m, 3H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (20)：

N- (4- { 4- [(4- { butyl [(2,4,6- trimethylphenyls (mesityl) amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.77；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.34-1.46 (m, 2H), 1.61-1.73 (m, 2H), 1.94-2.04 (m, 2H), 2.13-2.30 (m, 2H), 2.15 (s, 6H), 2.23 (s, 3H), 2.95 (s, 3H), 3.04-3.16 (m, 2H), 3.24-3.32 (m, 2H), 3.52-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.87 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (21)：

N- { 4- [4- ({ 4- [{ [(3- acetylphenyls) amino] carbonyl } (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.79；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.33-1.45 (m, 2H), 1.55-1.68 (m, 2H), 1.96-2.06 (m, 2H), 2.15-2.32 (m, 2H), 2.58 (s, 3H), 2.95 (s, 3H), 3.06-3.19 (m, 2H), 3.25-3.35 (m, 2H), 3.53-3.62 (m, 2H), 4.19 (m, 1H), 4.30 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.41 (t, J=8.0Hz, 1H), 7.50 (d, J=8.7Hz, 2H), 7.62 (ddd, J=8.0, 2.1, 1.2Hz, 1H), 7.68 (ddd, J=8.0, 1.5, 1.2Hz, 1H), 8.00 (m, 1H).

Embodiment 23 (22)：

N- { 4- [4- ({ 4- [[(benzylamino) carbonyl] (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.26-1.40 (m, 2H), 1.47-1.60 (m, 2H), 1.87-1.98 (m, 2H), 2.06-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.18 (m, 4H), 3.49-3.59 (m, 2H), 4.15 (m, 1H), 4.27 (s, 2H) 4.36 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (J=8.7Hz, 2H), 7.23-7.31 (m, 7H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (23)：

N- { 4- [4- ({ 4- [[(1- adamantylaminos) carbonyl] (3- hydroxybutyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.66；

NMR(CD₃OD)：δ 1.18 (d, J=6.3Hz, 3H), 1.38-1.50 (m, 2H), 1.64-1.80 (m, 7H), 1.80-1.94 (m, 2H), 1.95-2.12 (m, 10H), 2.95 (s, 3H), 3.00-3.54 (m, 4H), 3.48-3.57 (m, 2H), 3.74 (m, 1H), 4.12 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (24)：

N- [4- (4- { [4- (butyl { [(2- cyclohexyl-ethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 0.85-1.02 (m, 2H), 1.13-1.58 (m, 10H), 1.61-1.80 (m, 5H), 1.83-1.95 (m, 2H), 2.03-2.19 (m, 2H), 2.95 (s, 3H), 3.02-3.13 (m, 6H), 3.48-3.58 (m, 2H), 4.14 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (25)：

N- [4- (4- { [4- ({ [(2- cyclohexyl-ethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.24；

NMR(CD₃OD)：δ 0.85-1.00 (m, 2H), 1.10-1.40 (m, 7H), 1.60-1.78 (m, 6H), 2.08-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.18 (m, 4H), 3.45-3.55 (m, 2H), 3.72 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (26)：

N- { 4- [4- ({ 4- [{ [(2- cyclohexyl-ethyls) amino] carbonyl } (methyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.29；

NMR(CD₃OD)：δ 0.84-1.00 (m, 2H), 1.15-1.44 (m, 7H), 1.60-1.78 (m, 6H), 1.97-2.13 (m, 2H), 2.74 (s, 3H), 2.95 (s, 3H), 3.03-3.20 (m, 4H), 3.51-3.60 (m, 2H), 4.28 (s, 2H), 4.30 (m, 1H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (27)：

N- { 4- [4- ({ 4- [{ [(2- cyclohexyl-ethyls) amino] carbonyl } (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.57；

NMR(CD₃OD)：δ 0.84-1.01 (m, 2H), 1.12 (t, J=6.9Hz, 3H), 1.08-1.45 (m, 6H), 1.58-1.80 (m, 5H), 1.85-1.94 (m, 2H), 1.97-2.18 (m, 2H), 2.95 (s, 3H), 3.02-3.14 (m, 6H), 3.48-3.59 (m, 2H), 4.20 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (28)：

N- { 4- [4- ({ 4- [{ [(2- cyclohexyl-ethyls) amino] carbonyl } (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 0.91 (t, J=7.5Hz, 3H), 0.82-1.00 (m, 2H), 1.15-1.40 (m, 6H), 1.42-1.80 (m, 6H), 1.80-2.20 (m, 5H), 2.95 (s, 3H), 2.98-3.22 (m, 6H), 3.42-3.58 (m, 2H), 4.12 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.30 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (29)：

N- { 4- [4- ({ 4- [{ [(2- cyclohexyl-ethyls) amino] carbonyl } (2- methoxy ethyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.85-1.00 (m, 2H), 1.08-1.40 (m, 6H), 1.60-1.80 (m, 5H), 1.87-2.18 (m, 4H), 2.95 (s, 3H), 3.02-3.18 (m, 2H), 3.15 (t, J=6.2Hz, 2H), 3.29-3.38 (m, 2H), 3.36 (s, 3H), 3.45-3.57 (m, 4H), 4.08 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 23 (30)：

N- [4- (4- { [4- (benzyl { [(2- cyclohexyl-ethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.78-0.93 (m, 2H), 1.02-1.33 (m, 6H), 1.56-1.70 (m, 5H), 1.85-2.03 (m, 4H), 2.95 (s, 3H), 2.98-3.20 (m, 4H), 3.42-3.53 (m, 2H), 4.23 (s, 2H), 4.36 (m, 1H), 4.45 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.15-7.38 (m, 7H), (7.45 d, J=8.7Hz, 2H).

Embodiment 23 (31)：

N- { 4- [4- ({ 4- [{ [(2- cyclohexyl-ethyls) amino] carbonyl } (cyclohexyl methyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.83-1.12 (m, 4H), 1.15-1.41 (m, 10H), 1.52-1.80 (m, 10H), 1.87-1.95 (m, 2H), 2.18-2.30 (m, 2H), 2.95 (s, 3H), 3.02-3.14 (m, 4H), 3.17 (t, J=6.2Hz, 2H), 3.48-3.57 (m, 2H), 3.91 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (32)：

N- [4- (4- { [4- (butyl { [(cyclohexyl methyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：(the t of δ 0.95, J=7.2Hz, 3H), 0.82-1.05 (m, 2H), 1.14-1.42 (m, 5H), 1.43-1.58 (m, 3H), 1.62-1.81 (m, 5H), 1.85-1.98 (m, 2H), 1.99-2.22 (m, 2H), 2.95 (s, 3H), 2.99 (d, J=6.9Hz, 2H), 3.02-3.17 (m, 4H), 3.48-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (33)：

N- [4- (4- { [4- ({ [(cyclohexyl methyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.48；

NMR(CD₃OD)：δ 0.83-1.02 (m, 2H), 1.12-1.33 (m, 4H), 1.58-1.80 (m, 6H), 2.03 (m, 1H), 2.09-2.11 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.50-3.58 (m, 2H), 3.72 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (34)：

N- { 4- [4- ({ 4- [{ [(cyclohexyl methyl) amino] carbonyl } (methyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：δ 0.81-1.00 (m, 2H), 1.13-1.32 (m, 4H), 1.48 (m, 1H), 1.60-1.90 (m, 6H), 1.93-2.12 (m, 2H), 2.75 (s, 3H), 2.95 (s, 3H), 2.98 (d, J=6.9Hz, 2H), 3.04-3.19 (m, 2H), 3.49-3.60 (m, 2H), 4.28 (s, 2H), 4.33 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (35)：

N- { 4- [4- ({ 4- [{ [(cyclohexyl methyl) amino] carbonyl } (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.55；

NMR(CD₃OD)：δ 0.83-0.99 (m, 2H), 1.14 (t, J=6.9Hz, 3H), 1.08-1.32 (m, 2H), 1.47 (m, 1H), 1.60-1.79 (m, 6H), 1.86-1.95 (m, 2H), 2.00-2.17 (m, 2H), 2.95 (s, 3H), 2.98 (dd, J=7.2, 2.0Hz, 2H), 3.02-3.25 (m, 4H), 3.49-3.58 (m, 2H), 4.22 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (36)：

N- { 4- [4- ({ 4- [{ [(cyclohexyl methyl) amino] carbonyl } (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.59；

NMR(CD₃OD)：(the t of δ 0.91, J=7.2Hz, 3H), 0.83-0.99 (m, 2H), 1.10-1.33 (m, 4H), 1.40-1.80 (m, 7H), 1.85-1.96 (m, 2H), 2.02-2.20 (m, 2H), 2.95 (s, 3H), 2.98 (d, J=7.2Hz, 2H), 3.00-3.17 (m, 4H), 3.50-3.58 (m, 2H), 4.14 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (37)：

N- { 4- [4- ({ 4- [{ [(cyclohexyl methyl) amino] carbonyl } (2- methoxy ethyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.57；

NMR(CD₃OD)：δ 0.85-1.00 (m, 2H), 1.15-1.35 (m, 3H), 1.43 (m, 1H), 1.63-1.80 (m, 5H), 1.88-2.18 (m, 4H), 2.95 (s, 3H), 2.95 (d, J=6.6Hz, 2H), 3.02-3.15 (m, 2H), 3.25-3.38 (m, 2H), 3.36 (s, 3H), 3.46-3.58 (m, 4H), 4.10 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (38)：

N- [4- (4- { [4- (benzyl { [(cyclohexyl methyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 070；

NMR(CD₃OD)：δ 0.72-0.85 (m, 2H), 1.08-1.40 (m, 4H), 1.50-1.79 (m, 5H), 1.90-2.08 (m, 4H), 2.95 (s, 3H), 2.96 (d, J=6.9Hz, 2H), 3.02-3.17 (m, 2H), 3.44-3.56 (m, 2H), 4.24 (s, 2H), 4.38 (m, 1H), 4.46 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.20-7.38 (m, 7H), (7.46 d, J=8.7Hz, 2H).

Embodiment 23 (39)：

N- [4- (4- { [4- ((cyclohexyl methyl) { [(cyclohexyl methyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.72；

NMR(CD₃OD)：δ 0.82-1.05 (m, 4H), 1.13-1.35 (m, 6H), 1.46 (m, 1H), 1.60-1.85 (m, 11H), 1.87-1.98 (m, 2H), 2.15-2.31 (m, 2H), 2.95 (s, 3H), 2.98 (d, J=6.6Hz, 2H), 2.94-3.13 (m, 4H), 3.50-3.59 (m, 2H), 3.89 (m, 1H), 4.26 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.30 (d, J=8.7Hz, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 23 (40)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 1.12 (t, J=7.0Hz, 3H), 1.07-1.43 (m, 5H), 1.59-1.96 (m, 7H), 1.97-2.18 (m, 2H), 2.95 (s, 3H), 3.03-3.26 (m, 4H), 3.48-3.61 (m, 3H), 4.21 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.30 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (41)：

N- { 4- [4- ({ 4- [(anilinocarbonyl) (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.56；

NMR(CD₃OD)：δ 1.23 (t, J=7.0Hz, 3H), 1.94-2.04 (m, 2H), 2.10-2.29 (m, 2H), 2.95 (s, 3H), 3.05-3.19 (m, 2H), 3.38 (q, J=7.0Hz, 2H), 3.52-3.61 (m, 2H), 4.25 (m, 1H), 4.30 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.24-7.38 (m, 7H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (42)：

N- { 4- [4- ({ 4- [[(benzylamino) carbonyl] (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：δ 1.16 (t, J=7.0Hz, 3H), 1.89-1.97 (m, 2H), 2.02-2.18 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.25 (q, J=7.0Hz, 2H), 3.50-3.58 (m, 2H), 4.21 (m, 1H), 4.28 (s, 2H), 4.36 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.18-7.30 (m, 7H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (43)：

N- [4- (4- { [4- (ethyl { [(2- phenylethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.67；

NMR(CD₃OD)：δ 1.06 (t, J=7.0Hz, 3H), 1.84-1.93 (m, 2H), 1.98-2.15 (m, 2H), 2.79 (t, J=7.5Hz, 2H), 2.95 (s, 3H), 3.01-3.20 (m, 4H), 3.38 (t, J=7.5Hz, 2H), 3.50-3.59 (m, 2H), 4.19 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.12-7.33 (m, 7H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (44)：

N- (4- { 4- [(4- { ethyl [(ethylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.20；

NMR(CD₃OD)：δ 1.09 (t, J=7.2Hz, 3H), 1.13 (t, J=7.2Hz, 3H), 1.85-1.95 (m, 2H), 1.98-2.18 (m, 2H), 2.95 (s, 3H), 3.03-3.24 (m, 6H), 3.50-3.59 (m, 2H), 4.21 (m, 1H), 4.29 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.30 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (45)：

N- { 4- [4- ({ 4- [[(tert-butylamino) carbonyl] (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.41；

NMR(CD₃OD)：δ 1.13 (t, J=7.2Hz, 3H), 1.33 (s, 9H), 1.82-1.93 (m, 2H), 1.95-2.11 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.18 (t, J=7.2Hz, 2H), 3.49-3.59 (m, 2H), 4.22 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (46)：

N- { 4- [4- ({ 4- [[(butylamino) carbonyl] (ethyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.37；

NMR(CD₃OD)：δ 0.93 (t, J=7.2Hz, 3H), 1.13 (t, J=7.0Hz, 3H), 1.26-1.40 (m, 2H), 1.42-1.54 (m, 2H), 1.85-1.96 (m, 2H), 1.98-2.15 (m, 2H), 2.95 (s, 3H), 3.02-3.24 (m, 6H), 3.49-3.58 (m, 2H), 4.21 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (47)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.93 (t, J=7.2Hz, 3H), 1.13-1.41 (m, 5H), 1.48-1.67 (m, 3H), 1.71-1.92 (m, 6H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.03-3.14 (m, 4H), 3.50-3.59 (m, 3H), 4.10 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (48)：

N- { 4- [4- ({ 4- [(anilinocarbonyl) (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.59-1.72 (m, 2H), 1.95-2.06 (m, 2H), 2.15-2.31 (m, 2H), 2.95 (s, 3H), 3.05-3.18 (m, 2H), 3.22-3.32 (m, 2H), 3.52-3.61 (m, 2H), 4.18 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.23-7.37 (m, 7H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (49)：

N- { 4- [4- ({ 4- [[(benzylamino) carbonyl] (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.91 (t, J=7.0Hz, 3H), 1.50-1.66 (m, 2H), 1.87-1.98 (m, 2H), 2.04-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.49-3.58 (m, 2H), 4.14 (m, 1H), 4.27 (s, 2H), 4.36 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.15-7.32 (m, 7H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (50)：

N- { 4- [4- ({ 4- [{ [(2- phenylethyls) amino] carbonyl } (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.72；

NMR(CD₃OD)：δ 0.85 (t, J=7.2Hz, 3H), 1.38-1.51 (m, 2H), 1.84-1.93 (m, 2H), 2.00-2.19 (m, 2H), 2.75-2.82 (m, 2H), 2.95 (s, 3H), 2.94-3.15 (m, 4H), 3.33-3.41 (m, 2H), 3.48-3.58 (m, 2H), 4.11 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.13-7.31 (m, 7H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (51)：

N- { 4- [4- ({ 4- [[(ethylamino) carbonyl] (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.56；

NMR(CD₃OD)：δ 0.91 (t, J=7.0Hz, 3H), 1.09 (t, J=7.2Hz, 3H), 1.46-1.60 (m, 2H), 1.86-1.95 (m, 2H), 2.03-2.19 (m, 2H), 2.95 (s, 3H), 3.00-3.22 (m, 6H), 3.50-3.59 (m, 2H), 4.13 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (52)：

N- { 4- [4- ({ 4- [[(tert-butylamino) carbonyl] (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.68；

NMR(CD₃OD)：δ 0.91 (t, J=7.2Hz, 3H), 1.32 (s, 9H), 1.47-1.61 (m, 2H), 1.84-1.94 (m, 2H), 1.95-2.11 (m, 2H), 2.95 (s, 3H), 3.01-3.15 (m, 4H), 3.50-3.57 (m, 2H), 4.16 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (53)：

N- { 4- [4- ({ 4- [[(butylamino) carbonyl] (propyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.91 (t, J=7.5Hz, 3H), 0.92 (t, J=7.5Hz, 3H), 1.27-1.39 (m, 2H), 1.41-1.59 (m, 4H), 1.85-1.96 (m, 2H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.22 (m, 6H), 3.50-3.58 (m, 2H), 4.13 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (54)：

N- (4- { 4- [(4- { butyl [(pentyl amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 0.91 (t, J=7.2Hz, 3H), 0.95 (t, J=7.2Hz, 3H), 1.23-1.41 (m, 6H), 1.44-1.58 (m, 4H), 1.86-1.95 (m, 2H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.17 (m, 6H), 3.48-3.58 (m, 2H), 4.14 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (55)：

N- (4- { 4- [(4- { benzyl [(pentyl amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.86 (t, J=7.2Hz, 3H), 1.10-1.50 (m, 6H), 1.88-2.09 (m, 4H), 2.95 (s, 3H), 3.01-3.17 (m, 2H), 3.13 (t, J=7.0Hz, 2H), 3.44-3.52 (m, 2H), 4.24 (s, 2H), 4.35 (m, 1H), 4.46 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.20-7.36 (m, 7H), 7.45 (d, J=8.7Hz, 2H).

Embodiment 23 (56)：

N- (4- { 4- [(4- { (2- methoxy ethyls) [(pentyl amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.29；

NMR(CD₃OD)：(the t of δ 0.91, J=7.0Hz, 3H), 1.22-1.38 (m, 4H), 1.41-1.54 (m, 2H), 1.87-2.19 (m, 4H), 2.95 (s, 3H), 3.02-3.16 (m, 2H), 3.11 (t, J=7.0Hz, 2H), 3.28-3.38 (m, 2H), 3.36 (s, 3H), 3.45-3.58 (m, 4H), 4.10 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (57)：

N- (4- { 4- [(4- { butyl [(isopropylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.65；

NMR(CD₃OD)：(the t of δ 0.91, J=7.2Hz, 3H), 1.13 (d, J=6.6Hz, 6H), 1.28-1.40 (m, 2H), 1.43-1.57 (m, 2H), 1.85-1.96 (m, 2H), 2.02-2.19 (m, 2H), 2.95 (s, 3H), 3.03-3.15 (m, 4H), 3.48-3.58 (m, 2H), 3.91 (m, 1H), 4.13 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (58)：

N- (4- { 4- [(4- { benzyl [(isopropylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.70；

NMR(CD₃OD)：δ 1.05 (d, J=6.6Hz, 6H), 1.86-2.10 (m, 4H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.44-3.53 (m, 2H), 3.91 (m, 1H), 4.24 (s, 2H), 4.35 (m, 1H), 4.47 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.21-7.39 (m, 7H), (7.46 d, J=8.7Hz, 2H).

Embodiment 23 (59)：

N- { 4- [4- ({ 4- [[(butylamino) carbonyl] (2- methoxy ethyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.33；

NMR(CD₃OD)：(the t of δ 0.93, J=7.2Hz, 3H), 1.26-1.51 (m, 4H), 1.87-1.98 (m, 2H), 2.00-2.18 (m, 2H), 2.95 (s, 3H), 3.01-3.16 (m, 2H), 3.12 (t, J=7.0Hz, 2H), 3.28-3.37 (m, 2H), 3.36 (s, 3H), 3.45-3.58 (m, 4H), 4.10 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (60)：

N- [4- (4- { [4- ({ [(2- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.39；

NMR(CD₃OD)：δ 1.66-1.73 (m, 2H), 2.22-2.26 (m, 2H), 2.95 (s, 3H), 3.08-3.17 (m, 2H), 3.51-3.55 (m, 2H), 3.80 (m, 1H), 3.86 (s, 3H), 4.29 (s, 2H), 6.86 (m, 1H), 6.94 (m, 2H), 7.04 (d, J=9.0Hz, 2H), 7.07 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.49 (d, J=9.0Hz, 2H), 7.96 (m, 1H).

Embodiment 23 (61)：

N- [4- (4- { [4- ({ [(3- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：δ 1.67-1.79 (m, 2H), 2.20-2.24 (m, 2H), 2.96 (s, 3H), 3.08-3.16 (m, 2H), 3.51-3.55 (m, 2H), 3.75 (s, 3H), 3.81 (m, 1H), 4.29 (s, 2H), 6.56 (m, 1H), 6.82 (m, 1H), 7.02-7.16 (m, 6H), 7.30 (d, J=9.0Hz, 2H), (7.50 d, J=9.0Hz, 2H).

Embodiment 23 (62)：

N- [4- (4- { [4- ({ [(4- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.25；

NMR(d₆-DMSO)：δ 1.66-1.75 (m, 2H), 1.99-2.23 (m, 2H), 2.97 (s, 3H), 2.97-3.05 (m, 2H), 3.31-3.35 (m, 2H), 3.64 (m, 1H), 3.67 (s, 3H), 4.22 (d, J=4.8Hz, 2H), 6.38 (br-d, J=7.2Hz, 1H), 6.79 (d, J=9.0Hz, 2H), 7.03 (d, J=9.0Hz, 2H), 7.06 (d, J=9.0Hz, 2H), 7.25 (d, J=9.0Hz, 2H), 7.26 (d, J=9.0Hz, 2H), 7.55 (d, J=9.0Hz, 2H), 8.24 (s, 1H), 9.70 (s, 1H).

Embodiment 23 (63)：

N- (4- { 4- [(4- { [(Cyclohexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.25；

NMR(CD₃OD)：δ 1.06-1.41 (m, 5H), 1.53-1.88 (m, 6H), 2.01 (m, 1H), 2.09-2.18 (m, 2H), 2.95 (s, 3H), 3.02-3.12 (m, 2H), 3.40-3.55 (m, 3H), 3.72 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (64)：

N- { 4- [4- ({ 4- [(anilinocarbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.26；

NMR(CD₃OD)：δ 1.64-1.89 (m, 2H), 2.10-2.25 (m, 2H), 2.95 (s, 3H), 3.03-3.25 (m, 2H), 3.36-3.57 (m, 2H), 3.85 (m, 1H), 4.29 (s, 2H), 6.97 (t, J=7.5Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.20-7.38 (m, 6H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (65)：

N- (4- { 4- [(4- { butyl [(cyclopropylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：δ 0.42-0.50 (m, 2H), 0.62-0.71 (m, 2H), 0.93 (t, J=7.2Hz, 3H), 1.23-1.37 (m, 2H), 1.41-1.53 (m, 2H), 1.84-1.96 (m, 2H), 2.04-2.23 (m, 2H), 2.51 (m, 1H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.49-3.59 (m, 2H), 4.09 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (66)：

N- (4- { 4- [(4- { butyl [(Cyclobutylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.58；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.26-1.41 (m, 2H), 1.44-1.56 (m, 2H), 1.60-1.73 (m, 2H), 1.84-2.30 (m, 8H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.48-3.59 (m, 2H), 4.10 (m, 1H), 4.20 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (67)：

N- (4- { 4- [(4- { butyl [(clopentylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.25-1.76 (m, 10H), 1.85-1.98 (m, 4H), 2.02-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.16 (m, 4H), 3.48-3.59 (m, 2H), 4.03 (m, 1H), 4.14 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (68)：

N- (4- { 4- [(4- { butyl [(tetrahydrochysene -2H- pyrans -4- bases amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.31；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.26-1.64 (m, 6H), 1.72-1.95 (m, 4H), 2.03-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.17 (m, 4H), 3.38-3.59 (m, 4H), 3.78 (m, 1H), 3.86-3.96 (m, 2H), 4.13 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (69)：

N- (4- { 4- [(4- { butyl [(cyclo-heptylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.26-1.72 (m, 14H), 1.78-1.94 (m, 4H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.16 (m, 4H), 3.49-3.59 (m, 2H), 3.74 (m, 1H), 4.14 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (70)：

N- { 4- [4- ({ 4- [(anilinocarbonyl) (amyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.76；

NMR(CD₃OD)：(the t of δ 0.92, J=7.2Hz, 3H), 1.28-1.44 (m, 4H), 1.55-1.69 (m, 2H), 1.93-2.04 (m, 2H), 2.12-2.30 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.23-3.32 (m, 2H), 3.51-3.60 (m, 2H), 4.19 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.22-7.35 (m, 5H), 7.41 (d, J=7.5Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (71)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (amyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.78；

NMR(CD₃OD)：δ 0.91 (t, J=7.2Hz, 3H), 1.12-1.41 (m, 9H), 1.46-1.93 (m, 9H), 2.02-2.19 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.48-3.60 (m, 3H), 4.13 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7H z, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (72)：

N- (4- { 4- [(4- { pi-allyl [(Cyclohexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.74；

NMR(CD₃OD)：δ 1.08-1.42 (m, 6H), 1.55-2.12 (m, 8H), 2.95 (s, 3H), 3.03-3.16 (m, 2H), 3.47-3.59 (m, 3H), 3.81 (d, J=5.0Hz, 2H), 4.27 (s, 2H), 4.32 (m, 1H), 5.18 (dd, J=10.5, 1.5Hz, 1H), 5.20 (dd J=20.2, 1.5Hz, 1H), 5.83 (ddd, J=20.2, 10.5, 5.0Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (73)：

N- (4- { 4- [(4- { 2- butynyls [(Cyclohexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.75；

NMR(CD₃OD)：δ 1.15-1.43 (m, 5H), 1.77 (t, J=2.4Hz, 3H), 1.58-2.00 (m, 7H), 2.05-2.20 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.50-3.62 (m, 3H), 3.92 (d, J=2.4Hz, 2H), 4.23 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (74)：

N- (4- { 4- [(4- { butyl [(propylcarbamic) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.89 (t, J=7.2Hz, 3H), 0.94 (t, J=7.2Hz, 3H), 1.26-1.41 (m, 2H), 1.45-1.58 (m, 4H), 1.85-1.95 (m, 2H), 2.04-2.22 (m, 2H), 2.95 (s, 3H), 3.03-3.16 (m, 6H), 3.48-3.59 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (75)：

N- (4- { 4- [(4- { amyl group [(propylcarbamic) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.73；

NMR(CD₃OD)：δ 0.89 (t, J=7.2Hz, 3H), 0.92 (t, J=7.0Hz, 3H), 1.23-1.40 (m, 4H), 1.44-1.59 (m, 4H), 1.85-1.95 (m, 2H), 2.03-2.21 (m, 2H), 2.95 (s, 3H), 3.04-3.15 (m, 6H), 3.49-3.58 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (76)：

N- { 4- [4- ({ 4- [[(butylamino) carbonyl] (amyl group) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.75；

NMR(CD₃OD)：δ 0.91 (d, J=7.2Hz, 3H), 0.92 (t, J=7.2Hz, 3H), 1.24-1.41 (m, 6H), 1.43-1.59 (m, 4H), 1.85-1.96 (m, 2H), 2.03-2.21 (m, 2H), 2.95 (s, 3H), 3.03-3.20 (m, 6H), 3.49-3.58 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (77)：

N- { 4- [4- ({ 4- [[(butylamino) carbonyl] (cyclohexyl methyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.74；

NMR(CD₃OD)：δ 0.92 (t, J=7.2Hz, 3H), 0.83-1.00 (m, 2H), 1.15-1.80 (m, 13H), 1.87-1.98 (m, 2H), 2.13-2.32 (m, 2H), 2.95 (s, 3H), 3.00-3.17 (m, 6H), 3.48-3.57 (m, 2H), 3.89 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 23 (78)：

N- (4- { 4- [(4- { butyl [(hexylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.72；

NMR(CD₃OD)：δ 0.89 (t, J=7.2Hz, 3H), 0.94 (t, J=7.2Hz, 3H), 1.22-1.39 (m, 8H), 1.41-1.56 (m, 4H), 1.85-1.94 (m, 2H), 2.03-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.19 (m, 6H), 3.49-3.58 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (79)：

N- (4- { 4- [(4- { amyl group [(pentyl amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.90 (t, J=7.2Hz, 3H), 0.92 (t, J=7.2Hz, 3H), 1.23-1.40 (m, 8H), 1.44-1.60 (m, 4H), 1.86-1.95 (m, 2H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.20 (m, 6H), 3.49-3.58 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (80)：

N- (4- { 4- [(4- { benzyl [(tert-butylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 1.18 (s, 9H), 1.90-2.09 (m, 4H), 2.95 (s, 3H), 3.05-3.17 (m, 2H), 3.47-3.56 (m, 2H), 4.26 (s, 2H), 4.42 (s, 2H), 4.45 (m, 1H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.23-7.39 (m, 7H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (81)：

N- [4- (4- { [4- ({ [(2- hydroxy phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 1.65-1.77 (m, 2H), 2.20-2.25 (m, 2H), 2.95 (s, 3H), 3.07-3.15 (m, 2H), 3.50-3.55 (m, 2H), 3.81 (m, 1H), 4.29 (s, 2H), 6.72-6.85 (m, 3H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.69 (m, 1H).

Embodiment 23 (82)：

N- [4- (4- { [(3aR, 6aS) -5- { butyl [(Cyclohexylamino) carbonyl] amino } hexahydro cyclopenta [c] pyrroles -2 (1H)-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.88-1.00 (m, 3H), 1.14-1.84 (m, 16H), 2.00-2.22 (m, 2H), 2.70-3.79 (m, 9H), 2.95 (s, 3H), 4.08 (m, 1H), 4.35 (m, 2H), 7.00-7.10 (m, 4H), 7.22-7.34 (m, 2H), 7.45-7.58 (m, 2H).

Embodiment 23 (83)：

N- [4- (4- { [4- (butyl { [(2- methoxy ethyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.27；

NMR(CD₃OD)：(the t of δ 0.95, J=7.2Hz, 3H), 1.27-1.41 (m, 2H), 1.45-1.59 (m, 2H), 1.87-1.97 (m, 2H), 2.03-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.33 (s, 3H), 3.32-3.36 (m, 2H), 3.40-3.47 (m, 2H), 3.51-3.58 (m, 2H), 4.14 (m, 1H), 4, 28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (84)：

N- [4- (4- { [4- (butyl { [(4- hydroxy phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.97 (t, J=7.5Hz, 3H), 1.39 (m, 2H), 1.62 (m, 2H), 1.92 (m, 2H), 2.22 (m, 2H), 2.95 (s, 3H), 3.18 (m, 2H), 3.25 (m, 2H), 3.52 (m, 2H), 4.14 (m, 1H), 4.27 (s, 2H), 6.68-6.78 (m, 2H), 7.00-7.10 (m, 6H), 7.24-7.34 (m, 2H), (7.49 brd, J=8.4Hz, 2H).

Embodiment 23 (85)：

N- [4- (4- { [4- (butyl { [(3- hydroxy phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.96 (t, J=7.5Hz, 3H), 1.39 (m, 2H), 1.60 (m, 2H), 1.98 (m, 2H), 2.21 (m, 2H), 2.95 (s, 3H), 3.11 (m, 2H), 3.28 (m, 2H), 3.58 (m, 2H), 4.18 (m, 1H), 4.28 (s, 2H), 6.48 (m, 1H), 6.78 (m, 1H), 6.84 (m, 1H), 7.00-7.12 (m, 5H), 7.22-7.40 (m, 2H), (7.50 brd, J=8.7Hz, 2H).

Embodiment 23 (86)：

N- [4- (4- { [4- ({ [(4- hydroxy phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.44；

NMR(CD₃OD)：δ 1.70 (m, 2H), 2.19 (m, 2H), 2.95 (s, 3H), 3.08 (m, 2H), 3.48 (m, 2H), 3.78 (m, 1H), 4.25 (s, 2H), 6.62-6.78 (m, 2H), 7.00-7.36 (m, 8H), 7.47 (brd, J=8.4Hz, 2H).

Embodiment 23 (87)：

N- [4- (4- { [4- ({ [(3- hydroxy phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.51；

NMR(CD₃OD)：δ 1.52 (m, 2H), 1.95 (m, 2H), 2.24 (m, 2H), 2.89 (m, 2H), 2.93 (s, 3H), 3.56 (s, 2H), 3.60 (m, 1H), 6.39 (m, 1H), 6.71 (m, 1H), 6.90-7.08 (m, 5H), 7.18-7.38 (m, 5H).

Embodiment 23 (88)：

N- [4- (4- { [4- (butyl { [(4- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:Rf0.71 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.26-1.44 (m, 2H), 1.52-1.80 (m, 6H), 2.28 (m, 2H), 2.93 (s, 3H), 3.02 (m, 2H), 3.22 (m, 2H), 3.54 (s, 2H), 3.75 (s, 3H), 4.04 (m, 1H), 6.80-6.88 (m, 2H), 6.90-7.02 (m, 4H), 7.18-7.38 (m, 6H).

Embodiment 23 (89)：

N- { 4- [4- ({ 4- [butyl ({ [4- (trifluoromethyl) phenyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 0.97 (t, J=7.5Hz, 3H), 1.32-1.50 (m, 2H), 1.53-1.68 (m, 2H), 1.94-2.06 (m, 2H), 2.08-2.34 (m, 2H), 2.95 (s, 3H), 3.12 (m, 2H), 3.32 (m, 2H), 3.58 (m, 2H), 4.18 (m, 1H), 4.30 (s, 2H), 7.00-7.12 (m, 4H), 7.22-7.38 (m, 2H), 7.42-7.60 (m, 6H).

Embodiment 23 (90)：

N- { 4- [4- ({ 4- [(amino carbonyl) (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.15；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.27-1.42 (m, 2H), 1.50-1.63 (m, 2H), 1.81-2.02 (m, 2H), 2.11-2.30 (m, 2H), 2.95 (s, 3H), 3.05-3.21 (m, 4H), 3.51-3.60 (m, 2H), 4.13 (m, 1H), 4.29 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.52 d, J=8.7Hz, 2H).

Embodiment 23 (91)：

N- [4- (4- { [4- (butyl { [(4- hydroxy-cyclohexyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.19；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.27-1.41 (m, 2H), 1.45-1.79 (m, 10H), 1.86-1.95 (m, 2H), 2.03-2.22 (m, 2H), 2.95 (s, 3H), 3.02-3.17 (m, 4H), 3.48-3.65 (m, 3H), 3.87 (m, 1H), 4.15 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (92)：

N- [4- (4- { [4- (butyl { [(2- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.73；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.32-1.48 (m, 2H), 1.58-1.72 (m, 2H), 1.95-2.06 (m, 2H), 2.14-2.33 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.25-3.35 (m, 2H), 3.52-3.61 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.10-7.18 (m, 3H), 7.29 (d, J=8.7Hz, 2H), 7.45 (dt, J=2.4, 7.2Hz, 1H), 7.51 (d, J=8.7Hz, 2H).

Embodiment 23 (93)：

N- [4- (4- { [4- (butyl { [(3- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.73；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.33-1.46 (m, 2H), 1.54-1.67 (m, 2H), 1.93-2.06 (m, 2H), 2.15-2.32 (m, 2H), 2.95 (s, 3H), 3.05-3.18 (m, 2H), 3.26-3.35 (m, 2H), 3.52-3.62 (m, 2H), 4.18 (m, 1H), 4.29 (s, 2H), 6.74 (dt, J=2.4, 8.1Hz, 1H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.12 (d, J=4.0Hz, 1H), 7.20-7.31 (m, 2H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H).

Embodiment 23 (94)：

N- (4- { 4- [(4- { butyl [(4- pyridinylaminos) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：(the t of δ 0.96, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 2H), 3.40-3.50 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.6Hz, 2H), 7.54 (d, J=8.6Hz, 2H), 8.09 (d, J=7.5Hz, 2H), 8.47 (d, J=7.5Hz, 2H).

Embodiment 23 (95)：

N- (4- { 4- [(4- { butyl [(3- pyridinylaminos) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.70 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.53 (d, J=9.0Hz, 2H), 7.95 (dd, J=8.5, 2.4Hz, 1H), 8.43 (d, J=8.5Hz, 1H), 8.61 (d, J=8.5Hz, 1H), 9.20 (d, J=2.4Hz, 1H).

Embodiment 23 (96)：

2- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.36；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.35-1.51 (m, 2H), 1.60-1.72 (m, 2H), 1.92-2.04 (m, 2H), 2.16-2.35 (m, 2H), 2.95 (s, 3H), 3.08-3.11 (m, 2H), 3.23-3.35 (m, 2H), 3.52-3.63 (m, 2H), 4.22-4.36 (m, 3H), 7.02 (t, J=7.8Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (dt, J=1.8, 7.8Hz, 1H), 7.54 (d, J=8.7Hz, 2H), 8.05 (dd, J=7.8, 1.8Hz, 1H), 8.42 (d, J=7.8Hz, 1H).

Embodiment 23 (97)：

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.30；

NMR(CD₃OD)：(the t of δ 0.95, J=7.5Hz, 3H), 1.30-1.44 (m, 2H), 1.53-1.64 (m, 2H), 1.90-2.03 (m, 2H), 2.20-2.38 (m, 2H), 2.95 (s, 3H), 3.05-3.19 (m, 2H), 3.25-3.36 (m, 2H), 3.49-3.59 (m, 2H), 4.23 (m, 1H), 4.29 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.36 (t, J=7.8Hz, 1H), 7.53 (d, J=8.7Hz, 2H), 7.60 (ddd, J=7.8, 2.4, 1.8Hz, 1H), 7.69 (dt, J=7.8, 2.4Hz, 1H), 8.04 (t, J=1.8Hz, 1H).

Embodiment 23 (98)：

4- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] benzoate hydrochlorate

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.34；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.33-1.46 (m, 2H), 1.54-1.66 (m, 2H), 1.94-2.05 (m, 2H), 2.20-2.38 (m, 2H), 2.95 (s, 3H), 3.06-3.20 (m, 2H), 3.25-3.37 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.5Hz, 2H), 7.52 (d, J=8.7Hz, 2H), 7.92 (d, J=8.5Hz, 2H).

Embodiment 23 (99)：

[({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] acetic acid hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.41；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.27-1.41 (m, 2H), 1.48-1.62 (m, 2H), 1.84-1.95 (m, 2H), 2.08-2.26 (m, 2H), 2.95 (s, 3H), 2.98-3.18 (m, 4H), 3.44-3.53 (m, 2H), 3.80 (s, 2H), 4.15 (m, 1H), 4.25 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H).

Embodiment 23 (100)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (3- hydroxypropyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 1.10-1.50 (m, 6H), 1.60-1.80 (m, 4H), 1.80-2.00 (m, 4H), 2.00-2.20 (m, 2H), 2.95 (s, 3H), 3.00-3.15 (m, 2H), 3.20-3.30 (m, 2H), 3.40-3.70 (m, 5H), 4.10 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=9.0Hz, 2H), (7.48 d, J=9.0Hz, 2H).

Embodiment 23 (101)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (4- hydroxybutyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.42；

NMR(CD₃OD)：δ 1.10-1.40 (m, 6H), 1.40-1.70 (m, 5H), 1.70-2.00 (m, 6H), 2.00-2.20 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 4H), 3.50-3.60 (m, 2H), 3.59 (t, J=6.0Hz, 2H), 4.10 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.8Hz, 2H), (7.07 d, J=8.8Hz, 2H), (7.29 d, J=8.8Hz, 2H), (7.48 d, J=8.8Hz, 2H).

Embodiment 23 (102)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (3- hydroxybutyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.43；

NMR(CD₃OD)：δ 1.10-1.50 (m, 6H), 1.17 (d, J=6.3Hz, 3H), 1.70-2.00 (m, 9H), 2.00-2.20 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 4H), 3.50-3.60 (m, 2H), 3.70 (m, 1H), 4.10 (m, 1H), 4.27 (s, 2H), 7.02-7.07 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 23 (103)：

N- { 4- [4- ({ 4- [[(Cyclohexylamino) carbonyl] (2- hydroxybutyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.10-2.20 (m, 16H), 2.99 (s, 3H), 3.10-3.20 (m, 4H), 3.40-3.60 (m, 4H), 4.10 (m, 1H), 4.27 (s, 2H), 7.01-7.08 (m, 4H), 7.28-7.31 (m, 2H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 23 (104)：

4- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] butyrate hydrochlorate

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.73；

NMR(CD₃OD)：(the t of δ 0.95, J=7.5Hz, 3H), 1.28-1.41 (m, 2H), 1.44-1.59 (m, 2H), 1.74-1.85 (m, 2H), 1.87-1.97 (m, 2H), 2.03-2.20 (m, 2H), 2.31 (t, J=6.9Hz, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.20 (t, J=6.9Hz, 2H), 3.50-3.58 (m, 2H), 4.13 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (105)：

N- [4- (4- { [4- (butyl { [(4- chlorphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.30-1.40 (m, 2H), 1.55-1.60 (m, 2H), 1.95-2.00 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.01-7.08 (m, 4H), 7.23-7.40 (m, 6H), (7.51 d, J=8.4Hz, 2H).

Embodiment 23 (106)：

N- [4- (4- { [4- (butyl { [(3- chlorphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.55-1.65 (m, 2H), 1.95-2.05 (m, 2H), 2.20-2.30 (m, 2H), 2.96 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.00-7.09 (m, 5H), 7.23-7.31 (m, 4H), 7.48-7.51 (m, 3H).

Embodiment 23 (107)：

N- [4- (4- { [4- (butyl { [(2- chlorphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：(the t of δ 0.99, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.10 (m, 4H), 7.14 (dd, J=7.5, 1.5Hz, 1H), 7.27-7.31 (m, 3H), 7.42 (dd, J=7.5, 1.5Hz, 1H), 7.50 (d, J=8.4Hz, 2H), 7.63 (dd, J=7.5, 1.5Hz, 1H).

Embodiment 23 (108)：

N- [4- (4- { [4- (butyl { [(4- aminomethyl phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.55-1.65 (m, 2H), 1.95-2.05 (m, 2H), 2.20-2.30 (m, 2H), 2.28 (s, 3H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.30 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.10 (m, 6H), 7.19 (d, J=8.4Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.50 (d, J=9.0Hz, 2H).

Embodiment 23 (109)：

N- [4- (4- { [4- (butyl { [(3- aminomethyl phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.59；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.30 (s, 3H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.29 (s, 2H), 6.87 (d, J=6.6Hz, 1H), 7.01-7.15 (m, 7H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 23 (110)：

N- [4- (4- { [4- (butyl { [(2- aminomethyl phenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.22 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.14 (m, 1H), 4.28 (s, 2H), 7.02-7.15 (m, 7H), 7.19 (m, 1H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (111)：

N- [4- (4- { [4- (butyl { [(3- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.76 (s, 3H), 4.15 (m, 1H), 4.29 (s, 2H), 6.63 (m, 1H), 6.91 (m, 1H), 7.01-7.08 (m, 5H), 7.16 (m, 1H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 23 (112)：

N- [4- (4- { [4- (butyl { [(2- methoxyphenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.55；

NMR(CD₃OD)：(the t of δ 1.02, J=7.4Hz, 3H), 1.40-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.87 (s, 3H), 4.26 (m, 1H), 4.29 (s, 2H), 6.89 (m, 1H), 6.99-7.08 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H), 7.76 (dd, J=7.8, 1.5Hz, 1H).

Embodiment 23 (113)：

N- { 4- [4- ({ 4- [butyl ({ [3- (trifluoromethyl) phenyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.55；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.27-7.31 (m, 3H), 7.45 (m, 1H), 7.51 (d, J=8.7Hz, 2H), 7.60 (d, J=8.4Hz, 1H), 7.78 (s, 1H).

Embodiment 23 (114)：

N- [4- (4- { [4- ({ [(4- hydroxy-cyclohexyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.19；

NMR(CD₃OD)：δ 1.52-1.72 (m, 9H), 2.01 (m, 1H), 2.10-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.14 (m, 2H), 3.47-3.62 (m, 3H), 3.72 (m, 1H), 3.78 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (115)：

2- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] -4- methylpentanoic acid hydrochlorides

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.39；

NMR(CD₃OD)：(the d of δ 0.93, J=6.0Hz, 6H), 0.95 (t, J=7.5Hz, 3H), 1.28-1.42 (m, 2H), 1.48-1.79 (m, 5H), 1.82-1.95 (m, 2H), 1.97-2.19 (m, 2H), 2.95 (s, 3H), 2.90-3.05 (m, 2H), 3.08-3.25 (m, 2H), 3.42-3.52 (m, 2H), 4.13 (m, 1H), 4.19 (s, 2H), 4.32 (dd, J=9.0, 6.0Hz, 1H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.28 (d, J=8.7Hz, 2H), 7.47 (d, J=8.7Hz, 2H).

Embodiment 23 (116)：

N- { 3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.32；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 2.96 (s, 3H), 3.05-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.23 (m, 1H), 4.29 (s, 2H), 6.90 (m, 1H), 6.99-7.08 (m, 4H), 7.11 (m, 1H), 7.22 (t, J=8.1Hz, 1H), 7.29 (d, J=9.0Hz, 2H), 7.38 (t, J=2.1Hz, 1H), 7.53 (d, J=9.0Hz, 2H).

Embodiment 23 (117)：

N- { 4- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } carbonyl) amino] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.90 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.18 (t, J=9.0Hz, 2H), 7.28-7.33 (m, 4H), 7.55 (d, J=9.0Hz, 2H).

Embodiment 23 (118)：

N- [4- (4- { [4- (butyl { [(3- hydroxypropyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.70；

NMR(CD₃OD)：(the t of δ 0.95, J=7.2Hz, 3H), 1.26-1.41 (m, 2H), 1.45-1.58 (m, 2H), 1.65-1.77 (m, 2H), 1.86-1.97 (m, 2H), 2.03-2.22 (m, 2H), 2.95 (s, 3H), 3.03-3.15 (m, 4H), 3.27 (t, J=6.3Hz, 2H), 3.59 (t, J=6.3Hz, 2H), 3.50-3.65 (m, 2H), 4.14 (m, 1H), 4.25 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (119)：

N- [4- (4- { [4- ({ [(3- hydroxypropyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.32；

NMR(CD₃OD)：δ 1.60-1.84 (m, 3H), 2.02 (m, 1H), 2.09-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.20 (t, J=6.5Hz, 2H), 3.45-3.61 (m, 2H), 3.57 (t, J=6.5Hz, 2H), 3.72 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (120)：

N- (4- { 4- [(4- { butyl [(3- thienyls amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.31；

NMR(CD₃OD)：δ 0.96 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.11 (m, 5H), 7.18 (t, J=3.3,1.5Hz, 1H), 7.25-7.31 (m, 3H), 7.51 (d, J=8.7Hz, 2H).

Embodiment 23 (121)：N- (4- { 4- [(4- { butyl [(2- thienyls amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) Methanesulfomide

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.31；

NMR(CD₃OD)：δ 0.95 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.60 (m, 2H), 1.60-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.10-2.20 (m, 2H), 2.91 (s, 3H), 2.95-3.05 (m, 2H), 3.20-3.30 (m, 2H), 3.51 (s, 2H), 4.00 (m, 1H), 6.65 (m, 1H), 6.77-6.79 (m, 2H), 6.92-6.96 (m, 4H), 7.21-7.24 (m, 2H), (7.31 d, J=8.7Hz, 2H).

Embodiment 23 (122)：

N- (4- { 4- [(4- { butyl [(2,3- dihydros-Isosorbide-5-Nitrae-benzo dioxine -6- bases amino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：(the t of δ 0.96, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.20 (s, 4H), 4.28 (s, 2H), 6.72 (s, 2H), 6.85 (t, J=1.4Hz, 1H), 7.02-7.11 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.48 (d, J=8.9Hz, 2H).

Embodiment 23 (123)：

N- [4- (4- { [4- (butyl { [(3,5- difluorophenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.30 (s, 2H), 6.55 (m, 1H), 7.02-7.11 (m, 6H), (7.29 d, J=8.4Hz, 2H), (7.51 d, J=8.4Hz, 2H).

Embodiment 23 (124)：

N- [4- (4- { [4- (butyl { [(3,4- difluorophenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 0.97 (t, J=7.5Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.16 (m, 6H), 7.29 (d, J=8.6Hz, 2H), 7.40 (m, 1H), (7.55 d, J=8.6Hz, 2H).

Embodiment 23 (125)：

N- [4- (4- { [4- (butyl { [(1- oxygen -3- pyridine radicals) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.69；

NMR(CD₃OD)：(the t of δ 0.96, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.31 (s, 2H), 4.35 (m, 1H), 7.02-7.07 (m, 4H), 7.29 (d, J=8.6Hz, 2H), 7.55 (d, J=8.6Hz, 2H) 7.88 (dd, J=8.9, 3.5Hz, 1H), 8.39 (d, J=2.7Hz, 1H), 8.50 (d, J=2.7Hz, 1H), 9.39 (s, 1H).

Embodiment 23 (126)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.58；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 6.92-7.00 (m, 2H), 7.02-7.08 (m, 4H), 7.26-7.41 (m, 3H), 7.49-7.52 (m, 2H)；

It is unformed；

Softening point：About 196-198 DEG C

Embodiment 23 (127)：

N- { 4- [4- ({ 4- [{ [(4- bromophenyls) amino] carbonyl } (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.57；

NMR(CD₃OD)：δ 0.96 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.60 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.20-3.30 (m, 2H), 3.50-3.60 (m, 2H), 4.19 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.27-7.31 (m, 4H), (7.39 d, J=8.7Hz, 2H), (7.51 d, J=8.7Hz, 2H).

Embodiment 23 (128)：

N- (4- { 4- [(4- { butyl [(isobutylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.51；

NMR(CD₃OD)：(the d of δ 0.87, J=6.6Hz, 6H), 0.95 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.60 (m, 2H), 1.76 (m, 1H), 1.80-2.00 (m, 2H), 2.00-2.20 (m, 2H), 2.96 (s, 3H), 2.96 (d, J=7.5Hz, 2H), 3.00-3.40 (m, 4H), 3.50-3.60 (m, 2H), 4.16 (m, 1H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 23 (129)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- methyl-2-butenes base) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.62；

NMR(CD₃OD)：δ 1.75 (s, 6H), 1.92-2.03 (m, 2H), 2.07-2.23 (m, 2H), 2.95 (s, 3H), 3.05-3.19 (m, 2H), 3.50-3.60 (m, 2H), 3.94-4.02 (m, 2H), 4.20-4.35 (m, 3H), 5.18 (m, 1H), 6.98-7.10 (m, 6H), 7.26-7.34 (m, 4H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (130)：

N- [4- (4- { [4- (3- butynyls { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.61；

NMR(CD₃OD)：δ 1.97-2.10 (m, 2H), 2.19-2.20 (m, 2H), 2.43 (m, 1H), 2.49-2.58 (m, 2H), 2.95 (s, 3H), 3.02-3.19 (m, 2H), 3.46-3.61 (m, 4H), 4.08 (m, 1H), 4.29 (s, 2H), 6.98-7.10 (m, 6H), 7.26-7.34 (m, 4H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (131)：

N- [4- (4- { [4- (3- cyclobutenyls { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.61；

NM[R(CD₃OD)：δ 1.95-2.06 (m, 2H), 2.15-2.44 (m, 4H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.28-3.41 (m, 2H), 3.50-3.61 (m, 2H), 4.13 (m, 1H), 4.29 (s, 2H), (5.08 d, J=10.2Hz, 1H), (5.14 d, J=17.1Hz, 1H), 5.86 (m, 1H), 6.98-7.10 (m, 6H), 7.26-7.35 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (132)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- hydroxybutyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.59；

NMR(CD₃OD)：δ 1.02 (t, J=7.5Hz, 3H), 1.44-1.60 (m, 2H), 1.95-2.28 (m, 4H), 2.95 (s, 3H), 3.01-3.36 (m, 4H), 3.47-3.60 (m, 2H), 3.66 (m, 1H), 4.10 (m, 1H), 4.28 (s, 2H), 6.98-7.10 (m, 6H), 7.22-7.34 (m, 4H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (133)：

N- { 4- [4- ({ 4- [[(1,3- benzodioxole -5- bases amino) carbonyl] (butyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.29；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.20-3.30 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 5.90 (s, 2H), 6.70-6.71 (m, 2H), 6.89 (d, J=1.8Hz, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7

Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (134)：

N- [4- (4- { [4- ((4- luorobenzyls) { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=9: 1) of Rf 0.59；

NMR(CD₃OD)：δ 7.46 (brd, J=8.4Hz, 2H), 7.40-7.24 (m, 6H), 7.14-6.80 (m, 8H), 4.62 (s, 2H), 4.32 (m, 1H), 4.24 (s, 2H), 3.48 (m, 2H), 3.06 (m, 2H), 2.95 (s, 3H), 2.20-1.88 (m, 4H).

Embodiment 23 (135)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- methoxy-benzyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=9: 1) of Rf 0.62；

NMR(CD₃OD)：δ 7.45 (brd, J=8.7Hz, 2H), 7.30-7.19 (m, 6H), 7.16-6.90 (m, 8H), 4.59 (s, 2H), 4.32 (m, 1H), 4.23 (s, 2H), 3.88 (s, 3H), 3.47 (m, 2H), 3.08 (m, 2H), 2.95 (s, 3H), 2.18-1.88 (m, 4H).

Embodiment 23 (136)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- methyl-benzyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=9: 1) of Rf 0.68；

NMR(CD₃OD)：δ 7.45 (brd, J=8.7Hz, 2H), 7.30-7.10 (m, 8H), 7.08-6.90 (m, 6H), 4.56 (s, 2H), 4.43 (m, 1H), 4.24 (s, 2H), 3.49 (m, 2H), 3.07 (m, 2H), 2.95 (s, 3H), 2.35 (s, 3H), 2.16-1.86 (m, 4H).

Embodiment 23 (137)：

N- [4- (4- { [4- (butyl { [(3- hydroxy-4-methyls phenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.42；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.20-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.10-2.30 (m, 2H), 2.12 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.16 (m, 1H), 4.28 (s, 2H), 6.64 (dd, J=8.0, 2.0Hz, 1H), 6.83 (d, J=2.0Hz, 1H), 6.94 (d, J=8.0Hz, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.4Hz, 2H), 7.49 (d, J=8.4Hz, 2H).

Embodiment 23 (138)：

N- [4- (4- { [4- (butyl { [(3,5- dihydroxy phenyl) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.75；

NMR(d₆-DMSO)：(the t of δ 0.88, J=7.2Hz, 3H), 1.20-1.40 (m, 2H), 1.40-1.50 (m, 2H), 1.70-1.80 (m, 2H), 2.10-2.30 (m, 2H), 3.16 (s, 3H), 3.30-3.40 (m, 2H), 3.60-3.90 (m, 4H), 4.14 (m, 1H), 4.22 (d, J=4.8Hz, 2H), 5.83 (t, J=2.1Hz, 1H), 6.37 (d, J=2.1Hz, 2H), 7.02-7.08 (m, 4H), 7.25 (d, J=8.6Hz, 2H), 7.57 (d, J=8.6Hz, 2H), 7.88 (s, 1H), 9.71 (s, 1H), 10.51 (s, 1H).

Embodiment 23 (139)：

N- [4- (4- { [4- (butyl { [(2- hydroxy-2-methyls propyl group) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.15 (s, 6H), 1.28-1.44 (m, 2H), 1.50-1.62 (m, 2H), 1.88-1.98 (m, 2H), 2.08-2.25 (m, 2H), 2.95 (s, 3H), 3.02-3.22 (m, 6H), 3.50-3.60 (m, 2H), 4.16 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (140)：

N- [4- (4- { [4- ({ [(2- hydroxy-2-methyls propyl group) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.15；

NMR(CD₃OD)：δ 1.15 (s, 6H), 1.60-1.78 (m, 2H), 2.00-2.21 (m, 2H), 2.95 (s, 3H), 3.01-3.15 (m, 4H), 3.44-3.55 (m, 2H), 3.73 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (141)：

N- [4- (4- { [4- ((Cvclopropvlmethvl) { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.43；

NMR(CD₃OD)：δ 0.32-0.37 (m, 2H), 0.57-0.63 (m, 2H), 1.06 (m, 1H), 1.97-2.10 (m, 2H), 2.25-2.42 (m, 2H), 2.95 (s, 3H), 3.05-3.18 (m, 2H), 3.25 (d, J=6.6Hz, 2H), 3.51-3.62 (m, 2H), 4.06 (m, 1H), 4.29 (s, 2H), 6.98-7.10 (m, 6H), 7.27-7.35 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 23 (142)：

N- [4- (4- { [4- ((cyclobutylmethyl) { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.43；

NMR(CD₃OD)：δ 1.75-2.14 (m, 8H), 2.23-2.40 (m, 2H), 2.62 (m, 1H), 2.95 (s, 3H), 3.03-3.15 (m, 2H), 3.36 (d, J=6.9Hz, 2H), 3.50-3.60 (m, 2H), 3.95 (m, 1H), 4.28 (s, 2H), 6.98-7.08 (m, 6H), 7.27-7.32 (m, 4H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (143)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(1- oxygen -3- pyridine radicals) methyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.14；

NMR(CD₃OD)：δ 1.98-2.32 (m, 4H), 2.95 (s, 3H), 3.09-3.21 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (s, 2H), 4.40 (m, 1H), 4.72 (s, 2H), 6.97-7.10 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.37 (dd, J=9.0,5.1Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 7.84 (t, J=7.0Hz, 1H), 8.08 (d, J=7.0Hz, 1H), 8.62 (d, J=7.0Hz, 1H), 8.69 (s, 1H).

Embodiment 23 (144)：

N- [4- (4- { [4- ((3- luorobenzyls) { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 7.47 (m, 2H), 7.40-7.22 (m, 5H), 7.16 (m, 1H), 7.10-6.96 (m, 8H), 4.65 (s, 2H), 4.37 (m, 1H), 4.24 (s, 2H), 3.50 (m, 2H), 3.09 (m, 2H), 2.95 (s, 3H), 2.20-1.90 (m, 4H).

Embodiment 23 (145)：

N- [4- (4- { [4- ((2- luorobenzyls) { [(4- fluorophenyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 7.46 (brd, J=8.7Hz, 2H), 7.40-7.22 (m, 6H), 7.20-6.92 (m, 8H), 4.69 (s, 2H), 4.39 (m, 1H), 4.25 (s, 2H), 3.51 (m, 2H), 3.10 (m, 2H), 2.95 (s, 3H), 2.20-1.89 (m, 4H).

Embodiment 23 (146)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (4- methoxy-benzyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.69；

NMR(CD₃OD)：δ 7.45 (brd, J=8.7Hz, 2H), 7.40-7.20 (m, 6H), 7.10-6.88 (m, 8H), 4.57 (s, 2H), 4.29 (m, 1H), 4.23 (s, 2H), 3.76 (s, 3H), 3.49 (m, 2H), 3.08 (m, 2H), 2.95 (s, 3H), 2.22-1.86 (m, 4H).

Embodiment 23 (147)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- methoxy-benzyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.81；

NMR(CD₃OD)：δ 7.46 (brd, J=9.0Hz, 2H), 7.30-7.20 (m, 5H), 7.08-6.94 (m, 6H), 6.92-6.76 (m, 3H), 4.62 (s, 2H), 4.35 (m, 1H), 4.24 (s, 2H), 3.77 (s, 3H), 3.49 (m, 2H), 3.08 (m, 2H), 2.95 (s, 3H), 2.20-1.90 (m, 4H).

Embodiment 23 (148)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- methyl-benzyls) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.85；

NMR(CD₃OD)：δ 7.47 (brd, J=9.0Hz, 2H), 7.34-7.18 (m, 6H), 7.16-6.92 (m, 8H), 4.61 (s, 2H), 4.36 (m, 1H), 4.25 (s, 2H), 3.49 (m, 2H), 3.08 (m, 2H), 2.95 (s, 3H) 2.32 (s, 3H), 2.22-1.90 (m, 4H).

Embodiment 23 (149)：

4- { { [(4- fluorophenyls) amino] carbonyl } [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] amino } butyrate hydrochlorate

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.18；

NMR(CD₃OD)：δ 1.82-2.02 (m, 4H), 2.10-2.30 (m, 2H), 2.43 (t, J=6.3Hz, 2H), 2.95 (s, 3H), 3.04-3.18 (m, 2H), 3.25-3.35 (m, 2H), 3.50-3.60 (m, 2H), 4.22-4.35 (m, 3H), 7.00 (dd, J=17.1,9.0Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.42-7.55 (m, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 23 (150)：

N- [4- (4- { [4- (butyl { [(3,5- dimethyl -4- isoxazolyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.53；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.32-1.47 (m, 2H), 1.58-1.70 (m, 2H), 1.95-2.03 (m, 2H), 2.12 (s, 3H), 2.26 (s, 3H), 2.15-2.25 (m, 2H), 2.95 (s, 3H), 3.03-3.17 (m, 2H), 3.21-3.32 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.29 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 23 (151)：

N- [4- (4- { [4- (butyl { [(6- methyl -3- pyridine radicals) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.51；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.31-1.45 (m, 2H), 1.57-1.67 (m, 2H), 1.97-2.08 (m, 2H), 2.22-2.38 (m, 2H), 2.70 (s, 3H), 2.95 (s, 3H), 3.10-3.25 (m, 2H), 3.28-3.36 (m, 2H), 3.52-3.62 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 7.79 (d, J=8.7Hz, 1H), 8.49 (dd, J=8.7, 2.7Hz, 1H), 9.02 (s, 1H).

Embodiment 24：

N- [4- (4- { [4- (butyl { [(cyclohexyl methyl) amino] thiocarbonyl (carbonothioyl) } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

Triethylamine (38 μ L) is added in the dimethyl formamide solution (1mL) of the compound (70mg) prepared into embodiment 3.Solution is added dropwise in cyclohexyl methyl isothiocyanates (43mg) dimethyl formamide solution (0.5mL), and stirred the mixture for 1 hour.Add water into reactant mixture, be extracted with ethyl acetate.Organic layer is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=10: 1), and changes into hydrochloride to obtain the compound (81.9mg) of the invention with following physical datas using conventional method.

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 0.88-1.03 (m, 2H), 0.96 (t, J=7.2Hz, 3H), 1.14-1.44 (m, 5H), 1.47-1.60 (m, 2H), 1.62-1.82 (m, 6H), 1.93-2.08 (m, 4H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.24-3.36 (m, 2H), 3.47 (d, J=6.6Hz, 2H), 3.50-3.60 (m, 2H), 4.29 (s, 2H), 5.66 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H).

Embodiment 24 (1) and embodiment 24 (2)

Using the same step such as recorded in embodiment 24, the compound for replacing preparing in embodiment 3 using corresponding amine derivative obtains the compounds of this invention with following physical datas.

Embodiment 24 (1)：

N- [4- (4- { [4- ({ [(cyclohexyl methyl) amino] thiocarbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.62；

NMR(CD₃OD)：δ 0.88-1.05 (m, 2H), 1.13-1.34 (m, 3H), 1.50-1.83 (m, 8H), 2.22-2.35 (m, 2H), 2.95 (s, 3H), 3.05-3.18 (m, 2H), 3.21-3.42 (m, 2H), 3.47-3.58 (m, 2H), 4.28 (s, 2H), 4.42 (m, 1H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 24 (2)：

N- [4- (4- { [4- (benzyl { [(cyclohexyl methyl) amino] thiocarbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.67；

NMR(CD₃OD)：δ 0.62-0.78 (m, 2H), 1.00-1.14 (m, 3H), 1.30-1.62 (m, 6H), 1.89-2.13 (m, 4H), 2.95 (s, 3H), 3.09-3.21 (m, 2H), 3.36 (d, J=6.6Hz, 2H), 3.45-3.56 (m, 2H), 4.27 (s, 2H), 4.71 (s, 2H), 5.87 (m, 1H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.17-7.38 (m, 7H), (7.48 d, J=8.7Hz, 2H).

Embodiment 25：

N- [4- (4- { [4- (butyl { [(3- hydroxybutyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

Triethylamine (97 μ L) and triphosgene (44.1mg) are added into the tetrahydrofuran solution (1mL) of (3- { [tert-butyl group (dimethyl) silicyl] epoxide } butyl) amine (72.3mg) in the case where being cooled with ice and stirring, then solution is stirred at room temperature 1 hour.The DMF solution (1mL) of the compound (100mg) and triethylamine that are prepared in embodiment 3 (55 μ L) is added dropwise in reactant mixture, is stirred for 15 minutes.The sodium bicarbonate aqueous solution of saturation is added into reactant mixture, is extracted with ethyl acetate.Organic layer is dried and concentrated on anhydrous sodium sulfate.The ethyl acetate solution of 4N hydrochloric acids is added into obtained residue.Reactant mixture is stirred 15 minutes and concentrated.Organic layer is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=10: 1), and changes into hydrochloride to obtain the compound (99.6mg) of the invention with following physical datas using conventional method.

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.46；

NMR(CD₃OD)：(the t of δ 0.95, J=7.2Hz, 3H), 1.16 (d, J=6.0Hz, 3H), 1.26-1.41 (m, 2H), 1.44-1.70 (m, 4H), 1.85-1.97 (m, 2H), 2.05-2.21 (m, 2H), 2.95 (s, 3H), 3.03-3.13 (m, 4H), 3.17-3.38 (m, 2H), 3.50-3.58 (m, 2H), 3.78 (m, 1H), 4.13 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 25 (1)-embodiment 25 (10)

The step of using as described in embodiment 25, utilize (3- { [tert-butyl group (dimethyl) silicyl] epoxide } butyl) amine or corresponding amine derivative, and using the compound or corresponding amine derivative prepared in embodiment 3, obtain the compounds of this invention with following physical datas.

Embodiment 25 (1)：

N- { 4- [4- ({ 4- [butyl ({ [(1R, 2R) -2- hydroxy-cyclohexyls] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.29；

NMR(CD₃OD)：(the t of δ 0.95, J=7.2Hz, 3H), 1.23-1.42 (m, 6H), 1.47-1.61 (m, 2H), 1.65-1.77 (m, 2H), 1.88-2.05 (m, 4H), 2.05-2.22 (m, 2H), 2.95 (s, 3H), 3.02-3.20 (m, 4H), 3.34-3.48 (m, 2H), 3.50-3.59 (m, 2H), 4.14 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 25 (2)：

N- { 4- [4- ({ 4- [butyl ({ [(1S, 2S) -2- hydroxy-cyclohexyls] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.29；

Embodiment 25 (3)：

N- { 4- [4- ({ 4- [({ [(1- hydroxy-cyclohexyls) methyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.23；

NMR(CD₃OD)：δ 1.26-1.75 (m, 11H), 2.02 (m, 1H), 2.10-2.21 (m, 2H), 2.95 (s, 3H), 3.03-3.16 (m, 4H), 3.45-3.55 (m, 2H), 3.72 (m, 1H), 4.27 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 25 (4)：

N- { 4- [4- ({ 4- [({ [(1R, 2R) -2- hydroxy-cyclohexyls] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.64；

NMR(CD₃OD)：δ 1.12-1.40 (m, 4H), 1.59-1.76 (m, 3H), 1.88-2.06 (m, 3H), 2.11-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.14 (m, 2H), 3.18-3.38 (m, 2H), 3.46-3.55 (m, 2H), 3.73 (m, 1H), 4.27 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 25 (5)：

N- { 4- [4- ({ 4- [({ [(1S, 2S) -2- hydroxy-cyclohexyls] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.64；

Embodiment 25 (6)：

N- (4- { 4- [(4- { butyl [(4- piperidyl aminos) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the n-butanols: acetic acid: water=4: 2: 1) of Rf 0.24；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.30-1.40 (m, 2H), 1.40-1.50 (m, 2H), 1.70-1.80 (m, 2H), 1.80-2.00 (m, 2H), 2.00-2.20 (m, 4H), 2.95 (s, 3H), 3.00-3.20 (m, 6H), 3.30-3.50 (m, 2H), 3.50-3.60 (m, 2H), 3.80 (m, 1H), 4.10 (m, 1H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 25 (7)：

N- [4- (4- { [4- ({ [(2- hydroxybutyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.48；

NMR(CD₃OD)：(the t of δ 0.94, J=7.2Hz, 3H), 1.32-1.52 (m, 2H), 1.58-1.75 (m, 1.6H), 1.98-2.08 (m, 0.4H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 3.00-3.14 (m, 2H), 3.16-3.40 (m, 2.6H), 3.45-3.54 (m, 2.4H), 3.68-3.78 (m, 0.8H), 3.90-3.95 (m, 0.2H), 4.27 (s, 1.6H), 4.33 (s, 0.4H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 25 (8)：

N- [4- (4- { [4- ({ [(3- hydroxybutyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.33；

NMR(CD₃OD)：(the d of δ 1.16, J=6.3Hz, 2.4H), 1.17 (d, J=6.3Hz, 0.6H), 1.48-1.75 (m, 3.6H), 1.98-2.05 (m, 0.4H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 3.02-3.30 (m, 4H), 3.48-3.55 (m, 2H), 3.65-3.83 (m, 2H), 4.27 (s, 1.6H), 4.32 (s, 0.4H), 7.03 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 25 (9)：

N- [4- (4- { [4- (butyl { [(2- hydroxybutyls) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.48；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 6H), 1.28-1.61 (m, 6H), 1.88-1.97 (m, 2H), 2.04-2.22 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.22-3.32 (m, 2H), 3.48-3.59 (m, 3H), 4.14 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 25 (10)：

N- { 4- [4- ({ 4- [butyl ({ [(1- hydroxy-cyclohexyls) methyl] amino } carbonyl) amino] -1- piperidyls } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.56；

NMR(CD₃OD)：δ 0.96 (t, J=7.5Hz, 3H), 1.27-1.70 (m, 14H), 1.88-1.97 (m, 2H), 2.04-2.21 (m, 2H), 2.95 (s, 3H), 3.02-3.18 (m, 4H), 3.20 (s, 2H), 3.48-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 26：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] -1- piperidine formyl amine hydrochlorates

Under an argon atmosphere, the N of the compound (50.0mg) prepared into embodiment 3, triethylamine (30.0 μ L) and piperidines -1- carbonyls chlorine (13.4 μ L) are added in dinethylformamide solution (1mL), and solution is stirred 12 hours at 40 DEG C.Reactant mixture is diluted with ethyl acetate.Add water into reactant mixture, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (chloroform: methanol=7: 1), and changes into hydrochloride to obtain the compound (14.9mg) of the invention with following physical datas using conventional method.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.61；

NMR(CD₃OD)：δ 0.92 (t, J=7.5Hz, 3H), 1.20-1.70 (m, 10H), 1.90-2.05 (m, 2H), 2.06-2.24 (m, 2H), 2.95 (s, 3H), 3.02-3.18 (m, 4H), 3.18-3.38 (m, 4H), 3.45-3.62 (m, 3H), 4.27 (s, 2H), 7.00-7.12 (m, 4H), 7.24-7.34 (m, 2H), 7.44-7.58 (m, 2H).

Embodiment 26 (1)-embodiment 26 (4)

The step of using as described in embodiment 26, piperidines -1- carbonyl chlorine is replaced using corresponding chloride derivative, the compounds of this invention with following physical datas is obtained.

Embodiment 26 (1)：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] -4- morpholine carboxamide hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.93 (t, J=7.2Hz, 3H), 1.20-1.40 (m, 2H), 1.42-1.56 (m, 2H), 1.88-2.02 (m, 2H), 2.06-2.30 (m, 2H), 2.95 (s, 3H), 3.02-3.16 (m, 4H), 3.21-3.34 (m, 3H), 3.44-3.70 (m, 8H), 4.23 (s, 2H), 7.00-7.10 (m, 4H), 7.12-7.38 (m, 2H), (7.49 brd, J=8.7Hz, 2H).

Embodiment 26 (2)：

N- (4- { 4- [(4- { [(dibutylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.55；

NMR(CD₃OD)：δ 0.93 (t, J=7.5Hz, 6H), 1.31 (m, 4H), 1.49 (m, 4H), 1.70-1.88 (m, 2H), 2.04-2.14 (m, 2H), 2.95 (s, 3H), 3.08 (m, 2H), 3.14-3.35 (m, 4H), 3.50 (m, 2H), 3.79 (m, 1H), 4.27 (s, 2H), 7.00-7.10 (m, 4H), 7.22-7.34 (m, 2H), (7.49 brd, J=8.7Hz, 2H).

Embodiment 26 (3)：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) -4- piperidyls] -1- pyrrolidine formyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.63；

NMR(CD₃OD)：δ 0.92 (t, J=7.5Hz, 3H), 1.22-1.36 (m, 2H), 1.38-1.52 (m, 2H), 1.80-2.02 (m, 6H), 2.04-2.24 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 4H), 3.26-3.38 (m, 4H), 3.52 (m, 2H), 3.72 (m, 1H), 4.26 (s, 2H), 7.00-7.10 (m, 4H), 7.22-7.36 (m, 2H), 7.42-7.56 (m, 2H).

Embodiment 26 (4)：

N- (4- { 4- [(4- { butyl [(dibutylamino) carbonyl] amino } -1- piperidyls) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.59；

NMR(CD₃OD)：δ 0.80-1.02 (m, 9H), 1.20-1.60 (m, 12H), 1.92-2.20 (m, 4H), 2.95 (s, 3H), 3.00-3.40 (m, 7H), 3.44-3.68 (m, 4H), 4.26 (s 2H), 7.00-7.12 (m, 4H), (7.29 brd, J=9.0Hz, 2H), (7.48 brd, J=8.4Hz, 2H).

Embodiment 27：

N- [4- (4- { [4- ({ [(benzyloxy) amino] carbonyl } amino) -1- piperidyls] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

Under the lower and stirring that is cooled with ice, the tetrahydrofuran solution (6.5mL) of -1H- imidazoles (CDI) (129mg) of 1,1 '-carbonyl two is added dropwise in O- benzylhydroxylamines (100mg) tetrahydrofuran solution (2.5mL).After stirring 30 minutes, it will be added using N- (4- { 4- [(4- amino piperidine -1- bases) methyl] phenoxy group } phenyl) Methanesulfomide (200mg) prepared based on the method for embodiment 1 to wherein, and solution will be stirred 24 hours at 55 DEG C.Distilled water is added into reactant mixture, is extracted with ethyl acetate.Organic layer is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: methanol=10: 1), and changes into hydrochloride to obtain the compound (144.3mg) of the invention with following physical datas using conventional method.

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.42；

NMR(CD₃OD)：δ 1.63-1.79 (m, 2H), 1.96-2.07 (m, 2H), 2.96 (s, 3H), 3.00-3.12 (m, 2H), 3.44-3.54 (m, 2H), 3.74 (m, 1H), 4.26 (s, 2H), 4.76 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.33-7.43 (m, 5H), (7.48 d, J=8.7Hz, 2H).

Embodiment 28：

4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) benzoate hydrochlorate

N- tert-butoxycarbonylpiperidine -4- ketone and n-butylamine are subjected to reductive alkylation in room temperature in acetic acid and dimethylformamide using sodium triacetoxy borohydride.The reaction in the presence of triethylamine in dimethylformamide by obtained 1- tert-butoxycarbonyl -4- amino piperidines and 2,4- difluoro phenylisocyanate.Reactant mixture hydrochloric acid deprotection processing is obtained into N- butyl-N '-(2,4- difluorophenyl)-N- piperidin-4-yl urea hydrochlorides.Hydrochloride is changed into using the same step such as recorded in embodiment 1 and using conventional method; utilize N- butyl-N '-(2; 4- difluorophenyls)-N- piperidin-4-yls urea and 4- (4- formvlphenoxvs) benzoic acid, obtain the compounds of this invention (48mg) with following physical datas.

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.36-1.43 (m, 2H), 1.60-1.70 (m, 2H), 1.99-2.04 (m, 2H), 2.16-2.28 (m, 2H), 3.08-3.17 (m, 2H), 3.24-3.30 (m, 2H), 3.56-3.61 (m, 2H), 4.15 (m, 1H), 4.32 (s, 2H), 6.90-7.05 (m, 2H), 7.07 (d, J=8.7Hz, 2H), 7.18 (d, J=8.7Hz, 2H), 7.37 (m, 1H), 7.56 (d, J=8.7Hz, 2H), 8.04 (d, J=8.7Hz, 2H).

Embodiment 28 (1)-embodiment 28 (18)

Utilize the same step as described in embodiment 28; utilize N- butyl-N '-(2; 4- difluorophenyls)-N- piperidin-4-yls urea or corresponding piperidine derivative; and 4- (4- formvlphenoxvs) benzoic acid is replaced using corresponding aldehyde derivatives, obtain the compounds of this invention with following data.

Embodiment 28 (1)：

4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) benzenesulfonamide, hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.89；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.36-1.45 (m, 2H), 1.59-1.70 (m, 2H), 1.99-2.03 (m, 2H), 2.17-2.30 (m, 2H), 3.08-3.17 (m, 2H), 3.23-3.30 (m, 2H), 3.56-3.60 (m, 2H), 4.15 (m, 1H), 4.32 (s, 2H), 6.90-7.03 (m, 2H), 7.14 (d, J=8.7Hz, 2H), 7.18 (d, J=8.7Hz, 2H), 7.37 (m, 1H), 7.57 (d, J=8.7Hz, 2H), 7.91 (d, J=8.7Hz, 2H).

Embodiment 28 (2)：

N- butyl-N '-(2,4- difluorophenyl)-N- [1- ({ 3,5- dimethyl -1- [1- (mesyl) piperidin-4-yl] -1H- pyrazoles -4- bases } methyl) piperidin-4-yl] urea dihydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.12；

NMR(CD₃OD)：(the t of δ 0.98, J=7.5Hz, 3H), 1.33-1.45 (m, 2H), 1.59-1.70 (m, 2H), 1.98-2.01 (m, 4H), 2.12-2.30 (m, 4H), 2.33 (s, 3H), 2.43 (s, 3H), 2.89 (s, 3H), 2.93-3.01 (m, 2H), 3.09-3.17 (m, 2H), 3.25-3.30 (m, 2H), 3.58-3.63 (m, 2H), 3.86-3.90 (m, 2H), 4.19 (s, 2H), 4.19 (m, 1H), 4.39 (m, 1H), 6.89-7.03 (m, 2H), 7.37 (m, 1H).

Embodiment 28 (3)：

N- (3 '-{ [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } -1,1 '-biphenyl -4- bases) methanesulfonamide hydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.78；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.34-1.44 (m, 2H), 1.58-1.68 (m, 2H), 1.98-2.01 (m, 2H), 2.19-2.32 (m, 2H), 2.99 (s, 3H), 3.12-3.30 (m, 4H), 3.58-3.63 (m, 2H), 4.19 (m, 1H), 4.39 (s, 2H), 6.89-7.02 (m, 2H), 7.36 (d, J=8.4Hz, 2H), 7.37 (m, 1H), 7.49 (d, J=7.5Hz, 1H), 7.57 (t, J=7.5Hz, 1H), 7.68 (d, J=8.4Hz, 2H), 7.76 (d, J=7.5Hz, 1H), 7.82 (s, 1H).

Embodiment 28 (4)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } -3,5- dimethyl -1H- pyrazol-1-yls) phenyl] Methanesulfomide dihydrochloride

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.29；

NMR(CD₃OD)：δ 0.98 (t, J=7.5Hz, 3H), 1.36-1.44 (m, 2H), 1.60-1.70 (m, 2H), 1.98-2.00 (m, 2H), 2.20-2.35 (m, 2H), 2.35 (s, 3H), 2.35 (s, 3H), 3.03 (s, 3H), 3.03-3.13 (m, 2H), 3.27-3.30 (m, 2H), 3.58-3.62 (m, 2H), 4.17 (m, 1H), 4.17 (s, 2H), 6.90-7.03 (m, 2H), 7.35-7.45 (m, 5H).

Embodiment 28 (5)：

4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl }-N- { 4- [(mesyl) amino] benzyl } benzamide hydrochloride salt

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.36；

NMR(CD₃OD)：(the t of δ 0.96, J=7.5Hz, 3H), 1.28-1.40 (m, 2H), 1.69-1.89 (m, 4H), 2.11-2.18 (m, 2H), 2.92 (s, 3H), 2.96-3.00 (m, 2H), 3.22-3.37 (m, 4H), 3.59 (s, 2H), 4.02 (m, 1H), 4.53 (s, 2H), 6.87-7.01 (m, 2H), 7.21 (d, J=8.7Hz, 2H), 7.33 (d, J=8.7Hz, 2H), 7.38 (m, 1H), 7.44 (d, J=8.4Hz, 2H), 7.82 (d, J=8.4Hz, 2H).

Embodiment 28 (6)：

N- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenyl) -2- { 4- [(mesyl) amino] phenyl } acetamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.26；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.28-1.41 (m, 2H), 1.58-1.69 (m, 2H), 1.96-2.01 (m, 2H), 2.11-2.26 (m, 2H), 2.93 (s, 3H), 3.05-3.26 (m, 2H), 3.23-3.26 (m, 2H), 3.53-3.56 (m, 2H), 3.67 (s, 2H), 4.13 (m, 1H), 4.26 (s, 2H), 6.89-7.02 (m, 2H), 7.21 (d, J=8.7Hz, 2H), 7.32 (d, J=8.7Hz, 2H), 7.38 (m, 1H), 7.46 (d, J=8.4Hz, 2H), 7.70 (d, J=8.4Hz, 2H).

Embodiment 28 (7)：

N- { 4- [(4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } benzyl) epoxide] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.34-1.42 (m, 2H), 1.55-1.60 (m, 2H), 1.94-2.00 (m, 2H), 2.12-2.20 (m, 2H), 2.99 (s, 3H), 3.03-3.12 (m, 2H), 3.23-3.25 (m, 2H), 3.47-3.51 (m, 2H), 4.13 (m, 1H), 4.25 (s, 2H), 4.85 (s, 2H), 6.68 (d, J=8.7Hz, 2H), 6.89-7.03 (m, 2H), 7.13 (d, J=8.7Hz, 2H), 7.36 (m, 1H), 7.42 (s, 4H).

Embodiment 28 (8)：

4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } -3,5- dimethyl -1H- pyrazol-1-yls)-N- methyl benzenesulfonamide dihydrochlorides

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.38；

NMR(CD₃OD)：δ 0.98 (t, J=7.5Hz, 3H), 1.36-1.44 (m, 2H), 1.63-1.68 (m, 2H), 1.97-2.04 (m, 2H), 2.29-2.34 (m, 2H), 2.39 (s, 3H), 2.46 (s, 3H), 2.58 (s, 3H), 3.16-3.36 (m, 4H), 3.66-3.70 (m, 2H), 4.23 (m, 1H), 4.27 (s, 2H), 6.89-7.03 (m, 2H), 7.38 (m, 1H), (7.73 d, J=8.7Hz, 2H), (8.00 d, J=8.7Hz, 2H).

Embodiment 28 (9)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) benzyl] methanesulfonamide hydrochloride

TLC:Rf 0.30 (ethyl acetate)；

NMR(CD₃OD)：(the t of δ 0.98, J=7.5Hz, 3H), 1.33-1.45 (m, 2H), 1.59-1.69 (m, 2H), 1.98-2.02 (m, 2H), 2.15-2.28 (m, 2H), 2.88 (s, 3H), 3.06-3.15 (m, 2H), 3.24-3.30 (m, 2H), 3.54-3.59 (m, 2H), 4.14 (m, 1H), 4.24 (s, 2H), 4.28 (s, 2H), 6.89-7.03 (m, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.37 (m, 1H), 7.41 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 28 (10)：

N- { 4- [(4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) methyl] phenyl } methanesulfonamide hydrochloride

TLC:Rf 0.27 (ethyl acetate)；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.34-1.42 (m, 2H), 1.60-1.66 (m, 2H), 1.96-2.01 (m, 2H), 2.12-2.20 (m, 2H), 2.95 (s, 3H), 3.04-3.11 (m, 2H), 3.23-3.30 (m, 2H), 3.52-3.56 (m, 2H), 4.12 (m, 1H), 4.24 (s, 2H), 5.10 (s, 2H), 6.86-7.03 (m, 2H), 7.10 (d, J=8.7Hz, 2H), 7.25 (d, J=8.7Hz, 2H), 7.36 (m, 1H), 7.41 (d, J=8.7Hz, 2H), 7.42 (d, J=8.7Hz, 2H).

Embodiment 28 (11)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] acetamide hydrochloride

TLC:Rf 0.28 (ethyl acetate)；

NMR(CD₃OD)：(the t of δ 0.98, J=7.5Hz, 3H), 1.35-1.45 (m, 2H), 1.58-1.69 (m, 2H), 1.98-2.02 (m, 2H), 2.12 (s, 3H), 2.15-2.27 (m, 2H), 3.06-3.14 (m, 2H), 3.24-3.30 (m, 2H), 3.54-3.58 (m, 2H), 4.14 (m, 1H), 4.28 (s, 2H), 6.89-7.03 (m, 2H), 7.00 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.36 (m, 1H), 7.47 (d, J=8.7Hz, 2H), 7.57 (d, J=8.7Hz, 2H).

Embodiment 28 (12)：

N- [4- (4- { [4- ({ butyl [(Cyclohexylamino) carbonyl] amino } methyl) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.47；

NMR(CD₃OD)：δ 0.94 (t, J=7.5Hz, 3H), 2.00-1.06 (m, 19H), 2.95 (s, 3H), 3.02-2.88m, 2H), 3.30-3.16 (m, 4H), 3.56-3.44 (m, 3H), 4.25 (s, 2H), 7.10-7.00 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.48 (brd, J=8.4Hz, 2H).

Embodiment 28 (13)：

4- [4- ({ 4- [(N- acetyl group leucyl-) (butyl) amino] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.24；

NMR(CD₃OD)：δ 8.04 (d, J=9.0Hz, 2H), 7.58 (d, J=9.0Hz, 2H), 7.17 (d, J=9.0Hz, 2H), 7.07 (d, J=9.0Hz, 2H), 4.75 (m, 1H), 4.40-4.10 (m, 3H), 3.70-3.05 (m, 6H), 2.40-1.30 (m, 14H), 1.01-0.93 (m, 9H).

Embodiment 28 (14)：

4- [4- ({ 4- [(N- acetyl group -3- cyclohexyl alanyl) (butyl) amino] piperidin-1-yl } methyl) phenoxy group] benzoate hydrochlorate

TLC:(the ethyl acetate: methanol=10: 1) of Rf 0.27；

NMR(CD₃OD)：δ 8.04 (d, J=9.0Hz, 2H), 7.58 (d, J=8.7Hz, 2H), 7.17 (d, J=8.7Hz, 2H), 7.07 (d, J=9.0Hz, 2H), 4.75 (m, 1H), 4.40-4.10 (m, 3H), 3.70-3.00 (m, 6H), 2.40-0.80 (m, 27H).

Embodiment 28 (15)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } benzyl) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.68；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.34-1.41 (m, 2H), 1.58-1.69 (m, 2H), 1.96-2.00 (m, 2H), 2.12-2.23 (m, 2H), 2.91 (s, 3H), 3.05-3.13 (m, 2H), 3.23-3.30 (m, 2H), 3.53-3.56 (m, 2H), 3.99 (s, 2H), 4.10 (m, 1H), 4.27 (s, 2H), 6.89-7.03 (m, 2H), 7.16 (d, J=8.7Hz, 2H), 7.20 (d, J=8.7Hz, 2H), 7.35 (m, 1H), 7.35 (d, J=8.0Hz, 2H), 7.42 (d, J=8.0Hz, 2H).

Embodiment 28 (16)：

N- [4- (4- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) -3- chlorphenyls] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.63；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.32-1.45 (m, 2H), 1.59-1.69 (m, 2H), 1.98-2.01 (m, 2H), 2.13-2.26 (m, 2H), 3.01 (s, 3H), 3.06-3.14 (m, 2H), 3.24-3.30 (m, 2H), 3.54-3.58 (m, 2H), 4.13 (m, 1H), 4.28 (s, 2H), 6.90-7.05 (m, 2H), 7.00 (d, J=8.7Hz, 2H), 7.13 (d, J=8.7Hz, 1H), 7.24 (dd, J=8.7, 2.7Hz, 1H), 7.36 (dt, J=8.7, 6.0Hz, 1H), 7.43 (d, J=2.7Hz, 1H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 28 (17)：

N- butyl-N '-(2,4- difluorophenyl)-N- [1- ({ 3,5- dimethyl -1- [4- (trifluoromethyl) phenyl] -1H- pyrazoles -4- bases } methyl) piperidin-4-yl] urea dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.74；

NMR(CD₃OD)：(the t of δ 0.99, J=7.5Hz, 3H), 1.36-1.44 (m, 2H), 1.61-1.71 (m, 2H), 2.00-2.05 (m, 2H), 2.23-2.37 (m, 2H), 2.39 (s, 3H), 2.44 (s, 3H), 3.16-3.24 (m, 2H), 3.27-3.32 (m, 2H), 3.66-3.70 (m, 2H), 4.20 (m, 1H), 4.27 (s, 2H), 6.89-7.03 (m, 2H), 7.38 (dt, J=9.0, 6.0Hz, 1H), 7.72 (d, J=8.4Hz, 2H), 7.87 (d, J=8.4Hz, 2H).

Embodiment 28 (18)：

N- { 4- [(5- { [4- (butyl { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } pyridine -2- bases) epoxide] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.31；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.98 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.35 (s, 2H), 6.86-7.05 (m, 2H), 7.10-7.17 (m, 3H), 7.32-7.38 (m, 3H), 8.09 (dd, J=8.7, 2.2Hz, 1H), 8.32 (d, J=2.2Hz, 1H).

Embodiment 29 (1)-embodiment 29 (131)

Utilize the same step as described in embodiment 23; and if necessary; utilize conventional method hydrolysis, deprotection or oxidation; utilize the compound or corresponding amine derivative prepared in embodiment 3; and 1- methylcyclohexyl formic acid is replaced using corresponding carboxylic acid derivates, obtain the compounds of this invention with following data.

Embodiment 29 (1)：

N- (4- { 4- [(4- { butyl [(pyrimidine -5- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.44；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.32-1.48 (m, 2H), 1.55-1.70 (m, 2H), 1.97-2.08 (m, 2H), 2.23-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.23 (m, 2H), 3.29-3.38 (m, 2H), 3.50-3.62 (m, 2H), 4.25 (m, 1H), 4.31 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 9.03 (s, 1H), 9.27 (s, 2H).

Embodiment 29 (2)：

N- (4- { 4- [(4- { butyl [(pyridazine -4- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.45；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.32-1.47 (m, 2H), 1.55-1.69 (m, 2H), 2.00-2.10 (m, 2H), 2.27-2.45 (m, 2H), 2.95 (s, 3H), 3.12-3.27 (m, 2H), 3.33-3.45 (m, 2H), 3.50-3.62 (m, 2H), 4.24-4.35 (m, 3H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 8.49 (dd, J=7.2, 2.7Hz, 1H), 9.13 (d, J=7.2Hz, 1H), 9.49 (d, J=2.7Hz, 1H).

Embodiment 29 (3)：

N- { 4- [4- ({ 4- [{ [(6- azidos pyridin-3-yl) amino] carbonyl } (butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.47；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.30-1.45 (m, 2H), 1.55-1.70 (m, 2H), 1.97-2.08 (m, 2H), 2.24-2.41 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.25-3.38 (m, 2H), 3.55-3.65 (m, 2H), 4.19 (m, 1H), 4.31 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H), 7.88 (dd, J=9.6, 1.5Hz, 1H), 7.99 (dd, J=9.6, 1.5Hz, 1H), 9.42 (d, J=1.5Hz, 1H).

Embodiment 29 (4)：

N- { 4- [4- ({ 4- [butyl ({ [3- (trifluoromethoxy) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.49；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 6.93 (m, 1H), 7.02-7.08 (m, 4H), 7.27-7.34 (m, 4H), 7.45 (m, 1H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (5)：

N- { 4- [4- ({ 4- [{ [(4- acetylphenyls) amino] carbonyl } (butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.42；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.55 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.30 (s, 2H), 7.03 (d, J=8.9Hz, 2H), 7.07 (d, J=8.9Hz, 2H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.1Hz, 2H), 7.53 (d, J=8.1Hz, 2H), 7.92 (d, J=8.9Hz, 2H).

Embodiment 29 (6)：

N- { 4- [4- ({ 4- [butyl ({ [2- (trifluoromethoxy) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.51；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.35-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.40-3.60 (m, 2H), 4.16 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.19-7.34 (m, 5H), 7.48-7.51 (m, 2H), 7.60 (m, 1H).

Embodiment 29 (7)：

N- { 4- [4- ({ 4- [[(benzoyl-amido) carbonyl] (butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.92 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.60-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.27 (s, 2H), 7.02-7.06 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.48-7.53 (m, 4H), 7.61 (m, 1H), (7.87 d, J=7.2Hz, 2H).

Embodiment 29 (8)：

N- [4- (4- { [4- (butyl { [(2,6- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.56；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.30 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.97-7.08 (m, 6H), 7.28-7.31 (m, 3H), 7.49-7.52 (m, 2H).

Embodiment 29 (9)：

N- { 4- [4- ({ 4- [butyl ({ [4- (trifluoromethoxy) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.47；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.05-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.01-7.08 (m, 4H), 7.18 (d, J=9.0Hz, 2H), 7.29 (d, J=9.3Hz, 2H), 7.43 (d, J=9.3Hz, 2H), 7.51 (d, J=9.0Hz, 2H).

Embodiment 29 (10)：

N- (4- { 4- [(4- { butyl [(quinoline -3- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：(the t of δ 0.99, J=7.4Hz, 3H), 1.40-1.50 (m, 2H), 1.60-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.95 (s, 3H), 3.20-3.30 (m, 2H), 3.20-3.40 (m, 2H), 3.55-3.65 (m, 2H), 4.30 (m, 1H), 4.32 (s, 2H), 7.02-7.09 (m, 4H), 7.30 (d, J=8.9Hz, 2H), 7.54 (d, J=8.9Hz, 2H), 7.91 (td, J=7.2, 1.2Hz, 1H), 8.02 (td, J=7.2, 1.2Hz, 1H), 8.14 (d, J=8.4Hz, 1H), 8.20 (d, J=8.4Hz, 1H), 9.05 (d, J=2.4Hz, 1H), 9.53 (d, J=2.4Hz, 1H).

Embodiment 29 (11)：

N- (4- { 4- [(4- { butyl [(the amyl- 3- alkene -1- bases amino of ring) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.72；

NMR(CD₃OD)：(the t of δ 0.93, J=7.2Hz, 3H), 1.20-1.40 (m, 2H), 1.40-1.60 (m, 2H), 1.80-2.00 (m, 2H), 2.00-2.20 (m, 2H), 2.24 (dd, J=14.6, 5.6Hz, 2H) 2.69 (dd, J=14.6, 8.0Hz, 2H) 2.95 (s, 3H), 3.00-3.20 (m, 4H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 4.39 (m, 1H), 5.69 (s, 2H), 7.02-7.07 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.51 (d, J=8.9Hz, 2H).

Embodiment 29 (12)：

N- [4- (4- { [4- (butyl { [(4- chloro-3-hydroxyls phenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.41；

NMR(CD₃OD)：(the t of δ 0.96, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 6.77 (dd, J=8.9, 2.4Hz, 1H), 7.02-7.08 (m, 5H), 7.15 (d, J=9.0Hz, 1H), 7.29-7.31 (m, 2H), 7.47-7.51 (m, 2H).

Embodiment 29 (13)：

N- [4- (4- { [4- (butyl { [(the fluoro- 3- hydroxy phenyls of 4-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 6.70 (m, 1H), 6.90-7.00 (m, 2H), 7.02-7.08 (m, 4H), (7.29 d, J=8.9Hz, 2H), (7.49 d, J=8.9Hz, 2H).

Embodiment 29 (14)：

N- (4- { 4- [(4- { butyl [(quinoline -6- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 2H), 3.30-3.50 (m, 2H), 3.50-3.70 (m, 2H), 4.30 (m, 1H), 4.32 (s, 2H), 7.02-7.09 (m, 4H), 7.30 (d, J=8.9Hz, 2H), 7.53 (d, J=8.9Hz, 2H), 8.01 (dd, J=8.6, 5.6Hz, 1H), 8.15 (d, J=9.3Hz, 1H), 8.31 (dd, J=9.3, 2.4Hz, 1H), 8.42 (m, 1H), 9.01-9.05 (m, 2H).

Embodiment 29 (15)：

N- { 4- [4- ({ 4- [butyl ({ [2- (trifluoromethyl) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide

TLC:(the chloroforms: methanol=10: 1) of Rf 0.69；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.90 (m, 4H), 2.00-2.20 (m, 2H), 2.93 (s, 3H), 2.95-3.05 (m, 2H), 3.20-3.40 (m, 4H), 3.51 (s, 2H), 4.05 (m, 1H), 6.93-6.98 (m, 4H), 7.24 (d, J=9.0Hz, 2H), 7.32 (d, J=9.0Hz, 2H), 7.34 (m, 1H), 7.58-7.60 (m, 2H), (7.66 d, J=7.8Hz, 1H).

Embodiment 29 (16)：

N- [4- (4- { [4- (butyl { [(6- oxo -1,6- dihydropyridine -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=4: 1) of Rf 0.45；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.30-1.45 (m, 2H), 1.50-1.65 (m, 2H), 1.92-2.05 (m, 2H), 2.18-2.35 (m, 2H), 2.95 (s, 3H), 3.08-3.35 (m, 4H), 3.50-3.60 (m, 2H), 4.21 (m, 1H), 4.30 (s, 2H), 6.68 (d, J=9.6Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 7.72 (d, J=3.0Hz, 1H), 7.79 (dd, J=9.6, 3.0Hz, 1H).

Embodiment 29 (17)：

N- [4- (4- { [4- (butyl { [(4- oxocyclohexyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.47；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.26-1.58 (m, 7H), 1.70-1.80 (m, 2H), 1.85-2.20 (m, 7H), 2.95 (s, 3H), 3.02-3.17 (m, 4H), 3.48-3.65 (m, 3H), 4.13 (m, 1H), 4.28 (s, 2H), 7.03 (d, J=8.7H z, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (18)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- hydroxybenzyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.80；

NMR(CD₃OD)：δ 1.88-2.24 (m, 4H), 2.95 (s, 3H), 3.08 (m, 2H), 3.48 (m, 2H), 4.24 (s, 2H), 4.34 (m, 1H), 4.58 (s, 2H), 6.60-6.84 (m, 3H), 6.90-7.10 (m, 6H), 7.16 (m, 1H), 7.22-7.38 (m, 4H), 7.38-7.52 (m, 2H).

Embodiment 29 (19)：

N- [4- (4- { [4- (butyl { [(2,6- 3,5-dimethylphenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.59；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20 (s, 6H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.28 (s, 2H), 7.02-7.07 (m, 7H), (7.29 d, J=8.9Hz, 2H), (7.52 d, J=8.9Hz, 2H).

Embodiment 29 (20)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- methoxybutyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.34；

NMR(CD₃OD)：δ 1.00 (t, J=7.5Hz, 3H), 1.57-1.70 (m, 2H), 1.93-2.30 (m, 4H), 2.95 (s, 3H), 3.02-3.20 (m, 3H), 3.35-3.45 (m, 2H), 3.50 (s, 3H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.28 (s, 2H), 6.97-7.10 (m, 6H), 7.21-7.33 (m, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (21)：

N- { 4- [4- ({ 4- [4- ethyls -3- (4- fluorophenyls) -2- oxo -2,3- dihydro -1H- imidazoles -1- bases] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.33；

NMR(CD₃OD)：δ 1.02 (t, J=7.5Hz, 3H), 2.15-2.25 (m, 4H), 2.28 (q, J=7.5Hz, 2H), 2.96 (s, 3H), 3.13-3.29 (m, 2H), 3.58-3.70 (m, 2H), 4.26 (m, 1H), 4.33 (s, 2H), 6.39 (s, 1H), 7.04 (d, J=8.7Hz, 2H), 7.09 (d, J=8.7Hz, 2H), 7.20-7.35 (m, 6H), (7.52 d, J=8.7Hz, 2H).

Embodiment 29 (22)：

N- [4- (4- { [4- ({ [(4- fluorophenyls) amino] carbonyl } { 2- [(mesyl) amino] butyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.31；

NMR(CD₃OD)：δ 1.06 (t, J=7.5Hz, 3H), 1.48 (m, 1H), 1.69 (m, 1H), 2.05-2.18 (m, 2H), 2.21-2.43 (m, 2H), 2.95 (s, 3H), 2.97 (s, 3H), 3.03-3.14 (m, 2H), 3.34 (d, J=7.5Hz, 2H), 3.42-3.61 (m, 3H), 3.95 (m, 1H), 4.28 (s, 2H), 6.96-7.10 (m, 6H), 7.26-7.40 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (23)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(2S) -2- methyl butyls] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.94 (d, J=7.5Hz, 3H), 0.95 (t, J=7.5Hz, 3H), 1.16 (m, 1H), 1.50 (m, 1H), 1.74 (m, 1H), 1.95-2.07 (m, 2H), 2.28-2.47 (m, 2H), 2.95 (s, 3H), 3.02-3.24 (m, 4H), 3.50-3.60 (m, 2H), 3.90 (m, 1H), 4.28 (s, 2H), 6.96-7.10 (m, 6H), 7.25-7.32 (m, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (24)：

N- [4- (4- { [4- ((2- ethyl-butyls) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.93 (t, J=7.5Hz, 6H), 1.27-1.50 (m, 4H), 1.60 (m, 1H), 1.97-2.08 (m, 2H), 2.30-2.50 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.26 (d, J=7.5Hz, 2H), 3.50-3.60 (m, 2H), 3.87 (m, 1H), 4.28 (s, 2H), 6.96-7.10 (m, 6H), 7.24-7.33 (m, 4H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (25)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (thiophene -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.34；

NMR(CD₃OD)：δ 1.94-2.05 (m, 2H), 2.12-2.30 (m, 2H), 2.95 (s, 3H), 3.02-3.17 (m, 2H), 3.50-3.58 (m, 2H), 4.26 (s, 2H), 4.27 (m, 1H), 4.79 (s, 2H), 6.94-7.08 (m, 8H), 7.26-7.34 (m, 5H), (7.48 d, J=8.7Hz, 2H).

Embodiment 29 (26)：

N- { 3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] phenyl } acetamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.28-1.45 (m, 2H), 1.56-1.67 (m, 2H), 1.98-2.02 (m, 2H), 2.11 (s, 3H), 2.16-2.28 (m, 2H), 2.96 (s, 3H), 3.07-3.15 (m, 2H), 3.26-3.30 (m, 2H), 3.55-3.59 (m, 2H), 4.16 (m, 1H), 4.29 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.10-7.23 (m, 3H), 7.30 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.69 (m, 1H).

Embodiment 29 (27)：

N- { 4- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] phenyl } acetamide hydrochloride

TLC:(the ethyl acetate: methanol=5: 1) of Rf 0.70；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.29-1.42 (m, 2H), 1.55-1.67 (m, 2H), 1.98-2.02 (m, 2H), 2.10 (s, 3H), 2.13-2.28 (m, 2H), 2.96 (s, 3H), 3.03-3.15 (m, 2H), 3.25-3.30 (m, 2H), 3.55-3.59 (m, 2H), 4.16 (m, 1H), 4.29 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.27 (d, J=8.7Hz, 2H), 7.30 (d, J=8.7Hz, 2H) 7.46 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 29 (28)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2,2,3,3,4,4,4- seven fluorine butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.57；

NMR(CD₃OD)：δ 2.08-2.38 (m, 4H), 2.95 (s, 3H), 3.08-3.11 (m, 2H), 3.52-3.65 (m, 2H), 4.04 (m, 1H), 4.18-4.35 (m, 4H), 6.99-7.08 (m, 6H), 7.26-7.37 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (29)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (isopentyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.52；

NMR(CD₃OD)：δ 0.96 (d, J=6.6Hz, 6H), 1.45-1.55 (m, 2H), 1.65 (m, 1H), 1.95-2.05 (m, 2H), 2.12-2.30 (m, 2H), 2.95 (s, 3H), 3.05-3.10 (m, 2H), 3.22-3.33 (m, 2H), 3.51-3.61 (m, 2H), 4.19 (m, 1H), 4.29 (s, 2H), 6.97-7.10 (m, 6H), 7.26-7.33 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (30)：

N- [4- (4- { [4- ((2,6- difluorobenzyl) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.54；

NMR(CD₃OD)：δ 1.88-1.99 (m, 2H), 2.19-2.34 (m, 2H), 2.95 (s, 3H), 2.99-3.12 (m, 2H), 3.44-3.52 (m, 2H), 3.98 (m, 1H), 4.24 (s, 2H), 4.75 (s, 2H), 6.95-7.08 (m, 8H), 7.25-7.40 (m, 5H), (7.45 d, J=8.7Hz, 2H).

Embodiment 29 (31)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (pyridine -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.56；

NMR(CD₃OD)：δ 2.03-2.36 (m, 4H), 2.95 (s, 3H), 3.13-3.26 (m, 2H), 3.54-3.64 (m, 2H), 4.32 (s, 2H), 4.45 (m, 1H), 4.87 (s, 2H), 7.00 (d, J=9.0Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.39 (dd, J=9.0, 5.0Hz, 2H), 7.56 (d, J=8.7Hz, 2H), 7.94 (t, J=6.0Hz, 1H), 8.03 (d, J=8.0Hz, 1H), 8.54 (dt, J=1.8, 8.0Hz, 1H), 8.75 (dd, J=6.0, 1.8Hz, 1H).

Embodiment 29 (32)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (pyridin-3-yl methyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.47；

NMR(CD₃OD)：δ 1.98-2.10 (m, 2H), 2.18-2.35 (m, 2H), 2.95 (s, 3H), 3.10-3.23 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (s, 2H), 4.43 (m, 1H), 4.80 (s, 2H), 7.00 (d, J=9.0Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.38 (dd, J=9.0, 5.0Hz, 2H), 7.55 (d, J=8.7Hz, 2H), 8.05 (dd, J=8.4, 5.7Hz, 1H), 8.59 (d, J=8.4Hz, 1H), 8.75 (d, J=5.7Hz, 1H), 8.84 (s, 1H).

Embodiment 29 (33)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (pyridin-4-yl methyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.47；

NMR(CD₃OD)：δ 2.02-2.30 (m, 4H), 2.95 (s, 3H), 3.10-3.23 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (s, 2H), 4.48 (m, 1H), 4.88 (s, 2H), 6.99 (d, J=9.0Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.36 (dd, J=9.0, 5.0Hz, 2H), 7.54 (d, J=8.7Hz, 2H), 8.02 (d, J=6.6Hz, 2H), 8.77 (d, J=6.6Hz, 2H).

Embodiment 29 (34)：

N- (4- { 4- [(4- { butyl [(methylamino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.94 (t, J=7.5Hz, 3H), 1.30-1.40 (m, 2H), 1.40-1.60 (m, 2H), 1.80-2.00 (m, 2H), 2.10-2.20 (m, 2H), 2.72 (s, 3H), 2.95 (s, 3H), 3.00-3.15 (m, 4H), 3.50-3.60 (m, 2H), 4.12 (m, 1H), 4.27 (s, 2H), 7.02-7.08 (m, 4H), (7.29 d, J=8.9Hz, 2H), (7.49 d, J=8.9Hz, 2H).

Embodiment 29 (35)：

N- [4- (4- { [4- (butyl { [(5- pyridone -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.50；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.54 (d, J=8.9Hz, 2H), 7.93 (d, J=2.1Hz, 1H) 8.12 (d, J=2.1Hz, 1H), 8.68 (d, J=1.5Hz, 1H).

Embodiment 29 (36)：

N- [4- (4- { [4- (butyl { [(1- isopropyls -1H-1,2,3- BTA -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：(the t of δ 0.98, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.74 (d, J=6.6Hz, 6H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.96 (s, 3H), 3.10-3.30 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.32 (s, 2H), 5.34 (m, 1H), 7.02-7.08 (m, 4H), 7.30 (d, J=8.9Hz, 2H), 7.54 (d, J=8.9Hz, 2H), 7.77 (dd, J=9.0, 1.5Hz, 1H) 7.95 (d, J=9.0Hz, 1H), 8.17 (d, J=1.5Hz, 1H).

Embodiment 29 (37)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(6- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.50；

NMR(CD₃OD)：δ 2.08-2.18 (m, 2H), 2.20-2.38 (m, 2H), 2.80 (s, 3H), 2.95 (s, 3H), 3.14-3.26 (m, 2H), 3.52-3.62 (m, 2H), 4.32 (s, 2H), 4.47 (m, 1H), 4.83 (s, 2H), 7.00 (d, J=9.0Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.37 (dd, J=9.0, 5.0Hz, 2H), 7.57 (d, J=8.7Hz, 2H), 7.76 (d, J=8.0Hz, 1H), 7.78 (d, J=8.0Hz, 1H), 8.40 (t, J=8.0Hz, 1H).

Embodiment 29 (38)：

N- [4- (4- { [4- (butyl { [(3- cyano-phenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.28-1.44 (m, 2H), 1.55-1.66 (m, 2H), 1.98-2.03 (m, 2H), 2.20-2.33 (m, 2H), 2.95 (s, 3H), 3.09-3.17 (m, 2H), 3.30-3.40 (m, 2H), 3.55-3.59 (m, 2H), 4.17 (m, 1H), 4.30 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.36 (m, 1H), 7.44 (t, J=8.0Hz, 1H), 7.51 (d, J=8.7Hz, 2H), 7.64 (m, 1H), 7.82 (m, 1H).

Embodiment 29 (39)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (tetrahydrochysene -2H- pyrans -4- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.57；

NMR(CD₃OD)：δ 1.27-1.42 (m, 2H), 1.60-1.70 (m, 2H), 1.87-2.08 (m, 3H), 2.25-2.42 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.19-3.28 (m, 2H), 3.31-3.42 (m, 2H), 3.48-3.60 (m, 2H), 3.88-4.00 (m, 3H), 4.28 (s, 2H), 6.97-7.10 (m, 6H), 7.25-7.33 (m, 4H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 29 (40)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- phenylethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.68；

NMR(CD₃OD)：δ 1.82-2.92 (m, 2H), 2.10-2.28 (m, 2H), 2.93 (t, J=7.5Hz, 2H), 2.95 (s, 3H), 3.00-3.12 (m, 2H), 3.49-3.59 (m, 4H), 4.10 (m, 1H), 4.27 (s, 2H), 6.97-7.10 (m, 6H), 7.18-7.37 (m, 9H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 29 (41)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- pyridine -2- bases ethyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.59；

NMR(CD₃OD)：δ 1.98-2.10 (m, 2H), 2.28-2.44 (m, 2H), 2.95 (s, 3H), 3.09-3.22 (m, 2H), 3.34 (t, J=7.2Hz, 2H), 3.55-3.63 (m, 2H), 3.75 (t, J=7.2Hz, 2H), 4.25 (m, 1H), 4.33 (s, 2H), 6.97-7.10 (m, 6H), 7.26-7.33 (m, 4H), 7.57 (d, J=8.7Hz, 2H), 7.92 (ddd, J=8.1, 5.7, 1.8Hz, 1H), 8.06 (d, J=8.1Hz, 1H), 8.53 (dt, J=1.8, 8.1Hz, 1H), 8.74 (d, J=5.7Hz, 1H).

Embodiment 29 (42)：

N- [4- (4- { [4- (butyl { [(4- methyl isophthalic acids, 2,3- thiadiazoles -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.78；

NMR(CD₃OD)：δ 0.99 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.68 (s, 3H), 2.96 (s, 3H), 3.10-3.20 (m, 2H), 3.40-3.50 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), (7.29 d, J=8.9Hz, 2H), (7.53 d, J=8.9Hz, 2H).

Embodiment 29 (43)：

N- [4- (4- { [4- (butyl { [(the chloro- 4- fluorophenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.72；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 5H), 7.27 (m, 1H), 7.29 (d, J=9.0Hz, 2H), 7.50 (d, J=9.0Hz, 2H), 7.51 (m, 1H).

Embodiment 29 (44)：

N- [4- (4- { [4- (butyl { [(4- cyano-phenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.71；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.34-1.41 (m, 2H), 1.57-1.62 (m, 2H), 1.98-2.01 (m, 2H), 2.20-2.33 (m, 2H), 2.95 (s, 3H), 3.08-3.16 (m, 2H), 3.30-3.40 (m, 2H), 3.55-3.59 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 7.04 (d, J=8.9Hz, 2H), 7.07 (d, J=8.9Hz, 2H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H), 7.58 (d, J=9.0Hz, 2H), 7.61 (d, J=9.0Hz, 2H).

Embodiment 29 (45)：

N- [4- (4- { [4- (butyl { [(2,2- bis- fluoro- 1,3- benzodioxoles -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.34-1.42 (m, 2H), 1.55-1.65 (m, 2H), 1.98-2.03 (m, 2H), 2.15-2.25 (m, 2H), 2.95 (s, 3H), 3.07-3.15 (m, 2H), 3.25-3.30 (m, 2H), 3.55-3.59 (m, 2H), 4.14 (m, 1H), 4.29 (s, 2H), 7.02-7.11 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.33 (m, 1H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (46)：

N- [4- (4- { [4- (butyl { [(the chloro- 2- fluorophenyls of 4-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.15 (m, 1H), 7.22 (dd, J=6.3, 2.1Hz, 1H), 7.29 (d, J=8.9Hz, 2H), 7.43 (m, 1H), 7.43 (d, J=8.9Hz, 2H).

Embodiment 29 (47)：

N- [4- (4- { [4- (butyl { [(1- methyl isophthalic acids H-1,2,3- BTA -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：(the t of δ 0.98, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 4.39 (s, 3H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.53 (d, J=9.0Hz, 2H), 7.69 (dd, J=9.0, 1.8Hz, 1H), 7.80 (d, J=9.0Hz, 1H), 8.09 (d, J=1.8Hz, 1H).

Embodiment 29 (48)：

2- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] benzamide

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.37-1.44 (m, 2H), 1.59-1.91 (m, 6H), 2.15-2.22 (m, 2H), 2.93 (s, 3H), 3.00-3.04 (m, 2H), 3.22-3.27 (m, 2H), 3.54 (s, 2H), 4.05 (m, 1H), 6.93-7.02 (m, 5H), 7.25 (d, J=8.7Hz, 2H), (7.32 d, J=8.7Hz, 2H), (7.42 t, J=8.3Hz, 1H), (7.69 d, J=8.3Hz, 1H), (8.27 d, J=8.3Hz, 1H).

Embodiment 29 (49)：

N- [4- (4- { [4- (butyl { [(2,4- lutidines -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.45；

NMR(CD₃OD)：(the t of δ 1.00, J=7.5Hz, 3H), 1.39-1.46 (m, 2H), 1.63-1.70 (m, 2H), 2.01-2.06 (m, 2H), 2.22-2.35 (m, 2H), 2.52 (s, 3H), 2.64 (s, 3H), 2.95 (s, 3H), 3.12-3.20 (m, 2H), 3.30-3.37 (m, 2H), 3.56-3.60 (m, 2H), 4.24 (m, 1H), 4.30 (s, 2H), 7.03 (d, J=8.9Hz, 2H), 7.06 (d, J=8.9Hz, 2H), 7.29 (d, J=8.9Hz, 2H), 7.52 (d, J=8.9Hz, 2H), 7.83 (d, J=6.3Hz, 1H), 8.48 (d, J=6.3Hz, 1H).

Embodiment 29 (50)：

N- [4- (4- { [4- (butyl { [(4- fluoro-2-hydroxyphenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.99 (t, J=7.5Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 6.53-6.60 (m, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.46 (m, 1H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (51)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- hydroxy-3-methyls butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.45；

NMR(CD₃OD)：(the d of δ 0.99, J=6.9Hz, 3H), 1.00 (d, J=6.9Hz, 3H), 1.74 (m, 1H), 1.95-2.25 (m, 4H), 2.95 (s, 3H), 3.07-3.20 (m, 2H), 3.25-3.42 (m, 2H), 3.47-3.62 (m, 3H), 4.16 (m, 1H), 4.29 (s, 2H), 6.99 (d, J=9.0Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.24 (dd, J=9.0, 5.0Hz, 2H), 7.29 (d, J8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 29 (52)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- hydroxy-3-methyls butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.44；

NMR(CD₃OD)：(the s of δ 1.25, 6H), 1.79 (t, J=7.5Hz, 2H), 1.92-2.02 (m, 2H), 2.08-2.23 (m, 2H), 2.95 (s, 3H), 3.08-3.18 (m, 2H), 3.40 (t, J=7.5Hz, 2H), 3.52-3.62 (m, 2H), 4.26-4.36 (m, 3H), 6.98 (d, J=9.0Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J 8.7Hz, 2H), 7.36 (dd, J=9.0, 5.0Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 29 (53)：

N- [4- (4- { [4- (butyl { [(2,4- dimethyl-pyridine 1-oxide -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.43；

NMR(CD₃OD)：(the t of δ 1.00, J=7.2Hz, 3H), 1.39-1.46 (m, 2H), 1.63-1.75 (m, 2H), 1.97-2.05 (m, 2H), 2.23-2.35 (m, 2H), 2.43 (s, 3H), 2.59 (s, 3H), 2.96 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.38 (m, 2H), 3.53-3.59 (m, 2H), 4.21 (m, 1H), 4.30 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.30 (d, J=8.7Hz, 2H), 7.52 (d, J=8.7Hz, 2H), 7.66 (d, J=6.9Hz, 1H), 8.59 (d, J=6.9Hz, 1H).

Embodiment 29 (54)：

N- [4- (4- { [4- (butyl { [(pyridine 1-oxide -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=5: 1) of Rf 0.35；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.34-1.44 (m, 2H), 1.55-1.65 (m, 2H), 1.98-2.05 (m, 2H), 2.26-2.38 (m, 2H), 2.95 (s, 3H), 3.13-3.21 (m, 2H), 3.33-3.38 (m, 2H), 3.56-3.60 (m, 2H), 4.24 (m, 1H), 4.31 (s, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.4Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.52 (d, J=8.4Hz, 2H), 8.06 (d, J=7.0Hz, 2H), 8.59 (d, J=7.0Hz, 2H).

Embodiment 29 (55)：

N- [4- (4- { [4- (butyl { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.30 (m, 4H), 3.50-3.60 (m, 2H), 3.97 (s, 3H), 4.20 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.52 (d, J=8.9Hz, 2H), 7.88 (s, 1H), 7.99 (s, 1H)；

It is unformed；

Softening point：About 156-159 DEG C

Embodiment 29 (56)：

N- { 4- [4- ({ 4- [{ [(2,4- difluorophenyl) amino] carbonyl } (2- hydroxybutyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.51；

NMR(CD₃OD)：δ 1.00 (t, J=7.5Hz, 3H), 1.40-1.60 (m, 2H), 1.97-2.31 (m, 4H), 2.95 (s, 3H), 3.02-3.41 (m, 4H), 3.50-3.71 (m, 3H), 4.12 (m, 1H), 4.28 (s, 2H), 6.83-7.02 (m, 2H), 7.03 (d, J=8.7H z, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.63 (dt, J=5.7,9.0Hz, 1H).

Embodiment 29 (57)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.56；

NMR(CD₃OD)：δ 2.01-2.30 (m, 4H), 2.62 (s, 3H), 2.95 (s, 3H), 3.16-3.30 (m, 2H), 3.50-3.61 (m, 2H), 4.31 (s, 2H), 4.51 (m, 1H), 4.88 (s, 2H), 6.98-7.08 (m, 6H), 7.28 (d, J=8.7Hz, 2H), 7.42-7.50 (m, 2H), (7.56 d, J=8.7Hz, 2H), (7.86 t, J=6.5Hz, 1H), (8.39 d, J=6.5Hz, 1H), (8.54 d, J=6.5Hz, 1H).

Embodiment 29 (58)：

N- [4- (4- { [4- ((cyclopentyl-methyl) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.57；

NMR(CD₃OD)：δ 1.20-1.35 (m, 2H), 1.52-1.87 (m, 6H), 1.98-2.07 (m, 2H), 2.22 (m, 1H), 2.30-2.48 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.28-3.33 (m, 2H), 3.50-3.60 (m, 2H), 3.88 (m, 1H), 4.28 (s, 2H), 6.98-7.08 (m, 6H), 7.24-7.32 (m, 4H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 29 (59)：

N- [4- (4- { [4- (butyl { [(the fluoro- 5- methoxyphenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.75 (s, 3H), 4.20 (m, 1H), 4.29 (s, 2H), 6.67 (m, 1H), 7.02-7.12 (m, 6H), (7.29 d, J=8.9Hz, 2H), (7.52 d, J=8.9Hz, 2H).

Embodiment 29 (60)：

N- [4- (4- { [4- (butyl { [(the fluoro- 3- methoxyphenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.52；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.85 (s, 3H), 4.20 (m, 1H), 4.29 (s, 2H), 6.89 (m, 1H), 7.02-7.08 (m, 6H), (7.29 d, J=9.0Hz, 2H), (7.50 d, J=9.0Hz, 2H).

Embodiment 29 (61)：

N- [4- (4- { [4- (butyl { [(the fluoro- 4- aminomethyl phenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.56；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.40 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.31 (s, 3H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.90-7.00 (m, 2H), 7.02-7.08 (m, 4H), 7.26-7.31 (m, 3H), (7.50 d, J=9.0Hz, 2H).

Embodiment 29 (62)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1,3-thiazoles -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.63；

NMR(CD₃OD)：δ 2.00-2.13 (m, 2H), 2.13-2.31 (m, 2H), 2.95 (s, 3H), 3.16 (m, 2H), 3.58 (m, 2H), 4.31 (s, 2H), 4.38 (m, 1H), 4.93 (s, 2H), 6.98-7.18 (m, 6H), 7.24-7.42 (m, 4H), 7.52 (brd, J=8.7Hz, 2H), 7.75 (d, J=3.6Hz, 1H), 7.93 (d, J=3.6Hz, 1H).

Embodiment 29 (63)：

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino]-N-methyl-benzamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.34；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.90 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.30-7.50 (m, 3H), 7.50 (d, J=8.7Hz, 2H), 7.79 (s, 1H).

Embodiment 29 (64)：

N- { 4- [4- ({ 4- [butyl ({ [3- (dimethylamino) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.40 (m, 4H), 3.28 (s, 6H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 4H), 7.28-7.31 (m, 3H), 7.48-7.54 (m, 4H), 7.90 (m, 1H).

Embodiment 29 (65)：

N- [4- (4- { [4- (butyl { [(4- fluoro-2-methylbenzenes base) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.47；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.21 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.28 (s, 2H), 6.88 (m, 1H), 6.94-7.14 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H).

Embodiment 29 (66)：

N- [4- (4- { [4- (butyl { [(the fluoro- 4- methoxyphenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.63；

NMR(CD₃OD)：(the t of δ 0.98, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.77 (s, 3H), 4.15 (m, 1H), 4.28 (s, 2H), 6.70-6.75 (m, 2H), 7.02-7.08 (m, 4H), 7.22 (m, 1H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 29 (67)：

N- [4- (4- { [4- (butyl { [(3- ethylphenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.58；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.22 (t, J=7.5Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.60 (q, J=7.1Hz, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.19 (m, 1H), 4.29 (s, 2H), 6.89 (m, 1H), 7.01-7.08 (m, 4H), 7.12-7.20 (m, 3H), 7.29-7.32 (m, 2H), 7.49-7.52 (m, 2H).

Embodiment 29 (68)：

N- (4- 4- [(4- [[(4- fluorophenyls) amino] carbonyl } [(pyridine 1-oxide -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.14；

NMR(CD₃OD)：δ 2.02-2.30 (m, 4H), 2.95 (s, 3H), 3.12-3.25 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (s, 2H), 4.43 (m, 1H), 6.95-7.08 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.35 (dd, J=9.0,5.0Hz, 2H), 7.52 (d, J=8.7Hz, 2H), (7.73 t, J=7.5Hz, 1H), (7.85 d, J=7.5Hz, 1H), (8.01 t, J=7.5Hz, 1H), (8.68 d, J=7.5Hz, 1H).

Embodiment 29 (69)：

N- [4- (4- { [4- (butyl { [(the fluoro- 4- hydroxy phenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.44；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 6.52-6.56 (m, 2H), 7.02-7.09 (m, 6H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (70)：

N- [4- (4- { [4- (butyl { [(1- Methyl-1H-indole -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.42；

NMR(CD₃OD)：(the t of δ 0.99, J=7.4Hz, 3H), 1.40-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.76 (s, 3H), 4.25 (m, 1H), 4.26 (s, 2H), 7.02-7.07 (m, 5H), 7.10-7.20 (m, 2H), 7.29 (d, J=9.0Hz, 2H), 7.30 (m, 1H), 7.45 (m, 1H), 7.49 (d, J=9.0Hz, 2H).

Embodiment 29 (71)：

N- { 4- [4- ({ 4- [butyl ({ [3- (mesyl) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.26；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.10 (s, 3H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.3Hz, 2H), 7.51 (d, J=8.3Hz, 2H) 7.54-7.59 (m, 2H), 7.69 (m, 1H), 8.07 (m, 1H).

Embodiment 29 (72)：

N- [4- (4- { [4- (butyl { [(the chloro- 1- methyl isophthalic acids H- pyrazoles -4- bases of 3-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.42；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.81 (s, 3H), 4.10 (m, 1H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.45 (s, 1H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (73)：

N- [4- (4- { [4- ((2,6- dimethyl benzyl) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.50；

NMR(CD₃OD)：δ 1.40-1.49 (m, 2H), 1.79-1.90 (m, 2H), 2.15-2.32 (m, 2H), 2.39 (s, 6H), 2.80-2.90 (m, 2H), 2.92 (s, 3H), 3.14 (m, 1H), 3.40 (s, 2H), 4.68 (s, 2H), 6.87-7.15 (m, 10H), 7.20-7.32 (m, 5H).

Embodiment 29 (74)：

N- [4- (4- { [4- ((2- cyclopropylethyls) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.56；

NMR(CD₃OD)：δ 0.10-0.16 (m, 2H), 0.44-0.53 (m, 2H), 0.74 (m, 1H), 1.48-1.60 (m, 2H), 1.95-2.07 (m, 2H), 2.12-2.30 (m, 2H), 2.95 (s, 3H), 3.07-3.19 (m, 2H), 3.35-3.43 (m, 2H), 3.51-3.62 (m, 2H), 4.17 (m, 1H), 4.29 (s, 2H), 6.97-7.10 (m, 6H), 7.26-7.37 (m, 4H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (75)：

N- { 4- [4- ({ 4- [{ [(2,4- difluorophenyl) amino] carbonyl } (pyridine -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 2.06-2.38 (m, 4H), 2.95 (s, 3H), 3.18 (m, 2H), 3.59 (m, 2H), 4.32 (s, 2H), 4.40 (m, 1H), 4.88 (s, 2H), 6.88-7.08 (m, 6H), 7.21-7.34 (m, 2H), 7.41 (m, 1H), (7.56 brd, J=8.4Hz, 2H), 7.91 (m, 1H), 8.00 (m, 1H), 8.52 (m, 1H), (8.76 brd, J=5.4Hz, 1H).

Embodiment 29 (76)：

N- [4- (4- { [4- (butyl- 3- alkenyls { [(2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.82；

NMR(CD₃OD)：δ 2.01 (m, 2H), 2.25 (m, 2H), 2.42 (m, 2H), 2.95 (s, 3H), 3.10 (m, 2H), 3.37 (m, 2H), 3.56 (m, 2H), 4.12 (m, 1H), 4.28 (m, 2H), 5.09 (brd, J=9.9Hz, 1H), 5.16 (brd, J=17.1Hz, 1H), 5.88 (m, 1H), 6.88-7.12 (m, 6H), 7.22-7.42 (m, 3H), 7.42-7.52 (m, 2H).

Embodiment 29 (77)：

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] benzamide hydrochloride salt

TLC:(the chloroforms: methanol=5: 1) of Rf 0.45；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), (7.29 d, J=9.0Hz, 2H), 7.38 (m, 1H), 7.49-7.52 (m, 4H), 7.84 (m, 1H).

Embodiment 29 (78)：

N- (4- { 4- [(4- { butyl [(1H- pyrazoles -4- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.47；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.52 (d, J=9.0Hz, 2H), 8.10 (s, 2H).

Embodiment 29 (79)：

N- { 4- [4- ({ 4- [butyl ({ [1- methyl -5- (trifluoromethyl) -1H- pyrazoles -4- bases] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.88；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.30 (m, 2H), 3.50-3.60 (m, 2H), 3.90 (s, 3H), 4.10 (m, 1H), 4.28 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.49 (d, J=9.0Hz, 2H), 7.71 (s, 1H).

Embodiment 29 (80)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1H-TETRAZOLE -5- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the n-butanols: acetic acid: water=20: 4: 1) of Rf 0.29；

NMR(CD₃OD)：δ 1.98-2.25 (m, 4H), 2.95 (s, 3H), 3.15 (m, 2H), 3.58 (m, 2H), 4.30 (s, 2H), 4.34 (m, 1H), 4.84 (s, 2H), 6.98-7.08 (m, 6H), 7.24-7.41 (m, 4H), 7.51 (brd, J=8.7Hz, 2H).

Embodiment 29 (81)：

N- [4- (4- { [4- (butyl- 3- alkenyls { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.75；

NMR(CD₃OD)：δ 1.98 (m, 2H), 2.21 (m, 2H), 2.35 (m, 2H), 2.95 (s, 3H), 3.12 (m, 2H), 3.24-3.38 (m, 2H), 3.57 (m, 2H), 3.87 (s, 3H), 4.12 (m, 1H), 4.29 (s, 2H), 5.00-5.20 (m, 2H), 5.76-5.94 (m, 1H), 7.00-7.10 (m, 4H), 7.22-7.34 (m, 2H), 7.42-7.60 (m, 3H), 7.73 (m, 1H).

Embodiment 29 (82)：

N- { 4- [4- ({ 4- [{ [(6- picoline -3- bases) amino] carbonyl } (pyridine -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide tri hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.68；

NMR(CD₃OD)：δ 2.00 (m, 2H), 2.22 (m, 2H), 2.70 (s, 3H), 2.95 (s, 3H), 3.17 (m, 2H), 3.55 (m, 2H), 4.30 (s, 2H), 4.48 (m, 1H), 4.75 (s, 2H), 6.98-7.10 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.48-7.56 (m, 3H), 7.62 (m, 1H), 7.80 (d, J=8.7Hz, 1H), 8.02 (m, 1H), 8.42 (m, 1H), 8.63 (m, 1H), 9.02 (d, J=1.8Hz, 1H).

Embodiment 29 (83)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (phenyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.49；

NMR(CD₃OD)：δ 1.60-1.80 (m, 2H), 2.12-2.21 (m, 2H), 2.95 (s, 3H), 3.10-3.21 (m, 2H), 3.42-3.52 (m, 2H), 4.22 (s, 2H), 4.66 (m, 1H), 6.95 (t, J=9.0Hz, 2H), 7.01 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.19-7.35 (m, 6H), 7.42 (d, J=8.7Hz, 2H), 7.46-7.57 (m, 3H).

Embodiment 29 (84)：

N- (4- { 4- [(4- { butyl [(1H- indoles -5- bases amino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.25 (s, 2H), 7.02-7.07 (m, 6H), 7.21 (s, 1H), 7.28-7.32 (m, 3H), 7.44 (m, 1H), 7.50 (d, J=9.0Hz, 2H).

Embodiment 29 (85)：

N- { 4- [4- ({ 4- [butyl ({ [1- methyl -3- (trifluoromethyl) -1H- pyrazoles -4- bases] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.84；

NMR(CD₃OD)：δ 0.96 (t, J=7.2Hz, 3H), 1.30-1.40 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.90 (s, 3H), 4.15 (m, 1H), 4.28 (s, 2H), 7.02-7.07 (m, 4H), 7.29 (d, J=9.0Hz, 2H) 7.51 (d, J=9.0Hz, 2H), 7.71 (s, 1H).

Embodiment 29 (86)：

N- [4- (4- { [4- (butyl { [(the fluoro- 5- hydroxy phenyls of 2-) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.82；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.00 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 6.52 (m, 1H), 6.88 (m, 1H), 6.95 (m, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.51 (d, J=8.9Hz, 2H).

Embodiment 29 (87)：

N- { 4- [4- ({ 4- [[(Cyclobutylamino) carbonyl] (1,3-thiazoles -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.68；

NMR(CD₃OD)：δ 1.60-1.78 (m, 2H), 1.84-2.36 (m, 8H), 2.95 (s, 3H), 3.12 (m, 2H), 3.56 (m, 2H), 4.16-4.30 (m, 2H), 4.29 (s, 2H), 4.81 (m, 2H), 7.00-7.12 (m, 4H), 7.29 (brd, J=8.7Hz, 2H), 7.52 (brd, J=8.7Hz, 2H), 7.77 (brd, J=3.6Hz, 1H), 7.92 (brd, J=3.6Hz, 1H).

Embodiment 29 (88)：

N- { 4- [4- ({ 4- [{ [(6- picoline -3- bases) amino] carbonyl } (1,3-thiazoles -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.61；

NMR(CD₃OD)：δ 2.00-2.18 (m, 2H), 2.18-2.40 (m, 2H), 2.71 (s, 3H), 2.95 (s, 3H), 3.29 (m, 2H), 3.57 (m, 2H), 4.32 (s, 2H), 4.59 (m, 1H), 5.00 (s, 2H), 7.00-7.12 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.55 (brd, J=8.4Hz, 2H), 7.77 (m, 1H), 7.82 (d, J=9.0Hz, 1H), 7.94 (brd, J=2.1Hz, 1H), 8.58 (m, 1H), 9.08 (brd, J=2.1Hz, 1H).

Embodiment 29 (89)：

N- { 4- [4- ({ 4- [{ [(2,4- difluorophenyl) amino] carbonyl } (1,3-thiazoles -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.73；

NMR(CD₃OD)：δ 2.00-2.32 (m, 4H), 2.95 (s, 3H), 3.12 (m, 2H), 3.57 (m, 2H), 4.29 (s, 2H), 4.32 (m, 1H), 4.91 (s, 2H), 6.90-7.12 (m, 6H), 7.29 (brd, J=9.0Hz, 2H), 7.39-7.60 (m, 3H), 7.70 (brd, J=3.3Hz, 1H), 7.88 (brd, J=3.3Hz, 1H).

Embodiment 29 (90)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(2- picoline -3- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：δ 2.00-2.11 (m, 2H), 2.12-2.38 (m, 2H), 2.82 (s, 3H), 2.95 (s, 3H), 3.13 (m, 2H), 3.54 (m, 2H), 4.29 (s, 2H), 4.49 (m, 1H), 4.69 (s, 2H), 6.96-7.10 (m, 6H), 7.14-7.38 (m, 4H), 7.54 (brd, J=8.4Hz, 2H), 7.82 (m, 1H), 8.32 (m, 1H), (8.56 d, J=5.4Hz, 1H).

Embodiment 29 (91)：

N- (4- { 4- [(4- { { [(2,4- difluorophenyl) amino] carbonyl } [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.55；

NMR(CD₃OD)：δ 2.08-2.35 (m, 4H), 2.62 (s, 3H), 2.95 (s, 3H), 3.12-3.25 (m, 2H), 3.52-3.61 (m, 2H), 4.31 (s, 2H), 4.47 (m, 1H), 4.92 (s, 2H), 6.90-7.00 (m, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.28 (d, J=8.7Hz, 2H), 7.47 (dt, J=6.0, 9.0Hz, 1H), 7.56 (d, J=8.7Hz, 2H), 7.89 (dd, J=7.5, 5.7Hz, 1H), 8.44 (d, J=7.5Hz, 1H), 8.57 (d, J=5.7Hz, 1H).

Embodiment 29 (92)：

N- (4- { 4- [(4- { [(Cyclobutylamino) carbonyl] [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.50；

NMR(CD₃OD)：δ 1.63-1.75 (m, 2H), 1.95-2.30 (m, 8H), 2.59 (s, 3H), 2.95 (s, 3H), 3.10-3.22 (m, 2H), 3.49-3.58 (m, 2H), 4.20-4.37 (m, 4H), 4.74 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7H z, 2H), 7.28 (d, J=8.7Hz, 2H), 7.54 (d, J=8.7Hz, 2H), 7.86 (dd, J=7.5, 6.0Hz, 1H), 8.40 (d, J=7.5Hz, 1H), 8.51 (d, J=6.0Hz, 1H).

Embodiment 29 (93)：

N- (4- { 4- [(4- { { [(6- picoline -3- bases) amino] carbonyl } [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide tri hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.47；

NMR(CD₃OD)：δ 2.10-2.39 (m, 4H), 2.64 (s, 3H), 2.71 (s, 3H), 2.95 (s, 3H), 3.22-3.35 (m, 2H), 3.50-3.60 (m, 2H), 4.32 (s, 2H), 4.75 (m, 1H), 4.96 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.28 (d, J=8.7Hz, 2H), 7.57 (d, J=8.7Hz, 2H), 7.83 (d, J=8.7Hz, 1H), 7.89 (dd, J=7.5, 5.1Hz, 1H), 8.44 (d, J=7.5Hz, 1H), 8.57 (d, J=5.1Hz, 1H), 8.68 (dd, J=8.7, 2.4Hz, 1H), 9.12 (d, J=2.4Hz, 1H).

Embodiment 29 (94)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (pyrimidine -2-base methyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.40；

NMR(DMSO-d₆)：δ 1.80-1.89 (m, 2H), 2.10-2.30 (m, 2H), 2.96 (s, 3H), 2.97-3.10 (m, 2H), 4.21 (s, 2H), 4.36 (m, 1H), 4.70 (s, 2H), 6.98-7.07 (m, 6H), 7.28 (d, J=8.7Hz, 2H), 7.35-7.43 (m, 3H), 7.55 (d, J=8.7Hz, 2H), 8.60 (m, 1H), 8.78 (d, J=5.1Hz, 2H), 9.35 (m, 1H).

Embodiment 29 (95)：

N- [4- (4- { [4- (butyl { [(2,4,6- trifluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.88-6.94 (m, 2H), 7.02-7.07 (m, 4H), (7.29 d, J=9.2Hz, 2H), (7.51 d, J=9.2Hz, 2H).

Embodiment 29 (96)：

N- (4- { 4- [(4- { { [(2- hydroxybutyls) amino] carbonyl } [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.39；

NMR(CD₃OD)：(the t of δ 0.96, J=7.2Hz, 3H), 1.37-1.58 (m, 2H), 1.97-2.25 (m, 4H), 2.60 (s, 3H), 2.95 (s, 3H), 3.10-3.23 (m, 4H), 3.50-3.67 (m, 3H), 4.27-4.38 (m, 3H), 4.80 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.55 (d, J=8.7Hz, 2H), 7.88 (dd, J=7.8, 6.0Hz, 1H), 8.42 (d, J=7.8Hz, 1H), 8.54 (d, J=6.0Hz, 1H).

Embodiment 29 (97)：

N- { 4- [4- ({ 4- [[(Cyclobutylamino) carbonyl] (pyridine -2- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.54；

NMR(CD₃OD)：δ 1.60-1.74 (m, 2H), 1.90-2.30 (m, 8H), 2.95 (s, 3H), 3.11 (m, 2H), 3.56 (m, 2H), 4.18-4.32 (m, 2H), 4.30 (s, 2H), 4.72 (s, 2H), 7.00-7.10 (m, 4H), 7.29 (brd, J=9.0Hz, 2H), 7.53 (brd, J=8.7Hz, 2H), 7.80-7.92 (m, 2H), 8.44 (m, 1H), (8.71 brd, J=5.4Hz, 1H).

Embodiment 29 (98)：

N- { 4- [4- ({ 4- [{ [(2- hydroxybutyls) amino] carbonyl } (2- methyl-benzyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.61；

NMR(CD₃OD)：δ 0.90 (t, J=7.5Hz, 3H), 1.20-1.50 (m, 2H), 1.90-2.02 (m, 4H), 2.32 (s, 3H), 2.95 (s, 3H), 3.00-3.34 (m, 4H), 3.42-3.51 (m, 3H), 4.24 (s, 2H), 4.39 (s, 2H), 4.41 (m, 1H), 6.98-7.04 (m, 4H), 7.08-7.20 (m, 4H), (7.28 brd, 9.0Hz, 2H), (7.45 brd, J=8.4Hz, 2H).

Embodiment 29 (99)：

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2- fluorobenzoyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.67；

NMR(CD₃OD)：(the t of δ 0.97, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.07 (m, 4H), 7.13 (m, 1H), 7.29 (d, J=9.0Hz, 2H), 7.50 (d, J=9.0Hz, 2H), 7.52 (m, 1H), 7.78 (m, 1H).

Embodiment 29 (100)：

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,6- difluorobenzoyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 7.02-7.07 (m, 5H), 7.29 (d, J=8.7Hz, 2H), 7.44 (m, 1H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (101)：

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorobenzoyl amine hydrochlorates

TLC:(the chloroforms: methanol=5: 1) of Rf 0.65；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.28 (s, 2H), 7.02-7.07 (m, 4H), 7.17 (t, J=10.5Hz, 1H), 7.29 (d, J=9.0Hz, 2H), 7.49 (d, J=9.0Hz, 2H), 7.85 (m, 1H).

Embodiment 29 (102)：

N- [4- (4- { [4- (butyl { [(3- cyano group -4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.66；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.07 (m, 4H), 7.23-7.31 (m, 3H), 7.50 (d, J=8.7Hz, 2H), 7.66 (m, 1H), 7.91 (m, 1H).

Embodiment 29 (103)：

N- [4- (4- { [4- (butyl { [(5- cyano group -2,4- difluorophenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.64；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.35 (m, 1H) 7.49 (d, J=8.9Hz, 2H), 7.87 (m, 1H).

Embodiment 29 (104)：

N- [4- (4- { [4- ((2- fluorophenyls) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.51；

NMR(CD₃OD)：δ 1.55-1.80 (m, 2H), 2.16-2.23 (m, 2H), 2.95 (s, 3H), 3.10-3.22 (m, 2H), 3.47-3.56 (m, 2H), 4.23 (s, 2H), 4.64 (m, 1H), 6.93-7.06 (m, 6H), 7.20-7.45 (m, 9H), 7.51 (m, 1H).

Embodiment 29 (105)：

N- [4- (4- { [4- ((3- fluorophenyls) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.52；

NMR(CD₃OD)：δ 1.63-1.82 (m, 2H), 2.12-2.23 (m, 2H), 2.95 (s, 3H), 3.10-3.21 (m, 2H), 3.44-3.55 (m, 2H), 4.23 (s, 2H), 4.64 (m, 1H), 6.93-7.07 (m, 6H), 7.15 (d, J=6.9Hz, 2H), 7.20-7.32 (m, 5H), 7.42 (d, J=8.7Hz, 2H), 7.54 (q, J=6.9Hz, 1H).

Embodiment 29 (106)：

N- [4- (4- { [4- ((4- fluorophenyls) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.54；

NMR(CD₃OD)：δ 1.59-1.79 (m, 2H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 3.09-3.21 (m, 2H), 3.45-3.54 (m, 2H), 4.22 (s, 2H), 4.64 (m, 1H), 6.91-7.05 (m, 6H), 7.20-7.38 (m, 8H), (7.43 d, J=8.7Hz, 2H).

Embodiment 29 (107)：

N- [4- (4- { [4- (butyl { [(4- cyano group -2- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.81；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.07 (m, 4H), 7.29 (d, J=8.7Hz, 2H), 7.50 (m, 1H), 7.50 (d, J=8.7Hz, 2H), 7.56 (dd, J=10.5, 1.8Hz, 1H), 7.83 (m, 1H).

Embodiment 29 (108)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (pyridin-3-yl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.46；

NMR(CD₃OD)：δ 1.95-2.10 (m, 2H), 2.18-2.24 (m, 2H), 2.95 (s, 3H), 3.11-3.23 (m, 2H), 3.49-3.58 (m, 2H), 4.26 (s, 2H), 4.64 (m, 1H), 6.97-7.07 (m, 6H), 7.26-7.35 (m, 4H), 7.50 (d, J=8.7Hz, 2H), 8.15 (dd, J=8.7,5.7Hz, 1H), 8.58 (dq, J=8.7,2.4Hz, 1H), (8.89 d, J=5.7Hz, 1H), (9.04 d, J=2.4Hz, 1H).

Embodiment 29 (109)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (2- aminomethyl phenyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.57；

NMR(CD₃OD)：δ 1.62 (m, 1H), 1.97-2.10 (m, 2H), 2.28-2.40 (m, 4H), 2.95 (s, 3H), 3.07-3.20 (m, 2H), 3.40-3.57 (m, 2H), 4.22 (s, 2H), 4.55 (m, 1H), 6.95 (t, J=9.0Hz, 2H), 7.01 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.08-7.47 (m, 10H).

Embodiment 29 (110)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (3- aminomethyl phenyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.57；

NMR(CD₃OD)：δ 1.62-1.80 (m, 2H), 2.11-2.20 (m, 2H), 2.40 (s, 3H), 2.95 (s, 3H), 3.09-3.21 (m, 2H), 3.45-3.54 (m, 2H), 4.23 (s, 2H), 4.63 (m, 1H), 6.95 (t, J=9.0Hz, 2H), 7.01 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.12 (d, J=7.5Hz, 1H), 7.15 (s, 1H), 7.21 (dd, J=9.0, 5.0Hz, 2H), 7.25-7.35 (m, 3H), 7.40 (d, J=7.5Hz, 1H), 7.42 (d, J=8.7Hz, 2H).

Embodiment 29 (111)：

N- 4- [4- (4- [[4- fluorophenyls) amino] carbonyl } (4- aminomethyl phenyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.58；

NMR(CD₃OD)：δ 1.59-1.78 (m, 2H), 2.10-2.20 (m, 2H), 2.40 (s, 3H), 2.95 (s, 3H), 3.08-3.20 (m, 2H), 3.44-3.50 (m, 2H), 4.21 (s, 2H), 4.67 (m, 1H), 6.95 (t, J=9.0Hz, 2H), 6.98-7.08 (m, 4H), 7.18-7.23 (m, 4H), (7.29 d, J=8.7Hz, 2H), (7.36 d, J=7.8Hz, 2H), (7.42 d, J=8.7Hz, 2H).

Embodiment 29 (112)：

N- [4- (4- { [4- (butyl { [(2- hydroxy phenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:Rf 0.63 (ethyl acetate)；

NMR(CD₃OD)：(the t of δ 1.00, J=7.2Hz, 3H), 1.37-1.49 (m, 2H), 1.63-1.71 (m, 2H), 1.98-2.03 (m, 2H), 2.14-2.27 (m, 2H), 2.96 (s, 3H), 3.09-3.17 (m, 2H), 3.25-3.30 (m, 2H), 3.55-3.59 (m, 2H), 4.24 (m, 1H), 4.30 (s, 2H), 6.76-6.94 (m, 3H), 7.04 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.30 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.59 (dd, J=7.8, 1.5Hz, 1H).

Embodiment 29 (113)：

N- { 2- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.50；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 2.00-2.10 (m, 2H), 2.10-2.20 (m, 2H), 2.95 (s, 3H), 2.97 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.60-3.80 (m, 2H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.15 (m, 1H), 7.26-7.31 (m, 4H), 7.50 (d, J=9.0Hz, 2H), 7.75 (d, J=8.1Hz, 1H).

Embodiment 29 (114)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (4- methyl-benzyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 7.47 (brd, J=8.7Hz, 2H), 7.36-7.14 (m, 8H), 7.10-6.92 (m, 6H), 4.60 (brs, 2H), 4.37 (m, 1H), 4.25 (s, 2H), 3.50 (m, 2H), 3.09 (m, 2H), 2.95 (s, 3H), 2.30 (s, 3H), 2.26-1.84 (m, 4H).

Embodiment 29 (115)：

N- [4- (4- { [4- (butyl { [(3,4- dihydroxy phenyl) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.40；

NMR(CD₃OD)：(the t of δ 0.96, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.58 (dd, J=8.4, 2.4Hz, 1H), 6.68 (d, J=8.4Hz, 1H), 6.79 (d, J=2.4Hz, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 29 (116)：

N- [4- (4- { [4- ((cyano methyl) { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.55；

NMR(CD₃OD)：δ 2.00-2.28 (m, 4H), 2.95 (s, 3H), 3.00-3.10 (m, 2H), 3.50-3.65 (m, 2H), 4.04-4.30 (m, 5H), 7.00-7.20 (m, 4H), 7.25-7.52 (m, 8H).

Embodiment 29 (117)：

N- { 4- [4- ({ 4- [butyl ({ [3- (2H- tetrazolium -5- bases) phenyl] amino } carbonyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.09；

NM[R(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 1.40 (m, 3H), 1.62 (m, 3H), 1.88 (m, 2H), 2.60 (m, 4H), 2.94 (s, 3H), 3.24 (m, 2H), 3.92 (s, 2H), 4.18 (m, 1H), 7.00 (m, 4H), 7.20-7.50 (m, 5H), 7.71 (brd, J=7.8Hz, 1H), 7.86 (m, H).

Embodiment 29 (118)：

N- [4- (4- { [4- (butyl- 3- alkene -1- bases { [(6- picoline -3- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.51；

NMR(CD₃OD)：δ 1.98-2.09 (m, 2H), 2.22-2.45 (m, 4H), 2.70 (s, 3H), 2.95 (s, 3H), 3.12-3.25 (m, 2H), 3.42 (t, J=7.8Hz, 2H), 3.54-3.66 (m, 2H), 4.26 (m, 1H), 4.31 (s, 2H), 5.08 (d, J=10.2Hz, 1H), 5.15 (d, J=17.1Hz, 1H), 5.85 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.07 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.52 (d, J=8.7Hz, 2H), 7.80 (d, J=9.0Hz, 1H), 8.47 (dd, J=9.0, .2.4Hz, 1H), 9.02 (d, J=2.4Hz, 1H).

Embodiment 29 (119)：

N- (4- { 4- [(4- { butyl- 3- alkene -1- bases [(Cyclobutylamino) carbonyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.61；

NMR(CD₃OD)：δ 1.62-1.74 (m, 2H), 1.88-2.35 (m, 10H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.20 (t, J=7.8Hz, 2H), 3.50-3.59 (m, 2H), 4.06 (m, 1H), 4.20 (m, 1H), 4.28 (s, 2H), 5.05 (d, J=10.2Hz, 1H), 5.11 (dd, J=17.1, 2.1Hz, 1H), 5.81 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 29 (120)：

N- { 4- [4- ({ 4- [[(Cyclobutylamino) carbonyl] (3- methyl but-2-ene -1- bases) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.60；

NMR(CD₃OD)：δ 1.60-2.18 (m, 14H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.02-3.15 (m, 2H), 3.49-3.59 (m, 2H), 3.77-3.82 (m, 2H), 4.15-4.25 (m, 2H), 4.27 (s, 2H), 5.06 (m, 1H), (7.03 d, J=8.7Hz, 2H), (7.05 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.49 d, J=8.7Hz, 2H).

Embodiment 29 (121)：

N- { 4- [4- ({ 4- [{ [(cis -4- hydroxy-cyclohexyls) amino] carbonyl } (3- methyl but-2-ene -1- bases) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.45；

NMR(CD₃OD)：δ 1.54-1.70 (m, 8H), 1.74 (s, 6H), 1.80-2.10 (m, 4H), 2.95 (s, 3H), 3.05-3.15 (m, 2H), 3.49-3.66 (m, 3H), 3.74-3.84 (m, 3H), 4.27 (s, 2H), 4.31 (m, 1H), 5.08 (m, 1H), (7.03 d, J=8.7Hz, 2H), (7.06 d, J=8.7Hz, 2H), (7.29 d, J=8.7Hz, 2H), (7.50 d, J=8.7Hz, 2H).

Embodiment 29 (122)：

N- { 4- [4- ({ 4- [{ [(cis -4- hydroxy-cyclohexyls) amino] carbonyl } (2- methyl-benzyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.51；

NMR(CD₃OD)：δ 1.50-1.60 (m, 8H), 1.90-2.03 (m, 4H), 2.33 (s, 3H), 2.95 (s, 3H), 3.02-3.14 (m, 2H), 3.45-3.53 (m, 2H), 3.63 (m, 1H), 3.79 (m, 1H), 4.24 (s, 2H), 4.40 (s, 2H), 4.45 (m, 1H), 7.01 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.07-7.21 (m, 4H), (7.28 d, J=8.7Hz, 2H), (7.46 d, J=8.7Hz, 2H).

Embodiment 29 (123)：

N- [4- (4- { [4- ((2- methyl-benzyls) { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.53；

NMR(CD₃OD)：δ 1.91-2.19 (m, 4H), 2.35 (s, 3H), 2.95 (s, 3H), 3.06-3.17 (m, 2H), 3.44-3.52 (m, 2H), 3.94 (s, 3H), 4.29 (s, 2H), 4.49 (m, 1H), 4.52 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06-7.20 (m, 4H), 7.28 (d, J=8.7Hz, 2H), 7.48 (d, J=8.7Hz, 2H), 7.77 (s, 1H), 7.94 (s, 1H).

Embodiment 29 (124)：

N- (4- { 4- [(4- { { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } [(3- picoline -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) Methanesulfomide tri hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.49；

NMR(CD₃OD)：δ 2.00-2.10 (m, 2H), 2.18-2.35 (m, 2H), 2.63 (s, 3H), 2.95 (s, 3H), 3.18-3.34 (m, 2H), 3.50-3.60 (m, 2H), 3.96 (s, 3H), 4.32 (s, 2H), 4.54 (m, 1H), 4.91 (s, 2H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.28 (d, J=8.7Hz, 2H), 7.57 (d, J=8.7Hz, 2H), 7.89 (dd, J=7.8, 6.0Hz, 1H), 7.94 (s, 1H), 8.06 (s, 1H), 8.45 (d, J=7.8Hz, 1H), 8.54 (d, J=6.0Hz, 1H).

Embodiment 29 (125)：

N- [4- (4- { [4- ((3- methyl but-2-ene -1- bases) { [(1- methyl isophthalic acid H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.52；

NMR(CD₃OD)：δ 1.72 (s, 3H), 1.73 (s, 3H), 1.90-2.22 (m, 4H), 2.95 (s, 3H), 3.08-3.20 (m, 2H), 3.50-3.60 (m, 2H), 3.90-3.97 (m, 2H), 3.97 (s, 3H), 4.23-4.32 (m, 3H), 5.12 (m, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.51 (d, J=8.7Hz, 2H), 7.85 (s, 1H), 7.98 (s, 1H).

Embodiment 29 (126)：

N- { 3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorophenyls } acetamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.44；

NMR(CD₃OD)：δ 0.98 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.14 (s, 3H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 6.97-7.08 (m, 5H), 7.29 (d, J=9.0Hz, 2H), 7.49 (d, J=9.0Hz, 2H), 7.65 (m, 1H).

Embodiment 29 (127)：

N- { 5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorophenyls } acetamide hydrochloride

TLC:Rf0.56 (chloroforms: methanol=5: 1)；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.14 (s, 3H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.28 (s, 2H), 7.02-7.10 (m, 5H), 7.29 (d, J=8.9Hz, 2H), 7.49 (d, J=8.9Hz, 2H), 7.95 (t, J=7.5Hz, 1H).

Embodiment 29 (128)：

N- { 3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -4- fluorophenyls } acetamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.48；

NMR(CD₃OD)：(the t of δ 0.98, J=7.5Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.10 (s, 3H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.15 (m, 1H), 4.29 (s, 2H), 7.02-7.09 (m, 5H), 7.25 (m, 1H), 7.29 (d, J=8.7Hz, 2H), 7.49 (d, J=8.7Hz, 2H), 7.77 (dd, J=6.9, 2.4Hz, 1H).

Embodiment 29 (129)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (tetrahydrochysene -2H- pyrans -4- bases) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.50；

NMR(CD₃OD)：δ 1.65-1.78 (m, 2H), 1.80-1.90 (m, 2H), 1.95-2.08 (m, 2H), 2.78-2.92 (m, 2H), 2.95 (s, 3H), 3.03-3.18 (m, 2H), 3.47-3.60 (m, 5H), 3.88-4.05 (m, 3H), 4.27 (s, 2H), 6.97-7.09 (m, 6H), 7.23-7.31 (m, 4H), 7.48 (d, J=8.7Hz, 2H).

Embodiment 29 (130)：

N- [4- (4- { [4- (butyl { [(1,3- dimethyl -1H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=4: 1) of Rf 0.66；

NMR(CD₃OD)：(the t of δ 0.97, J=7.5Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.28 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.99 (s, 3H), 4.20 (m, 1H), 4.29 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=9.0Hz, 2H), 7.52 (d, J=9.0Hz, 2H), 7.95 (m, 1H).

Embodiment 29 (131)：

N- [4- (4- { [4- ({ [(4- fluorophenyls) amino] carbonyl } { [3- (trifluoromethyl) pyridine -2- bases] methyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.56；

NMR(CD₃OD)：δ 1.95-2.12 (m, 4H), 2.95 (s, 3H), 3.08-3.21 (m, 2H), 3.47-3.58 (m, 2H), 4.27 (s, 2H), 4.38 (m, 1H), 4.90 (s, 2H), 6.95-7.06 (m, 6H), 7.25-7.35 (m, 4H), 7.48 (d, J=8.7Hz, 2H), 7.62 (dd, J=8.0,5.0Hz, 1H), (8.28 d, J=8.0Hz, 1H), (8.81 d, J=5.0Hz, 1H).

Embodiment 30 (1)-embodiment 30 (12)

By the same step as described in embodiment 25, replaced using corresponding amine derivative (3- [tert-butyl group (dimethyl) siloxy } butyl) amine, obtain following compounds of the invention.

Embodiment 30 (1)：

N- [4- (4- { [4- (butyl { [(3S)-piperidines -3- bases amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the n-butanols: acetic acid: water=4: 2: 1) of Rf 0.15；

NMR(DMSO-d₆)：(the t of δ 0.91, J=7.1Hz, 3H), 1.20-1.40 (m, 2H), 1.40-1.60 (m, 2H), 1.60-2.00 (m, 6H), 2.20-2.40 (m, 2H), 2.80-3.60 (m, 10H), 2.96 (s, 3H), 3.99 (m, 1H), 4.15 (m, 1H), 4.18 (s, 2H), 6.23 (m, 1H), 7.03 (d, J=7.2Hz, 4H), 7.28 (d, J=8.7Hz, 2H), 7.61 (d, J=8.7Hz, 2H), 8.83 (m, 1H), 9.35 (m, 1H), 9.47 (m, 1H).

Embodiment 30 (2)：

N- [4- (4- { [4- (butyl { [(3R)-piperidines -3- bases amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the n-butanols: acetic acid: water=4: 2: 1) of Rf 0.15；

NMR(DMSO-d₆)：(the t of δ 0.91, J=7.4Hz, 3H), 1.20-1.40 (m, 2H), 1.40-1.60 (m, 2H), 1.60-2.00 (m, 6H), 2.20-2.40 (m, 2H), 2.80-3.60 (m, 10H), 2.96 (s, 3H), 3.98 (m, 1H), 4.15 (m, 1H), 4.20 (s, 2H), 6.22 (m, 1H), 7.03 (d, J=8.7Hz, 4H), 7.28 (d, J=7.7Hz, 2H), 7.61 (d, J=7.7Hz, 2H), 8.83 (m, 1H), 9.36 (m, 1H), 9.47 (m, 1H).

Embodiment 30 (3)：

N- [4- (4- { [4- (butyl { [(3- methyl-isothiazol -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.35；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.40 (m, 2H), 2.56 (s, 3H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.31 (s, 2H), 7.02-7.08 (m, 5H), (7.29 d, J=8.9Hz, 2H), (7.53 d, J=8.9Hz, 2H).

Embodiment 30 (4)：

N- [4- (4- { [4- (butyl { [(3- methyl isophthalic acids, 2- benzisothiazole -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.46；

NMR(CD₃OD)：(the t of δ 0.98, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.80 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.70 (s, 3H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.52 (d, J=8.9Hz, 2H), 7.60 (dd, J=9.0, 1.7Hz, 1H), 7.90 (d, J=9.0Hz, 1H), 8.08 (d, J=1.7Hz, 1H).

Embodiment 30 (5)：

N- [4- (4- { [4- (butyl { [(1- methyl isophthalic acid H- pyrazoles -5- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=10: 1) of Rf 0.30；

NMR(CD₃OD)：(the t of δ 0.98, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 2.00-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.78 (s, 3H), 4.20 (m, 1H), 4.29 (s, 2H), 6.34 (d, J=2.4Hz, 1H), 7.02-7.08 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.51 (d, J=8.9Hz, 2H), 7.79 (d, J=2.4Hz, 1H).

Embodiment 30 (6)：

N- [4- (4- { [4- (butyl { [(3- hydroxy-cyclohexyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

TLC:Rf.0.24 (dichloromethane: methanol=9: 1)；

NMR(CD₃OD)：δ 0.95 (t, J=7.2Hz, 3H), 1.23-2.20 (m, 16H), 2.95 (s, 3H), 3.02-3.16 (m, 4H), 3.50-3.59 (m, 2H), 3.66 (m, 1H), 3.95-4.22 (m, 2H), 4.28 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H).

Embodiment 30 (7)：

N- [4- (4- { [4- (butyl { [(1,3,5- trimethyl -1H- pyrazoles -4- bases) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.60；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.27 (s, 6H), 2.95 (s, 3H), 3.10-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 3.93 (s, 3H), 4.24 (m, 1H), 4.30 (s, 2H), 7.02-7.07 (m, 4H), (7.29 d, J=8.7Hz, 2H), (7.54 d, J=8.7Hz, 2H).

Embodiment 30 (8)：

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluoro-benzoic acid hydrochlorides

TLC:(the chloroforms: methanol=5: 1) of Rf 0.17；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.25 (s, 2H), 7.01-7.06 (m, 5H), 7.29 (d, J=8.7Hz, 2H), 7.50 (d, J=8.7Hz, 2H), 7.89 (m, 1H).

Embodiment 30 (9)：

5- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2- fluobenzoic acid hydrochlorides

TLC:(the ethyl acetate: methanol=7: 1) of Rf 0.21；

NMR(CD₃OD)：(the t of δ 0.97, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.30 (s, 2H), 7.02-7.08 (m, 4H), 7.12 (d, J=9.0Hz, 1H), 7.29 (d, J=8.7Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 7.58 (m, 1H), 7.92 (m, 1H).

Embodiment 30 (10)：

3- [({ butyl [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,6- difluoro-benzoic acid hydrochlorides

TLC:(the ethyl acetate: methanol=7: 1) of Rf 0.21；

NMR(CD₃OD)：δ 0.97 (t, J=7.4Hz, 3H), 1.30-1.50 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.20-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.20 (m, 1H), 4.28 (s, 2H), 6.90 (m, 1H), 7.02-7.07 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.40 (m, 1H), 7.50 (d, J=8.9Hz, 2H).

Embodiment 30 (11)：

2,4- bis- fluoro- 5- [({ [(3- picoline -2- bases) methyl] [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] benzamide dihydrochlorides

TLC:(the chloroforms: methanol=4: 1) of Rf 0.70；

NMR(CD₃OD)：δ 2.10-2.20 (m, 2H), 2.20-2.40 (m, 2H), 2.62 (s, 3H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.50-3.60 (m, 2H), 4.31 (s, 2H), 4.50 (m, 1H), 7.00-7.06 (m, 4H), 7.17 (t, J=10.2Hz, 1H), 7.28 (d, J=9.0Hz, 2H), 7.56 (d, J=9.0Hz, 2H), 7.90-7.98 (m, 2H), (8.44 d, J=7.2Hz, 1H), (8.57 d, J=8.7Hz, 1H).

Embodiment 30 (12)：

5- [({ butyl- 3- alkene -1- bases [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino } carbonyl) amino] -2,4- difluorobenzoyl amine hydrochlorates

TLC:(the chloroforms: methanol=4: 1) of Rf 0.63；

NMR(CD₃OD)：δ 2.10-2.20 (m, 2H), 2.20-2.30 (m, 2H), 2.40-2.50 (m, 2H), 2.95 (s, 3H), 3.00-3.20 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.10 (m, 1H), 4.29 (s, 2H), 5.08-5.19 (m, 2H), 5.85 (m, 1H), 7.02-7.08 (m, 4H), 7.14 (t, J=10.4Hz, 1H), 7.29 (d, J=8.9Hz, 2H), 7.49 (d, J=8.9Hz, 2H), 7.86 (m, 1H).

Embodiment 31 (1) and embodiment 31 (2)

Pass through the same step as described in embodiment 27, utilize O- benzylhydroxylamines or corresponding amine derivative, and N- (4- { 4- [(4- amino piperidine -1- bases) methyl] phenoxy group } phenyl) Methanesulfomide is replaced using the compound prepared in embodiment 3, obtain following compounds of the invention.

Embodiment 31 (1)：

N- { 4- [4- ({ 4- [{ [(benzyloxy) amino] carbonyl } (butyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.53；

NMR(CD₃OD)：δ 0.90 (t, J=7.2Hz, 3H), 1.21-1.32 (m, 2H), 1.40-1.52 (m, 2H), 1.87-1.97 (m, 2H), 2.11-2.30 (m, 2H), 2.95 (s, 3H), 2.98-3.13 (m, 4H), 3.47-3.58 (m, 2H), 3.97 (m, 1H), 4.27 (s, 2H), 4.79 (s, 2H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.27-7.44 (m, 7H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 31 (2)：

N- [4- (4- { [4- (butyl { [(2- methyl isophthalic acids, 3- benzothiazol-6-yls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74；

NMR(CD₃OD)：(the t of δ 0.96, J=7.1Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 2H), 1.90-2.10 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 2.99 (s, 3H), 3.10-3.30 (m, 2H), 3.30-3.40 (m, 2H), 3.50-3.60 (m, 2H), 4.30 (m, 1H), 4.31 (s, 2H), 7.01-7.05 (m, 4H), 7.29 (d, J=8.9Hz, 2H), 7.56 (d, J=8.9Hz, 2H), 7.67 (d, J=8.3Hz, 1H), 7.97 (d, J=8.3Hz, 1H), 8.23 (s, 1H).

Embodiment 32：

N- [4- (4- { [4- ([(3,5- dimethyl isoxazole -4- bases) methyl] { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] methanesulfonamide hydrochloride

Utilize the same step such as recorded in embodiment 1; utilize N- (4- { 4- [(4- amino piperidine -1- bases) methyl] phenoxy group } phenyl) Methanesulfomide and 3 for embodiment 27; 5- dimethyl isoxazole -4- formaldehyde respectively replaces 4- hydroxy piperidines and 4- (4- methanesulfonylaminobenzenes epoxide) benzaldehyde, obtains compound.Using the same step as described in embodiment 23, using obtained compound and 4- fluobenzoic acids respectively instead of the compound and 1- hexahydrotoluenes that are prepared in embodiment 3, the title compound (100.2mg) with following physical datas is obtained.

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.56；

NMR(CD₃OD)：δ 1.91-2.00 (m, 2H), 2.12-2.32 (m, 2H), 2.25 (s, 3H), 2.39 (s, 3H), 2.95 (s, 3H), 3.02-3.16 (m, 2H), 3.48-3.57 (m, 2H), 4.05 (m, 1H), 4.26 (s, 2H), 4.42 (s, 2H), 6.97-7.08 (m, 6H), 7.25-7.37 (m, 4H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 32 (1)-embodiment 32 (4)

Using the same step as described in embodiment 32,3,5- dimethyl isoxazole -4- formaldehyde is replaced using corresponding aldehyde derivatives, the compounds of this invention with following data is obtained.

Embodiment 32 (1)：

N- [4- (4- { [4- ([(chloro- 1, the 3- dimethyl -1H- pyrazoles -4- bases of 5-) methyl] { [(4- fluorophenyls) amino] carbonyl } amino) piperidin-1-yl] methyl } phenoxy group) phenyl] Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.55；

NMR(CD₃OD)：δ 1.92-2.01 (m, 2H), 2.15-2.31 (m, 2H), 2.23 (s, 3H), 2.95 (s, 3H), 3.00-3.15 (m, 2H), 3.43-3.55 (m, 2H), 3.76 (s, 3H), 4.01 (m, 1H), 4.25 (s, 2H), 4.48 (s, 2H), 6.97-7.08 (m, 6H), 7.25-7.37 (m, 4H), 7.49 (d, J=8.7Hz, 2H).

Embodiment 32 (2)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1,3-thiazoles -4- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } methanesulfonamide hydrochloride

TLC:(the chloroforms: methanol=5: 1) of Rf 0.42；

NMR(CD₃OD)：δ 1.92-2.04 (m, 2H), 2.16-2.33 (m, 2H), 2.95 (s, 3H), 3.11 (m, 2H), 3.54 (m, 2H), 4.29 (s, 2H), 4.31 (m, 1H), 4.69 (s, 2H), 6.98-7.08 (m, 6H), 7.22-7.40 (m, 4H), 7.44-7.58 (m, 2H), 7.64 (m, 1H), 9.22 (m, 1H).

Embodiment 32 (3)：

N- (4- { 4- [(4- { { [(4- fluorophenyls) amino] carbonyl } [(6- oxo -1,6- dihydropyridine -2- bases) methyl] amino } piperidin-1-yl) methyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.17；

NMR(CD₃OD)：δ 2.00-2.30 (m, 4H), 2.95 (s, 3H), 3.10-3.22 (m, 2H), 3.50-3.62 (m, 2H), 4.30 (s, 2H), 4.38 (m, 1H), 4.57 (s, 2H), 6.78 (d, J=9.0Hz, 1H), 6.82 (d, J=7.5Hz, 1H), 7.01 (t, J=9.0Hz, 2H), 7.02 (d, J=8.7Hz, 2H), 7.05 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.37 (dd, J=9.0, 5.0Hz, 2H), 7.53 (d, J=8.7Hz, 2H), 7.90 (dd, J=9.0, 7.5Hz, 1H).

Embodiment 32 (4)：

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1H- imidazol-4 yls methyl) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide dihydrochloride

TLC:(the dichloromethane: methanol=9: 1) of Rf 0.13；

NMR(CD₃OD)：δ 1.97-2.08 (m, 2H), 2.20-2.40 (m, 2H), 2.95 (s, 3H), 3.08-3.21 (m, 2H), 3.52-2.60 (m, 2H), 4.25-4.40 (m, 3H), 4.62 (s, 2H), 6.98-7.08 (m, 6H), 7.29 (d, J=8.7Hz, 2H), 7.40 (dd, J=9.0,5.0Hz, 2H), 7.51 (s, 1H), 7.56 (d, J=8.7Hz, 2H), 8.80 (s, 1H).

Embodiment 33：

4- [4- ({ 4- [(pi-allyl epoxide) imido grpup] piperidin-1-yl } methyl) phenoxy group]-N-methyl-benzamide hydrochloride

Utilize the same step as described in embodiment 16, using N- methyl -4- { 4- [(4- oxo-piperidine -1- bases) methyl] phenoxy group } benzamides and O- allyl hydroxyls amine respectively instead of the compound and n-butylamine that are prepared in embodiment 15, the compounds of this invention with following data is obtained.

TLC:(the chloroforms: methanol=10: 1) of Rf 0.60；

NMR(CD₃OD)：δ 7.84 (d, J=9.0Hz, 2H), 7.57 (d, J=8.4Hz, 2H), 7.15 (d, J=8.4Hz, 2H), 7.08 (d, J=9.0Hz, 2H), 5.97 (m, 1H), 5.30-5.15 (m, 2H), 4.54 (dt, J=5.7,1.5Hz, 2H), 4.38 (s, 2H), 3.68-3.59 (m, 2H), 3.44 (m, 1H), 3.23-3.07 (m, 2H), 2.91 (s, 3H), 2.68-2.63 (m, 2H), 2.40 (m, 1H).

Reference example 11：

2- [4- (4-nitrophenoxy) phenyl] ethanol

Potassium carbonate (4.41g) is added into the solution (21mL) of 4- (2- hydroxyethyls) phenol (2.94g) and the fluoro- 4- nitrobenzene (3.0g) of 1- in dimethylformamide, and solution is stirred 4 hours at 120 DEG C.It is cooled to after room temperature, adds water into reaction solution, is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (hexane: ethyl acetate=1: 1) obtains the title compound with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.80.

Reference example 12：

2- [4- (4- amino-benzene oxygens) phenyl] ethanol

In a hydrogen atmosphere, palladium-charcoal (wet, 10%, 100mg) is added into the ethanol solution (15mL) of the compound (803mg) prepared in reference example 11 and is stirred at room temperature 1.5 hours.Reaction solution is filtered into CELITE (trade (brand) name) and concentrated.Obtained residue is obtained into the title compound (641.5mg) with following physical datas through being washed with tbutoxymethyl ether.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.55；

NMR(CDCl₃)：δ 1.37 (t, J=6.6Hz, 1H), 2.83 (t, J=6.6Hz, 2H), 3.57 (m, 2H), 3.84 (q, J=6.6Hz, 2H), 6.62-6.70 (m, 2H), 6.80-6.92 (m, 4H), 7.12-7.20 (m, 2H).

Reference example 13：

2- (4- { 4- [double (mesyl) amino] phenoxy group } phenyl) ethyl methanesulfonate

At 0 DEG C, with addition triethylamine (0.239mL) and mesyl chloride (0.133mL) in 30 minutes dichloromethane solutions (8.6mL) to the compound (196.5mg) prepared in reference example 12.Reaction solution is stirred at room temperature 12 hours.The aqueous solution of sodium acid carbonate is added into reaction solution, it is extracted with dichloromethane.By organic layer salt water washing, the title compound (292.4mg) obtained with following physical datas is dried and concentrated on anhydrous sodium sulfate.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.89；

NMR(CD₃OD)：δ 2.97 (s, 3H), 3.05 (t, J=6.6Hz, 2H), 3.41 (s, 6H), 4.43 (t, J=6.6Hz, 2H), 6.98-7.08 (m, 4H), 7.30-7.42 (m, 4H).

Embodiment 34：

N- (4- { 4- [2- (4- { butyl [(Cyclohexylamino) carbonyl] amino } piperidin-1-yl) ethyl] phenoxy group } phenyl)-N- (mesyl) Methanesulfomide

Triethylamine (60.2 μ L) and sodium iodide (64.6mg) are added into the compound (68.6mg) and N- butyl-N ' prepared in reference example 13-solution (2mL) of the cyclohexyl-N- piperidin-4-yls urea (100mg) in dimethylformamide and is stirred at room temperature 12 hours.Add water into reaction solution, be extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography to (hexane: ethyl acetate=2: 1) to obtain the compound (32.2mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.74.

Embodiment 35：

N- (4- { 4- [2- (4- { butyl [(Cyclohexylamino) carbonyl] amino } piperidin-1-yl) ethyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

Potassium carbonate (13.7mg) is added in solution of the compound (32.2mg) prepared into embodiment 34 in ethanol (5mL) and water (1mL) and stirs solution 3 hours at 60 DEG C.Reaction solution is concentrated.Obtained residue is purified (ethyl acetate) through silica gel column chromatography, and changes into hydrochloride to obtain the compound (30.3mg) of the invention with following physical datas using conventional method.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.69；

NMR(CD₃OD)：δ 0.97 (t, J=7.2Hz, 3H), 2.00-1.10 (m, 16H), 2.25-2.08 (m, 2H), 2.93 (s, 3H), 3.16-3.00 (m, 6H), 3.38-3.24 (m, 2H), 3.38-3.24 (m, 2H), 3.55 (m, 1H), 3.71 (m, 2H), 4.13 (m, 1H), 7.00-6.90 (m, 4H), 7.32-7.20 (m, 4H).

Reference example 14：

The tert-butyl group [1- (4- hydroxy phenyls) ethyl] carbamate

At 0 DEG C, di-t-butyl pyrocarbonate (4.77g) and sodium hydroxide (146mg) are added into the ethanol solution (24mL) of 4- (1- amino-ethyls) phenol (1.0g), and solution is stirred at room temperature 4.5 hours.Reaction solution is concentrated and added water to wherein.Solution is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous magnesium sulfate.Obtained residue is purified through silica gel column chromatography and (hexane: ethyl acetate=7: 1) obtains the title compound (2.18g) with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.88；

NMR(CDCl₃)：δ 1.36-1.50 (m, 13H), 4.79 (m, 1H), 7.10-7.18 (m, 2H), 7.26-7.32 (m, 2H).

Reference example 15：

{ 1- [4- (4-nitrophenoxy) phenyl] ethyl } amine hydrochlorate

Potassium carbonate (1.21g) is added into solution of the fluoro- 4- nitrobenzene (1.028g) of the compound (2.18g) and 1- that are prepared in reference example 14 in dimethylformamide (30mL) and stirs solution 3 hours at 150 DEG C.It is cooled to after room temperature, adds water into reaction solution, is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous magnesium sulfate.Obtained residue is purified into (hexane: ethyl acetate=6: 1) through silica gel column chromatography.4N hydrochloric acids/ethyl acetate solution (7.15mL) is added into the ethyl acetate solution (30mL) of described compound (2.05g).Solution is stirred 4 hours and is stirred at room temperature 3 days at 40 DEG C.Collect precipitation and obtain the title compound (1.37g) with following physical datas.

NMR(DMSO-d₆)：δ 1.52 (d, J=6.6Hz, 3H), 4.45 (m, 1H), 7.12 (brd, J=9.3Hz, 2H), 7.26 (brd, J=8.7Hz, 2H), 7.62 (brd, J=8.7Hz, 2H), 8.28 (brd, J=9.3Hz, 2H), 8.44 (m, 2H).

Embodiment 36：

1- { 1- [4- (4-nitrophenoxy) phenyl] ethyl } piperidin-4-one hydrochloride

N- Benzyl-N-methyl -4- piperidones iodide (927mg) and potassium carbonate (670mg) are added into solution of the compound (550mg) prepared in reference example 15 in ethanol (9.33mL) and water (4.67mL) and solution flows back 5 hours.It is cooled to after room temperature, adds water into reaction solution, is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous magnesium sulfate.Obtained residue is purified through silica gel column chromatography and (hexane: ethyl acetate=3: 1), and changes into hydrochloride to obtain the compound (515mg) of the invention with following physical datas using conventional method.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.79；

NMR(DMSO-d₆)：δ 1.75 (d, J=6.9Hz, 3H), 3H), 2.38-3.20 (m, 6H), 3.52 (m, 1H), 3.82 (m, 1H), 4.78 (m, 1H), 7.19 (d, J=9.0Hz, 2H), 7.29 (d, J=9.0Hz, 2H), 7.73 (d, J=9.0Hz, 2H), 8.27 (d, J=9.0Hz, 2H).

Embodiment 37：

N- (4- { 4- [1- (4- { butyl [(Cyclohexylamino) carbonyl] amino } piperidin-1-yl) ethyl] phenoxy group } phenyl) methanesulfonamide hydrochloride

Using the same step as described in embodiment 3, the compound for replacing preparing in embodiment 2 using the compound prepared in embodiment 36 obtains compound.Using such as the same step described in 23 → reference example of embodiment, 12 → reference example 13, using obtained compound and hexahydrobenzoid acid, the compound (107mg) of the invention with following physical datas is obtained.

TLC:(the chloroforms: methanol=9: 1) of Rf 0.39；

NMR(CD₃OD)：δ 0.94 (t, J=7.2Hz, 3H), 1.14-2.28 (m, 18H), 1.76 (d, J=6.9Hz, 3H), 2.80-3.05 (m, 2H), 2.95 (s, 3H), 3.12 (m, 2H), 3.41 (m, 1H), 3.52 (m, 1H), 3.74 (m, 1H), 4.02 (m, 1H), 4.46 (m, 1H), 7.00-7.19 (m, 4H), (7.29 brd, J=9.3Hz, 2H), (7.50 brd, J=8.7Hz, 2H).

Embodiment 38：

N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amion acetic acid ester hydrochloride

Sodium triacetoxy borohydride (345mg) is added in solution of the compound (510mg) and amion acetic acid ethyl ester (190mg) prepared into embodiment 2 in dimethylformamide (10mL) and acetic acid (1mL) and is stirred at room temperature 12 hours.Reaction solution is concentrated.Obtained residue is purified (ethyl acetate) through silica gel column chromatography, and changes into hydrochloride to obtain the compound (583mg) of the invention with following physical datas using conventional method.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.53.

Embodiment 39：

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amion acetic acid

The compound hydrochloride (303mg) prepared into embodiment 38 sequentially adds butyraldehyde (56.2 μ L) and sodium triacetoxy borohydride (144mg) in the solution in dimethylformamide (6mL) and acetic acid (0.6mL).Solution is stirred at room temperature 12 hours.Reaction solution is concentrated.Add water to wherein and by solution being extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified (ethyl acetate) through silica gel column chromatography.2N sodium hydrate aqueous solutions (0.91mL) are added in the solution (15mL) of ethanol to obtained compound (179.2mg), and solution is stirred 12 hours at 40 DEG C.Reaction solution is concentrated and purified through silica gel column chromatography and (ethyl acetate: methanol=2: 1) obtains the compound of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.19.

Embodiment 40：

N2- butyl-N1- cyclohexyl-N2- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidin-4-yl] amino acetamide dihydrochloride

Cyclo-hexylamine (41.7 μ L), 1- ethyls -3- (3- dimethylaminopropyls)-carbodiimide hydrochloride (87.2mg) and 1- hydroxyl -7- azepines BTAs (61.9mg) are added in solution (5mL) of the compound prepared into embodiment 39 in dimethylformamide, and solution is stirred at room temperature 12 hours.Reaction solution is concentrated and purified (ethyl acetate) through silica gel column chromatography, and hydrochloride is changed into using conventional method and obtains the compound (41.4mg) of the invention with following physical datas.

TLC:(the chloroforms: methanol=5: 1) of Rf 0.71；

NMR(CD₃OD)：δ 0.98 (t, J=7.2Hz, 3H), 1.16-1.48 (m, 7H), 1.58-1.94 (m, 7H), 2.08-2.38 (m, 4H), 2.95 (s, 3H), 3.08-3.35 (m, 4H), 3.56-4.15 (m, 6H), 4.31 (s, 2H), 7.00-7.08 (m, 4H), 7.24-7.34 (m, 2H), 7.55 (brd, J=8.7Hz, 2H).

Reference example 16：

1- (2- chlorine pyrimidine-4-yl) azepan

At 0 DEG C, azepan (17g) is added into solution of 2, the 4- dichloro pyrimidines (25g) in triethylamine (47mL) and tetrahydrofuran (300mL).Recover to room temperature, solution is stirred 1 hour.Add water to wherein and solution is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified through silica gel column chromatography and (ethyl acetate: hexane=1: 5 → 1: 2) obtains the title compound (7.25g) with following physical datas.

TLC:(the hexanes: ethyl acetate=3: 1) of Rf 0.43；

NMR(CDCl₃)：δ 1.57 (m, 4H), 1.79 (m, 4H), 3.45 (m, 2H), 3.79 (m, 2H), 6.29 (d, J=6.3Hz, 1H), 7.98 (d, J=6.3Hz, 1H).

Reference example 17：

4- azacyclo- hept- 1- base-N- piperidin-4-yl pyrimidine -2- amine tri hydrochlorides

The mixture of the compound (500mg) prepared in reference example 16 and 1- tert-butoxycarbonyl -4- amino piperidines is stirred 6 hours at 125 DEG C.After cooling, the sodium bicarbonate aqueous solution of saturation is added into reactant mixture, is extracted with ethyl acetate.By organic layer salt water washing, it is dried and concentrated on anhydrous sodium sulfate.Obtained residue is purified into (hexane: ethyl acetate=3: 1 → 0: 1) through silica gel column chromatography.4N hydrochloric acids/ethyl acetate solution (4mL) is added into solution of the obtained residue in ethyl acetate (1mL), and solution is stirred at room temperature 1.5 hours.Reaction solution is concentrated to give to the title compound (290mg) with following physical datas.

TLC:(the dichloromethane: methanol: acetic acid=5: 1: 0.1) of Rf 0.23；

NMR(CD₃OD)：δ 1.59-1.61 (m, 4H), 1.83-1.92 (m, 6H), 2.22-2.27 (m, 2H), 3.14-3.22 (m, 2H), 3.44-3.49 (m, 2H), 3.69 (t, J=6.1Hz, 2H), 3.91 (t, J=6.1Hz, 2H), 4.17 (m, 1H), 6.41 (d, J=7.5Hz, 1H), 7.68 (d, J=7.5Hz, 1H).

Embodiment 41：

N- { 4- [4- ({ 4- [(4- azacyclo- hept- 1- yl pyrimidines -2- bases) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide tri hydrochloride

Using the same step as described in embodiment 1,4- hydroxy piperidines are replaced using the compound prepared in reference example 17, the compound (159mg) of the invention with following physical datas is obtained.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.38；

NMR(CD₃OD)：δ 1.61-1.62 (m, 4H), 1.83-1.98 (m, 6H), 2.20-2.33 (m, 2H), 2.95 (s, 3H), 3.16-3.24 (m, 2H), 3.55-3.61 (m, 2H), 3.69 (t, J=6.0Hz, 2H), 3.91 (t, J=6.0Hz, 2H), 4.15 (m, 1H), 4.31 (s, 2H), 6.40 (d, J=7.5Hz, 1H), 7.03 (d, J=8.7Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.54 (d, J=8.7Hz, 2H), 7.66 (d, J=7.5Hz, 1H).

Embodiment 41 (1)：

N- { 4- [4- ({ 3- [(4- azacyclo- hept- 1- yl pyrimidines -2- bases) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide tri hydrochloride

Using the same step as described in 17 → embodiment of reference example 37,1- tert-butoxycarbonyl -4- amino piperidines are replaced using 1- tert-butoxycarbonyl -3- amino piperidines, the compound (51mg) of the invention with following physical datas is obtained.

TLC:(the dichloromethane: methanol=10: 1) of Rf 0.53；

NMR(CD₃OD)：δ 1.55-1.80 (m, 9H), 2.00-2.17 (m, 3H), 2.79 (m, 1H), 2.95 (s, 3H), 3.04 (m, 1H), 3.53-3.86 (m, 7H), 4.25 (d, J=13.5Hz, 1H), 4.33 (m, 1H), 4.44 (d, J=13.5Hz, 1H), 6.40 (d, J=7.5Hz, 1H), 7.02 (d, J=8.7Hz, 2H), 7.04 (d, J=8.7Hz, 2H), 7.29 (d, J=8.7Hz, 2H), 7.55 (d, J=8.7Hz, 2H), 7.66 (d, J=7.5Hz, 1H).

Biological example

The fact that the compound of the present invention has CCR5 antagonistic activities is confirmed for example, by following experiments.All operations, to prepare the cell of gene high expression, and use usual way based on basic genetic engineering.In addition, in the analysis method of the present invention, in order to evaluate the compound of the present invention, improving precision of analysis and/or sensitivity as follows.Experimental detail is as follows.

Biological example 1

The suppression test that RANTES is combined with CCR5：

(1) separation of CCR5 gene

Human plactnta cDNA is prepared using Marathon cDNA amplification kits (Clontech).According to GenBank U54994 sequences Design PCR primer hCCR5Xbal-F1：

5′-AGCTAGTCTAGATCCGTTCCCCTACAAGAAACTCTCC-3′(SEQ IDNO：1)

And hCCR5Xbal-R1：

5′-AGCTAGTCTAGAGTGCACAACTCTGACTGGGTCACCA-3′(SEQID NO：2).

Make template with Human plactnta cDNA, and with Ex Taq (Takara), enter performing PCR reaction (95 DEG C/2 minutes/→ (95 DEG C/30 seconds, 60 DEG C/45 seconds, 72 DEG C/1 minute) × 35 times).The PCR primer so expanded is carried out 1% agarose gel electrophoresis, purified, then digested with restriction enzyme XbaI using QIAquick Gel Extraction Kit (QUIAGEN).With DNA Ligation Kit Ver.2 (Takara), the fragment digested is connected on expression vector pEF-BOS-bsr, and is transformed into escherichia coli DH5a.The plasmid pEF-BOS-bsr/hCCR5 as obtained by preparing, its DNA sequence dna is verified.

(2) culture of Chinese hamster ovary celI

CHO-dhfr (-) is cultivated, using Ham ' s F-12 (containing hyclone (10%), penicillin (50U/ml) and streptomysin (50mg/ml)).In addition, by adding in blasticidin S (5mg/ml) to above-mentioned culture medium, cultivating transduceed cell.

(3) transduction is into Chinese hamster ovary celI

Using DMRIE-C reagents (Gibco BRL), plasmid pEF-BOS-bsr/hCCR5 transductions are arrived in CHO-dhfr (-) cell.After 48 hours, the culture medium is replaced with the culture medium of the blasticidin S containing 5mg/ml, to be selected, and then stable overexpressing cell is set up.

(4) (RANTES causes the activity that Ca ions are temporarily increased) is tested on the suppression that RANTES is combined to CCR5

The Chinese hamster ovary celI (CCR5/CHO cells) of the stable overexpression of the CCR5 so established is suspended in the Ham ' s F-12 culture mediums containing FBS (10%), and with 3.0 × 10⁶The density distribution of cells/well is into 96 orifice plates.After being cultivated one day at 37 DEG C, culture supernatants are discarded, and Ham ' s F-12 culture mediums (are contained into Fura-2AM (5 μM), probenecid (2.5mM) and HEPES (20mM；PH 7.4)) it is allocated with the number in 80 μ l/ holes, to carry out the culture of 1 hour under the conditions of 37 DEG C and lucifuge.Stand-by 1 × Hanks/HEPES (20mM；PH 7.4) after solution washes twice, identical solution is allocated with the number in 100 μ l/ holes.Each test compound is added in this CCR5/CHO cells for introducing Fura-2AM, after 3 minutes, added thereto with 1 × Hanks/HEPES (20mM；PH 7.4) solution dilution recombined human RANTES (PeproTach), to 10nM ultimate density.Utilize the Ca of 96 orifice plates²⁺Detector (Hamamatsu Photonics), intracellular Ca caused by measurement people RANTES²⁺Concentration is instantly increased, and passes through the inhibiting rate (%) that following formula calculates test compound：

Inhibiting rate=(Ec-Ea)/Ec × 100

Ec：Ca caused by the RANTES measured²⁺It is instantly increased value,

Ea：Add Ca caused by the RANTES measured during test compound²⁺It is instantly increased value.

As a result, compound of the invention provides 50% or higher inhibiting rate under 10 μM.For example, the compound of embodiment 5 (2) provides 0.077 μM of IC₅₀Value.

Biological example 2

Express the migration test of the cell (hCCR5-Ba/F3 cells) of CCR5：

(1) foundation of CCR5 cell is expressed

The separation of (1-A) CCR5 gene

Separated according to the method for the separation CCR5 gene described in above-mentioned biological example 1.

The culture of (1-B) Ba/F3 cells

Ba/F3 cells utilize RMMI-1640 culture mediums (Gibco BRL) (final concentration comprising antibiotic (Antibiotic-Antimycotic)：Novocillin (100U/mL), streptomycin sulphate (100 μ g/mL), amphotericin B (0.25 μ g/mL)) (Gibco BRL), hyclone (FBS) (10%), 2 mercapto ethanol (55 μM) and mouse interlekin-3 (IL-3) (5ng/mL) (Pepro Tech, Inc) are in carbon dioxide incubator (temperature：37 DEG C, CO₂Concentration：5%, humidity：95%) still cultivated in.The cell of the stable high expression of allogenic gene is cultivated in above-mentioned culture medium, and blasticidin (KakenPharmaceutical) is added thereto and obtains final concentration of 10 μ g/ml.

(1-C) Ba/F3 transformations

CCR5 expression plasmid (pEF-BOS-bsr/hCCR5) is digested with AatII to be linearized.The plasmid of linearisation is purified using QIA quick PCR Purification Kit (QIAGEN), and imported into using electroporation (Gene Pulser (BIO RAD), 960 μ F/250V) in Ba/F3 cells.Seed cells into 96- well culture plates, density is the μ l/ holes of 1,000,100,10 cell/100, and is cultivated 48 hours.Then, blasticidin is added thereto to obtain 10 μ g/ml final concentration, then clones blastocidin-resistance cell line to set up the high-expression clone (hCCR5-Ba/F3 cells) for the allogenic gene that stable expression is imported.

The analysis of (1-D) CCR5 expression

CCR5 expression FACSort (trade names in the clone that method described in above-mentioned (1-C) is obtained, Becton, Dickinson) detect, detect cell by using the anti-human CCR5 antibody (BD Pharmingen) of fluorescein isothiocyanate (FITC)-mark and analyzed.In this case, it is used as Isotype control antibodies using the FITC- mouse IgG 2a κ (BD Pharmingen) marked.

(2) cell migration is tested

The ability that test compound expresses people CCR5 migration of the Ba/F3 cells relative to RANTES, MIP-1 α or MIP-1 β is investigated.First, culture mediums of the 0 of the 0.3ml or 3nM comprising chemotactic factor (CF) (RANTES, MIP-1 α or MIP-1 β) is added separately in the lower room of the orifice plate (Neuro Probe) of Chemo T × 96.Then, filter (aperture is loaded onto：5 μm) and by the mixed solution (1 × 10 of the test-compound prepared in advance and CCR5-Ba/F3 cells⁵Cells/well) added with 65 μ l.The test-compound that will be added by by it with to be diluted comprising 0.1%DMSO- culture mediums with the concentration obtained on filter be respectively 0,0.01,0.03,0.1 or 0.3 μM.These cells are in CO₂Incubator (37 DEG C, 5%CO₂, relative humidity：95%) culture 3 hours in, and remove the culture medium on filter and the cell not migrated.In addition, removing filter, microtiter plate is centrifuged into (1,500rpm, 10 minutes, RT) and removes supernatant by being decanted.Cell on microtiter plate is suspended in 100 μ l phosphate buffer (PBS), and its 1/10 part is further diluted with 90 μ l PBS, moves on to and fluorometric investigation is carried out on blank, and the analysis sample as migrating cell quantity is (final：100μl/well).

Then, by the Cell Titer-Glo Reagent (trade names prepared at room temperature in advance, Promega) it is added in the analysis sample of above-mentioned migrating cell quantity (100 μ l/well), then KA-SCHUTTLERMTS4 is used) slight mixing (300rpm, 2 minutes) with cell lysis, by mixture in incubation at room temperature 10 minutes, and measurement fluorescence (is measured) with counting/second with wallac ARVO SX 1420MULTILABEL COUNTER (trade name, PerkinElmer).

Chemotactic factor (CF) concentration counts (natural whereabouts cell count) for 0nmol/l migrating cell and is used as background, and calculates the inhibiting rate of the test compound relative to 0.1%DMSO control groups.

The inhibition of metastasis rate (%) of test-compound is calculated according to following equalities：

Ec：(fluorescent value for adding 0.1%DMSO measurements)

- (fluorescence measurement value of natural whereabouts cell)

Ea：(fluorescent value for adding test compound measurement)

- (fluorescence measurement value of natural whereabouts cell)

As a result：

The compound prepared in concentration 10 and 30 μM, embodiment 23 (126) shows 42% and 77% cellular migration inhibition rate to RANTES respectively.

Preparation example 1：

Following compositions are mixed in a conventional manner and gone out and obtain 100 tablets, every includes 50mg active components.

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines

- 4- bases] cyclohexane carboxamide hydrochloride 5.0g

Carboxy methyl cellulose calcium (disintegrant) 0.2g

Magnesium stearate (lubricant) 0.1g

Microcrystalline cellulose 4.7g

Preparation example 2：

Following compositions are mixed in a conventional manner.Solution is sterilized using conventional technique, loads ampoule, each ampoule includes 5ml, and obtains 100 ampoules using routine techniques is lyophilized, respectively comprising 20mg active components.

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines

- 4- bases] cyclohexane carboxamide hydrochloride 2.0g

Mannitol 20g

Distilled water 500ml

Preparation example 3：

Following compositions are mixed in a conventional manner and gone out and obtain 10,000 tablet, every include 10mg active component.

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines

- 4- bases] cyclohexane carboxamide hydrochloride 100g

Carboxy methyl cellulose calcium (disintegrant) 20.0g

Magnesium stearate (lubricant) 10.0g

Microcrystalline cellulose 870g

Preparation example 4：

The method of following each components utilising standards is mixed and dust-proof filter is filtered, and then by 5ml etc. be distributed into ampoule, autoclaving is so as to obtaining 10,000 ampoule, each active component comprising 20mg.

N- butyl-N- [1- (4- { 4- [(mesyl) amino] phenoxy group } benzyl) piperidines

- 4- bases] cyclohexane carboxamide hydrochloride 200g

Mannitol 2kg

Distilled water 50L

Industrial usability

The compound that formula (I) of the present invention is represented adjusts the activity of CCR5 acceptors, therefore they can be used for preventing and/or treating a variety of inflammatory disease (asthma, ephritis, nephrosis, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis etc.), immunity disease (autoimmune disease, organ-graft refection, immunosupress, psoriasis, multiple sclerosis etc.), human immunodeficiency virus infection's (acquired immunodeficiency syndrome etc.), anaphylactia (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, anaphylaxis acidophilia enterogastritis etc.), ischemical reperfusion injury, ARDS, with the shock of bacterium infection, diabetes, cancer metastasis etc..Therefore, CCR5 antagonists can be used as medicine.

Sequence table

<110>ONO Pharmaceutical Co., Ltd. (ONO Pharmaceutical Co., Ltd.s)

<120>Nitogen-contained heterocycle derivant and include medicine of the compound as active component

<130>ONF-4932PCT

<150>JP 2003-070347

<151>2003-03-14

<150>JP 2003-385683

<151>2003-11-14

<160>2

<170>PatentIn version 3.1

<210>1

<211>37

<212>DNA

<213>Artificial sequence

<220>

<223>The description of artificial sequence：HCCR5Xbal forward primers

<400>1

agctagtcta gatccgttcc cctacaagaa actctcc 37

<210>2

<211>37

<212>DNA

<213>Artificial sequence

<220>

<223>The description of artificial sequence：HCCR 5Xbal reverse primers

<400>2

agctagtcta gagtgcacaa ctctgactgg gtcacca 37

Claims

1. the compound or its salt that formula (I) is represented：

Wherein R¹Expression hydrogen atom can protected acidic-group；

X represents key or comprising interval base of 1~3 atom as main chain；

Y represents-CH₂-；

Ring A represents to have the 3- of substituent to 15- person's carbocylic radical or heterocyclic radical；

Ring B represents the phenyl ring or 5- that can be substituted to 6- person's aromatic rings；

Ring D represents piperidines；

R²Represent

Wherein arrow represents the bonding position with ring D；R⁵¹、R⁵²And R⁵³(1) hydrogen atom is represented independently of one another, (2) there can be the alkyl of substituent, (3) there can be the 3- of substituent to 15- element heterocycle bases, (4) there can be the C1-4 alkoxies of substituent, (5) can have the phenoxy group of substituent or (6) can the benzyloxy with substituent.

2. compound according to claim 1, it is selected from

N- { 4- [4- ({ 4- [{ [(4- fluorophenyls) amino] carbonyl } (1,3-thiazoles -4- ylmethyls) amino] piperidin-1-yl } methyl) phenoxy group] phenyl } Methanesulfomide.

3. pharmaceutical composition, it includes the compound or its salt of formula according to claim 1 (I) expression.

4. a kind of medicine, one or at least two in its compound or its salt combination RTI for including formula according to claim 1 (I) expression, protease inhibitors, CCR2 antagonists, CCR3 antagonists, CCR4 antagonists, CCR5 antagonists, CXCR4 antagonists, fusion inhibitor, antibody of anti-HIV-1 surface antigen, and HIV-1 vaccines.

5. the compound or its salt described in the claim 1 that formula (I) is represented is preparing the purposes in being used to prevent and/or treat the medicine of the disease intervened by CCR5：

The wherein markd implication of institute is identical with claim 1.

6. the compound described in claim 1, as shown in formula (I-d)

Wherein, R^1-1aFor-SO₂NR¹⁰²R¹⁰³Or-NR¹⁰¹SO₂R¹⁰⁴,

R¹⁰¹Represent hydrogen atom or there can be the alkyl of substituent,

R¹⁰²~R¹⁰⁴Hydrogen atom or protection group are represented,

X^1aFor singly-bound ,-CR⁷R⁸-、-NR⁹-、-CO-、-O-、-S-、-SO-、-SO₂- ,-C (=N-OR¹⁰)-

Wherein R⁷And R⁸It is each independently hydrogen atom, C1-4 alkyl ,-OR¹¹Or phenyl,

R⁹For hydrogen atom, C1-4 alkyl or phenyls,

R¹⁰And R¹¹Hydrogen atom or C1-4 alkyl are each independently,

Ring A^1bWith ring B^1bIt is each independently the phenyl ring that can be substituted or 5~6 Yuans aromatic rings, ring D^1aFor piperidines

And other symbols have the identical implication with foregoing description.

7. the compound described in claim 6, wherein X^1aFor key ,-O- or-CH₂。

8. the compound described in claim 6, its middle ring A^1bFor the benzene that can be substituted.

9. the compound described in claim 6, its middle ring B^1bFor the benzene, pyridine or pyrazoles that can be substituted.

10. the compound described in claim 6, wherein R⁵¹And R⁵²Represent there can be the alkyl of substituent independently of one another.

11. the compound described in claim 10, wherein R⁵¹And R⁵²Represent that (1) there can be the C1-8 alkyl of substituent independently of one another, (2) there can be the C2-8 alkenyls of substituent, (3) there can be the C3-8 cycloalkyl of substituent, (4) can have substituent C3-8 cycloalkyl-can have substituent C1-4 alkyl, (5) can have substituent phenyl or (6) can have substituent benzyl.

12. the compound described in claim 11, wherein R⁵¹For that can have the C1-8 alkyl of substituent or can have the C2-8 alkenyls of substituent.

13. the compound described in claim 11, wherein R⁵²For that can have the phenyl of substituent.

14. the compound described in claim 2, wherein R¹⁰¹、R¹⁰²、R¹⁰³And R¹⁰⁴It is hydrogen atom or C1-8 alkyl independently of one another.

15. the pharmaceutical composition described in claim 3, wherein the compound or its salt that described formula (I) is represented is CCR5 conditioning agents.

16. the pharmaceutical composition described in claim 15, wherein described CCR5 conditioning agents are CCR5 inhibitor.

17. the purposes described in claim 5, wherein being human immunodeficiency virus infection disease, immunological diseases or inflammatory disease by the CCR5 diseases intervened.

18. the purposes described in claim 17, wherein HIV infections disease are Immune Deficiency Syndrome.

19. the purposes described in claim 17, wherein immunological diseases are organ transplant rejection.

20. the purposes described in claim 17, wherein inflammatory disease are asthma.